0001600620-24-000108.txt : 20241107 0001600620-24-000108.hdr.sgml : 20241107 20241107061750 ACCESSION NUMBER: 0001600620-24-000108 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 84 CONFORMED PERIOD OF REPORT: 20240930 FILED AS OF DATE: 20241107 DATE AS OF CHANGE: 20241107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aurinia Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001600620 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 981231763 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36421 FILM NUMBER: 241432960 BUSINESS ADDRESS: STREET 1: #140, 14315 - 118 AVENUE CITY: EDMONTON STATE: A0 ZIP: T5L 4S6 BUSINESS PHONE: 250-744-2487 MAIL ADDRESS: STREET 1: #140, 14315 - 118 AVENUE CITY: EDMONTON STATE: A0 ZIP: T5L 4S6 10-Q 1 auph-20240930.htm 10-Q auph-20240930
false2024Q3000160062012-31xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureauph:segmentutr:sqftauph:extension_option00016006202024-01-012024-09-3000016006202024-11-0600016006202024-09-3000016006202023-12-310001600620us-gaap:RelatedPartyMember2024-09-300001600620us-gaap:RelatedPartyMember2023-12-310001600620us-gaap:ProductMember2024-07-012024-09-300001600620us-gaap:ProductMember2023-07-012023-09-300001600620us-gaap:ProductMember2024-01-012024-09-300001600620us-gaap:ProductMember2023-01-012023-09-300001600620auph:LicenseRoyaltyAndCollaborationRevenueMember2024-07-012024-09-300001600620auph:LicenseRoyaltyAndCollaborationRevenueMember2023-07-012023-09-300001600620auph:LicenseRoyaltyAndCollaborationRevenueMember2024-01-012024-09-300001600620auph:LicenseRoyaltyAndCollaborationRevenueMember2023-01-012023-09-3000016006202024-07-012024-09-3000016006202023-07-012023-09-3000016006202023-01-012023-09-300001600620us-gaap:CommonStockMember2024-06-300001600620us-gaap:AdditionalPaidInCapitalMember2024-06-300001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001600620us-gaap:RetainedEarningsMember2024-06-3000016006202024-06-300001600620us-gaap:CommonStockMember2024-07-012024-09-300001600620us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001600620us-gaap:RetainedEarningsMember2024-07-012024-09-300001600620us-gaap:CommonStockMember2024-09-300001600620us-gaap:AdditionalPaidInCapitalMember2024-09-300001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001600620us-gaap:RetainedEarningsMember2024-09-300001600620us-gaap:CommonStockMember2023-06-300001600620us-gaap:AdditionalPaidInCapitalMember2023-06-300001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001600620us-gaap:RetainedEarningsMember2023-06-3000016006202023-06-300001600620us-gaap:CommonStockMember2023-07-012023-09-300001600620us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001600620us-gaap:RetainedEarningsMember2023-07-012023-09-300001600620us-gaap:CommonStockMember2023-09-300001600620us-gaap:AdditionalPaidInCapitalMember2023-09-300001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001600620us-gaap:RetainedEarningsMember2023-09-3000016006202023-09-300001600620us-gaap:CommonStockMember2023-12-310001600620us-gaap:AdditionalPaidInCapitalMember2023-12-310001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001600620us-gaap:RetainedEarningsMember2023-12-310001600620us-gaap:CommonStockMember2024-01-012024-09-300001600620us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300001600620us-gaap:RetainedEarningsMember2024-01-012024-09-300001600620us-gaap:CommonStockMember2022-12-310001600620us-gaap:AdditionalPaidInCapitalMember2022-12-310001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001600620us-gaap:RetainedEarningsMember2022-12-3100016006202022-12-310001600620us-gaap:CommonStockMember2023-01-012023-09-300001600620us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001600620us-gaap:RetainedEarningsMember2023-01-012023-09-3000016006202024-01-012024-03-310001600620us-gaap:EmployeeSeveranceMemberauph:StrategicRestructuringPlanMemberus-gaap:SubsequentEventMember2024-11-072024-11-070001600620us-gaap:EmployeeSeveranceMemberauph:StrategicRestructuringPlanMembersrt:MinimumMembersrt:ScenarioForecastMember2024-10-012024-12-310001600620us-gaap:EmployeeSeveranceMemberauph:StrategicRestructuringPlanMembersrt:MaximumMembersrt:ScenarioForecastMember2024-10-012024-12-310001600620auph:MajorCustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-09-300001600620auph:MajorCustomerTwoMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-09-300001600620auph:MajorCustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-300001600620auph:MajorCustomerTwoMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-300001600620srt:MinimumMember2024-01-012024-09-300001600620srt:MaximumMember2024-01-012024-09-300001600620us-gaap:FairValueInputsLevel1Memberauph:CashCashEquivalentsAndRestrictedCashMember2024-09-300001600620us-gaap:FairValueInputsLevel2Memberauph:CashCashEquivalentsAndRestrictedCashMember2024-09-300001600620us-gaap:FairValueInputsLevel3Memberauph:CashCashEquivalentsAndRestrictedCashMember2024-09-300001600620auph:CashCashEquivalentsAndRestrictedCashMember2024-09-300001600620us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateBondSecuritiesMember2024-09-300001600620us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2024-09-300001600620us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateBondSecuritiesMember2024-09-300001600620us-gaap:CorporateBondSecuritiesMember2024-09-300001600620us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMember2024-09-300001600620us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2024-09-300001600620us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMember2024-09-300001600620us-gaap:CommercialPaperMember2024-09-300001600620us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryBillSecuritiesMember2024-09-300001600620us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryBillSecuritiesMember2024-09-300001600620us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryBillSecuritiesMember2024-09-300001600620us-gaap:USTreasuryBillSecuritiesMember2024-09-300001600620us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryBondSecuritiesMember2024-09-300001600620us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryBondSecuritiesMember2024-09-300001600620us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryBondSecuritiesMember2024-09-300001600620us-gaap:USTreasuryBondSecuritiesMember2024-09-300001600620us-gaap:FairValueInputsLevel1Member2024-09-300001600620us-gaap:FairValueInputsLevel2Member2024-09-300001600620us-gaap:FairValueInputsLevel3Member2024-09-300001600620us-gaap:FairValueInputsLevel1Memberauph:CashCashEquivalentsAndRestrictedCashMember2023-12-310001600620us-gaap:FairValueInputsLevel2Memberauph:CashCashEquivalentsAndRestrictedCashMember2023-12-310001600620us-gaap:FairValueInputsLevel3Memberauph:CashCashEquivalentsAndRestrictedCashMember2023-12-310001600620auph:CashCashEquivalentsAndRestrictedCashMember2023-12-310001600620us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateBondSecuritiesMember2023-12-310001600620us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2023-12-310001600620us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateBondSecuritiesMember2023-12-310001600620us-gaap:CorporateBondSecuritiesMember2023-12-310001600620us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMember2023-12-310001600620us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2023-12-310001600620us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMember2023-12-310001600620us-gaap:CommercialPaperMember2023-12-310001600620us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryBillSecuritiesMember2023-12-310001600620us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryBillSecuritiesMember2023-12-310001600620us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryBillSecuritiesMember2023-12-310001600620us-gaap:USTreasuryBillSecuritiesMember2023-12-310001600620us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryBondSecuritiesMember2023-12-310001600620us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryBondSecuritiesMember2023-12-310001600620us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryBondSecuritiesMember2023-12-310001600620us-gaap:USTreasuryBondSecuritiesMember2023-12-310001600620us-gaap:FairValueInputsLevel1Member2023-12-310001600620us-gaap:FairValueInputsLevel2Member2023-12-310001600620us-gaap:FairValueInputsLevel3Member2023-12-310001600620us-gaap:FairValueInputsLevel2Member2023-01-012023-12-310001600620us-gaap:FairValueInputsLevel2Member2024-01-012024-09-300001600620auph:CashCashEquivalentsAndRestrictedCashMember2024-01-012024-09-300001600620auph:ShortTermCorporateDebtSecuritiesMember2024-09-300001600620auph:ShortTermCorporateDebtSecuritiesMember2024-01-012024-09-300001600620us-gaap:CommercialPaperMember2024-01-012024-09-300001600620us-gaap:USTreasuryBillSecuritiesMember2024-01-012024-09-300001600620us-gaap:USTreasuryBondSecuritiesMember2024-01-012024-09-300001600620auph:LongTermCorporateDebtSecuritiesMember2024-09-300001600620auph:LongTermCorporateDebtSecuritiesMember2024-01-012024-09-300001600620auph:CashCashEquivalentsAndRestrictedCashMember2023-01-012023-12-310001600620auph:ShortTermCorporateDebtSecuritiesMember2023-12-310001600620auph:ShortTermCorporateDebtSecuritiesMember2023-01-012023-12-310001600620us-gaap:CommercialPaperMember2023-01-012023-12-310001600620us-gaap:USTreasuryBillSecuritiesMember2023-01-012023-12-310001600620us-gaap:USTreasuryBondSecuritiesMember2023-01-012023-12-3100016006202023-01-012023-12-310001600620auph:LongTermCorporateDebtSecuritiesMember2023-12-310001600620auph:LongTermCorporateDebtSecuritiesMember2023-01-012023-12-310001600620us-gaap:PatentsMember2024-09-300001600620us-gaap:IntellectualPropertyMember2024-09-300001600620us-gaap:ComputerSoftwareIntangibleAssetMember2024-09-300001600620us-gaap:PatentsMember2023-12-310001600620us-gaap:IntellectualPropertyMember2023-12-310001600620us-gaap:ComputerSoftwareIntangibleAssetMember2023-12-310001600620us-gaap:LeaseholdImprovementsMember2024-09-300001600620us-gaap:LeaseholdImprovementsMember2023-12-310001600620us-gaap:OfficeEquipmentMember2024-09-300001600620us-gaap:OfficeEquipmentMember2023-12-310001600620us-gaap:FurnitureAndFixturesMember2024-09-300001600620us-gaap:FurnitureAndFixturesMember2023-12-310001600620us-gaap:ComputerEquipmentMember2024-09-300001600620us-gaap:ComputerEquipmentMember2023-12-310001600620auph:RockvilleMarylandMember2020-03-310001600620auph:RockvilleMarylandMember2024-09-300001600620auph:RockvilleMarylandMember2023-12-310001600620auph:RockvilleMarylandMember2023-01-012023-12-310001600620auph:RockvilleMarylandMember2020-03-120001600620auph:EdmontonAlbertaMember2022-10-310001600620auph:VispSwitzerlandMember2023-07-310001600620auph:VispSwitzerlandMember2024-09-300001600620auph:VispSwitzerlandMember2023-12-310001600620auph:VispSwitzerlandMember2024-07-012024-09-300001600620auph:VispSwitzerlandMember2024-01-012024-09-300001600620auph:BeinheimFranceMember2020-03-012020-03-310001600620auph:BeinheimFranceMember2023-07-310001600620auph:BeinheimFranceMember2024-09-300001600620us-gaap:LicenseAgreementTermsMemberauph:OtuskaPharmaceuticalCoLtdMember2020-01-012020-12-310001600620us-gaap:LicenseAgreementTermsMemberauph:OtuskaPharmaceuticalCoLtdMembersrt:MinimumMember2020-12-310001600620us-gaap:LicenseAgreementTermsMemberauph:OtuskaPharmaceuticalCoLtdMembersrt:MaximumMember2020-12-310001600620us-gaap:LicenseAgreementTermsMemberauph:OtuskaPharmaceuticalCoLtdMember2024-09-242024-09-240001600620us-gaap:LicenseAgreementTermsMemberauph:OtuskaPharmaceuticalCoLtdMember2024-07-012024-09-300001600620us-gaap:LicenseAgreementTermsMemberauph:OtuskaPharmaceuticalCoLtdMemberus-gaap:ServiceMember2024-07-012024-09-300001600620us-gaap:LicenseAgreementTermsMemberauph:OtuskaPharmaceuticalCoLtdMemberus-gaap:ServiceMember2024-01-012024-09-300001600620us-gaap:LicenseAgreementTermsMemberauph:OtuskaPharmaceuticalCoLtdMemberus-gaap:ServiceMember2023-07-012023-09-300001600620us-gaap:LicenseAgreementTermsMemberauph:OtuskaPharmaceuticalCoLtdMemberus-gaap:ServiceMember2023-01-012023-09-3000016006202024-02-1500016006202024-02-292024-02-290001600620srt:MinimumMember2024-02-292024-02-290001600620srt:MaximumMember2024-02-292024-02-290001600620auph:StockOptionsRSUsPerformanceAwardsAndESPPMember2024-07-012024-09-300001600620auph:StockOptionsRSUsPerformanceAwardsAndESPPMember2023-07-012023-09-300001600620auph:StockOptionsRSUsPerformanceAwardsAndESPPMember2024-01-012024-09-300001600620auph:StockOptionsRSUsPerformanceAwardsAndESPPMember2023-01-012023-09-300001600620auph:AmendedAndRestatedEquityIncentivePlanMember2021-06-012021-06-300001600620us-gaap:EmployeeStockMember2021-06-300001600620us-gaap:EmployeeStockMember2024-01-012024-09-300001600620auph:RestrictedStockUnitsAndPerformanceAwardsMember2023-12-310001600620auph:RestrictedStockUnitsAndPerformanceAwardsMember2024-01-012024-09-300001600620auph:RestrictedStockUnitsAndPerformanceAwardsMember2024-09-300001600620us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001600620us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001600620us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001600620us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001600620us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-300001600620us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001600620us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300001600620us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001600620us-gaap:InventoriesMember2024-07-012024-09-300001600620us-gaap:InventoriesMember2023-07-012023-09-300001600620us-gaap:InventoriesMember2024-01-012024-09-300001600620us-gaap:InventoriesMember2023-01-012023-09-300001600620auph:DrRobertTFosterMemberauph:EmployeeBenefitObligationsMember2024-09-300001600620auph:DrRobertTFosterMemberauph:EmployeeBenefitObligationsMember2023-12-310001600620auph:DrRobertTFosterMember2024-01-012024-09-300001600620auph:DrRobertTFosterMember2023-01-012023-12-310001600620us-gaap:EmployeeSeveranceMember2024-01-012024-09-300001600620us-gaap:ContractTerminationMember2024-01-012024-09-300001600620us-gaap:OtherRestructuringMember2024-01-012024-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
_____________________________________________
FORM 10-Q
_____________________________________________
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2024
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from_____________ to ________________
Commission file number: 001-36421
__________________________________________
Aurinia Pharmaceuticals Inc.
(Exact Name of Registrant as Specified in its Charter)
__________________________________________
Alberta, Canada
(State or other jurisdiction of
incorporation or organization)
#140, 14315 - 118 Avenue
Edmonton, Alberta T5L 4S6
98-1231763
(Address of principal executive offices)(I.R.S. Employer
Identification Number)
(250) 744-2487
Registrant’s telephone number, including area code
_____________________________________________
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes  x    No  o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  x    No  o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  o    No  x 
Indicate the number of shares outstanding of each of the registrant's classes of common shares, as of the latest predictable date. As of November 6, 2024, the registrant had 143,179,269 of common shares outstanding.
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of exchange on which registered
Common shares, no par valueAUPHThe Nasdaq Global Market LLC


AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
TABLE OF CONTENTS
Page


PART I—FINANCIAL INFORMATION
Item 1. Financial Statements
AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)September 30, 2024December 31, 2023
ASSETS
Current assets
Cash, cash equivalents, and restricted cash$37,142 $48,875 
Short-term investments311,605 301,614 
Accounts receivable, net36,483 24,089 
Inventories, net38,714 39,705 
Prepaid expenses and deposits13,815 9,486 
Other current assets2,700 1,031 
Total current assets440,459 424,800 
Non-current assets
Long-term investments— 201 
Other non-current assets868 1,517 
Property and equipment, net2,887 3,354 
Acquired intellectual property and other intangible assets, net4,509 4,977 
Finance right-of-use assets, net96,459 108,715 
Operating right-of-use assets, net4,179 4,498 
Total assets$549,361 $548,062 
LIABILITIES
Current liabilities
Accounts payable and accrued liabilities56,770 54,389 
Deferred revenue4,304 4,813 
Other current liabilities (of which $0.8 million and $0.8 million at September 30, 2024 and December 31, 2023 is due to a related party, respectively)
1,590 2,388 
Finance lease liabilities14,927 14,609 
Operating lease liabilities1,018 989 
Total current liabilities78,609 77,188 
Non-current liabilities
Finance lease liabilities65,955 75,479 
Operating lease liabilities5,951 6,530 
Deferred compensation and other non-current liabilities (of which $7.0 million at September 30, 2024 and $7.6 million in December 31, 2023 is due to a related party, respectively)
10,844 10,911 
Total liabilities161,359 170,108 
Commitments and contingencies (Note 18)
SHAREHOLDER’S EQUITY
Common shares - no par value, unlimited shares authorized, 143,109 and 143,833 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively
1,206,613 1,200,218 
Additional paid-in capital119,773 120,788 
Accumulated other comprehensive loss(385)(730)
Accumulated deficit(937,999)(942,322)
Total shareholders' equity388,002 377,954 
Total liabilities and shareholders' equity$549,361 $548,062 
The accompanying notes are an integral part of these condensed consolidated financial statements.
1

AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(in thousands, except per share data)
Three months endedNine months ended
September 30,September 30,
2024202320242023
(unaudited)
Revenue
Product revenue, net$55,503 $40,781 $158,604 $116,218 
License, collaboration, and royalty revenue
12,268 13,734 16,662 14,200 
Total revenue, net67,771 54,515 175,266 130,418 
Operating expenses
Cost of sales6,035 6,769 22,696 8,753 
Selling, general and administrative42,367 47,759 134,996 144,964 
Research and development3,047 13,605 12,678 39,413 
Restructuring expenses— — 7,755 — 
Other expense (income), net4,574 2,645 159 (695)
Total cost of sales and operating expenses56,023 70,778 178,284 192,435 
Income (Loss) from operations11,748 (16,263)(3,018)(62,017)
Interest expense(1,208)(1,400)(3,689)(1,465)
Interest income4,267 4,514 12,982 12,429 
Net income (loss) before income taxes14,807 (13,149)6,275 (51,053)
Income tax expense457 298 1,952 92 
Net income (loss)$14,350 $(13,447)$4,323 $(51,145)
Other comprehensive (loss) gain:
Unrealized gain on available-for-sale securities, net of tax of nil
474 73 345 114 
Comprehensive income (loss)$14,824 $(13,374)$4,668 $(51,031)
Net income (loss) per share:
Basic$0.10 $(0.09)$0.03 $(0.36)
Diluted$0.10 $(0.09)$0.03 $(0.36)
Weighted-average common shares outstanding:
Basic143,051 142,847 143,353 143,085 
Diluted145,651 142,847 145,010 143,085 
The accompanying notes are an integral part of these condensed consolidated financial statements.






2

AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
(in thousands)
(unaudited)
Common Shares
Three Months Ended September 30, 2024
SharesAmountAdditional
paid in
capital		Accumulated
Other
Comprehensive
(Loss) Income		Accumulated
Deficit		Total
Shareholders'
Equity
Balance at June 30, 2024142,984 $1,205,554 $112,270 $(859)$(952,349)$364,616 
Shares issued on exercise of stock options and vesting of restricted stock units125 1,059 (824)— — 235 
Share-based compensation— — 8,327 — — 8,327 
Unrealized gain on available-sale-securities, net— — — 474 — 474 
Net income— — — — 14,350 14,350 
Balance at September 30, 2024143,109 $1,206,613 $119,773 $(385)$(937,999)$388,002 
Common Shares
Three Months Ended September 30, 2023
SharesAmountAdditional
paid in
capital		Accumulated
Other
Comprehensive
(Loss) Income		Accumulated
Deficit		Total
Shareholders'
Equity
Balance at June 30, 2023143,369 $1,196,480 $98,832 $(1,020)$(902,000)$392,292 
Shares issued on exercise of stock options and vesting of restricted stock units236 2,080 (929)— — 1,151 
Shared-based compensation— — 11,808 — — 11,808 
Unrealized gain on available-for-sale securities, net— — — 73 — 73 
Net loss— — — — (13,447)(13,447)
Balance at September 30, 2023143,605 $1,198,560 $109,711 $(947)$(915,447)$391,877 

The accompanying notes are an integral part of these condensed consolidated financial statements.
3

AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
(in thousands)
(unaudited)
Common Shares
Nine Months Ended September 30, 2024SharesAmountAdditional
paid in
capital		Accumulated
Other
Comprehensive
(Loss) Income		Accumulated
Deficit		Total
Shareholders'
Equity
Balance at December 31, 2023143,833 $1,200,218 $120,788 $(730)$(942,322)$377,954 
Shares issued on exercise of stock options and vesting of restricted stock units2,548 23,966 (23,320)— — 646 
Shares repurchased and cancelled, inclusive of transaction costs(3,424)(18,619)— — (18,619)
Issuance of common shares in conjunction with ESPP program152 1,048 (345)— — 703 
Share-based compensation— — 22,650 — — 22,650 
Unrealized gain on available-for-sale securities, net— — — 345 — 345 
Net income— — — — 4,323 4,323 
Balance at September 30, 2024143,109 $1,206,613 $119,773 $(385)$(937,999)$388,002 
Common Shares
Nine Months Ended September 30, 2023SharesAmountAdditional
paid in
capital		Accumulated
Other
Comprehensive
(Loss) Income		Accumulated
Deficit		Total
Shareholders'
Equity
Balance at December 31, 2022142,268 $1,185,309 $85,489 $(1,061)$(864,302)$405,435 
Shares issued on exercise of stock options and vesting of restricted stock units1,127 11,141 (8,117)— — 3,024 
Issuance of common shares in conjunction with ESPP program210 2,110 (1,204)— — 906 
Shared-based compensation— — 33,543 — — 33,543 
Unrealized gain on available-for-sale securities, net— — — 114 — 114 
Net loss— — — — (51,145)(51,145)
Balance at September 30, 2023143,605 $1,198,560 $109,711 $(947)$(915,447)$391,877 

The accompanying notes are an integral part of these condensed consolidated financial statements.
4

AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Nine Months Ended September 30,
20242023
(in thousands)(unaudited)
Cash flows from operating activities
Net income (loss)$4,323 $(51,145)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization14,583 6,698 
Net amortization of premiums and discounts on short-term investments(9,752)(8,836)
Share-based compensation expense22,650 33,543 
Foreign exchange on finance lease liability(718)(1,335)
Other, net220 (1,659)
Net changes in operating assets and liabilities
Accounts receivable, net(12,394)(24,463)
Inventories, net991 (8,984)
Prepaid expenses and other current assets(6,001)(2,889)
Non-current operating assets(12)(16)
Accounts payable, accrued and other liabilities934 11,812 
Operating lease liabilities(550)(499)
Net cash provided by (used in) operating activities 14,274 (47,773)
Cash flows from investing activities
Purchase of investments(461,140)(379,213)
Proceeds from investments461,448 391,287 
Upfront lease payment(44)(11,864)
Purchase of property and equipment— (419)
Capitalized patent costs(225)(240)
Net cash provided by (used in) investing activities 39 (449)
Cash flows from financing activities
Repurchase of common shares(18,435)— 
Principal portion of finance lease payments(8,959)(3,482)
Proceeds from exercise of stock options and employee share purchase plan1,348 3,929 
Cash (used in) provided by financing activities (26,046)447 
Net decrease in cash, cash equivalents, and restricted cash(11,733)(47,775)
Cash, cash equivalents, and restricted cash, beginning of period48,875 94,172 
Cash, cash equivalents, and restricted cash, end of period$37,142 $46,397 
Supplemental cash flow information
Cash received for interest$2,803 $3,559 
Cash paid for income taxes$(1,459)$(339)
Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets
Cash, cash equivalents$36,630 $45,557 
Restricted cash512 840 
Total cash, cash equivalents, and restricted cash
$37,142 $46,397 
The accompanying notes are an integral part of these condensed consolidated financial statements.
5


AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
1.Organization and Description of Business
Aurinia Pharmaceuticals Inc. (Aurinia or the Company) is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first U.S. Food and Drug Administration (FDA) approved oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. Aurinia contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for development and commercialization of LUPKYNIS in the European Union (EU), Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine (collectively, the Otsuka Territories).
On February 15, 2024, the Company announced the conclusion of its previously announced strategic review process and actions designed to enhance shareholder value. Aurinia executed a corporate restructuring in the first quarter that reduced employee headcount by approximately 25% and discontinued its AUR300 research and development program. For further discussion, refer to Note 19, Restructuring.
On November 7, 2024, Aurinia announced it was implementing a strategic restructuring to sharpen the Company's focus on continued LUPKYNIS® growth and the rapid development of AUR200. This restructuring will result in a workforce reduction of approximately 45% and Aurinia anticipates a one-time restructuring charge in the fourth quarter of 2024 of approximately $15 to $19 million and will focus the Company’s LUPKYNIS commercial strategy on the highest growth drivers.
The Company is also developing its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). On September 5, 2024, the Company announced the first participant has been dosed in a Phase 1 single ascending dose (SAD) study of AUR200. The SAD study will assess the safety, tolerability, pharmacokinetics, and changes in biomarkers for AUR200 in healthy volunteers, with data expected in the first half of 2025.
Aurinia's head office and registered office is located at #140, 14315-118 Avenue, Edmonton, Alberta, Canada T5L 4S6. Aurinia also has a United States commercial office located at 77 Upper Rock Circle Suite 700, Rockville, Maryland, 20850.
Aurinia is incorporated pursuant to the Business Corporations Act (Alberta). The Company’s common shares are traded on the Nasdaq Global Market (Nasdaq) under the symbol AUPH.
2.Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.
In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of September 30, 2024 was derived from audited annual consolidated financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. The results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the full year or any other future periods.
These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation and operate in one segment.
6


These unaudited condensed consolidated financial statements are presented in U.S. dollars, which is the Company's and all of its foreign subsidiaries' functional currency. Therefore, there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statements of operations. All monetary assets and liabilities denominated in a foreign currency are remeasured into U.S. dollars at the exchange rate on the balance sheet date. Non-monetary assets and liabilities (along with their related expenses) are translated at the rate of exchange in effect on the date the assets were acquired. Monetary income and expense items are translated at the average foreign currency rate. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the consolidated statements of operations and recorded in other expense (income), net.
Significant Accounting Policies
The Company's significant accounting policies have not changed from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, other than as stated below.
Product Revenues
We sell LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor, and semi-finished product directly to our ex-U.S. partner Otsuka. These customers subsequently distribute the Company's products. Revenues from product sales are recognized when the customer obtains control of the Company's product, which occurs upon delivery to the customer.
Reserves for discounts and allowances: Product sales are recorded at the net sales price, which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a liability (if the amount is payable to a party other than the customer).
The Company's estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available.
Significant judgment is required in estimating variable consideration. In making these estimates, the Company considers historical data, including patient mix and inventory sold to customers that has not yet been dispensed to patients. The Company uses a data aggregator and historical claims to estimate variable consideration for inventory sold to its specialty pharmacies that has not yet been dispensed. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment. As of September 30, 2024, the Company did not have any material adjustments to variable consideration estimates based on actual results. These specific adjustments are detailed further in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.
Major Customers: The Company currently has two main specialty pharmacies for U.S. commercial sales of LUPKYNIS and a collaboration partnership with Otsuka for sales of semi-finished product and royalty, collaboration, and manufacturing services revenue in the Otsuka Territories. Revenues from our two main customers represented approximately 49% and 38% of revenues for the nine months ended September 30, 2024. Revenues from our two main customers represented approximately 50% and 39% of revenues for the nine months ended September 30, 2023.
In late March 2022, the Company provided a nominal additional discount to both of its two main U.S. specialty pharmacies, applicable for the 2022 calendar year, in connection with holding additional amounts of LUPKYNIS on hand for risk mitigation and supply chain concerns. In December 2022, the Company extended the nominal discount to the end of 2024. Such discounts, or any future discounts, may result in reduced sales to these customers in subsequent periods and substantial fluctuations in revenues from period to period. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances. Global economic conditions and customer specific factors may require the Company to periodically reevaluate the collectability of its receivables and based on this evaluation the Company could potentially incur credit losses. The Company has had no historical write-offs related to customers or receivables.
Accounts Receivable, net: Accounts receivable are stated at their net realizable value. The Company's accounts receivable primarily represent amounts due to the Company from product sales and from its Otsuka collaboration agreement (Note 12). As
7

of September 30, 2024, and December 31, 2023, accounts receivable, net are $36.5 million and $24.1 million, respectively. The Company's standard credit terms range from 30 to 45 days. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised good to the customer and receipt of payment will be one year or less. The Company estimates the allowances using the current expected credit loss, or CECL, model. Under the CECL model, the allowances reflect the net amount expected to be collected from the accounts receivable. Aurinia evaluates the collectability of these cash flows based on the asset’s amortized cost, the risk of loss even when that risk is remote, losses over an asset’s contractual life, and other relevant information available to the Company. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. Given the nature of the Company's accounts receivable, it determined that an allowance for current expected credit losses was nil as of September 30, 2024, and December 31, 2023.
Share-Based Compensation: The Company follows ASC Topic 718, Compensation - Stock Compensation, which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date using the graded accelerated vesting method for all share-based payments related to stock options, performance awards (PAs), restricted stock units (RSUs) and purchases under the Company's 2021 Employee Share Purchase Plan (ESPP). The estimated fair value of performance-based awards is measured on the grant date and is recognized when it is determined that it is probable that the performance condition will be achieved. The Company has elected a policy for all share-based awards to estimate forfeitures based on historical forfeiture experience at the time of grant and revise in subsequent periods if actual forfeitures differ from those estimates.
Restructuring Expenses: Restructuring expenses consist primarily of employee severance, contract termination costs and other costs. Liabilities for costs associated with a restructuring activity are recognized when the liability is incurred and are measured at fair value. According to ASC 420, Exit or Disposal Cost Obligations, one-time employee severance and termination benefits are expensed at the date the entity notifies the employee of the plan, unless the employee must provide future service, in which case the benefits are expensed in the period when the service ends. One-time termination benefits include severance, continuation of health insurance coverage for certain employees, and other benefits such as outplacement support services for a specified period of time.
Common Shares: The Company’s shares have no par value or stated value and therefore, upon issuance or repurchase of shares, all amounts related to the shares are recorded under common shares on the balance sheet. The value of common shares includes cash amounts paid or received for the shares and the fair value of equity awards and warrants. Amounts for common shares are offset by share issue costs or transactions costs associated with repurchases or equity offerings.
Recent Accounting Pronouncements
In December 2023, the FASB issued final guidance in ASU No. 2023-09, Income Taxes (ASC 740): Improvements to Income Tax Disclosures requiring entities to provide additional information in the rate reconciliation and disclosures about income taxes paid. For public business entities, the guidance is effective for annual periods beginning after December 15, 2024. The Company is not early adopting, and therefore, this ASU is not adopted in the current period. The Company is currently assessing the potential impact this ASU may have on the consolidated financial statements.
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures which requires public entities to disclose significant segment expenses regularly provided to the chief operating decision-maker. Public entities with a single reporting segment have to provide all disclosures required by ASC 280, including the significant segment expense disclosures. For public business entities, the guidance is effective for annual periods beginning after December 15, 2023. This ASU does not have a material impact on the consolidated financial statements.
3.    Fair Value Measurements
The Company's financial instruments consist primarily of cash, cash equivalents, restricted cash, investments, accounts receivable, accounts payable, and accrued liabilities. The carrying value of accounts receivable, accounts payable, and accrued liabilities approximate their fair value because of their short-term nature. Estimated fair value of available-for-sale debt securities are generally based on prices obtained from commercial pricing services.
In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market participants would price assets and liabilities). As a basis for considering such
8

assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:
•Level 1 - Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
•Level 2 - Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
•Level 3 - Unobservable inputs that reflect the reporting entity’s own assumptions.
The following table summarizes the financial assets (cash, cash equivalents, restricted cash, and investments) measured at fair value on a recurring basis:
September 30, 2024
(in thousands)Level 1Level 2Level 3Total
Financial assets:
Cash, cash equivalents, and restricted cash
$37,142 $— $— $37,142 
Corporate bonds— 601 — 601 
Commercial paper— 2,028 — 2,028 
Treasury bills— 196,471 — 196,471 
Treasury bonds— 112,505 — 112,505 
Total financial assets$37,142 $311,605 $— $348,747 
December 31, 2023
(in thousands)Level 1Level 2Level 3Total
Financial assets:
Cash, cash equivalents, and restricted cash
$48,875 $— $— $48,875 
Corporate bonds— 33,781 — 33,781 
Commercial paper— 39,304 — 39,304 
Treasury bills— 122,806 — 122,806 
Treasury bonds— 105,924 — 105,924 
Total financial assets$48,875 $301,815 $— $350,690 
The Company's Level 1 instruments include cash, cash equivalents, and restricted cash that are valued using quoted market prices. Aurinia estimates the fair values of investments in corporate debt securities, government and government related securities and certificates of deposits by taking into consideration valuations obtained from third-party pricing services. The fair value of the Company's investments classified within Level 2 is based upon observable inputs that may include benchmark yield curves, reported trades, issuer spreads, benchmark securities and reference data including market research publications. At September 30, 2024 and December 31, 2023, the weighted average remaining contractual maturities of Aurinia's Level 2 investments were approximately 7 months for both periods. The Company's policy is for these investments to have an overall rating of A-1, or higher, by Standard & Poor's, or an equivalent rating by Moody’s or Fitch.
No credit loss allowance was recorded as of September 30, 2024 and December 31, 2023, as the Company does not believe the unrealized loss is a result of a credit loss due to the nature of the investments. Aurinia also considered the current and expected future economic and market conditions and determined that the estimate of credit losses was not significantly impacted.
Refer to Note 4, Cash, Cash Equivalents, Restricted Cash, and Investments, for the carrying amount and related unrealized gains (losses) by type of investment.
9

4.    Cash, Cash Equivalents, Restricted Cash, and Investments
As of September 30, 2024, and December 31, 2023, the Company had $348.7 million and $350.7 million, respectively of cash, cash equivalents, restricted cash, and investments summarized below. As of September 30, 2024, and December 31, 2023, $311.6 million and $301.8 million were available-for-sale debt securities which are carried at fair market value.
September 30, 2024
(in thousands)Amortized CostUnrealized Gains
Unrealized Losses
Estimated Fair Value
Cash, cash equivalents, and restricted cash
$37,142 $— $— $37,142 
Corporate bonds599 2 — 601 
Commercial paper2,028 — — 2,028 
Treasury bills196,311 160 — 196,471 
Treasury bonds112,246 259 — 112,505 
Total cash, cash equivalents, restricted cash, and short-term investments
348,326 421 — 348,747 
Total long-term investment corporate bond— — — — 
Total cash, cash equivalents, restricted cash, and investments
$348,326 $421 $— $348,747 
December 31, 2023
(in thousands)Amortized CostUnrealized GainsUnrealized LossesEstimated Fair Value
Cash, cash equivalents, and restricted cash
$48,875 $— $— $48,875 
Corporate bonds33,576 4 — 33,580 
Commercial paper39,305 — (1)39,304 
Treasury bills122,757 49 — 122,806 
Treasury bonds105,903 21 — 105,924 
Total cash, cash equivalents, restricted cash, and short-term investments
350,416 74 (1)350,489 
Total long-term investment corporate bond
200 1 — 201 
Total cash, cash equivalents, restricted cash, and investments
$350,616 $75 $(1)$350,690 

As of September 30, 2024, and December 31, 2023, accrued interest receivable from investments was $0.5 million and $0.7 million, respectively. During the three and nine months ended September 30, 2024, the Company had $0.5 million and $0.3 million of unrealized gains on available-for-sale securities, net of tax, respectively, which are included as a component of comprehensive income (loss) on the consolidated statements of operations. During the three and nine months ended September 30, 2023, the Company had $0.1 million and $0.1 million of unrealized gains on available-for-sale securities, net of tax, respectively, which are included as a component of comprehensive income (loss) on the consolidated statements of operations. Currently, the Company does not intend to sell investments that are in an unrealized loss position, and it is unlikely the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. The Company has determined that the gross unrealized gains on investments at September 30, 2024, were temporary in nature. Realized gains or losses were immaterial during the three and nine months ended September 30, 2024, and 2023.

The Company's short-term investments as of September 30, 2024 mature at various dates through August 2025.

5.    Inventories, net

Inventories are valued under a standard costing methodology on a first-in, first-out basis and are stated at the lower of cost or net realizable value. The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of
10

regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. Capitalized costs of inventories for LUPKYNIS (voclosporin) mainly include third party manufacturing costs, transportation, storage, insurance, and allocated internal labor. Due to the nature of the Company's supply chain process, inventory that is owned by the Company, is physically stored at third-party warehouses, logistics providers, and contract manufacturers.

The Company assesses recoverability of inventory each reporting period to determine if any write-down to net realizable value is necessary. As of September 30, 2024, and December 31, 2023, Aurinia recorded reserves of finished goods inventories of nil and $0.8 million, respectively, which were primarily related to potential inventory obsolescence.

The components of inventory, net are as follows:
(in thousands)September 30, 2024December 31, 2023
Raw materials$1,702 $1,746 
Work in process34,990 37,376 
Finished goods, net of reserve2,022 583 
Total inventories, net$38,714 $39,705 


6.Prepaid Expenses and Deposits
Prepaid expenses are as follows:

(in thousands)September 30, 2024December 31, 2023
Prepaid assets$7,730 $6,892 
Prepaid deposits4,189 1,345 
Prepaid insurance1,896 1,249 
Total prepaid expenses and deposits
$13,815 $9,486 


7.Intangible Assets
The following table summarizes the carrying amount of intangible assets, net of accumulated amortization.
September 30, 2024
(in thousands)Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents$2,073 $(1,354)$719 
Acquired intellectual property and reacquired rights15,126 (11,336)3,790 
Internal-use software implementation costs2,873 (2,873)— 
$20,072 $(15,563)$4,509 
December 31, 2023
(in thousands)Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents$1,847 $(1,297)$550 
Acquired intellectual property and reacquired rights15,126 (10,737)4,389 
Internal-use software implementation costs2,873 (2,835)38 
$19,846 $(14,869)$4,977 
11

Amortization expense for the three months ended September 30, 2024, and 2023, was approximately $0.2 million and $0.5 million, respectively. Amortization for the nine months ended September 30, 2024, and 2023, was approximately $0.7 million and $1.4 million, respectively.
8.    Property and Equipment, net
Property and equipment, net are as follows:
(in thousands)September 30, 2024December 31, 2023
Leasehold improvements$3,243 $3,243 
Office equipment631 631 
Furniture1,155 1,155 
Computer equipment235 235 
5,2645,264
Less accumulated depreciation(2,377)(1,910)
Property and equipment, net$2,887 $3,354 
9.    Lease Obligations
The Company has the following lease obligations:
Rockville, Maryland
During March 2020, the Company entered into a lease for its U.S. commercial office in Rockville, Maryland for a total of 30,531 square feet of office space. The lease has a remaining term of approximately seven years and has an option to extend for two five-year periods after the initial term of 11 years has elapsed and has an option to terminate after seven years. As of September 30, 2024, the Company had a right-of-use (ROU) asset of $4.1 million and lease liability of $6.8 million included in the condensed consolidated balance sheets. As of December 31, 2023, the Company had a right-of-use asset of $4.5 million and lease liability of $7.4 million included in the condensed consolidated balance sheets. The Company recorded leasehold improvement incentives in the amount of $2.3 million as additions to the lease liability.
When measuring the lease liability, the Company discounted lease payments using its incremental borrowing rate at the lease commencement date on March 12, 2020. The incremental borrowing rate applied to the lease liability was 5.2% based on the financial position of the Company, geographical region and term of lease.
Edmonton, Alberta
During October 2022, the Company entered into a long term lease in Edmonton for a total of 4,375 square feet of office space. The lease is a six year lease and has an option to renew after five years at prevailing market rates. The lease commenced on November 1, 2022 and the Company recorded the lease as an operating lease. The lease is not material to the Company's financial position.
For all leases, the Company incurs variable lease costs. These costs include operation and maintenance costs included in SG&A and are expensed as incurred. The variable lease costs are not material to the Company's financial position.
The operating lease costs for all leases for the three and nine months ended September 30, 2024, and September 30, 2023, were $0.2 million and $0.6 million, respectively.
12

Monoplant
At lease inception, the Company recorded an ROU asset of approximately $117.6 million and a corresponding lease liability of $94.1 million, which is the present value of the minimum lease payments beginning July 2023 and expiring in 2030. The incremental borrowing rate applied to value the lease liability at inception is 6.19%, which was based on the financial position of the Company, geographical region and term of lease. As the monoplant finance lease is denominated in Swiss francs, the company incurs unrealized and realized foreign exchange gains and losses each reporting period related to the valuation of the lease liability and timing of lease payments.

As of September 30, 2024, the ROU asset, net and corresponding lease liability balance were $95.6 million and $80.7 million, respectively. As of December 31, 2023, the ROU asset, net and corresponding lease liability balance were $108.7 million and $90.1 million, respectively. For the three and nine months ended September 30, 2024, ROU amortization was $4.4 million and $13.1 million, respectively. For the three and nine months ended September 30, 2024, interest expense was $1.2 million and $3.7 million, respectively.
Beinheim
The Company entered into an equipment and facility finance lease for a backup manufacturing encapsulation site in Beinheim, France that commenced operations during June 2024 with a lease term of seven years. The incremental borrowing rate applied to value the lease liability at inception is 6.19%, which was based on the financial position of the Company, geographical region and term of lease.
As of September 30, 2024, the ROU asset, net and corresponding lease liability balance were $0.8 million and $0.1 million, respectively.
The following table represents the weighted-average remaining lease terms and discount rates as of September 30, 2024:
As of September 30, 2024
Weighted Average Remaining Lease Term (years)Weighted Average Discount Rate
Operating leases6.95.27%
Finance lease
5.56.19%
Supplemental cash flow information related to leases are as follows:
Nine Months Ended
September 30,
20242023
(in thousands)
Cash paid for amounts included in the measurement of lease liabilities
Financing cash flows for finance leases
$(8,959)$(3,482)
Operating cash flows for finance leases
$(3,354)$(718)
Operating cash flows for operating leases
$(831)$(805)
Supplemental disclosure of noncash transactions
Finance right-of-use asset obtained in exchange for lease obligations
$96,459 $113,069 
Finance lease liability arising from obtaining right-of-use assets
$80,882 $85,521 
13

Future maturities of lease liabilities as of September 30, 2024 are as follows:
(in thousands)Finance Lease PaymentsOperating Lease Payments
Remainder of 2024$4,295 $283 
202517,203 1,141 
202617,204 1,169 
202717,204 1,198 
202817,205 1,227 
Thereafter21,554 3,302 
Total lease payments
94,665 8,320 
Less: imputed interest
(13,783)(1,351)
Total
$80,882 $6,969 

10.Accounts Payable and Accrued Liabilities
Accounts payable and accrued liabilities are as follows:
(in thousands)September 30, 2024December 31, 2023
Commercial accruals
$25,523 $16,216 
Employee accruals
14,180 22,486 
Trade payables
8,878 4,327 
Other accrued liabilities
4,672 5,190 
Accrued R&D projects
2,331 5,503 
Income taxes payable
1,007 667 
Restructuring accruals
179 — 
Total accounts payable and accrued liabilities$56,770 $54,389 

11.Deferred Compensation and Other Non-current Liabilities

The Company recorded other non-current liabilities of $10.8 million and $10.9 million as of September 30, 2024, and December 31, 2023, respectively. The balance for both periods primarily included deferred compensation arrangements whereby certain former executive officers as of March 8, 2012 were provided with future potential employee benefit obligations for remaining with the Company for a certain period of time. These obligations were also contingent on the occurrence of uncertain future events. One of the former officers, Dr. Robert T. Foster, is considered a related party following his appointment to the Board of Directors (the Board) on September 21, 2023. For further discussion, refer to Note 17, Related Party Transactions.
12.License and Collaboration Agreements
Otsuka Contract

On December 17, 2020, the Company entered into a collaboration and license agreement with Otsuka for the development and commercialization of oral LUPKYNIS in the Otsuka Territories. For full description of the agreements the Company has entered into with Otsuka, please refer to the Annual Report on Form 10-K for the year ended December 31, 2023.

As part of the agreement, the Company received an upfront cash payment of $50.0 million in 2020 for the license agreement and has received $50.0 million in regulatory and pricing approval related milestones. The Company provides semi-finished product of LUPKYNIS to Otsuka on a cost-plus basis, sharing capacity of the monoplant and receives tiered royalties ranging from 10 to 20 percent (dependent on territory and achievement of sale thresholds) on net product sales by Otsuka, along with
14

additional milestone payments based on the attainment of certain annual sales. In addition, certain collaboration services are to be provided to Otsuka on agreed upon rates.
On September 24, 2024, the Company announced that the Japanese Ministry of Health, Labour, and Welfare has approved LUPKYNIS, a second-generation calcineurin inhibitor, in combination with mycophenolate mofetil (MMF) to treat LN. As part of the December 2020 agreement with Otsuka, the Company is eligible to receive a payment of $10.0 million U.S. dollars upon approval in Japan along with low double-digit royalties on net sales once launched. As a result, the $10.0 million milestone was recognized as collaboration revenue in the quarter.
For the three and nine months ended September 30, 2024, the Company recognized $12.3 million and $16.7 million, respectively of license, collaboration, and royalty revenue from services provided under the Otsuka agreement. For the three and nine months ended September 30, 2023, the Company recognized $12.7 million and $13.2 million, respectively.

13.    Shareholder's Equity

On February 15, 2024, Aurinia announced that the Board had approved a share repurchase program of up to $150 million common shares of the Company, affirming its confidence in the Company's growth prospects.

On February 29, 2024, Canadian securities regulators granted exemptive relief for the Company’s share repurchase program, authorizing the Company to purchase up to 15 percent of its issued and outstanding shares in any 12-month period for up to 36 months, including under the current program. This program may be implemented through open market or privately negotiated purchases, including under a plan intended to comply with the affirmative defense under Rule 10b5-1, Rule 10b-18 or an automatic securities purchase plan, an accelerated share repurchase program, or other mechanisms. The timing and amount of repurchase transactions will be determined by management based on its evaluation of market conditions, share price, legal requirements, including applicable blackout period restrictions, and other factors. The purchase price of any Common Shares will be determined in accordance with applicable U.S. securities laws.
As of September 30, 2024, the Company had repurchased approximately 3.4 million of Aurinia's common shares for $18.6 million (including transaction costs, which consist of commissions and excise tax). The cost of repurchased shares are reported as a reduction in common shares and under Alberta law, the shares were cancelled and not reissued.
14.Net Income (Loss) per Common Share
Basic and diluted net loss per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding. For the periods in a loss position, diluted net loss per share is the same as basic net loss per share. The treasury stock method is used to determine the dilutive effect of the Company's stock options, RSUs, performance awards and ESPP. The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:
Three Months Ended
 September 30,
Nine Months Ended
September 30,
(in thousands, except per share data)2024202320242023
Numerator:
Net income (loss) used for the calculation of basic and diluted EPS
$14,350 $(13,447)$4,323 $(51,145)
Denominator:
Weighted-average common shares outstanding, basic
143,051 142,847 143,353 143,085 
Effect of dilutive shares:
Stock options, RSUs, performance awards and ESPP
2,600 — 1,657 — 
Weighted-average diluted common shares outstanding, diluted
145,651 142,847 145,010 143,085 
Net income (loss) per share, basic
$0.10 $(0.09)0.03 (0.36)
Net income (loss) per share, diluted
$0.10 $(0.09)$0.03 $(0.36)
15

The Company did not include certain shares issuable under share-based compensation plans because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.

15.Share-based Compensation
The Company's Amended and Restated Equity Incentive Plan (the Plan), which was adopted and approved by the Company's shareholders in June 2021, allows for an issuance of up to an aggregate of 23.8 million shares (inclusive of then outstanding awards) and provides for grants of stock options, performance awards (PAs), and restricted stock units (RSUs) that may be settled in cash and common shares. Also in June 2021, the Company's shareholders adopted and approved the Company's Employee Stock Purchase Plan (2021 ESPP), which allows for the issuance of up to 2.5 million shares. The 2021 ESPP is intended to qualify as an “employee stock purchase plan” under Section 423 of the Internal Revenue Code but also permits the Company to include the employees, including non-United States employees, in offerings not intended to qualify under Section 423. The purpose of the 2021 ESPP is to provide eligible employees with opportunities to purchase the Company’s common shares at a discounted price. As of September 30, 2024, 0.9 million shares have been purchased under the ESPP.
In addition to stock options, PAs and RSUs granted under the Plan, the Company has granted certain stock options and RSUs as inducements material to new employees entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The inducements were granted outside of the Plan.
Stock Options
The Plan requires the exercise price of each option not to be less than the closing market price of the Company’s common shares on the business day immediately prior to the date of grant. The Board approves the vesting criteria and periods at its discretion. The options issued under the Plan are accounted for as equity-settled share-based payments.
The Company used the Black-Scholes option pricing model to estimate the fair value of the options granted. The assumptions used for the annual volatility and expected life of the options are reviewed and updated annually. The Company considers historical volatility of its common shares in estimating its future stock price volatility. The risk-free interest rate for the expected life of the options was based on the yield available on government benchmark bonds with an approximate equivalent
16

remaining term at the time of the grant. The expected life is based upon the contractual term, taking into account expected employee exercise and expected post-vesting employment termination behavior.
The following weighted average assumptions were used to estimate the fair value of the options granted during the nine months ended September 30, 2024, and September 30, 2023:
20242023
Annualized volatility77 %71 %
Risk-free interest rate4.08 %3.92 %
Expected life of options in years5.0 years5.0 years
Estimated forfeiture rate13.0 %12.7 %
Dividend rate0.0 %0.0%
Fair value per common share option$3.82 $5.94 
The following table summarizes the option award activity for the nine months ended September 30, 2024:

September 30, 2024
Number of shares (in thousands)Weighted average exercise price $
Outstanding - December 31, 2023
11,556 $10.63 
Granted325 5.89 
Exercised(125)5.18 
Forfeited or cancelled
(2,006)12.81 
Outstanding - September 30, 2024
9,750 $10.09 
Restricted Stock Units and Performance Awards
The Company has granted RSUs and PAs under the Plan, as well as inducements for certain new hires as discussed above. The RSUs and PAs are fair valued based on the previous business days' market price of common shares on the date of the grant.
The following table summarizes the RSU and PA activity for the nine months ended September 30, 2024:
September 30, 2024
Number of shares (in thousands)Weighted average fair value price $
Unvested balance, December 31, 2023
7,807 $9.29 
Granted4,663 6.89 
Vested(2,422)9.50 
Forfeited(1,673)8.99 
Unvested balance - September 30, 2024
8,375 $7.96 
17

Share-based Compensation Expense
The Company recognized share-based compensation expense for the three and nine months ended September 30, 2024, and September 30, 2023, as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands)2024202320242023
Research and development$306 $1,975 $(1,773)$5,679 
Selling, general and administrative7,812 9,560 23,427 26,969 
Capitalized under inventories209 273 996 895 
Share-based compensation expense$8,327 $11,808 $22,650 $33,543 
As of September 30, 2024, there was $25.7 million of unrecognized share-based compensation expense related to unvested awards granted which is expected to be recognized over a weighted-average period of approximately 1.3 years.

16.Income Taxes

The effective tax rates for the three and nine months ended September 30, 2024, and September 30, 2023, differed from the Canadian statutory rate applied to income or losses before income taxes primarily as a result of the mix of income, losses and valuation allowances.

The Company recognized an income tax expense of approximately $0.5 million and $2.0 million for the three and nine months ended September 30, 2024, respectively. The Company recognized an income tax expense of approximately $0.3 million and $0.1 million for the three and nine months ended September 30, 2023, respectively. The income tax expense recognized for these periods is a result of income in certain jurisdictions. This tax expense is not offset by a tax benefit as the Company has losses which are fully offset by a valuation allowance in its significant jurisdictions.
17.Related Party Transactions
On September 21, 2023, the Company appointed Dr. Robert T. Foster to the Board. Dr. Foster is considered a related party since he is one of the former executive officers of the Company who, as of March 8, 2012 was provided with future potential employee benefit obligations for remaining with the Company for a certain period of time. These obligations are contingent on the occurrence of uncertain future events. Dr. Foster was not a related party of the Company between his resignation from the Company in 2014, and his appointment to the Board on September 21, 2023. As of September 30, 2024, the Company had $0.8 million and $7.0 million of current and non-current liabilities related to Dr. Foster, respectively. As of December 31, 2023, the Company had $0.8 million and $7.6 million of current and non-current liabilities related to Dr. Foster, respectively. As of September 30, 2024, and December 31, 2023, the Company made payments of $0.4 million and $0.1 million, respectively for each period as a related party for the deferred compensation.
18.Commitments and Contingencies
The Company may, from time to time, be subject to claims and legal proceedings brought against it in the normal course of business. Such matters are subject to many uncertainties. Management believes the ultimate resolution of such contingencies will not have a material adverse effect on the consolidated financial position of the Company. Other than as described under Part II, Item I, the Company's material commitments and contingencies have not changed in any material manner from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.
Other Funding Commitments
In the normal course of business, the Company enters into agreements with contract research organizations, contract manufacturing organizations and other third parties for services to be provided to the Company. Generally, these agreements provide for termination upon notice, with specified amounts due upon termination based on the timing of termination and the terms of the agreement. The actual amounts and timing of payments under these agreements are uncertain and contingent upon the initiation and completion of services to be provided to the Company.
18

19.Restructuring
On February 15, 2024, the Company announced the conclusion of its strategic review process and actions designed to enhance shareholder value. Aurinia executed a corporate restructuring in the first quarter that reduced employee headcount by approximately 25%. The Company discontinued its AUR300 research and development program.
As of September 30, 2024, the restructuring expenses are included within operating expenses on the condensed consolidated statements of operations and comprehensive income (loss). For the three and nine months ended September 30, 2024, restructuring expenses were nil and $7.8 million, respectively. Restructuring expenses consisted of the following:
(in thousands)
Nine Months Ended September 30, 2024
Employee severance and one time benefits
$6,075 
Contract terminations
1,105 
Other costs
575 
Total
$7,755 

20.Subsequent Events
Effective November 7, 2024, Aurinia appointed Craig Johnson to the Board. Mr. Johnson has more than 30 years of experience serving in senior financial management roles and governing companies in the biotechnology industry.
The Company also announced that Dr. Robert T. Foster has retired from the Board effective November 5, 2024.
19

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q. The information in this discussion contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended, (the Exchange Act), which are subject to the “safe harbor” created by those sections, as well as “forward-looking information” as defined in applicable Canadian securities laws. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. These forward-looking statements include, but are not limited to, statements concerning our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans; objectives of management; the key potential benefits of LUPKYNIS; our anticipation of a one-time restructuring charge in the fourth quarter of 2024 of $15 to $19 million, with post‑restructuring annualized cash-based operating expense savings of more than $40 million; our estimate that we will reduce our workforce by approximately 45%; our expectation that our restructuring will further improve operational efficiency; our estimate, based on our patient-specific estimated glomerular filtration rate (eGFR) dosing regimens, the average utilization in our clinical trials, and accounting for factors including mandatory rebates, channel discounts, and anticipated patient adherence, that we expect our average annualized net realizable revenue per patient to be approximately $70,000 to $75,000; timing for data the AUR200 SAD study; our belief that we have sufficient financial resources to fund our current plans for at least the next few years; and our potential to receive certain payments and royalties under our agreement with Otsuka Pharmaceuticals Co. Ltd., or Otsuka. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “predict,” “propose,” “intend,” “continue,” “potential,” “possible,” “foreseeable,” “likely,” “unforeseen” and similar expressions intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance, time frames or achievements to be materially different from any future results, performance, time frames or achievements expressed or implied by the forward-looking statements. We have made numerous assumptions about the forward-looking statements and information contained herein, including among other things, assumptions about: the accuracy of reported data from third-party studies and reports; that our IP rights are valid and do not infringe the IP rights of third parties; our assumptions relating to the capital required to fund operations for the next few years; the timing and ability to execute on our restructuring plans; the costs, benefits and scope of our restructuring plans; the assumption that our current good relationships with our suppliers, service providers and other third parties will be maintained; assumptions relating to the burn rate of our cash for operations; assumptions relating to the capital required to fund operations for the next few years; assumptions relating to the progress of our pre-clinical activities that our third party service providers will comply with their contractual obligations. Even though management believes that the assumptions made, and the expectations represented by such statements or information are reasonable, there can be no assurance that the forward-looking information will prove to be accurate. We discuss many of these risks, uncertainties and other factors in greater detail under the heading “Risk Factors” in Part I, Item 1A of our 2023 Annual Report on Form 10-K, as filed with the U.S. Securities and Exchange Commission on February 15, 2024 and with applicable Canadian securities regulatory authorities. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this filing. You should read this discussion completely and with the understanding that our actual future results may be materially different from what we expect. We hereby qualify our forward-looking statements by our cautionary statements. Except as required by law, we assume no obligation to update our forward-looking statements publicly, or to update the reasons that actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
Overview
Aurinia is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, we introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active LN. We continue to conduct clinical and regulatory activities to support the LUPKYNIS development program. We contracted with Otsuka as a collaboration partner for the development and commercialization of LUPKYNIS in the Otsuka Territories.
The price of LUPKYNIS is based on one unit of 60 capsules we refer to as a “wallet”. As of January 1, 2024, the wholesale acquisition cost (WAC) of a LUPKYNIS wallet is $4,898. Based on our patient-specific eGFR dosing regimens, the average utilization in our clinical trials, and accounting for factors including mandatory rebates, channel discounts, and anticipated patient adherence, duration of therapy and compliance, we have adjusted our expected average annualized net realizable revenue per patient to be approximately $70,000 - $75,000. When determining the price of LUPKYNIS, we considered the burden of LN disease in the context of value that LUPKYNIS offers to patients and the U.S. healthcare system.
20

On February 15, 2024, the Company announced the conclusion of its previously announced strategic review process and actions designed to enhance shareholder value. Aurinia executed a corporate restructuring in the first quarter that reduced employee headcount by approximately 25% and discontinued its AUR300 research and development program. For further discussion, refer to Note 19, Restructuring.
On November 7, 2024, Aurinia announced it was implementing a strategic restructuring to sharpen the Company's focus on continued LUPKYNIS® growth and the rapid development of AUR200. The restructuring will result in a workforce reduction of approximately 45% and Aurinia anticipates a one-time restructuring charge in the fourth quarter of 2024 of approximately $15 to $19 million and will focus the Company’s LUPKYNIS commercial strategy on the highest growth drivers. The restructuring will also improve operational efficiency, with anticipated post-restructuring annualized cash savings of more than $40 million.
The Company is also developing its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand).
Recent Developments
On September 5, 2024, the Company announced the first participant has been dosed in a Phase 1 SAD study of AUR200, a differentiated, potential best-in-class therapy for autoimmune diseases that targets both BAFF and APRIL. The SAD study will assess the safety, tolerability, pharmacokinetics, and changes in biomarkers for AUR200 in healthy volunteers, with data expected in the first half of 2025.
On September 24, 2024, the Company announced that the Japanese Ministry of Health, Labour, and Welfare has approved LUPKYNIS in combination with mycophenolate mofetil (MMF) to treat LN. As part of the December 2020 agreement with Otsuka, the Company is eligible to receive a payment of $10.0 million U.S. dollars upon approval in Japan along with low double-digit royalties on net sales once launched. As a result, the $10.0 million milestone was recognized as collaboration revenue in the quarter.
In September 2024, the Board appointed Kevin Tang, President of Tang Capital Management, LLC, a life sciences-focused investment company that he founded in 2002, as a Director and Chair of the Board. Mr. Tang has more than 20 years of experience investing in, governing and leading companies in the biopharmaceutical industry. The Company also announced the acceptance of the conditional resignations of three directors who received less than majority support at the 2024 Annual General Meeting.
Effective November 7, 2024, Aurinia appointed Craig Johnson to the Board. Mr. Johnson has more than 30 years of experience serving in senior financial management roles and governing companies in the biotechnology industry.
The Company also announced that Dr. Robert T. Foster has retired from the Board effective November 5, 2024.
Policies and Significant Judgments and Estimates
There have been no material changes to our critical accounting policies and significant judgments and estimates as described in our Annual Report on Form 10-K for the year ended December 31, 2023 other than as stated below.
Product Revenues
We sell LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor and semi-finished product directly to our ex-U.S. partner Otsuka. These customers subsequently distribute our products. Revenues from product sales are recognized when the customer obtains control of our product, which occurs upon delivery to the customer.
Reserves for discounts and allowances: Product sales are recorded at the net sales price, which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer).
Our estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of
21

the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available.
Significant judgment is required in estimating variable consideration. In making these estimates, we consider historical data, including patient mix to accrue for variable consideration related to inventory sold to our customers that has not yet been dispensed to patients. We use a data aggregator and historical claims to estimate variable consideration for inventory sold to our specialty pharmacies that has not yet been dispensed. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment. As of September 30, 2024, we did not have any material adjustments to variable consideration estimates based on actual results. These specific adjustments are detailed further in our Annual Report on Form 10-K for the year ended December 31, 2023.
Results of Operations
Three and Nine Months ended September 30, 2024 compared to Three and Nine Months ended September 30, 2023
The following table sets forth our results of operations for the three and nine months ended September 30, 2024 and September 30, 2023.
Three Months Ended September 30,
Nine Months Ended September 30,
(in thousands)20242023Change20242023Change
Revenue
Product revenue, net$55,503 $40,781 $14,722 $158,604 $116,218 $42,386 
License, collaboration, and royalty revenue
12,268 13,734 (1,466)16,662 14,200 2,462 
Total revenue, net67,771 54,515 13,256 175,266 130,418 44,848 
Operating expenses
Cost of sales6,035 6,769 (734)22,696 8,753 13,943 
Selling, general and administrative42,367 47,759 (5,392)134,996 144,964 (9,968)
Research and development3,047 13,605 (10,558)12,678 39,413 (26,735)
Restructuring expenses— — — 7,755 — 7,755 
Other expense (income), net4,574 2,645 1,929 159 (695)854 
Total cost of sales and operating expenses56,023 70,778 (14,755)178,284 192,435 (14,151)
Income (Loss) from operations11,748 (16,263)28,011 (3,018)(62,017)58,999 
Interest expense(1,208)(1,400)192 (3,689)(1,465)(2,224)
Interest income4,267 4,514 (247)12,982 12,429 553 
Net income (loss) before income taxes14,807 (13,149)27,956 6,275 (51,053)57,328 
Income tax expense457 298 159 1,952 92 1,860 
Net income (loss)$14,350 $(13,447)$27,797 $4,323 $(51,145)$55,468 
22

Total Revenue, Net
Total net revenue was $67.8 million and $54.5 million for the three months ended September 30, 2024, and September 30, 2023, respectively. Total net revenue was $175.3 million and $130.4 million for the nine months ended September 30, 2024, and September 30, 2023, respectively.
We currently sell to two main specialty pharmacies for U.S. commercial sales of LUPKYNIS and a collaboration partnership with Otsuka for sales of semi-finished product and license, collaboration, and royalty revenue in the Otsuka Territories.
The percentage of total net revenues from our main customers were as follows:
Three Months Ended September 30,
Nine Months Ended September 30,
2024202320242023
Two main specialty pharmacies
81%77%87%90%
Collaboration partnership
16%21%11%9%
Product Revenue, Net
Net product revenue was $55.5 million and $40.8 million for the three months ended September 30, 2024, and September 30, 2023, respectively. Net product revenue was $158.6 million and $116.2 million for the nine months ended September 30, 2024, and September 30, 2023, respectively. The increase in both periods is primarily due to increased LUPKYNIS sales to our two main specialty pharmacies, driven predominantly by further penetration of the LN market. Additionally, for the nine months ended September 30, 2024, we had sales of semi-finished product to Otsuka as Otsuka continues to commercialize in its territories.
The U.S. penetration can be demonstrated by a total of approximately 2,422 patients on therapy as of September 30, 2024, compared to approximately 1,939 patients on therapy as of September 30, 2023. Additionally, our 12-month persistency rate has increased to 57% at September 30, 2024, from approximately 54% at September 30, 2023.
License, Collaboration, and Royalty Revenues
License, collaboration, and royalty revenues were $12.3 million and $13.7 million for the three months ended September 30, 2024, and September 30, 2023, respectively. License, collaboration, and royalty revenues were $16.7 million and $14.2 million for the nine months ended September 30, 2024, and September 30, 2023, respectively. The revenue is primarily due to a $10.0 million milestone recognized in third quarter of 2024 for the Japanese Ministry of Health, Labour, and Welfare approval of LUPKYNIS and a $10.0 million milestone recognized in third quarter of 2023 for pricing and reimbursement approval in certain European jurisdictions, coupled with manufacturing services revenue from Otsuka related to shared capacity services that commenced in late June 2023.
Cost of Sales
Cost of sales was $6.0 million and $6.8 million for the three months ended September 30, 2024, and September 30, 2023, respectively. Cost of sales was $22.7 million and $8.8 million for the nine months ended September 30, 2024, and September 30, 2023, respectively. The decrease for the three months ended September 30, 2024, is primarily due to inventory write downs and semi-finished product sales to Otsuka in the prior three months ended September 30, 2023. The increase for
23

the nine months ended September 30, 2024, is primarily due to the amortization of the monoplant finance right of use asset, which was placed into service in late June 2023 and therefore only partially impacted prior year results.
Gross Margin
Gross margin for the three months ended September 30, 2024, and September 30, 2023, was approximately 91% and 88%, respectively. Gross margin for the nine months ended September 30, 2024, and September 30, 2023, was approximately 87% and 93%, respectively.
Selling, General and Administrative Expenses
SG&A expenses decreased to $42.4 million for the three months ended September 30, 2024, compared to $47.8 million for the three months ended September 30, 2023. For the nine months ended September 30, 2024, and September 30, 2023, SG&A expenses were $135.0 million and $145.0 million, respectively. SG&A expenses consisted of the following:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands)2024202320242023
Salaries, incentive pay and employee benefits$17,563 $19,563 $57,493 $61,851 
Professional fees and services11,982 12,716 38,727 37,202 
Share-based compensation expense7,812 9,560 23,427 26,969 
Other public company costs, facility costs, insurance, information technology, amortization of property and equipment2,728 3,284 8,225 10,546 
Travel, trade shows and sponsorships2,282 2,636 7,124 8,396 
$42,367 $47,759 $134,996 $144,964 
The primary drivers for the decrease in both periods were lower employee related costs including share-based compensation and overhead costs due to the reduction in general and administrative headcount, which occurred late in the first quarter of 2024.
Research and Development Expenses
R&D expenses were $3.0 million and $13.6 million for the three months ended September 30, 2024, and September 30, 2023, respectively. For the nine months ended September 30, 2024, and September 30, 2023, R&D expenses were $12.7 million and $39.4 million, respectively. R&D expenses consisted of the following:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands)2024202320242023
Contract research organizations (CRO) and developmental expenses$1,380 $5,751 $6,486 $14,046 
Clinical supply and distribution354 2,208 2,353 8,355 
Salaries, incentive pay and employee benefits900 3,619 5,240 10,879 
Share-based compensation expense306 1,975 (1,773)5,679 
Other costs107 52 372 454 
$3,047 $13,605 $12,678 $39,413 

The primary drivers for the decrease in both periods were lower employee costs related to the reduction in headcount, which occurred late in the first quarter of 2024, a decrease of expenses related to ceasing our AUR300 development program, and lower expenses related to developing AUR200.
24

Restructuring Expenses
During the three and nine months ended September 30, 2024, restructuring expenses were approximately nil and $7.8 million and nil for the three and nine months ended September 30, 2023. Restructuring expenses primarily included employee severance, one-time benefit payments, and contract termination expenses related to the restructuring, which occurred late in the first quarter of 2024.
Other Expense (Income), net

Other expense (income), net was $4.6 million and $2.6 million for the three months ended September 30, 2024, and September 30, 2023, respectively. Other expense (income), net was $0.2 million and $(0.7) million for the nine months ended September 30, 2024, and September 30, 2023, respectively. The change is primarily driven by changes in the fair value assumptions related to our deferred compensation liability and the foreign exchange remeasurement of the monoplant lease liability, which commenced in June 2023 and is denominated in CHF.

Interest Expense
Interest expense was $1.2 million and $1.4 million for the three months ended September 30, 2024, and September 30, 2023, respectively. Interest expense was $3.7 million and $1.5 million for the nine months ended September 30, 2024, and September 30, 2023, respectively. The interest expense is due to the monoplant finance lease, which commenced in June 2023.

Interest Income

Interest income was $4.3 million and $4.5 million for the three months ended September 30, 2024, and September 30, 2023, respectively. Interest income was $13.0 million and $12.4 million for the nine months ended September 30, 2024, and September 30, 2023, respectively.
Liquidity and Capital Resources
As of September 30, 2024, we had cash, cash equivalents, and restricted cash of approximately $37.1 million and investments of $311.6 million compared to cash, cash equivalents, and restricted cash of $48.9 million and investments of $301.8 million at December 31, 2023. Cash needs were primarily related to the continued investment in LUPKYNIS commercialization activities, post approval commitments for LUPKYNIS, monoplant payments, share repurchases and restructuring related payments and were partially offset by an increase in cash receipts from sales of LUPKYNIS and cash payments from Otsuka. Cash, cash equivalents, restricted cash, and investments are primarily held in U.S. dollars. As of September 30, 2024, and December 31, 2023, we had working capital of $361.9 million and $347.6 million, respectively.
We are devoting the majority of our operational efforts and financial resources towards the commercialization and post- approval commitments for LUPKYNIS. Taking into consideration the cash, cash equivalents, and investments as of September 30, 2024, we believe that our cash position is sufficient to fund our current plans which include funding commercial activities, such as our FDA related post approval commitments, manufacturing and packaging commercial drug supply, funding our supporting commercial infrastructure, advancement of our pipeline, funding our working capital obligations and share repurchases for at least the next few years.

25

Cash Flow Summary
The following table summarizes our cash flows for the nine months ended September 30, 2024, and September 30, 2023:
Nine Months Ended September 30,
(in thousands)20242023
Net cash (used in) provided by:
Operating activities$14,274 $(47,773)
Investing activities39 (449)
Financing activities(26,046)447 
Net decrease in cash and cash equivalents
$(11,733)$(47,775)

Net cash provided by operating activities was $14.3 million for the nine months ended September 30, 2024, compared to net cash used in operating activities of $47.8 million for the nine months ended September 30, 2023. The increase in net cash provided by operating activities is primarily due to an increase in cash receipts from sales of LUPKYNIS and cash receipts from Otsuka, coupled with a reduction in operating expenses year over year, as a result of the restructuring in the first quarter of 2024. See "Total Revenue" above for further discussion regarding our increased sales of LUPKYNIS.
Cash provided by investing activities was $39 thousand during the nine months ended September 30, 2024, compared to net cash used of $0.4 million during the nine months ended September 30, 2023. The increase in cash provided by investing activities was primarily related to the timing of purchases and proceeds of investments and an upfront capital expenditure payment for the monoplant in 2023.
Cash used in financing activities was $26.0 million during the nine months ended September 30, 2024, compared to cash provided by financing activities of $0.4 million during the nine months ended September 30, 2023. The decrease was primarily due to share repurchases, which began in February 2024, and quarterly lease payments for our monoplant finance lease, which commenced during the third quarter of 2023.
Share Repurchase Program
In February 2024, the Board approved a share repurchase program of up to $150 million of our common shares. On February 29, 2024, Canadian securities regulators granted exemptive relief for the Company’s share repurchase program, authorizing the Company to purchase up to 15 percent of its issued and outstanding shares in any 12-month period for up to 36 months, including under the current program.
As of September 30, 2024, we had repurchased approximately 3.4 million of our common shares for $18.6 million (including transaction costs which consist of commissions and excise tax). The cost of repurchased shares are reported as a reduction in common shares and under Alberta law, the shares were cancelled and not reissued.
Off‑Balance Sheet Arrangements
During the periods presented, we did not have, nor do we currently have, any off‑balance sheet arrangements as such term is defined in Item 303(a)(4)(ii) of Regulation S-K under the Securities Act.
Contractual Obligations
There have been no material changes outside the ordinary course of business to our contractual obligations and commitments as described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2023.
26

Item 3. Quantitative and Qualitative Disclosures About Market Risks
Our activities can expose us to market risks which include interest rate risk, foreign currency risk, inflation risk and credit risk. Risk management is carried out by management under policies approved by the Board, with oversight provided by the Audit Committee of the Board. Our overall risk management program seeks to minimize adverse effects on our financial performance.
Interest Rate Risk
Financial assets and financial liabilities with variable interest rates expose us to cash flow interest rate risk. We manage our interest rate risk by maximizing the interest income earned on excess funds while maintaining the liquidity necessary to conduct
operations on a day-to-day basis. As of September 30, 2024, our investment portfolio includes cash, cash equivalents, restricted cash, and investments of $348.7 million that earn interest at various rates. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. Our investments held during the year were comprised of highly rated instruments such as certificates of deposits, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities. As of September 30, 2024, these instruments primarily have a maturity of less than a year.

As of September 30, 2024, a hypothetical decrease of 100 basis points on the interest rates of our investments would result annually in approximately $3.1 million less interest in our portfolio. We do not believe that the results of operations or cash flows would be affected to any significant degree by a sudden change in market interest rates relative to our investment portfolio, due to the short-term nature of the investments and our current ability to hold these investments to maturity.

Accounts receivable, accounts payable and accrued liabilities bear no interest unless payments are not received timely. We do not believe that our results of operations or cash flows would be affected to a significant degree by a sudden change in market interest rates relative to our investment portfolio.

Foreign Currency Risk

We are exposed to financial risk related to the fluctuation of foreign currency exchange rates. Foreign currency risk for the Company is the risk variations in exchange rates between the U.S. dollar and foreign currencies, primarily with the Swiss franc, Canadian dollar and Great Britain Pound, which could affect our operating and financial results.

As of September 30, 2024, we had an $80.7 million finance lease liability on our balance sheet related to the monoplant. An assumed 10% fluctuation in the Swiss franc would have an approximate $8.1 million fluctuation in the valuation of the lease liability.

There were no other foreign currency fluctuations that would have had a material impact on our financial condition or results of operations as of September 30, 2024.

Inflation Risk

Inflation has been volatile in recent periods and may continue to be volatile in the future. Inflation generally affects us by increasing our cost of labor, commercial support, manufacturing and clinical trial expenditures. In addition, inflation also impacts our government and payer rebates as it pertains to the consumer price index (CPI) penalty. Our investment portfolio may experience the risk of realized losses on our investments if we were to sell before maturity due to the market volatility caused by increased interest rates.

Credit Risk

Our exposure to credit risk generally consists of cash and cash equivalents, investments and accounts receivable. We place our cash and cash equivalents with highly rated financial institutions and invest the excess cash in highly rated investments. It is the
Company's intent for these investments to have an overall rating of A-1, or higher, by Standard & Poor’s, or an equivalent rating by Moody’s or Fitch. Our investment policy limits investments to certain types of debt and money market instruments issued by institutions primarily with investment grade credit ratings and places restriction on maturities and concentrations by asset class and issuer.

We are subject to credit risk in connection with our accounts receivable due from our two main specialty pharmacies for U.S. commercial sales, specialty distributor and collaboration partnership with Otsuka which accounted for the majority of our accounts receivable, net balances as of September 30, 2024. We monitor economic conditions, including the creditworthiness of
27

our customers and collaboration partner. We regularly communicate with our customers regarding the status of receivable balances and have not experienced and issues with collectability. The timing between the recognition of revenue for product sales and the receipt of payment is not significant. Our standard credit terms range from 30 to 45 days. During the quarter ended September 30, 2024, we did not recognize any allowance for credit losses related to credit risk for our customers or write any amounts off.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of September 30, 2024, have concluded that, based on such evaluation, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the quarter ended September 30, 2024, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
28

PART II—OTHER INFORMATION
Item 1. Legal Proceedings.
From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. For further discussion, refer to Note 18, Commitments and Contingencies.
Other than as set out below, there are no material developments to report in respect of the litigation described in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.
On April 15, 2022, a purported shareholder class action complaint, Ortmann v. Aurinia Pharmaceuticals, Inc. et al., case no. 1:22-cv-02185, was filed in the United States District Court for the Eastern District of New York (Eastern District of New York), naming the Company and certain of its officers as defendants. The lawsuit alleges that the Company made materially false and misleading statements regarding its financial guidance and commercial prospects in violation of certain federal securities laws. The plaintiff sought unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys’ fees. On June 2, 2022, the case was transferred from the Eastern District of New York to the United States District Court for the District of Maryland. On February 20, 2023, the Court appointed a lead plaintiff and approved lead plaintiff’s selection of lead counsel. On May 22, 2023, the lead plaintiff filed its amended complaint. On October 20, 2023, the Company filed a motion to dismiss the amended complaint (the "Motion to Dismiss"). On December 8, 2023, the lead plaintiff filed its opposition to the Motion to Dismiss. On January 12, 2024, the Company filed its reply in support of the Motion to Dismiss. On August 13, 2024, the Court entered an order granting the Motion to Dismiss, with prejudice. The lead plaintiff did not file a motion for reconsideration or appeal the Court's order, and as such the action is dismissed in its entirety.
Item 1A. Risk Factors.
Under Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2023, we identified important factors that could affect our financial performance and could cause our actual results for future periods to differ materially from our anticipated results or other expectations, including those expressed in any forward-looking statements made in this Quarterly Report. There has been no material change in our risk factors subsequent to the filing of our prior reports referenced above, other than as set out below. However, the risks described in our reports are not the only risks we face. Additional risks and uncertainties that we currently deem to be immaterial or not currently known to us, as well as other risks reported from time to time in our reports to the SEC, also could cause our actual results to differ materially from our anticipated results or other expectations.
Aurinia's restructuring program and associated organizational changes may not adequately reduce its operating costs or improve operating margins, may lead to additional workforce attrition, and may cause operational disruptions, and there can be no assurance that Aurinia will realize the anticipated benefits of the restructuring program.
On November 7, 2024, Aurinia announced it was implementing a strategic restructuring to sharpen the Company's focus on continued LUPKYNIS growth and the rapid development of AUR200. This restructuring will result in a workforce reduction of approximately 45% and anticipates a one-time restructuring charge in the fourth quarter of 2024 of approximately $15 to $19 million and will focus the Company’s LUPKYNIS commercial strategy on the highest growth drivers.

The estimates of charges and expenditures, and the associated annual cost savings, Aurinia expects to incur in connection with the restructuring program, and timing thereof, are subject to a number of assumptions, including local law requirements in various jurisdictions, and Aurinia may incur costs that are greater, or recognize lower annual cost savings, than Aurinia currently anticipates in connection with the restructuring program.

The restructuring program may yield unintended consequences, such as the loss of institutional knowledge and expertise, employee attrition beyond Aurinia's intended reduction in force, a reduction in morale among Aurinia's remaining employees, greater than anticipated costs incurred in connection with implementing the restructuring program, and the risks that Aurinia may not achieve the anticipated benefits from the restructuring program to the extent or as quickly as Aurinia anticipates, if at all, all of which may materially adversely affect Aurinia's results of operations or financial condition. These restructuring initiatives could place substantial demands on Aurinia's management and employees, which could lead to the diversion of management’s and employees’ attention from other business priorities. In addition, while certain positions are being eliminated in connection with the restructuring program, many functions necessary to Aurinia's reduced operations remain, and Aurinia may be unsuccessful in distributing the duties and obligations of departed employees among its remaining employees or to
29

external service providers, which could result in disruptions to Aurinia's operations. Aurinia may also discover that the workforce reduction and other restructuring efforts will make it difficult for Aurinia to pursue new opportunities and initiatives and require Aurinia to hire qualified replacement personnel, which may require Aurinia to incur additional and unanticipated costs and expenses. Aurinia may further discover that, despite the implementation of its restructuring program, Aurinia may require additional capital to continue expanding its business, and Aurinia may not be able to obtain such capital on acceptable terms, if at all. Aurinia's failure to successfully accomplish any of the above activities and goals may have a material adverse impact on its business, financial condition and results of operations.

Additionally, the workforce reduction Aurinia will implement as part of the restructuring program may negatively impact its ability to attract, integrate, retain and motivate highly qualified employees, and may harm Aurinia's reputation with current or prospective employees.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Issuer Purchases of Equity Securities
The following table summarizes the common share activity of our repurchased shares under our share repurchase program announced on February 15, 2024. Refer to Part I, Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources" for further details of the share repurchase program.
Period
Total number of shares purchased
Average price paid per share in $
Total number of shares purchased as part of publicly announced program
Approximate dollar value of shares that may yet be purchased under program
(in thousands)(1)(2)
2/21/2024-3/21/2024
1,732,787$5.771,732,787$140,000
3/22/2024-3/28/2024
640,587$4.98640,587$136,809
4/1/2024-4/30/2024
1,049,556$4.931,049,556$131,638
5/1/2024-5/31/2024
891$4.99891$131,633
Total
3,423,8213,423,821
(1)The approximate value of shares that may yet be purchased under the program does not include commissions that may be paid to brokers in connection with such purchases.
(2)The approximate dollar value of shares that may be purchased under the program may differ from time to time from the value set out in the table above, as the Company is limited in how much it may repurchase both by the maximum dollar value of the program established by the Board, and also the maximum number of shares that may be repurchased in any 12 month period is limited by the Exemptive Relief (which may produce a lower maximum dollar value depending on the prices that common shares are repurchased under the program). As of September 30, 2024, the maximum dollar value would be approximately $131.6 million.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
None.
Item 5. Other Information.
None.
30

Item 6. Exhibits.
The following exhibits are filed as part of this report:
Exhibit
Number		Description
3.1
3.2
31.1*
31.2*
32.1**
32.2**
101.INS*Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH*Inline XBRL Taxonomy Extension Schema Document
101.CAL*
Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*
Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

*Filed herewith.
**Furnished herewith. Exhibits 32.1 and 32.2 are being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise specifically stated in such filing.

31

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
AURINIA PHARMACEUTICALS INC.
November 6, 2024By:/s/ Peter Greenleaf
Peter Greenleaf
Chief Executive Officer, Director
(Principal Executive Officer)
November 6, 2024By:/s/ Joseph Miller
Joseph Miller
Chief Financial Officer
(Principal Financial and Accounting Officer)
32
 EX-31.1 2 auph-2024q3exx311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE RULES 13a-14(a) AND 15d-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Peter Greenleaf, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Aurinia Pharmaceuticals Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date:November 6, 2024By:/s/ Peter Greenleaf
Peter Greenleaf
Chief Executive Officer
(Principal Executive Officer)

 EX-31.2 3 auph-2024q3exx312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULES 13a-14(a) AND 15d-14(a),
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Joseph Miller, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Aurinia Pharmaceuticals Inc..;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date:November 6, 2024By:/s/ Joseph Miller
Joseph Miller
Chief Financial Officer
(Principal Financial and Accounting Officer)

 EX-32.1 4 auph-2024q3exx321.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Aurinia Pharmaceuticals Inc. (the “Company”) on Form 10-Q for the period ending September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Peter Greenleaf, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:
1.The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date:November 6, 2024By:/s/ Peter Greenleaf
Peter Greenleaf
Chief Executive Officer
(Principal Executive Officer)

 EX-32.2 5 auph-2024q3exx322.htm EX-32.2 Document

Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Aurinia Pharmaceuticals Inc. (the “Company”) on Form 10-Q for the period ending September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Joseph Miller, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:
1.The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date:November 6, 2024By:/s/ Joseph Miller
Joseph Miller
Chief Financial Officer
(Principal Financial and Accounting Officer)

 EX-101.SCH 6 auph-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - COVER link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 9952157 - Disclosure - Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Investments link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Inventories, net link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Prepaid Expenses and Deposits link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Property and Equipment, net link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Lease Obligations link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - Accounts Payable and Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - Deferred Compensation and Other Non-current Liabilities link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - License and Collaboration Agreements link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - Shareholder's Equity link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - Net Income (Loss) per Common Share link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - Share-based Compensation link:presentationLink link:calculationLink link:definitionLink 9952172 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 9952173 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 9952174 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 9952175 - Disclosure - Restructuring link:presentationLink link:calculationLink link:definitionLink 9952176 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Inventories, net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Prepaid Expenses and Deposits (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Property and Equipment, net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Lease Obligations (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Net Income (Loss) per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Share-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Restructuring (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Organization and Description of Business (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Summary of Significant Accounting Policies- Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Investments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Investments - Schedule of Cash, Cash Equivalents, Restricted Cash and Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Inventories, net (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Prepaid Expenses and Deposits (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Intangible Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Property and Equipment, net (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Lease Obligations - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Lease Obligations - Schedule of Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Lease Obligations - Schedule of Maturities of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Lease Obligations - Schedule of Maturities of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Accounts Payable and Accrued Liabilities - Schedule of Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Deferred Compensation and Other Non-current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - License and Collaboration Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Shareholder's Equity (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Net Income (Loss) per Common Share - Schedule of Earnings Per Share, Basic and Diluted (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Share-based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Share-based Compensation - Schedule of Share-based Payment Award Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Share-based Compensation - Schedule of Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Share-based Compensation - Schedule of Allocation of Share-Based Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Share-based Compensation - Allocated Share-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Related-Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Restructuring - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Restructuring - Schedule of Restructuring and Related Costs (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 auph-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 auph-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 auph-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Accounts receivable, net Accounts and Other Receivables, Net, Current Operating Lease Payments Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Adjustments to reconcile net loss to net cash used in operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Statistical Measurement [Domain] Statistical Measurement [Domain] Related Party Transactions Related Party Transactions Disclosure [Text Block] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense Schedule of Lease Cost Lease, Cost [Table Text Block] Restructuring Expenses Restructuring Costs [Policy Text Block] Restructuring Costs Schedule of Prepaid Expenses and Deposits Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Cover [Abstract] Net decrease in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Tiered royalty percentages on future sales Research And Development Arrangement, Contract To Perform For Others, Tiered Royalty, Percent Research And Development Arrangement, Contract To Perform For Others, Tiered Royalty, Percent Schedule of Maturities of Lease Liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Other current liabilities (of which $0.8 million and $0.8 million at September 30, 2024 and December 31, 2023 is due to a related party, respectively) Other current liabilities Other Liabilities, Current Trading Symbol Trading Symbol Schedule of Earnings (Loss) Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cash paid for income taxes Income Taxes Paid, Net Schedule of Allocation of Share-Based Payments Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Total cash, cash equivalents, restricted cash and investments, unrealized losses Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Investments, Unrealized Losses Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Investments, Unrealized Losses Total cash, cash equivalents, restricted cash, and investments Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Investments Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Investments Organization and Description of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Operating lease liabilities Increase (Decrease) in Operating Lease Liability License Agreement Terms License Agreement Terms [Member] Fair Value Measurements Fair Value Disclosures [Text Block] Proceeds from exercise of stock options and employee share purchase plan Proceeds from Stock Options Exercised Restructuring and Related Activities [Abstract] Commercial accruals Commercial Related Accruals, Current Commercial Related Accruals, Current Lease Obligations Lessee, Operating Leases [Text Block] Common stock, outstanding (in shares) Beginning Balance (in shares) Ending Balance (in shares) Common Stock, Shares, Outstanding Operating lease costs Operating Lease, Cost Proceeds from investments Proceeds from Sale and Maturity of Marketable Securities Operating lease liabilities Operating Lease, Liability, Noncurrent Interest receivable Interest Receivable Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Interest expense Finance Lease, Interest Expense Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Revenue from Contract with Customer [Abstract] Deferred revenue Contract with Customer, Liability, Current Plan Name [Domain] Plan Name [Domain] Stock options, RSUs, performance awards and ESPP (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Other non-current assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Leases [Abstract] Gross Carrying Value Finite-Lived Intangible Assets, Gross Schedule of Finite-Lived Intangible Assets [Table] Intangible Asset, Finite-Lived [Table] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Corporate bonds Corporate Bond Securities [Member] Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Patents Patents [Member] Income taxes payable Taxes Payable, Current Plan Name [Axis] Plan Name [Axis] Equity Components [Axis] Equity Components [Axis] Total lease payments Finance Lease, Liability, to be Paid Other current assets Other Assets, Current Office equipment Office Equipment [Member] Estimated Fair Value Debt Securities, Available-for-Sale Restructuring Type [Axis] Restructuring Type [Axis] Accounts Receivable, net Accounts Receivable [Policy Text Block] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Finance lease, operating lease, weighted average remaining lease term (years) Finance Lease, Weighted Average Remaining Lease Term Total cost of sales and operating expenses Costs and Expenses Additional paid-in capital Additional Paid in Capital, Common Stock Payables and Accruals [Abstract] Denominator: Earnings Per Share, Diluted [Abstract] Unrealized gain on available-for-sale securities, net of tax of nil Unrealized gain on available-for-sale securities, net Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Entity Small Business Entity Small Business Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Geographical [Axis] Geographical [Axis] Schedule of Restructuring and Related Costs Restructuring and Related Costs [Table Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Stock repurchased during period, value Stock Repurchased During Period, Value Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Issuance of common shares in conjunction with ESPP program (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Deferred Compensation and Other Non-current Liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Noncurrent [Text Block] Finance right-of-use asset obtained in exchange for lease obligations Finance Right-of-Use Asset Obtained in Exchange for Lease Obligations Finance Right-of-Use Asset Obtained in Exchange for Lease Obligations Less: imputed interest Finance Lease, Liability, Undiscounted Excess Amount Major Customer Two Major Customer Two [Member] Major Customer Two Cash, cash equivalents, and restricted cash Cash, cash equivalents, and restricted cash, beginning of period Cash, cash equivalents, and restricted cash, end of period Total cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Net amortization of premiums and discounts on short-term investments Accretion (Amortization) of Discounts and Premiums, Investments Beinheim Beinheim, France [Member] Beinheim, France Current assets Assets, Current [Abstract] Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss Stock repurchase program, authorized amount Share Repurchase Program, Authorized, Amount Inventories, net Inventory Disclosure [Text Block] Monoplant Visp, Switzerland [Member] Visp, Switzerland Product and Service [Domain] Product and Service [Domain] Weighted average grant date fair value (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Fair Value Disclosures [Abstract] Depreciation and amortization Depreciation 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Finance lease, weighted average discount rate Finance Lease, Weighted Average Discount Rate, Percent Security Exchange Name Security Exchange Name 2025 Finance Lease, Liability, to be Paid, Year One Award Type [Axis] Award Type [Axis] Related Party Transaction [Domain] Related Party Transaction [Domain] Numerator: Earnings Per Share, Basic [Abstract] Exercised (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Purchase of property and equipment Payments to Acquire Other Productive Assets Work in process Inventory, Work in Process, Net of Reserves Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Total liabilities Liabilities Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Research and development Research and Development Expense Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Finance lease liability arising from obtaining right-of-use assets Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Number of shares (in thousands) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Goodwill and Intangible Assets Disclosure [Abstract] Operating lease liabilities Operating Lease, Liability, Current Common stock, issued (in shares) Common Stock, Shares, Issued Concentration risk (as percent) Concentration Risk, Percentage Computer equipment Computer Equipment [Member] Restructuring costs and asset impairment charges Restructuring Costs and Asset Impairment Charges Total long-term investment corporate bond Long-Term Corporate Debt Securities [Member] Long-Term Corporate Debt Securities Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, plant and equipment, gross Property, Plant and Equipment, Gross Prepaid insurance Prepaid Insurance Shares issued on exercise of stock options and vesting of performance awards and restricted stock units (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Research and development Research and Development Expense [Member] Weighted average exercise price $ Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Number of customers Concentration Risk, Number of Customers Concentration Risk, Number of Customers Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Diluted (in shares) Weighted average common shares outstanding diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Other comprehensive (loss) gain: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Restructuring expenses Restructuring Costs Performance Share sand Restricted Stock Units (RSUs) Restricted Stock Units And Performance Awards [Member] Restricted Stock Units And Performance Awards Total shareholders' equity Beginning Balance Ending Balance Equity, Attributable to Parent Dr. Robert T. Foster Dr. Robert T. Foster [Member] Dr. Robert T. Foster Related Party Related Party [Member] Lease extension term (in years) Lessee, Operating Lease, Renewal Term Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Interest Expense, Nonoperating Interest Expense, Nonoperating Property and Equipment, net Property, Plant and Equipment Disclosure [Text Block] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Product revenue, net Product [Member] Number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Document Fiscal Period Focus Document Fiscal Period Focus Restructuring accruals Restructuring Accruals, Current Restructuring Accruals, Current ASSETS Assets [Abstract] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Document Type Document Type Commercial paper Commercial Paper [Member] Internal-use software implementation costs Computer Software, Intangible Asset [Member] 2027 Finance Lease, Liability, to be Paid, Year Three Purchase of investments Payments to Acquire Marketable Securities Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Risk-free interest rate (as percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Maximum Maximum [Member] Amortization of intangible assets Amortization of Intangible Assets Furniture Furniture and Fixtures [Member] Acquired intellectual property and other intangible assets, net Net Carrying Amount Finite-Lived Intangible Assets, Net Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounting Policies [Abstract] LIABILITIES Liabilities [Abstract] Revenue Revenues [Abstract] Leasehold improvements Leasehold Improvements [Member] Schedule of Share-based Payment Award Valuation Assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Non-current assets Assets, Noncurrent [Abstract] Statistical Measurement [Axis] Statistical Measurement [Axis] Net income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Award Type [Domain] Award Type [Domain] Additional paid in capital Additional Paid-in Capital [Member] Finance lease liabilities Finance Lease, Liability, Noncurrent Total cash, cash equivalents, restricted cash and investments, Amortized Cost Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Investments, Amortized Cost Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Investments, Amortized Cost Subsequent Event Type [Domain] Subsequent Event Type [Domain] Class of Stock [Line Items] Class of Stock [Line Items] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Forecast Forecast [Member] Diluted (in usd per share) Net income (loss) per share, diluted (in usd per share) Earnings Per Share, Diluted Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Counterparty Name [Domain] Counterparty Name [Domain] 2028 Finance Lease, Liability, to be Paid, Year Four Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Product Revenues Revenue from Contract with Customer [Policy Text Block] Entity Interactive Data Current Entity Interactive Data Current Type of Restructuring [Domain] Type of Restructuring [Domain] Otuska Otuska Pharmaceutical Co., Ltd. [Member] Otuska Pharmaceutical Co., Ltd. Thereafter Finance Lease, Liability, to be Paid, Due after Year Four Finance Lease, Liability, to be Paid, Due after Year Four Number of operating segments Number of Operating Segments Number of positions eliminated, percent Restructuring and Related Cost, Number of Positions Eliminated, Period Percent Customer [Axis] Customer [Axis] Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Employee severance and one time benefits Employee Severance [Member] Statement of Financial Position [Abstract] Treasury bills US Treasury Bill Securities [Member] Restructuring Restructuring and Related Activities Disclosure [Text Block] Accounts receivable, net Increase (Decrease) in Receivables Share-based compensation expense Share-Based Payment Arrangement, Noncash Expense Income tax expense Income tax (benefit) expense Income Tax Expense (Benefit) Number of extension options (in years) Lessee, Operating Lease, Number of Extension Options Lessee, Operating Lease, Number of Extension Options Prepaid deposits Deposits Assets, Current Forfeited or cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Supplemental cash flow information Supplemental disclosure of noncash transactions Supplemental Cash Flow Information [Abstract] Unrecognized share-based compensation expense weighted average recognition period (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Cash, cash equivalents, restricted cash and investments Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Short Term Investments Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Short Term Investments Total revenue, net Revenues Revenue from Contract with Customer, Excluding Assessed Tax Capitalized patent costs Payments to Acquire Intangible Assets Service Revenue Service [Member] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Prepaid expenses and deposits Total prepaid expenses and deposits Prepaid Expenses and Deposits Current Prepaid Expenses and Deposits Current Edmonton, Alberta Edmonton, Alberta [Member] Edmonton, Alberta Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Income (Loss) from operations Operating Income (Loss) Capitalized under inventories Inventories [Member] Number of additional shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Remainder of 2024 Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Total liabilities and shareholders' equity Liabilities and Equity Subsequent Events Subsequent Events [Text Block] Employee accruals Employee-related Liabilities, Current Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Lease termination option term (in years) Lessee, Operating Lease, Lease Termination Term Lessee, Operating Lease, Lease Termination Term 2026 Finance Lease, Liability, to be Paid, Year Two Restructuring charges Restructuring Charges Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Commitments and Contingencies Disclosure [Abstract] Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table] Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table] Interest income Investment Income, Interest Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Upfront payments received Research and Development Arrangement, Contract to Perform for Others, Compensation Earned Scenario [Domain] Scenario [Domain] Common shares - no par value, unlimited shares authorized, 143,109 and 143,833 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively Common Stock, Value, Outstanding Related Party Transaction [Axis] Related Party Transaction [Axis] Accumulated Other Comprehensive (Loss) Income AOCI Attributable to Parent [Member] Expected life of options in years Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Inventories, net Total inventories, net Inventory, Net Amended and Restated Equity Incentive Plan Amended and Restated Equity Incentive Plan [Member] Amended and Restated Equity Incentive Plan License, collaboration, and royalty revenue License, Royalty and Collaboration Revenue [Member] License, Royalty and Collaboration Revenue Product and Service [Axis] Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Unrealized gain (loss) on available-for-sale securities, net of tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax Trade payables Accounts Payable, Trade, Current Operating expenses Operating Expenses [Abstract] Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Outstanding, Weighted average exercise price - Beginning of Period (in usd per share) Outstanding, Weighted average exercise price - End of Period (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Minimum Minimum [Member] Cash received for interest Proceeds from Interest Received Related Party Transactions [Abstract] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Research and Development, Contract to Perform for Others [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Beginning balance (in usd per share) Ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Operating right-of-use assets, net Operating Lease, Right-of-Use Asset Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Prepaid assets Prepaid Assets, Current Prepaid Assets, Current Foreign exchange on finance lease liability Foreign Translation on Finance Lease Liability Foreign Translation on Finance Lease Liability Property, Plant and Equipment [Abstract] Net Income (Loss) per Common Share Earnings Per Share [Text Block] Issuance of common shares in conjunction with ESPP program Stock Issued During Period, Value, Employee Stock Purchase Plan Subsequent Event Subsequent Event [Member] Shares issued on exercise of stock options and vesting of performance awards and restricted stock units Stock Issued During Period, Value, Stock Options Exercised Weighted average grant date fair value (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Marketable Securities [Table] Marketable Securities [Table] Restructuring Plan [Axis] Restructuring Plan [Axis] Finance lease, liability Total Finance Lease, Liability Income Tax Disclosure [Abstract] Payments of deferred compensation Deferred Compensation Arrangement with Individual, Compensation Expense Statement of Stockholders' Equity [Abstract] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Total cash, cash equivalents, restricted cash and investments, unrealized gains Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Investments, Unrealized Gains Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Investments, Unrealized Gains Non-current operating assets Increase (Decrease) in Other Noncurrent Assets Remaining lease term (in years) Lessee, Operating Lease, Remaining Lease Term Employee Benefit Obligations Employee Benefit Obligations [Member] Employee Benefit Obligations Financial assets: Assets, Fair Value Disclosure [Abstract] Related Party [Domain] Related and Nonrelated Parties [Domain] Accounts payable and accrued liabilities Total accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Local Phone Number Local Phone Number Accrued R&D projects Accrued Research, Current Accrued Research, Current Other costs Other Restructuring [Member] Stock repurchased during period, (in shares) Stock Repurchased During Period, Shares Net changes in operating assets and liabilities Increase (Decrease) in Operating Capital [Abstract] Amortized Cost Debt Securities, Available-for-Sale, Allowance for Credit Loss Non-current liabilities Liabilities, Noncurrent [Abstract] Short-term investments Debt Securities, Current Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Common Shares Common Stock [Member] Thereafter Lessee, Operating Lease, Liability, to be Paid, After Year Four Lessee, Operating Lease, Liability, to be Paid, After Year Four Entity Emerging Growth Company Entity Emerging Growth Company Entity Central Index Key Entity Central Index Key Scenario [Axis] Scenario [Axis] Selling, general and administrative General and Administrative Expense [Member] Schedule of Inventories, Net Schedule of Inventory, Current [Table Text Block] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Dividend rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Treasury bonds US Treasury Bond Securities [Member] Stock repurchase program, percentage Stock Repurchase Program, Percentage Stock Repurchase Program, Percentage Finance right-of-use assets, net Finance Lease, Right-of-Use Asset, after Accumulated Amortization Shareholder's Equity Equity [Text Block] Accounts payable, accrued and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Equity Component [Domain] Equity Component [Domain] Financial Instrument [Axis] Financial Instrument [Axis] Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Statement [Table] Statement [Table] Counterparty Name [Axis] Counterparty Name [Axis] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] City Area Code City Area Code Current liabilities Liabilities, Current [Abstract] Contract terminations Contract Termination [Member] Stock repurchase program, period Share Repurchase Program, Period in Force Level 1 Fair Value, Inputs, Level 1 [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Total current assets Assets, Current Statement of Cash Flows [Abstract] Repurchase of common shares Payments for Repurchase of Common Stock Unrealized Losses Debt Securities, Available-for-Sale, Unrealized Loss Weighted average exercise price $ Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Fair value per common share option (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Cash, cash equivalents, and restricted cash Cash, Cash Equivalents And Restricted Cash [Member] Cash, Cash Equivalents And Restricted Cash Member Subsequent Event Type [Axis] Subsequent Event Type [Axis] Income Taxes Income Tax Disclosure [Text Block] Shares repurchased and cancelled, inclusive of transaction costs Stock Repurchased and Retired During Period, Value 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Net income (loss) per share: Earnings Per Share [Abstract] Equity [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Accumulated deficit Retained Earnings (Accumulated Deficit) Shares repurchased and cancelled, inclusive of transaction costs (in shares) Stock Repurchased and Retired During Period, Shares Long-term investments Debt Securities, Noncurrent Forfeited or cancelled (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Eligible to receive a payment Research And Development Arrangement, New Drug Application, Eligibility Payment Receivable Upon Approval Research And Development Arrangement, New Drug Application, Eligibility Payment Receivable Upon Approval Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Inventories, net Increase (Decrease) in Inventories Selling, general and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Operating lease, weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Operating lease liability Total Operating Lease, Liability Cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Intangible Assets Intangible Assets Disclosure [Text Block] Finance lease, right-of-use asset, amortization Finance Lease, Right-of-Use Asset, Amortization Customer Concentration Risk Customer Concentration Risk [Member] Subsequent Events [Abstract] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Corporate bonds Short-Term Corporate Debt Securities [Member] Short-Term Corporate Debt Securities Level 2 Fair Value, Inputs, Level 2 [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] SHAREHOLDER’S EQUITY Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Geographical [Domain] Geographical [Domain] Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets Additional Cash Flow Elements, Summations [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Principles of Consolidation Consolidation, Policy [Policy Text Block] Schedule of Restructuring and Related Costs [Table] Restructuring Cost [Table] Title of 12(b) Security Title of 12(b) Security Concentration Risk Type [Axis] Concentration Risk Type [Axis] Operating cash flows for finance leases Finance Lease, Interest Payment on Liability Share-Based Payment Arrangement [Abstract] Stock options, RSUs, performance awards and ESPP Stock options, RSUs, performance awards and ESPP [Member] Stock options, RSUs, performance awards and ESPP Cash, cash equivalents Cash and Cash Equivalents, at Carrying Value Proceeds from tenant improvements Payments for (Proceeds from) Tenant Allowance Unrealized Gains Debt Securities, Available-for-Sale, Unrealized Gain Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Rockville, Maryland Rockville, Maryland [Member] Rockville, Maryland Weighted average exercise price (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Regulatory and pricing approval milestone revenue Research and Development Arrangement, Contract to Perform for Others, Compensation Received Research and Development Arrangement, Contract to Perform for Others, Compensation Received Finished goods inventories Inventory, Finished Goods, Gross Number of shares (in thousands) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Employee Stock [Member] Employee Stock [Member] Basic (in usd per share) Net income (loss) per share, basic (in usd per share) Earnings Per Share, Basic Estimated forfeiture rate (as percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate Operating cash flows for operating leases Operating Lease, Payments Principal portion of finance lease payments Financing cash flows for finance leases Finance Lease, Principal Payments Cash paid for amounts included in the measurement of lease liabilities Cash Flow, Lessee [Abstract] Cash Flow, Lessee Schedule of Stock by Class [Table] Stock, Class of Stock [Table] Total current liabilities Liabilities, Current Weighted-average common shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Unrecognized share-based compensation expense Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Total assets Assets Major Customers Concentration Risk, Credit Risk, Policy [Policy Text Block] Annualized volatility (as percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Deferred compensation and other non-current liabilities (of which $7.0 million at September 30, 2024 and $7.6 million in December 31, 2023 is due to a related party, respectively) Other non-current liabilities Other Liabilities, Noncurrent Commitments and contingencies (Note 18) Commitments and Contingencies Share-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Prepaid Expenses and Deposits Prepaid Expenses and Deposits [Text Block] Prepaid Expenses and Deposits Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Table] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Share-based Compensation Share-Based Payment Arrangement [Text Block] Entity Address, City or Town Entity Address, City or Town Schedule of Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Share-based compensation expense Share-Based Payment Arrangement, Expense Net income (loss) Net income (loss) Net Income (Loss) Attributable to Parent Other expense (income), net Other Operating Income (Expense), Net Investments, Debt and Equity Securities [Abstract] Granted (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Schedule of Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Area of property (in sqft) Area of Real Estate Property Number of shares purchased (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award Entity File Number Entity File Number Finance Lease Payments Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] License and Collaboration Agreements Revenue from Contract with Customer [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Upfront lease payment Payments to Acquire Lease Receivables Other accrued liabilities Other Accrued Liabilities, Current Lease term (in years) Lessee, Operating Lease, Term of Contract Total financial assets Assets, Fair Value Disclosure Restructuring Plan [Domain] Restructuring Plan [Domain] Remainder of 2024 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Operating lease, weighted average remaining lease term (years) Operating Lease, Weighted Average Remaining Lease Term Document Period End Date Document Period End Date Major Customer One Major Customer One [Member] Major Customer One Finance lease liabilities Finance Lease, Liability, Current Finished goods, net of reserve Inventory, Finished Goods, Net of Reserves Other, net Other Noncash Income (Expense) Total lease payments Lessee, Operating Lease, Liability, to be Paid Outstanding - Beginning of Period (in shares) Outstanding - End of Period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Schedule of Performance Shares Activity Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block] Inventory Disclosure [Abstract] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three Acquired intellectual property and reacquired rights Intellectual Property [Member] Schedule of Cash, Cash Equivalents, Restricted Cash and Investments Marketable Securities [Table Text Block] Cost of sales Cost of Revenue Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Customer [Domain] Customer [Domain] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Accumulated Deficit Retained Earnings [Member] Restricted cash Restricted Cash and Cash Equivalents Strategic Restructuring Plan Strategic Restructuring Plan [Member] Strategic Restructuring Plan Basic (in shares) Weighted average common shares outstanding basic (in shares) Weighted Average Number of Shares Outstanding, Basic Related Party [Axis] Related and Nonrelated Parties [Axis] Marketable Securities [Line Items] Marketable Securities [Line Items] Unrealized gain on available-for-sale securities Debt Securities, Available-for-Sale, Unrealized Gain (Loss) Derivative, average remaining maturity (in months) Derivative, Average Remaining Maturity Common Shares Stockholders' Equity, Policy [Policy Text Block] Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Receivable standard credit terms (in days) Accounts Receivable, Credit Term Accounts Receivable, Credit Term Revenue Benchmark Revenue Benchmark [Member] Entity Filer Category Entity Filer Category Income Statement Location [Domain] Statement of Income Location, Balance [Domain] EX-101.PRE 10 auph-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.3
COVER - shares
 9 Months Ended
Sep. 30, 2024
Nov. 06, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2024  
Document Transition Report false  
Entity File Number 001-36421  
Entity Registrant Name Aurinia Pharmaceuticals Inc.  
Entity Incorporation, State or Country Code Z4  
Entity Address, Address Line One #140, 14315 - 118 Avenue  
Entity Address, City or Town Edmonton  
Entity Address, State or Province AB  
Entity Address, Postal Zip Code T5L 4S6  
Entity Tax Identification Number 98-1231763  
City Area Code (250)  
Local Phone Number 744-2487  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   143,179,269
Title of 12(b) Security Common shares, no par value  
Trading Symbol AUPH  
Security Exchange Name NASDAQ  
Amendment Flag false  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q3  
Entity Central Index Key 0001600620  
Current Fiscal Year End Date --12-31  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Current assets    
Cash, cash equivalents, and restricted cash $ 37,142 $ 48,875
Short-term investments 311,605 301,614
Accounts receivable, net 36,483 24,089
Inventories, net 38,714 39,705
Prepaid expenses and deposits 13,815 9,486
Other current assets 2,700 1,031
Total current assets 440,459 424,800
Non-current assets    
Long-term investments 0 201
Other non-current assets 868 1,517
Property and equipment, net 2,887 3,354
Acquired intellectual property and other intangible assets, net 4,509 4,977
Finance right-of-use assets, net 96,459 108,715
Operating right-of-use assets, net 4,179 4,498
Total assets 549,361 548,062
Current liabilities    
Accounts payable and accrued liabilities 56,770 54,389
Deferred revenue 4,304 4,813
Other current liabilities (of which $0.8 million and $0.8 million at September 30, 2024 and December 31, 2023 is due to a related party, respectively) 1,590 2,388
Finance lease liabilities 14,927 14,609
Operating lease liabilities 1,018 989
Total current liabilities 78,609 77,188
Non-current liabilities    
Finance lease liabilities 65,955 75,479
Operating lease liabilities 5,951 6,530
Deferred compensation and other non-current liabilities (of which $7.0 million at September 30, 2024 and $7.6 million in December 31, 2023 is due to a related party, respectively) 10,844 10,911
Total liabilities 161,359 170,108
Commitments and contingencies (Note 18)
SHAREHOLDER’S EQUITY    
Common shares - no par value, unlimited shares authorized, 143,109 and 143,833 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 1,206,613 1,200,218
Additional paid-in capital 119,773 120,788
Accumulated other comprehensive loss (385) (730)
Accumulated deficit (937,999) (942,322)
Total shareholders' equity 388,002 377,954
Total liabilities and shareholders' equity $ 549,361 $ 548,062
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
shares in Thousands, $ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Other current liabilities (of which $0.8 million and $0.8 million at September 30, 2024 and December 31, 2023 is due to a related party, respectively) $ 1,590 $ 2,388
Deferred compensation and other non-current liabilities (of which $7.0 million at September 30, 2024 and $7.6 million in December 31, 2023 is due to a related party, respectively) $ 10,844 $ 10,911
Common stock, par value (in usd per share) $ 0 $ 0
Common stock, issued (in shares) 143,109 143,833
Common stock, outstanding (in shares) 143,109 143,833
Related Party    
Other current liabilities (of which $0.8 million and $0.8 million at September 30, 2024 and December 31, 2023 is due to a related party, respectively) $ 800 $ 800
Deferred compensation and other non-current liabilities (of which $7.0 million at September 30, 2024 and $7.6 million in December 31, 2023 is due to a related party, respectively) $ 7,000 $ 7,600
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Revenue        
Total revenue, net $ 67,771 $ 54,515 $ 175,266 $ 130,418
Operating expenses        
Cost of sales 6,035 6,769 22,696 8,753
Selling, general and administrative 42,367 47,759 134,996 144,964
Research and development 3,047 13,605 12,678 39,413
Restructuring expenses 0 0 7,755 0
Other expense (income), net 4,574 2,645 159 (695)
Total cost of sales and operating expenses 56,023 70,778 178,284 192,435
Income (Loss) from operations 11,748 (16,263) (3,018) (62,017)
Interest Expense, Nonoperating (1,208) (1,400) (3,689) (1,465)
Interest income 4,267 4,514 12,982 12,429
Net income (loss) before income taxes 14,807 (13,149) 6,275 (51,053)
Income tax expense 457 298 1,952 92
Net income (loss) 14,350 (13,447) 4,323 (51,145)
Other comprehensive (loss) gain:        
Unrealized gain on available-for-sale securities, net of tax of nil 474 73 345 114
Comprehensive income (loss) $ 14,824 $ (13,374) $ 4,668 $ (51,031)
Net income (loss) per share:        
Basic (in usd per share) $ 0.10 $ (0.09) $ 0.03 $ (0.36)
Diluted (in usd per share) $ 0.10 $ (0.09) $ 0.03 $ (0.36)
Weighted-average common shares outstanding:        
Basic (in shares) 143,051 142,847 143,353 143,085
Diluted (in shares) 145,651 142,847 145,010 143,085
Product revenue, net        
Revenue        
Total revenue, net $ 55,503 $ 40,781 $ 158,604 $ 116,218
License, collaboration, and royalty revenue        
Revenue        
Total revenue, net $ 12,268 $ 13,734 $ 16,662 $ 14,200
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Statement [Abstract]        
Unrealized gain (loss) on available-for-sale securities, net of tax $ 0 $ 0 $ 0 $ 0
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
Common Shares
Additional paid in capital
Accumulated Other Comprehensive (Loss) Income
Accumulated Deficit
Beginning Balance (in shares) at Dec. 31, 2022   142,268      
Beginning Balance at Dec. 31, 2022 $ 405,435 $ 1,185,309 $ 85,489 $ (1,061) $ (864,302)
Increase (Decrease) in Stockholders' Equity          
Shares issued on exercise of stock options and vesting of performance awards and restricted stock units (in shares)   1,127      
Shares issued on exercise of stock options and vesting of performance awards and restricted stock units 3,024 $ 11,141 (8,117)    
Issuance of common shares in conjunction with ESPP program (in shares)   210      
Issuance of common shares in conjunction with ESPP program 906 $ 2,110 (1,204)    
Share-based compensation 33,543   33,543    
Unrealized gain on available-for-sale securities, net 114     114  
Net income (loss) (51,145)       (51,145)
Ending Balance (in shares) at Sep. 30, 2023   143,605      
Ending Balance at Sep. 30, 2023 391,877 $ 1,198,560 109,711 (947) (915,447)
Beginning Balance (in shares) at Jun. 30, 2023   143,369      
Beginning Balance at Jun. 30, 2023 392,292 $ 1,196,480 98,832 (1,020) (902,000)
Increase (Decrease) in Stockholders' Equity          
Shares issued on exercise of stock options and vesting of performance awards and restricted stock units (in shares)   236      
Shares issued on exercise of stock options and vesting of performance awards and restricted stock units 1,151 $ 2,080 (929)    
Share-based compensation 11,808   11,808    
Unrealized gain on available-for-sale securities, net 73     73  
Net income (loss) (13,447)       (13,447)
Ending Balance (in shares) at Sep. 30, 2023   143,605      
Ending Balance at Sep. 30, 2023 $ 391,877 $ 1,198,560 109,711 (947) (915,447)
Beginning Balance (in shares) at Dec. 31, 2023 143,833 143,833      
Beginning Balance at Dec. 31, 2023 $ 377,954 $ 1,200,218 120,788 (730) (942,322)
Increase (Decrease) in Stockholders' Equity          
Shares issued on exercise of stock options and vesting of performance awards and restricted stock units (in shares) 125 2,548      
Shares issued on exercise of stock options and vesting of performance awards and restricted stock units $ 646 $ 23,966 (23,320)    
Shares repurchased and cancelled, inclusive of transaction costs (in shares)   (3,424)      
Shares repurchased and cancelled, inclusive of transaction costs (18,619) $ (18,619)      
Issuance of common shares in conjunction with ESPP program (in shares)   152      
Issuance of common shares in conjunction with ESPP program 703 $ 1,048 (345)    
Share-based compensation 22,650   22,650    
Unrealized gain on available-for-sale securities, net 345     345  
Net income (loss) $ 4,323       4,323
Ending Balance (in shares) at Sep. 30, 2024 143,109 143,109      
Ending Balance at Sep. 30, 2024 $ 388,002 $ 1,206,613 119,773 (385) (937,999)
Beginning Balance (in shares) at Jun. 30, 2024   142,984      
Beginning Balance at Jun. 30, 2024 364,616 $ 1,205,554 112,270 (859) (952,349)
Increase (Decrease) in Stockholders' Equity          
Shares issued on exercise of stock options and vesting of performance awards and restricted stock units (in shares)   125      
Shares issued on exercise of stock options and vesting of performance awards and restricted stock units 235 $ 1,059 (824)    
Share-based compensation 8,327   8,327    
Unrealized gain on available-for-sale securities, net 474     474  
Net income (loss) $ 14,350       14,350
Ending Balance (in shares) at Sep. 30, 2024 143,109 143,109      
Ending Balance at Sep. 30, 2024 $ 388,002 $ 1,206,613 $ 119,773 $ (385) $ (937,999)
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Cash flows from operating activities    
Net income (loss) $ 4,323 $ (51,145)
Adjustments to reconcile net loss to net cash used in operating activities    
Depreciation and amortization 14,583 6,698
Net amortization of premiums and discounts on short-term investments (9,752) (8,836)
Share-based compensation expense 22,650 33,543
Foreign exchange on finance lease liability (718) (1,335)
Other, net 220 (1,659)
Net changes in operating assets and liabilities    
Accounts receivable, net (12,394) (24,463)
Inventories, net 991 (8,984)
Prepaid expenses and other current assets (6,001) (2,889)
Non-current operating assets (12) (16)
Accounts payable, accrued and other liabilities 934 11,812
Operating lease liabilities (550) (499)
Net cash provided by (used in) operating activities 14,274 (47,773)
Cash flows from investing activities    
Purchase of investments (461,140) (379,213)
Proceeds from investments 461,448 391,287
Upfront lease payment (44) (11,864)
Purchase of property and equipment 0 (419)
Capitalized patent costs (225) (240)
Net cash provided by (used in) investing activities 39 (449)
Cash flows from financing activities    
Repurchase of common shares (18,435) 0
Principal portion of finance lease payments (8,959) (3,482)
Proceeds from exercise of stock options and employee share purchase plan 1,348 3,929
Cash (used in) provided by financing activities (26,046) 447
Net decrease in cash, cash equivalents, and restricted cash (11,733) (47,775)
Cash, cash equivalents, and restricted cash, beginning of period 48,875 94,172
Cash, cash equivalents, and restricted cash, end of period 37,142 46,397
Supplemental cash flow information    
Cash received for interest 2,803 3,559
Cash paid for income taxes (1,459) (339)
Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets    
Cash, cash equivalents 36,630 45,557
Restricted cash 512 840
Total cash, cash equivalents, and restricted cash $ 37,142 $ 46,397
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.3
Organization and Description of Business
 9 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Description of Business Organization and Description of Business
Aurinia Pharmaceuticals Inc. (Aurinia or the Company) is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first U.S. Food and Drug Administration (FDA) approved oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. Aurinia contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for development and commercialization of LUPKYNIS in the European Union (EU), Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine (collectively, the Otsuka Territories).
On February 15, 2024, the Company announced the conclusion of its previously announced strategic review process and actions designed to enhance shareholder value. Aurinia executed a corporate restructuring in the first quarter that reduced employee headcount by approximately 25% and discontinued its AUR300 research and development program. For further discussion, refer to Note 19, Restructuring.
On November 7, 2024, Aurinia announced it was implementing a strategic restructuring to sharpen the Company's focus on continued LUPKYNIS® growth and the rapid development of AUR200. This restructuring will result in a workforce reduction of approximately 45% and Aurinia anticipates a one-time restructuring charge in the fourth quarter of 2024 of approximately $15 to $19 million and will focus the Company’s LUPKYNIS commercial strategy on the highest growth drivers.
The Company is also developing its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). On September 5, 2024, the Company announced the first participant has been dosed in a Phase 1 single ascending dose (SAD) study of AUR200. The SAD study will assess the safety, tolerability, pharmacokinetics, and changes in biomarkers for AUR200 in healthy volunteers, with data expected in the first half of 2025.
Aurinia's head office and registered office is located at #140, 14315-118 Avenue, Edmonton, Alberta, Canada T5L 4S6. Aurinia also has a United States commercial office located at 77 Upper Rock Circle Suite 700, Rockville, Maryland, 20850.
Aurinia is incorporated pursuant to the Business Corporations Act (Alberta). The Company’s common shares are traded on the Nasdaq Global Market (Nasdaq) under the symbol AUPH.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.3
Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.
In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of September 30, 2024 was derived from audited annual consolidated financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. The results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the full year or any other future periods.
These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation and operate in one segment.
These unaudited condensed consolidated financial statements are presented in U.S. dollars, which is the Company's and all of its foreign subsidiaries' functional currency. Therefore, there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statements of operations. All monetary assets and liabilities denominated in a foreign currency are remeasured into U.S. dollars at the exchange rate on the balance sheet date. Non-monetary assets and liabilities (along with their related expenses) are translated at the rate of exchange in effect on the date the assets were acquired. Monetary income and expense items are translated at the average foreign currency rate. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the consolidated statements of operations and recorded in other expense (income), net.
Significant Accounting Policies
The Company's significant accounting policies have not changed from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, other than as stated below.
Product Revenues
We sell LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor, and semi-finished product directly to our ex-U.S. partner Otsuka. These customers subsequently distribute the Company's products. Revenues from product sales are recognized when the customer obtains control of the Company's product, which occurs upon delivery to the customer.
Reserves for discounts and allowances: Product sales are recorded at the net sales price, which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a liability (if the amount is payable to a party other than the customer).
The Company's estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available.
Significant judgment is required in estimating variable consideration. In making these estimates, the Company considers historical data, including patient mix and inventory sold to customers that has not yet been dispensed to patients. The Company uses a data aggregator and historical claims to estimate variable consideration for inventory sold to its specialty pharmacies that has not yet been dispensed. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment. As of September 30, 2024, the Company did not have any material adjustments to variable consideration estimates based on actual results. These specific adjustments are detailed further in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.
Major Customers: The Company currently has two main specialty pharmacies for U.S. commercial sales of LUPKYNIS and a collaboration partnership with Otsuka for sales of semi-finished product and royalty, collaboration, and manufacturing services revenue in the Otsuka Territories. Revenues from our two main customers represented approximately 49% and 38% of revenues for the nine months ended September 30, 2024. Revenues from our two main customers represented approximately 50% and 39% of revenues for the nine months ended September 30, 2023.
In late March 2022, the Company provided a nominal additional discount to both of its two main U.S. specialty pharmacies, applicable for the 2022 calendar year, in connection with holding additional amounts of LUPKYNIS on hand for risk mitigation and supply chain concerns. In December 2022, the Company extended the nominal discount to the end of 2024. Such discounts, or any future discounts, may result in reduced sales to these customers in subsequent periods and substantial fluctuations in revenues from period to period. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances. Global economic conditions and customer specific factors may require the Company to periodically reevaluate the collectability of its receivables and based on this evaluation the Company could potentially incur credit losses. The Company has had no historical write-offs related to customers or receivables.
Accounts Receivable, net: Accounts receivable are stated at their net realizable value. The Company's accounts receivable primarily represent amounts due to the Company from product sales and from its Otsuka collaboration agreement (Note 12). As
of September 30, 2024, and December 31, 2023, accounts receivable, net are $36.5 million and $24.1 million, respectively. The Company's standard credit terms range from 30 to 45 days. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised good to the customer and receipt of payment will be one year or less. The Company estimates the allowances using the current expected credit loss, or CECL, model. Under the CECL model, the allowances reflect the net amount expected to be collected from the accounts receivable. Aurinia evaluates the collectability of these cash flows based on the asset’s amortized cost, the risk of loss even when that risk is remote, losses over an asset’s contractual life, and other relevant information available to the Company. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. Given the nature of the Company's accounts receivable, it determined that an allowance for current expected credit losses was nil as of September 30, 2024, and December 31, 2023.
Share-Based Compensation: The Company follows ASC Topic 718, Compensation - Stock Compensation, which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date using the graded accelerated vesting method for all share-based payments related to stock options, performance awards (PAs), restricted stock units (RSUs) and purchases under the Company's 2021 Employee Share Purchase Plan (ESPP). The estimated fair value of performance-based awards is measured on the grant date and is recognized when it is determined that it is probable that the performance condition will be achieved. The Company has elected a policy for all share-based awards to estimate forfeitures based on historical forfeiture experience at the time of grant and revise in subsequent periods if actual forfeitures differ from those estimates.
Restructuring Expenses: Restructuring expenses consist primarily of employee severance, contract termination costs and other costs. Liabilities for costs associated with a restructuring activity are recognized when the liability is incurred and are measured at fair value. According to ASC 420, Exit or Disposal Cost Obligations, one-time employee severance and termination benefits are expensed at the date the entity notifies the employee of the plan, unless the employee must provide future service, in which case the benefits are expensed in the period when the service ends. One-time termination benefits include severance, continuation of health insurance coverage for certain employees, and other benefits such as outplacement support services for a specified period of time.
Common Shares: The Company’s shares have no par value or stated value and therefore, upon issuance or repurchase of shares, all amounts related to the shares are recorded under common shares on the balance sheet. The value of common shares includes cash amounts paid or received for the shares and the fair value of equity awards and warrants. Amounts for common shares are offset by share issue costs or transactions costs associated with repurchases or equity offerings.
Recent Accounting Pronouncements
In December 2023, the FASB issued final guidance in ASU No. 2023-09, Income Taxes (ASC 740): Improvements to Income Tax Disclosures requiring entities to provide additional information in the rate reconciliation and disclosures about income taxes paid. For public business entities, the guidance is effective for annual periods beginning after December 15, 2024. The Company is not early adopting, and therefore, this ASU is not adopted in the current period. The Company is currently assessing the potential impact this ASU may have on the consolidated financial statements.
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures which requires public entities to disclose significant segment expenses regularly provided to the chief operating decision-maker. Public entities with a single reporting segment have to provide all disclosures required by ASC 280, including the significant segment expense disclosures. For public business entities, the guidance is effective for annual periods beginning after December 15, 2023. This ASU does not have a material impact on the consolidated financial statements.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.3
Fair Value Measurements
 9 Months Ended
Sep. 30, 2024
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The Company's financial instruments consist primarily of cash, cash equivalents, restricted cash, investments, accounts receivable, accounts payable, and accrued liabilities. The carrying value of accounts receivable, accounts payable, and accrued liabilities approximate their fair value because of their short-term nature. Estimated fair value of available-for-sale debt securities are generally based on prices obtained from commercial pricing services.
In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market participants would price assets and liabilities). As a basis for considering such
assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:
•Level 1 - Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
•Level 2 - Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
•Level 3 - Unobservable inputs that reflect the reporting entity’s own assumptions.
The following table summarizes the financial assets (cash, cash equivalents, restricted cash, and investments) measured at fair value on a recurring basis:
September 30, 2024
(in thousands)Level 1Level 2Level 3Total
Financial assets:
Cash, cash equivalents, and restricted cash
$37,142 $— $— $37,142 
Corporate bonds— 601 — 601 
Commercial paper— 2,028 — 2,028 
Treasury bills— 196,471 — 196,471 
Treasury bonds— 112,505 — 112,505 
Total financial assets$37,142 $311,605 $— $348,747 
December 31, 2023
(in thousands)Level 1Level 2Level 3Total
Financial assets:
Cash, cash equivalents, and restricted cash
$48,875 $— $— $48,875 
Corporate bonds— 33,781 — 33,781 
Commercial paper— 39,304 — 39,304 
Treasury bills— 122,806 — 122,806 
Treasury bonds— 105,924 — 105,924 
Total financial assets$48,875 $301,815 $— $350,690 
The Company's Level 1 instruments include cash, cash equivalents, and restricted cash that are valued using quoted market prices. Aurinia estimates the fair values of investments in corporate debt securities, government and government related securities and certificates of deposits by taking into consideration valuations obtained from third-party pricing services. The fair value of the Company's investments classified within Level 2 is based upon observable inputs that may include benchmark yield curves, reported trades, issuer spreads, benchmark securities and reference data including market research publications. At September 30, 2024 and December 31, 2023, the weighted average remaining contractual maturities of Aurinia's Level 2 investments were approximately 7 months for both periods. The Company's policy is for these investments to have an overall rating of A-1, or higher, by Standard & Poor's, or an equivalent rating by Moody’s or Fitch.
No credit loss allowance was recorded as of September 30, 2024 and December 31, 2023, as the Company does not believe the unrealized loss is a result of a credit loss due to the nature of the investments. Aurinia also considered the current and expected future economic and market conditions and determined that the estimate of credit losses was not significantly impacted.
Refer to Note 4, Cash, Cash Equivalents, Restricted Cash, and Investments, for the carrying amount and related unrealized gains (losses) by type of investment.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.3
Cash, Cash Equivalents, Restricted Cash and Investments
 9 Months Ended
Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]  
Cash, Cash Equivalents, Restricted Cash and Investments Cash, Cash Equivalents, Restricted Cash, and Investments
As of September 30, 2024, and December 31, 2023, the Company had $348.7 million and $350.7 million, respectively of cash, cash equivalents, restricted cash, and investments summarized below. As of September 30, 2024, and December 31, 2023, $311.6 million and $301.8 million were available-for-sale debt securities which are carried at fair market value.
September 30, 2024
(in thousands)Amortized CostUnrealized Gains
Unrealized Losses
Estimated Fair Value
Cash, cash equivalents, and restricted cash
$37,142 $— $— $37,142 
Corporate bonds599 2 — 601 
Commercial paper2,028 — — 2,028 
Treasury bills196,311 160 — 196,471 
Treasury bonds112,246 259 — 112,505 
Total cash, cash equivalents, restricted cash, and short-term investments
348,326 421 — 348,747 
Total long-term investment corporate bond— — — — 
Total cash, cash equivalents, restricted cash, and investments
$348,326 $421 $— $348,747 
December 31, 2023
(in thousands)Amortized CostUnrealized GainsUnrealized LossesEstimated Fair Value
Cash, cash equivalents, and restricted cash
$48,875 $— $— $48,875 
Corporate bonds33,576 4 — 33,580 
Commercial paper39,305 — (1)39,304 
Treasury bills122,757 49 — 122,806 
Treasury bonds105,903 21 — 105,924 
Total cash, cash equivalents, restricted cash, and short-term investments
350,416 74 (1)350,489 
Total long-term investment corporate bond
200 1 — 201 
Total cash, cash equivalents, restricted cash, and investments
$350,616 $75 $(1)$350,690 

As of September 30, 2024, and December 31, 2023, accrued interest receivable from investments was $0.5 million and $0.7 million, respectively. During the three and nine months ended September 30, 2024, the Company had $0.5 million and $0.3 million of unrealized gains on available-for-sale securities, net of tax, respectively, which are included as a component of comprehensive income (loss) on the consolidated statements of operations. During the three and nine months ended September 30, 2023, the Company had $0.1 million and $0.1 million of unrealized gains on available-for-sale securities, net of tax, respectively, which are included as a component of comprehensive income (loss) on the consolidated statements of operations. Currently, the Company does not intend to sell investments that are in an unrealized loss position, and it is unlikely the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. The Company has determined that the gross unrealized gains on investments at September 30, 2024, were temporary in nature. Realized gains or losses were immaterial during the three and nine months ended September 30, 2024, and 2023.
The Company's short-term investments as of September 30, 2024 mature at various dates through August 2025.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.3
Inventories, net
 9 Months Ended
Sep. 30, 2024
Inventory Disclosure [Abstract]  
Inventories, net Inventories, net
Inventories are valued under a standard costing methodology on a first-in, first-out basis and are stated at the lower of cost or net realizable value. The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of
regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. Capitalized costs of inventories for LUPKYNIS (voclosporin) mainly include third party manufacturing costs, transportation, storage, insurance, and allocated internal labor. Due to the nature of the Company's supply chain process, inventory that is owned by the Company, is physically stored at third-party warehouses, logistics providers, and contract manufacturers.

The Company assesses recoverability of inventory each reporting period to determine if any write-down to net realizable value is necessary. As of September 30, 2024, and December 31, 2023, Aurinia recorded reserves of finished goods inventories of nil and $0.8 million, respectively, which were primarily related to potential inventory obsolescence.

The components of inventory, net are as follows:
(in thousands)September 30, 2024December 31, 2023
Raw materials$1,702 $1,746 
Work in process34,990 37,376 
Finished goods, net of reserve2,022 583 
Total inventories, net$38,714 $39,705 
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.3
Prepaid Expenses and Deposits
 9 Months Ended
Sep. 30, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Prepaid Expenses and Deposits Prepaid Expenses and Deposits
Prepaid expenses are as follows:

(in thousands)September 30, 2024December 31, 2023
Prepaid assets$7,730 $6,892 
Prepaid deposits4,189 1,345 
Prepaid insurance1,896 1,249 
Total prepaid expenses and deposits
$13,815 $9,486 
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.3
Intangible Assets
 9 Months Ended
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets Intangible Assets
The following table summarizes the carrying amount of intangible assets, net of accumulated amortization.
September 30, 2024
(in thousands)Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents$2,073 $(1,354)$719 
Acquired intellectual property and reacquired rights15,126 (11,336)3,790 
Internal-use software implementation costs2,873 (2,873)— 
$20,072 $(15,563)$4,509 
December 31, 2023
(in thousands)Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents$1,847 $(1,297)$550 
Acquired intellectual property and reacquired rights15,126 (10,737)4,389 
Internal-use software implementation costs2,873 (2,835)38 
$19,846 $(14,869)$4,977 
Amortization expense for the three months ended September 30, 2024, and 2023, was approximately $0.2 million and $0.5 million, respectively. Amortization for the nine months ended September 30, 2024, and 2023, was approximately $0.7 million and $1.4 million, respectively.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.3
Property and Equipment, net
 9 Months Ended
Sep. 30, 2024
Property, Plant and Equipment [Abstract]  
Property and Equipment, net Property and Equipment, net
Property and equipment, net are as follows:
(in thousands)September 30, 2024December 31, 2023
Leasehold improvements$3,243 $3,243 
Office equipment631 631 
Furniture1,155 1,155 
Computer equipment235 235 
5,2645,264
Less accumulated depreciation(2,377)(1,910)
Property and equipment, net$2,887 $3,354 
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.3
Lease Obligations
 9 Months Ended
Sep. 30, 2024
Leases [Abstract]  
Lease Obligations Lease Obligations
The Company has the following lease obligations:
Rockville, Maryland
During March 2020, the Company entered into a lease for its U.S. commercial office in Rockville, Maryland for a total of 30,531 square feet of office space. The lease has a remaining term of approximately seven years and has an option to extend for two five-year periods after the initial term of 11 years has elapsed and has an option to terminate after seven years. As of September 30, 2024, the Company had a right-of-use (ROU) asset of $4.1 million and lease liability of $6.8 million included in the condensed consolidated balance sheets. As of December 31, 2023, the Company had a right-of-use asset of $4.5 million and lease liability of $7.4 million included in the condensed consolidated balance sheets. The Company recorded leasehold improvement incentives in the amount of $2.3 million as additions to the lease liability.
When measuring the lease liability, the Company discounted lease payments using its incremental borrowing rate at the lease commencement date on March 12, 2020. The incremental borrowing rate applied to the lease liability was 5.2% based on the financial position of the Company, geographical region and term of lease.
Edmonton, Alberta
During October 2022, the Company entered into a long term lease in Edmonton for a total of 4,375 square feet of office space. The lease is a six year lease and has an option to renew after five years at prevailing market rates. The lease commenced on November 1, 2022 and the Company recorded the lease as an operating lease. The lease is not material to the Company's financial position.
For all leases, the Company incurs variable lease costs. These costs include operation and maintenance costs included in SG&A and are expensed as incurred. The variable lease costs are not material to the Company's financial position.
The operating lease costs for all leases for the three and nine months ended September 30, 2024, and September 30, 2023, were $0.2 million and $0.6 million, respectively.
Monoplant
At lease inception, the Company recorded an ROU asset of approximately $117.6 million and a corresponding lease liability of $94.1 million, which is the present value of the minimum lease payments beginning July 2023 and expiring in 2030. The incremental borrowing rate applied to value the lease liability at inception is 6.19%, which was based on the financial position of the Company, geographical region and term of lease. As the monoplant finance lease is denominated in Swiss francs, the company incurs unrealized and realized foreign exchange gains and losses each reporting period related to the valuation of the lease liability and timing of lease payments.

As of September 30, 2024, the ROU asset, net and corresponding lease liability balance were $95.6 million and $80.7 million, respectively. As of December 31, 2023, the ROU asset, net and corresponding lease liability balance were $108.7 million and $90.1 million, respectively. For the three and nine months ended September 30, 2024, ROU amortization was $4.4 million and $13.1 million, respectively. For the three and nine months ended September 30, 2024, interest expense was $1.2 million and $3.7 million, respectively.
Beinheim
The Company entered into an equipment and facility finance lease for a backup manufacturing encapsulation site in Beinheim, France that commenced operations during June 2024 with a lease term of seven years. The incremental borrowing rate applied to value the lease liability at inception is 6.19%, which was based on the financial position of the Company, geographical region and term of lease.
As of September 30, 2024, the ROU asset, net and corresponding lease liability balance were $0.8 million and $0.1 million, respectively.
The following table represents the weighted-average remaining lease terms and discount rates as of September 30, 2024:
As of September 30, 2024
Weighted Average Remaining Lease Term (years)Weighted Average Discount Rate
Operating leases6.95.27%
Finance lease
5.56.19%
Supplemental cash flow information related to leases are as follows:
Nine Months Ended
September 30,
20242023
(in thousands)
Cash paid for amounts included in the measurement of lease liabilities
Financing cash flows for finance leases
$(8,959)$(3,482)
Operating cash flows for finance leases
$(3,354)$(718)
Operating cash flows for operating leases
$(831)$(805)
Supplemental disclosure of noncash transactions
Finance right-of-use asset obtained in exchange for lease obligations
$96,459 $113,069 
Finance lease liability arising from obtaining right-of-use assets
$80,882 $85,521 
Future maturities of lease liabilities as of September 30, 2024 are as follows:
(in thousands)Finance Lease PaymentsOperating Lease Payments
Remainder of 2024$4,295 $283 
202517,203 1,141 
202617,204 1,169 
202717,204 1,198 
202817,205 1,227 
Thereafter21,554 3,302 
Total lease payments
94,665 8,320 
Less: imputed interest
(13,783)(1,351)
Total
$80,882 $6,969 
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.3
Accounts Payable and Accrued Liabilities
 9 Months Ended
Sep. 30, 2024
Payables and Accruals [Abstract]  
Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities
Accounts payable and accrued liabilities are as follows:
(in thousands)September 30, 2024December 31, 2023
Commercial accruals
$25,523 $16,216 
Employee accruals
14,180 22,486 
Trade payables
8,878 4,327 
Other accrued liabilities
4,672 5,190 
Accrued R&D projects
2,331 5,503 
Income taxes payable
1,007 667 
Restructuring accruals
179 — 
Total accounts payable and accrued liabilities$56,770 $54,389 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.3
Deferred Compensation and Other Non-current Liabilities
 9 Months Ended
Sep. 30, 2024
Payables and Accruals [Abstract]  
Deferred Compensation and Other Non-current Liabilities Deferred Compensation and Other Non-current Liabilities
The Company recorded other non-current liabilities of $10.8 million and $10.9 million as of September 30, 2024, and December 31, 2023, respectively. The balance for both periods primarily included deferred compensation arrangements whereby certain former executive officers as of March 8, 2012 were provided with future potential employee benefit obligations for remaining with the Company for a certain period of time. These obligations were also contingent on the occurrence of uncertain future events. One of the former officers, Dr. Robert T. Foster, is considered a related party following his appointment to the Board of Directors (the Board) on September 21, 2023. For further discussion, refer to Note 17, Related Party Transactions.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.3
License and Collaboration Agreements
 9 Months Ended
Sep. 30, 2024
Revenue from Contract with Customer [Abstract]  
License and Collaboration Agreements License and Collaboration Agreements
Otsuka Contract

On December 17, 2020, the Company entered into a collaboration and license agreement with Otsuka for the development and commercialization of oral LUPKYNIS in the Otsuka Territories. For full description of the agreements the Company has entered into with Otsuka, please refer to the Annual Report on Form 10-K for the year ended December 31, 2023.

As part of the agreement, the Company received an upfront cash payment of $50.0 million in 2020 for the license agreement and has received $50.0 million in regulatory and pricing approval related milestones. The Company provides semi-finished product of LUPKYNIS to Otsuka on a cost-plus basis, sharing capacity of the monoplant and receives tiered royalties ranging from 10 to 20 percent (dependent on territory and achievement of sale thresholds) on net product sales by Otsuka, along with
additional milestone payments based on the attainment of certain annual sales. In addition, certain collaboration services are to be provided to Otsuka on agreed upon rates.
On September 24, 2024, the Company announced that the Japanese Ministry of Health, Labour, and Welfare has approved LUPKYNIS, a second-generation calcineurin inhibitor, in combination with mycophenolate mofetil (MMF) to treat LN. As part of the December 2020 agreement with Otsuka, the Company is eligible to receive a payment of $10.0 million U.S. dollars upon approval in Japan along with low double-digit royalties on net sales once launched. As a result, the $10.0 million milestone was recognized as collaboration revenue in the quarter.
For the three and nine months ended September 30, 2024, the Company recognized $12.3 million and $16.7 million, respectively of license, collaboration, and royalty revenue from services provided under the Otsuka agreement. For the three and nine months ended September 30, 2023, the Company recognized $12.7 million and $13.2 million, respectively.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.3
Shareholder's Equity
 9 Months Ended
Sep. 30, 2024
Equity [Abstract]  
Shareholder's Equity Shareholder's Equity
On February 15, 2024, Aurinia announced that the Board had approved a share repurchase program of up to $150 million common shares of the Company, affirming its confidence in the Company's growth prospects.

On February 29, 2024, Canadian securities regulators granted exemptive relief for the Company’s share repurchase program, authorizing the Company to purchase up to 15 percent of its issued and outstanding shares in any 12-month period for up to 36 months, including under the current program. This program may be implemented through open market or privately negotiated purchases, including under a plan intended to comply with the affirmative defense under Rule 10b5-1, Rule 10b-18 or an automatic securities purchase plan, an accelerated share repurchase program, or other mechanisms. The timing and amount of repurchase transactions will be determined by management based on its evaluation of market conditions, share price, legal requirements, including applicable blackout period restrictions, and other factors. The purchase price of any Common Shares will be determined in accordance with applicable U.S. securities laws.
As of September 30, 2024, the Company had repurchased approximately 3.4 million of Aurinia's common shares for $18.6 million (including transaction costs, which consist of commissions and excise tax). The cost of repurchased shares are reported as a reduction in common shares and under Alberta law, the shares were cancelled and not reissued.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.3
Net Income (Loss) per Common Share
 9 Months Ended
Sep. 30, 2024
Earnings Per Share [Abstract]  
Net Income (Loss) per Common Share Net Income (Loss) per Common Share
Basic and diluted net loss per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding. For the periods in a loss position, diluted net loss per share is the same as basic net loss per share. The treasury stock method is used to determine the dilutive effect of the Company's stock options, RSUs, performance awards and ESPP. The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:
Three Months Ended
 September 30,
Nine Months Ended
September 30,
(in thousands, except per share data)2024202320242023
Numerator:
Net income (loss) used for the calculation of basic and diluted EPS
$14,350 $(13,447)$4,323 $(51,145)
Denominator:
Weighted-average common shares outstanding, basic
143,051 142,847 143,353 143,085 
Effect of dilutive shares:
Stock options, RSUs, performance awards and ESPP
2,600 — 1,657 — 
Weighted-average diluted common shares outstanding, diluted
145,651 142,847 145,010 143,085 
Net income (loss) per share, basic
$0.10 $(0.09)0.03 (0.36)
Net income (loss) per share, diluted
$0.10 $(0.09)$0.03 $(0.36)
The Company did not include certain shares issuable under share-based compensation plans because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.3
Share-based Compensation
 9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Share-based Compensation Share-based Compensation
The Company's Amended and Restated Equity Incentive Plan (the Plan), which was adopted and approved by the Company's shareholders in June 2021, allows for an issuance of up to an aggregate of 23.8 million shares (inclusive of then outstanding awards) and provides for grants of stock options, performance awards (PAs), and restricted stock units (RSUs) that may be settled in cash and common shares. Also in June 2021, the Company's shareholders adopted and approved the Company's Employee Stock Purchase Plan (2021 ESPP), which allows for the issuance of up to 2.5 million shares. The 2021 ESPP is intended to qualify as an “employee stock purchase plan” under Section 423 of the Internal Revenue Code but also permits the Company to include the employees, including non-United States employees, in offerings not intended to qualify under Section 423. The purpose of the 2021 ESPP is to provide eligible employees with opportunities to purchase the Company’s common shares at a discounted price. As of September 30, 2024, 0.9 million shares have been purchased under the ESPP.
In addition to stock options, PAs and RSUs granted under the Plan, the Company has granted certain stock options and RSUs as inducements material to new employees entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The inducements were granted outside of the Plan.
Stock Options
The Plan requires the exercise price of each option not to be less than the closing market price of the Company’s common shares on the business day immediately prior to the date of grant. The Board approves the vesting criteria and periods at its discretion. The options issued under the Plan are accounted for as equity-settled share-based payments.
The Company used the Black-Scholes option pricing model to estimate the fair value of the options granted. The assumptions used for the annual volatility and expected life of the options are reviewed and updated annually. The Company considers historical volatility of its common shares in estimating its future stock price volatility. The risk-free interest rate for the expected life of the options was based on the yield available on government benchmark bonds with an approximate equivalent
remaining term at the time of the grant. The expected life is based upon the contractual term, taking into account expected employee exercise and expected post-vesting employment termination behavior.
The following weighted average assumptions were used to estimate the fair value of the options granted during the nine months ended September 30, 2024, and September 30, 2023:
20242023
Annualized volatility77 %71 %
Risk-free interest rate4.08 %3.92 %
Expected life of options in years5.0 years5.0 years
Estimated forfeiture rate13.0 %12.7 %
Dividend rate0.0 %0.0%
Fair value per common share option$3.82 $5.94 
The following table summarizes the option award activity for the nine months ended September 30, 2024:

September 30, 2024
Number of shares (in thousands)Weighted average exercise price $
Outstanding - December 31, 2023
11,556 $10.63 
Granted325 5.89 
Exercised(125)5.18 
Forfeited or cancelled
(2,006)12.81 
Outstanding - September 30, 2024
9,750 $10.09 
Restricted Stock Units and Performance Awards
The Company has granted RSUs and PAs under the Plan, as well as inducements for certain new hires as discussed above. The RSUs and PAs are fair valued based on the previous business days' market price of common shares on the date of the grant.
The following table summarizes the RSU and PA activity for the nine months ended September 30, 2024:
September 30, 2024
Number of shares (in thousands)Weighted average fair value price $
Unvested balance, December 31, 2023
7,807 $9.29 
Granted4,663 6.89 
Vested(2,422)9.50 
Forfeited(1,673)8.99 
Unvested balance - September 30, 2024
8,375 $7.96 
Share-based Compensation Expense
The Company recognized share-based compensation expense for the three and nine months ended September 30, 2024, and September 30, 2023, as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands)2024202320242023
Research and development$306 $1,975 $(1,773)$5,679 
Selling, general and administrative7,812 9,560 23,427 26,969 
Capitalized under inventories209 273 996 895 
Share-based compensation expense$8,327 $11,808 $22,650 $33,543 
As of September 30, 2024, there was $25.7 million of unrecognized share-based compensation expense related to unvested awards granted which is expected to be recognized over a weighted-average period of approximately 1.3 years.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.3
Income Taxes
 9 Months Ended
Sep. 30, 2024
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The effective tax rates for the three and nine months ended September 30, 2024, and September 30, 2023, differed from the Canadian statutory rate applied to income or losses before income taxes primarily as a result of the mix of income, losses and valuation allowances.

The Company recognized an income tax expense of approximately $0.5 million and $2.0 million for the three and nine months ended September 30, 2024, respectively. The Company recognized an income tax expense of approximately $0.3 million and $0.1 million for the three and nine months ended September 30, 2023, respectively. The income tax expense recognized for these periods is a result of income in certain jurisdictions. This tax expense is not offset by a tax benefit as the Company has losses which are fully offset by a valuation allowance in its significant jurisdictions.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.3
Related Party Transactions
 9 Months Ended
Sep. 30, 2024
Related Party Transactions [Abstract]  
Related Party Transactions Related Party Transactions
On September 21, 2023, the Company appointed Dr. Robert T. Foster to the Board. Dr. Foster is considered a related party since he is one of the former executive officers of the Company who, as of March 8, 2012 was provided with future potential employee benefit obligations for remaining with the Company for a certain period of time. These obligations are contingent on the occurrence of uncertain future events. Dr. Foster was not a related party of the Company between his resignation from the Company in 2014, and his appointment to the Board on September 21, 2023. As of September 30, 2024, the Company had $0.8 million and $7.0 million of current and non-current liabilities related to Dr. Foster, respectively. As of December 31, 2023, the Company had $0.8 million and $7.6 million of current and non-current liabilities related to Dr. Foster, respectively. As of September 30, 2024, and December 31, 2023, the Company made payments of $0.4 million and $0.1 million, respectively for each period as a related party for the deferred compensation.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.3
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
The Company may, from time to time, be subject to claims and legal proceedings brought against it in the normal course of business. Such matters are subject to many uncertainties. Management believes the ultimate resolution of such contingencies will not have a material adverse effect on the consolidated financial position of the Company. Other than as described under Part II, Item I, the Company's material commitments and contingencies have not changed in any material manner from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.
Other Funding Commitments
In the normal course of business, the Company enters into agreements with contract research organizations, contract manufacturing organizations and other third parties for services to be provided to the Company. Generally, these agreements provide for termination upon notice, with specified amounts due upon termination based on the timing of termination and the terms of the agreement. The actual amounts and timing of payments under these agreements are uncertain and contingent upon the initiation and completion of services to be provided to the Company.
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.3
Restructuring
 9 Months Ended
Sep. 30, 2024
Restructuring and Related Activities [Abstract]  
Restructuring Restructuring
On February 15, 2024, the Company announced the conclusion of its strategic review process and actions designed to enhance shareholder value. Aurinia executed a corporate restructuring in the first quarter that reduced employee headcount by approximately 25%. The Company discontinued its AUR300 research and development program.
As of September 30, 2024, the restructuring expenses are included within operating expenses on the condensed consolidated statements of operations and comprehensive income (loss). For the three and nine months ended September 30, 2024, restructuring expenses were nil and $7.8 million, respectively. Restructuring expenses consisted of the following:
(in thousands)
Nine Months Ended September 30, 2024
Employee severance and one time benefits
$6,075 
Contract terminations
1,105 
Other costs
575 
Total
$7,755 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.3
Subsequent Events
 9 Months Ended
Sep. 30, 2024
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
Effective November 7, 2024, Aurinia appointed Craig Johnson to the Board. Mr. Johnson has more than 30 years of experience serving in senior financial management roles and governing companies in the biotechnology industry.
The Company also announced that Dr. Robert T. Foster has retired from the Board effective November 5, 2024.
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.3
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.
In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of September 30, 2024 was derived from audited annual consolidated financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. The results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the full year or any other future periods.
Principles of Consolidation
These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation and operate in one segment.
These unaudited condensed consolidated financial statements are presented in U.S. dollars, which is the Company's and all of its foreign subsidiaries' functional currency. Therefore, there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statements of operations. All monetary assets and liabilities denominated in a foreign currency are remeasured into U.S. dollars at the exchange rate on the balance sheet date. Non-monetary assets and liabilities (along with their related expenses) are translated at the rate of exchange in effect on the date the assets were acquired. Monetary income and expense items are translated at the average foreign currency rate. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the consolidated statements of operations and recorded in other expense (income), net.
Product Revenues
Product Revenues
We sell LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor, and semi-finished product directly to our ex-U.S. partner Otsuka. These customers subsequently distribute the Company's products. Revenues from product sales are recognized when the customer obtains control of the Company's product, which occurs upon delivery to the customer.
Reserves for discounts and allowances: Product sales are recorded at the net sales price, which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a liability (if the amount is payable to a party other than the customer).
The Company's estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available.
Significant judgment is required in estimating variable consideration. In making these estimates, the Company considers historical data, including patient mix and inventory sold to customers that has not yet been dispensed to patients. The Company uses a data aggregator and historical claims to estimate variable consideration for inventory sold to its specialty pharmacies that has not yet been dispensed. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment. As of September 30, 2024, the Company did not have any material adjustments to variable consideration estimates based on actual results. These specific adjustments are detailed further in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.
Major Customers Major Customers: The Company currently has two main specialty pharmacies for U.S. commercial sales of LUPKYNIS and a collaboration partnership with Otsuka for sales of semi-finished product and royalty, collaboration, and manufacturing services revenue in the Otsuka Territories.
Accounts Receivable, net
Accounts Receivable, net: Accounts receivable are stated at their net realizable value. The Company's accounts receivable primarily represent amounts due to the Company from product sales and from its Otsuka collaboration agreement (Note 12). As
of September 30, 2024, and December 31, 2023, accounts receivable, net are $36.5 million and $24.1 million, respectively. The Company's standard credit terms range from 30 to 45 days. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised good to the customer and receipt of payment will be one year or less. The Company estimates the allowances using the current expected credit loss, or CECL, model. Under the CECL model, the allowances reflect the net amount expected to be collected from the accounts receivable. Aurinia evaluates the collectability of these cash flows based on the asset’s amortized cost, the risk of loss even when that risk is remote, losses over an asset’s contractual life, and other relevant information available to the Company. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. Given the nature of the Company's accounts receivable, it determined that an allowance for current expected credit losses was nil as of September 30, 2024, and December 31, 2023.
Share-Based Compensation
Share-Based Compensation: The Company follows ASC Topic 718, Compensation - Stock Compensation, which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date using the graded accelerated vesting method for all share-based payments related to stock options, performance awards (PAs), restricted stock units (RSUs) and purchases under the Company's 2021 Employee Share Purchase Plan (ESPP). The estimated fair value of performance-based awards is measured on the grant date and is recognized when it is determined that it is probable that the performance condition will be achieved. The Company has elected a policy for all share-based awards to estimate forfeitures based on historical forfeiture experience at the time of grant and revise in subsequent periods if actual forfeitures differ from those estimates.
Restructuring Expenses
Restructuring Expenses: Restructuring expenses consist primarily of employee severance, contract termination costs and other costs. Liabilities for costs associated with a restructuring activity are recognized when the liability is incurred and are measured at fair value. According to ASC 420, Exit or Disposal Cost Obligations, one-time employee severance and termination benefits are expensed at the date the entity notifies the employee of the plan, unless the employee must provide future service, in which case the benefits are expensed in the period when the service ends. One-time termination benefits include severance, continuation of health insurance coverage for certain employees, and other benefits such as outplacement support services for a specified period of time.
Common Shares
Common Shares: The Company’s shares have no par value or stated value and therefore, upon issuance or repurchase of shares, all amounts related to the shares are recorded under common shares on the balance sheet. The value of common shares includes cash amounts paid or received for the shares and the fair value of equity awards and warrants. Amounts for common shares are offset by share issue costs or transactions costs associated with repurchases or equity offerings.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
In December 2023, the FASB issued final guidance in ASU No. 2023-09, Income Taxes (ASC 740): Improvements to Income Tax Disclosures requiring entities to provide additional information in the rate reconciliation and disclosures about income taxes paid. For public business entities, the guidance is effective for annual periods beginning after December 15, 2024. The Company is not early adopting, and therefore, this ASU is not adopted in the current period. The Company is currently assessing the potential impact this ASU may have on the consolidated financial statements.
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures which requires public entities to disclose significant segment expenses regularly provided to the chief operating decision-maker. Public entities with a single reporting segment have to provide all disclosures required by ASC 280, including the significant segment expense disclosures. For public business entities, the guidance is effective for annual periods beginning after December 15, 2023. This ASU does not have a material impact on the consolidated financial statements.
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.3
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2024
Fair Value Disclosures [Abstract]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
The following table summarizes the financial assets (cash, cash equivalents, restricted cash, and investments) measured at fair value on a recurring basis:
September 30, 2024
(in thousands)Level 1Level 2Level 3Total
Financial assets:
Cash, cash equivalents, and restricted cash
$37,142 $— $— $37,142 
Corporate bonds— 601 — 601 
Commercial paper— 2,028 — 2,028 
Treasury bills— 196,471 — 196,471 
Treasury bonds— 112,505 — 112,505 
Total financial assets$37,142 $311,605 $— $348,747 
December 31, 2023
(in thousands)Level 1Level 2Level 3Total
Financial assets:
Cash, cash equivalents, and restricted cash
$48,875 $— $— $48,875 
Corporate bonds— 33,781 — 33,781 
Commercial paper— 39,304 — 39,304 
Treasury bills— 122,806 — 122,806 
Treasury bonds— 105,924 — 105,924 
Total financial assets$48,875 $301,815 $— $350,690 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.3
Cash, Cash Equivalents, Restricted Cash and Investments (Tables)
 9 Months Ended
Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]  
Schedule of Cash, Cash Equivalents, Restricted Cash and Investments
September 30, 2024
(in thousands)Amortized CostUnrealized Gains
Unrealized Losses
Estimated Fair Value
Cash, cash equivalents, and restricted cash
$37,142 $— $— $37,142 
Corporate bonds599 2 — 601 
Commercial paper2,028 — — 2,028 
Treasury bills196,311 160 — 196,471 
Treasury bonds112,246 259 — 112,505 
Total cash, cash equivalents, restricted cash, and short-term investments
348,326 421 — 348,747 
Total long-term investment corporate bond— — — — 
Total cash, cash equivalents, restricted cash, and investments
$348,326 $421 $— $348,747 
December 31, 2023
(in thousands)Amortized CostUnrealized GainsUnrealized LossesEstimated Fair Value
Cash, cash equivalents, and restricted cash
$48,875 $— $— $48,875 
Corporate bonds33,576 4 — 33,580 
Commercial paper39,305 — (1)39,304 
Treasury bills122,757 49 — 122,806 
Treasury bonds105,903 21 — 105,924 
Total cash, cash equivalents, restricted cash, and short-term investments
350,416 74 (1)350,489 
Total long-term investment corporate bond
200 1 — 201 
Total cash, cash equivalents, restricted cash, and investments
$350,616 $75 $(1)$350,690 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.3
Inventories, net (Tables)
 9 Months Ended
Sep. 30, 2024
Inventory Disclosure [Abstract]  
Schedule of Inventories, Net
The components of inventory, net are as follows:
(in thousands)September 30, 2024December 31, 2023
Raw materials$1,702 $1,746 
Work in process34,990 37,376 
Finished goods, net of reserve2,022 583 
Total inventories, net$38,714 $39,705 
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.3
Prepaid Expenses and Deposits (Tables)
 9 Months Ended
Sep. 30, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Schedule of Prepaid Expenses and Deposits
Prepaid expenses are as follows:

(in thousands)September 30, 2024December 31, 2023
Prepaid assets$7,730 $6,892 
Prepaid deposits4,189 1,345 
Prepaid insurance1,896 1,249 
Total prepaid expenses and deposits
$13,815 $9,486 
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.3
Intangible Assets (Tables)
 9 Months Ended
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets
The following table summarizes the carrying amount of intangible assets, net of accumulated amortization.
September 30, 2024
(in thousands)Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents$2,073 $(1,354)$719 
Acquired intellectual property and reacquired rights15,126 (11,336)3,790 
Internal-use software implementation costs2,873 (2,873)— 
$20,072 $(15,563)$4,509 
December 31, 2023
(in thousands)Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents$1,847 $(1,297)$550 
Acquired intellectual property and reacquired rights15,126 (10,737)4,389 
Internal-use software implementation costs2,873 (2,835)38 
$19,846 $(14,869)$4,977 
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.3
Property and Equipment, net (Tables)
 9 Months Ended
Sep. 30, 2024
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment
Property and equipment, net are as follows:
(in thousands)September 30, 2024December 31, 2023
Leasehold improvements$3,243 $3,243 
Office equipment631 631 
Furniture1,155 1,155 
Computer equipment235 235 
5,2645,264
Less accumulated depreciation(2,377)(1,910)
Property and equipment, net$2,887 $3,354 
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.3
Lease Obligations (Tables)
 9 Months Ended
Sep. 30, 2024
Leases [Abstract]  
Schedule of Lease Cost
The following table represents the weighted-average remaining lease terms and discount rates as of September 30, 2024:
As of September 30, 2024
Weighted Average Remaining Lease Term (years)Weighted Average Discount Rate
Operating leases6.95.27%
Finance lease
5.56.19%
Supplemental cash flow information related to leases are as follows:
Nine Months Ended
September 30,
20242023
(in thousands)
Cash paid for amounts included in the measurement of lease liabilities
Financing cash flows for finance leases
$(8,959)$(3,482)
Operating cash flows for finance leases
$(3,354)$(718)
Operating cash flows for operating leases
$(831)$(805)
Supplemental disclosure of noncash transactions
Finance right-of-use asset obtained in exchange for lease obligations
$96,459 $113,069 
Finance lease liability arising from obtaining right-of-use assets
$80,882 $85,521 
Schedule of Maturities of Lease Liabilities
Future maturities of lease liabilities as of September 30, 2024 are as follows:
(in thousands)Finance Lease PaymentsOperating Lease Payments
Remainder of 2024$4,295 $283 
202517,203 1,141 
202617,204 1,169 
202717,204 1,198 
202817,205 1,227 
Thereafter21,554 3,302 
Total lease payments
94,665 8,320 
Less: imputed interest
(13,783)(1,351)
Total
$80,882 $6,969 
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.3
Accounts Payable and Accrued Liabilities (Tables)
 9 Months Ended
Sep. 30, 2024
Payables and Accruals [Abstract]  
Schedule of Accrued Liabilities
Accounts payable and accrued liabilities are as follows:
(in thousands)September 30, 2024December 31, 2023
Commercial accruals
$25,523 $16,216 
Employee accruals
14,180 22,486 
Trade payables
8,878 4,327 
Other accrued liabilities
4,672 5,190 
Accrued R&D projects
2,331 5,503 
Income taxes payable
1,007 667 
Restructuring accruals
179 — 
Total accounts payable and accrued liabilities$56,770 $54,389 
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.3
Net Income (Loss) per Common Share (Tables)
 9 Months Ended
Sep. 30, 2024
Earnings Per Share [Abstract]  
Schedule of Earnings (Loss) Per Share, Basic and Diluted The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:
Three Months Ended
 September 30,
Nine Months Ended
September 30,
(in thousands, except per share data)2024202320242023
Numerator:
Net income (loss) used for the calculation of basic and diluted EPS
$14,350 $(13,447)$4,323 $(51,145)
Denominator:
Weighted-average common shares outstanding, basic
143,051 142,847 143,353 143,085 
Effect of dilutive shares:
Stock options, RSUs, performance awards and ESPP
2,600 — 1,657 — 
Weighted-average diluted common shares outstanding, diluted
145,651 142,847 145,010 143,085 
Net income (loss) per share, basic
$0.10 $(0.09)0.03 (0.36)
Net income (loss) per share, diluted
$0.10 $(0.09)$0.03 $(0.36)
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.3
Share-based Compensation (Tables)
 9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Share-based Payment Award Valuation Assumptions
The following weighted average assumptions were used to estimate the fair value of the options granted during the nine months ended September 30, 2024, and September 30, 2023:
20242023
Annualized volatility77 %71 %
Risk-free interest rate4.08 %3.92 %
Expected life of options in years5.0 years5.0 years
Estimated forfeiture rate13.0 %12.7 %
Dividend rate0.0 %0.0%
Fair value per common share option$3.82 $5.94 
Schedule of Option Activity
The following table summarizes the option award activity for the nine months ended September 30, 2024:

September 30, 2024
Number of shares (in thousands)Weighted average exercise price $
Outstanding - December 31, 2023
11,556 $10.63 
Granted325 5.89 
Exercised(125)5.18 
Forfeited or cancelled
(2,006)12.81 
Outstanding - September 30, 2024
9,750 $10.09 
Schedule of Performance Shares Activity
The following table summarizes the RSU and PA activity for the nine months ended September 30, 2024:
September 30, 2024
Number of shares (in thousands)Weighted average fair value price $
Unvested balance, December 31, 2023
7,807 $9.29 
Granted4,663 6.89 
Vested(2,422)9.50 
Forfeited(1,673)8.99 
Unvested balance - September 30, 2024
8,375 $7.96 
Schedule of Allocation of Share-Based Payments
The Company recognized share-based compensation expense for the three and nine months ended September 30, 2024, and September 30, 2023, as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands)2024202320242023
Research and development$306 $1,975 $(1,773)$5,679 
Selling, general and administrative7,812 9,560 23,427 26,969 
Capitalized under inventories209 273 996 895 
Share-based compensation expense$8,327 $11,808 $22,650 $33,543 
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.3
Restructuring (Tables)
 9 Months Ended
Sep. 30, 2024
Restructuring and Related Activities [Abstract]  
Schedule of Restructuring and Related Costs
As of September 30, 2024, the restructuring expenses are included within operating expenses on the condensed consolidated statements of operations and comprehensive income (loss). For the three and nine months ended September 30, 2024, restructuring expenses were nil and $7.8 million, respectively. Restructuring expenses consisted of the following:
(in thousands)
Nine Months Ended September 30, 2024
Employee severance and one time benefits
$6,075 
Contract terminations
1,105 
Other costs
575 
Total
$7,755 
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.3
Organization and Description of Business (Details) - USD ($)
$ in Millions
 3 Months Ended
Nov. 07, 2024
Dec. 31, 2024
Mar. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Number of positions eliminated, percent     25.00%
Employee severance and one time benefits | Strategic Restructuring Plan | Minimum | Forecast      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Restructuring charges   $ 15.0  
Employee severance and one time benefits | Strategic Restructuring Plan | Maximum | Forecast      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Restructuring charges   $ 19.0  
Employee severance and one time benefits | Strategic Restructuring Plan | Subsequent Event      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Number of positions eliminated, percent 45.00%    
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.3
Summary of Significant Accounting Policies- Narrative (Details)
 9 Months Ended
Sep. 30, 2024
USD ($)
segment
Sep. 30, 2023
Dec. 31, 2023
USD ($)
Property, Plant and Equipment [Line Items]      
Number of operating segments | segment 1    
Number of customers | segment 2    
Accounts receivable, net | $ $ 36,483,000   $ 24,089,000
Allowance for doubtful accounts | $ $ 0   $ 0
Revenue Benchmark | Customer Concentration Risk | Major Customer One      
Property, Plant and Equipment [Line Items]      
Concentration risk (as percent) 49.00% 50.00%  
Revenue Benchmark | Customer Concentration Risk | Major Customer Two      
Property, Plant and Equipment [Line Items]      
Concentration risk (as percent) 38.00% 39.00%  
Minimum      
Property, Plant and Equipment [Line Items]      
Receivable standard credit terms (in days) 30 days    
Maximum      
Property, Plant and Equipment [Line Items]      
Receivable standard credit terms (in days) 45 days    
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.3
Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)
$ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Financial assets:    
Total financial assets $ 348,747 $ 350,690
Cash, cash equivalents, and restricted cash    
Financial assets:    
Total financial assets 37,142 48,875
Corporate bonds    
Financial assets:    
Total financial assets 601 33,781
Commercial paper    
Financial assets:    
Total financial assets 2,028 39,304
Treasury bills    
Financial assets:    
Total financial assets 196,471 122,806
Treasury bonds    
Financial assets:    
Total financial assets 112,505 105,924
Level 1    
Financial assets:    
Total financial assets 37,142 48,875
Level 1 | Cash, cash equivalents, and restricted cash    
Financial assets:    
Total financial assets 37,142 48,875
Level 1 | Corporate bonds    
Financial assets:    
Total financial assets 0 0
Level 1 | Commercial paper    
Financial assets:    
Total financial assets 0 0
Level 1 | Treasury bills    
Financial assets:    
Total financial assets 0 0
Level 1 | Treasury bonds    
Financial assets:    
Total financial assets 0 0
Level 2    
Financial assets:    
Total financial assets $ 311,605 $ 301,815
Derivative, average remaining maturity (in months) 7 months 7 months
Level 2 | Cash, cash equivalents, and restricted cash    
Financial assets:    
Total financial assets $ 0 $ 0
Level 2 | Corporate bonds    
Financial assets:    
Total financial assets 601 33,781
Level 2 | Commercial paper    
Financial assets:    
Total financial assets 2,028 39,304
Level 2 | Treasury bills    
Financial assets:    
Total financial assets 196,471 122,806
Level 2 | Treasury bonds    
Financial assets:    
Total financial assets 112,505 105,924
Level 3    
Financial assets:    
Total financial assets 0 0
Level 3 | Cash, cash equivalents, and restricted cash    
Financial assets:    
Total financial assets 0 0
Level 3 | Corporate bonds    
Financial assets:    
Total financial assets 0 0
Level 3 | Commercial paper    
Financial assets:    
Total financial assets 0 0
Level 3 | Treasury bills    
Financial assets:    
Total financial assets 0 0
Level 3 | Treasury bonds    
Financial assets:    
Total financial assets $ 0 $ 0
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.3
Cash, Cash Equivalents, Restricted Cash and Investments - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]          
Total cash, cash equivalents, restricted cash, and investments $ 348,700   $ 348,700   $ 350,690
Estimated Fair Value 311,600   311,600   301,800
Interest receivable 500   500   $ 700
Unrealized gain on available-for-sale securities $ 500 $ 100 $ 300 $ 100  
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.3
Cash, Cash Equivalents, Restricted Cash and Investments - Schedule of Cash, Cash Equivalents, Restricted Cash and Investments (Details) - USD ($)
$ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Marketable Securities [Line Items]    
Amortized Cost $ 348,326 $ 350,416
Unrealized Gains 421 74
Unrealized Losses 0 1
Estimated Fair Value 311,600 301,800
Total cash, cash equivalents, restricted cash and investments, Amortized Cost 348,326 350,616
Total cash, cash equivalents, restricted cash and investments, unrealized gains 421 75
Total cash, cash equivalents, restricted cash and investments, unrealized losses 0 (1)
Total cash, cash equivalents, restricted cash, and investments 348,700 350,690
Cash, cash equivalents, restricted cash and investments 348,747 350,489
Cash, cash equivalents, and restricted cash    
Marketable Securities [Line Items]    
Amortized Cost 37,142 48,875
Unrealized Gains 0 0
Unrealized Losses 0 0
Estimated Fair Value 37,142 48,875
Corporate bonds    
Marketable Securities [Line Items]    
Amortized Cost 599 33,576
Unrealized Gains 2 4
Unrealized Losses 0 0
Estimated Fair Value 601 33,580
Commercial paper    
Marketable Securities [Line Items]    
Amortized Cost 2,028 39,305
Unrealized Gains 0 0
Unrealized Losses 0 1
Estimated Fair Value 2,028 39,304
Treasury bills    
Marketable Securities [Line Items]    
Amortized Cost 196,311 122,757
Unrealized Gains 160 49
Unrealized Losses 0 0
Estimated Fair Value 196,471 122,806
Treasury bonds    
Marketable Securities [Line Items]    
Amortized Cost 112,246 105,903
Unrealized Gains 259 21
Unrealized Losses 0 0
Estimated Fair Value 112,505 105,924
Total long-term investment corporate bond    
Marketable Securities [Line Items]    
Amortized Cost 0 200
Unrealized Gains 0 1
Unrealized Losses 0 0
Estimated Fair Value $ 0 $ 201
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.3
Inventories, net (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Inventory Disclosure [Abstract]    
Finished goods inventories $ 0 $ 800
Raw materials 1,702 1,746
Work in process 34,990 37,376
Finished goods, net of reserve 2,022 583
Total inventories, net $ 38,714 $ 39,705
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.3
Prepaid Expenses and Deposits (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Prepaid assets $ 7,730 $ 6,892
Prepaid deposits 4,189 1,345
Prepaid insurance 1,896 1,249
Total prepaid expenses and deposits $ 13,815 $ 9,486
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.3
Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value $ 20,072 $ 19,846
Accumulated Amortization (15,563) (14,869)
Net Carrying Amount 4,509 4,977
Patents    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 2,073 1,847
Accumulated Amortization (1,354) (1,297)
Net Carrying Amount 719 550
Acquired intellectual property and reacquired rights    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 15,126 15,126
Accumulated Amortization (11,336) (10,737)
Net Carrying Amount 3,790 4,389
Internal-use software implementation costs    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 2,873 2,873
Accumulated Amortization (2,873) (2,835)
Net Carrying Amount $ 0 $ 38
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.3
Intangible Assets - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]        
Amortization of intangible assets $ 0.2 $ 0.5 $ 0.7 $ 1.4
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.3
Property and Equipment, net (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross $ 5,264 $ 5,264
Less accumulated depreciation (2,377) (1,910)
Property and equipment, net 2,887 3,354
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 3,243 3,243
Office equipment    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 631 631
Furniture    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 1,155 1,155
Computer equipment    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross $ 235 $ 235
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.3
Lease Obligations - Narrative (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Mar. 31, 2020
ft²
extension_option
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
Jul. 31, 2023
USD ($)
Oct. 31, 2022
ft²
Mar. 12, 2020
Lessee, Lease, Description [Line Items]                  
Operating right-of-use assets, net   $ 4,179   $ 4,179   $ 4,498      
Operating lease liability   $ 6,969   $ 6,969          
Operating lease, weighted average discount rate   5.27%   5.27%          
Operating lease costs   $ 200 $ 200 $ 600 $ 600        
Finance right-of-use assets, net   96,459   96,459   108,715      
Finance lease, liability   $ 80,882   $ 80,882          
Finance lease, weighted average discount rate   6.19%   6.19%          
Rockville, Maryland                  
Lessee, Lease, Description [Line Items]                  
Area of property (in sqft) | ft² 30,531                
Remaining lease term (in years) 7 years                
Number of extension options (in years) | extension_option 2                
Lease extension term (in years) 5 years                
Lease term (in years) 11 years                
Operating right-of-use assets, net   $ 4,100   $ 4,100   4,500      
Operating lease liability   6,800   6,800   7,400      
Proceeds from tenant improvements           2,300      
Operating lease, weighted average discount rate                 5.20%
Edmonton, Alberta                  
Lessee, Lease, Description [Line Items]                  
Area of property (in sqft) | ft²               4,375  
Remaining lease term (in years)               6 years  
Lease extension term (in years)               5 years  
Monoplant                  
Lessee, Lease, Description [Line Items]                  
Finance right-of-use assets, net   95,600   95,600   108,700 $ 117,600    
Finance lease, liability   80,700   80,700   $ 90,100 $ 94,100    
Finance lease, weighted average discount rate             6.19%    
Finance lease, right-of-use asset, amortization   4,400   13,100          
Interest expense   1,200   3,700          
Beinheim                  
Lessee, Lease, Description [Line Items]                  
Finance right-of-use assets, net   800   800          
Finance lease, liability   $ 100   $ 100          
Finance lease, weighted average discount rate             6.19%    
Lease termination option term (in years) 7 years                
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.3
Lease Obligations - Schedule of Lease Cost (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Leases [Abstract]    
Operating lease, weighted average remaining lease term (years) 6 years 10 months 24 days  
Operating lease, weighted average discount rate 5.27%  
Finance lease, operating lease, weighted average remaining lease term (years) 5 years 6 months  
Finance lease, weighted average discount rate 6.19%  
Cash paid for amounts included in the measurement of lease liabilities    
Financing cash flows for finance leases $ (8,959) $ (3,482)
Operating cash flows for finance leases (3,354) (718)
Operating cash flows for operating leases (831) (805)
Supplemental disclosure of noncash transactions    
Finance right-of-use asset obtained in exchange for lease obligations 96,459 113,069
Finance lease liability arising from obtaining right-of-use assets $ 80,882 $ 85,521
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.24.3
Lease Obligations - Schedule of Maturities of Lease Liabilities (Details)
$ in Thousands
Sep. 30, 2024
USD ($)
Finance Lease Payments  
Remainder of 2024 $ 4,295
2025 17,203
2026 17,204
2027 17,204
2028 17,205
Thereafter 21,554
Total lease payments 94,665
Less: imputed interest (13,783)
Total 80,882
Operating Lease Payments  
Remainder of 2024 283
2025 1,141
2026 1,169
2027 1,198
2028 1,227
Thereafter 3,302
Total lease payments 8,320
Less: imputed interest (1,351)
Total $ 6,969
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.24.3
Accounts Payable and Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Payables and Accruals [Abstract]    
Commercial accruals $ 25,523 $ 16,216
Employee accruals 14,180 22,486
Trade payables 8,878 4,327
Other accrued liabilities 4,672 5,190
Accrued R&D projects 2,331 5,503
Income taxes payable 1,007 667
Restructuring accruals 179 0
Total accounts payable and accrued liabilities $ 56,770 $ 54,389
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.3
Deferred Compensation and Other Non-current Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Payables and Accruals [Abstract]    
Other non-current liabilities $ 10,844 $ 10,911
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.24.3
License and Collaboration Agreements (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 24, 2024
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2020
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Revenues   $ 67,771 $ 54,515 $ 175,266 $ 130,418  
Otuska | License Agreement Terms            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Upfront payments received           $ 50,000
Regulatory and pricing approval milestone revenue           $ 50,000
Eligible to receive a payment $ 10,000          
Revenues   10,000        
Otuska | License Agreement Terms | Service Revenue            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Revenues   $ 12,300 $ 12,700 $ 16,700 $ 13,200  
Otuska | License Agreement Terms | Minimum            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Tiered royalty percentages on future sales           10.00%
Otuska | License Agreement Terms | Maximum            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Tiered royalty percentages on future sales           20.00%
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.24.3
Shareholder's Equity (Details)
$ in Millions
 9 Months Ended
Feb. 29, 2024
Sep. 30, 2024
USD ($)
shares
Feb. 15, 2024
USD ($)
Class of Stock [Line Items]      
Stock repurchase program, authorized amount     $ 150.0
Stock repurchase program, percentage 0.15    
Stock repurchased during period, (in shares) | shares   3,400,000  
Stock repurchased during period, value   $ 18.6  
Minimum      
Class of Stock [Line Items]      
Stock repurchase program, period 12 months    
Maximum      
Class of Stock [Line Items]      
Stock repurchase program, period 36 months    
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.24.3
Net Income (Loss) per Common Share - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Numerator:        
Net income (loss) $ 14,350 $ (13,447) $ 4,323 $ (51,145)
Denominator:        
Weighted average common shares outstanding basic (in shares) 143,051 142,847 143,353 143,085
Weighted average common shares outstanding diluted (in shares) 145,651 142,847 145,010 143,085
Net income (loss) per share, basic (in usd per share) $ 0.10 $ (0.09) $ 0.03 $ (0.36)
Net income (loss) per share, diluted (in usd per share) $ 0.10 $ (0.09) $ 0.03 $ (0.36)
Stock options, RSUs, performance awards and ESPP        
Denominator:        
Stock options, RSUs, performance awards and ESPP (in shares) 2,600 0 1,657 0
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.24.3
Share-based Compensation - Narrative (Details) - USD ($)
$ in Millions
 1 Months Ended 9 Months Ended
Jun. 30, 2021
Sep. 30, 2024
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Unrecognized share-based compensation expense   $ 25.7
Unrecognized share-based compensation expense weighted average recognition period (in years)   1 year 3 months 18 days
Employee Stock [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares authorized (in shares) 2,500,000  
Number of shares purchased (in shares)   900,000
Amended and Restated Equity Incentive Plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of additional shares authorized (in shares) 23,800,000  
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.24.3
Share-based Compensation - Schedule of Share-based Payment Award Valuation Assumptions (Details) - USD ($)
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]    
Annualized volatility (as percent) 77.00% 71.00%
Risk-free interest rate (as percent) 4.08% 3.92%
Expected life of options in years 5 years 5 years
Estimated forfeiture rate (as percent) 13.00% 12.70%
Dividend rate $ 0.000 $ 0.000
Fair value per common share option (in usd per share) $ 3.82 $ 5.94
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.24.3
Share-based Compensation - Schedule of Option Activity (Details)
shares in Thousands
 9 Months Ended
Sep. 30, 2024
$ / shares
shares
Dec. 31, 2023
$ / shares
Number of shares (in thousands)    
Beginning balance (in shares) | shares 11,556  
Granted (in shares) | shares 325  
Exercised (in shares) | shares (125)  
Forfeited or cancelled (in shares) | shares (2,006)  
Ending balance (in shares) | shares 9,750  
Weighted average exercise price $    
Beginning balance (in usd per share) | $ / shares $ 10.09 $ 10.63
Granted (in usd per share) | $ / shares 5.89  
Exercised (in usd per share) | $ / shares 5.18  
Forfeited or cancelled (in usd per share) | $ / shares 12.81  
Ending balance (in usd per share) | $ / shares $ 10.09  
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.24.3
Share-based Compensation - Schedule of Allocation of Share-Based Payments (Details) - Performance Share sand Restricted Stock Units (RSUs)
shares in Thousands
 9 Months Ended
Sep. 30, 2024
$ / shares
shares
Number of shares (in thousands)  
Outstanding - Beginning of Period (in shares) | shares 7,807
Granted (in shares) | shares 4,663
Vested (in shares) | shares (2,422)
Forfeited (in shares) | shares (1,673)
Outstanding - End of Period (in shares) | shares 8,375
Weighted average exercise price $  
Outstanding, Weighted average exercise price - Beginning of Period (in usd per share) | $ / shares $ 9.29
Weighted average grant date fair value (in usd per share) | $ / shares 6.89
Weighted average grant date fair value (in usd per share) | $ / shares 9.50
Weighted average exercise price (in usd per share) | $ / shares 8.99
Outstanding, Weighted average exercise price - End of Period (in usd per share) | $ / shares $ 7.96
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.24.3
Share-based Compensation - Allocated Share-Based Compensation Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation expense $ 8,327 $ 11,808 $ 22,650 $ 33,543
Research and development        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation expense 306 1,975 (1,773) 5,679
Selling, general and administrative        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation expense 7,812 9,560 23,427 26,969
Capitalized under inventories        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation expense $ 209 $ 273 $ 996 $ 895
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.24.3
Income Taxes (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Tax Disclosure [Abstract]        
Income tax (benefit) expense $ 457 $ 298 $ 1,952 $ 92
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.24.3
Related-Party Transactions (Details) - USD ($)
$ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Related Party Transaction [Line Items]    
Other current liabilities $ 1,590 $ 2,388
Other non-current liabilities 10,844 10,911
Dr. Robert T. Foster    
Related Party Transaction [Line Items]    
Payments of deferred compensation 400 100
Employee Benefit Obligations | Dr. Robert T. Foster    
Related Party Transaction [Line Items]    
Other current liabilities 800 800
Other non-current liabilities $ 7,000 $ 7,600
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.24.3
Restructuring - Narrative (Details)
 3 Months Ended
Mar. 31, 2024
Restructuring and Related Activities [Abstract]  
Number of positions eliminated, percent 25.00%
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.24.3
Restructuring - Schedule of Restructuring and Related Costs (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2024
Restructuring Cost and Reserve [Line Items]    
Restructuring costs and asset impairment charges $ 0 $ 7,755
Employee severance and one time benefits    
Restructuring Cost and Reserve [Line Items]    
Restructuring costs and asset impairment charges   6,075
Contract terminations    
Restructuring Cost and Reserve [Line Items]    
Restructuring costs and asset impairment charges   1,105
Other costs    
Restructuring Cost and Reserve [Line Items]    
Restructuring costs and asset impairment charges   $ 575
EXCEL 78 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-8?20$3;8T.P6BP^0"X99K>]9!:GI?BZD_$E>JE+H7FMMS.:FW=;YFE54_RDW3-@S2ZDJ:NRA6K7U1C%: MZ#5CIBK;4:>3M2O*1>ON]E#7@VK[!]*PW' I;*$K>.+L6?\^[P[)EFN^X"4W MK[U6\W_)6J3B@E?\C16]5J=%]%H^_R,5?Y/"T'*6*UF6O59W=^*)*\VFC@0Y&\B\KI@PNS@J5CI H==\HUM$T(KU M6O?3I^&CNQ_[ Z-B=V_&0GF14C?#3HS^W! M7_UQ?W(_)!YD!$!&%X3\-_(@8P RO@CD;&X_?@PG'F0"0"87A PBF0*0Z24A M8P\R R"S2T(F'N07 /(++N14K:C@;\T)0D5!!DSGBF^:8[GT(+\"D%]Q(6=U M55'U:GG(C*\$MU^CPI!^GLM:&.Y!?@,@O^%"?J= >Y-5*]_DS<7S+\5?,M+1W=9_+(M%$\]S%!V2#;9B2V]@*K?&;9!#,^ M%^27+K)@'A3;4%Z0X8NM1#.][RL;J7GXC"&_=)$%,[)9DEBY'R5]K5D(!CFE MBRP5FP]N;+;VVD3--;^-^\+1 X:,TD56RMCV64:FBY*O=B=],,@B762-[$6ZR&^C3,V:*1\3,DD7 M625C>YGMOPW8O9TVT(54.]3^2C'F8T(NZ2++9+:FBJUE63#UAVYZC'GU,VW( M)!&R22:VWI'(9<7(U5AJ_8G8ONT>>V6C.%O[F)!)(F23-"&\7MA>';9)GP^< ML2 ;91_".7UA_E@300*)D 7RZ IMO!ZH&ZSGBMJ8Y>]'PP@R280]/;'-C)LF ML]KW89L BA43.0_#"+DD0G9)DU/5N:F51?.A((]$R!Z9U0O-?M7V(C+_)U=Q9.8@F9(X(V1Q@GA^NA$ 2B9$E\C[/ M/X3QDP\(Z2-&U@>8\),K'Q.R2(QND7R$X!Z\% MS#"":$+>2;!W6T!,?_D] ;=;D+USG @-F*&\##IY GDG0?8.F F%G1SR3H+L MG>-,:-]O:EL2[&0DD'<29.^#K,8$$E" + MZ#AK.Q?-%!)0BBR@4YBGVV8*"2A%%A"(&>[]0@)*D04$)\*^@%)(0"FR@, 5 M\3":D(!2[(D/M"(>8H([_L@6.K4B?M*5*22A]**3GZ!I0A)*+S7YV8V>/B8D MH11[W_\\IAN6?$Q(0NE';-:!8&8P4LSD(2R"^W;6,Q^64H? M$Y)0]H';-R?'H0QR3_8Q&SG7QQLY#:N/";DG0W9/N+H1I&XNHCXFY)[L(_=S MPM3-32=]3/!]LT8^[>9B?7=;L"47K)C8G]"V/*=E_J"(^]B][9*D;@MZ69?E MO2V;BK&DQ>%EU,.+M'?_ 5!+ P04 " V,F=9'M^97AP" ])P &@ M 'AL+U]R96QS+W=O9-K*!I!3?BBV012M3G;?EC.P#^I!3R+."!6(RS_A$P*>?I5#.^Z[4]WM M^[KX.!Y.==7LQK'_D5)=[\JQK7==7T[G(YMN.+;C>3EL4]^NW]MM2;IGVYG+EX_^_(_$[O-9K\N/[OU[V,YC?\8G/YTPWO=E3(VB]=VV)9QU:2/ MPW5W39>-W)TG-XN7MU4SO+Q)D^8.4@C2^8,,@FS^((<@GS\H("CF#\H0E.@^_F#'B#H8?Z@1PAZG#](EBCCDB!I@C6!UH)<"X'7@F +@=B"9 N!V8)H M"X':@FP+@=N"< N!W()T"X'=@G@+@=Z*>BN!WHIZ*X'>.GG8)M!;46\ET%M1 M;R706U%O)=!;46\ET%M1;R706U%O)=!;46\ET-M0;R/0VU!O(]#;4&\CT-LF M+TL(]#;4VPCT-M3;"/0VU-L(]#;4VPCT-M3;"/0VU-L(]';4VPGT=M3;"?1V MU-L)]';4VPGT]LG+;@*]'?5V KT=]78"O1WU=@*]'?5V KT=]78"O0/U#@*] M _4. KT#]0X"O0/U#@*] _4. KUC\K&20.] O8- [T"]@T#O0+V#0.] O8- M[XQZ9P*],^J="?3.J'7M+2;-DVNMOGGV+A^7@1J8S&YV&T$,I\< M]\15X^-1WE"P+Q.&E>\#7L_=/%((34V36QO2M>WR+K9M64S/+<5R?XDO>G3+ M95-1[:I-EX^4T0>R=5P1I:XM=T6/]B>G?,.T^^0'YX]E]@7FG;?!^9@G%NCW M<6\C&4Y/?2Y$(37[7_$],9<^^/UHF'9-]0^S\_4^N; >YQ'9^#C\CC_.^+W^ M+_L0('U(D#X42!\:I \#TL&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 M Q0 ( #8R9UF=Q4,VV04 ,T> 8 " @0T( !X;"]W M;W)K&PO=V]R:W-H965T&UL M4$L! A0#% @ -C)G647NN'Q. P 6 L !@ ("!?14 M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ -C)G M697'&N/<"0 *%$ !@ ("!OR, 'AL+W=O&PO=V]R:W-H M965T&UL4$L! A0#% @ -C)G63#NXA2"$0 5C( !@ M ("!,#T 'AL+W=OA. !X;"]W M;W)K&UL4$L! A0#% @ -C)G68?6H]MN!0 M%! !D ("!YE8 'AL+W=OS_;N-8$ !W"@ &0 @(&+ M7 >&PO=V]R:W-H965T&UL4$L! A0#% @ -C)G6?8-5I!Z P 3@@ !D M ("!:&0 'AL+W=O&PO=V]R:W-H M965T8 @ #(8 9 M " @?)J !X;"]W;W)K&UL4$L! M A0#% @ -C)G68DP-6'< @ F 8 !D ("!B7, 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ -C)G M68*CVDRF! : H !D ("!T7\ 'AL+W=O&PO=V]R:W-H965TC0 D *86 9 " @1^) !X;"]W;W)K M&UL4$L! A0#% @ -C)G65[#+OPJ P Y0< M !D ("!5I( 'AL+W=O" &0 @(&WE0 M>&PO=V]R:W-H965T&UL4$L! A0#% @ -C)G610(1BZK P @@ !D M ("!P9T 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ -C)G6<%;2K9I P NP@ !D ("!J[0 'AL+W=O M&PO=V]R:W-H965T2G@( *H% 9 " @2F\ M !X;"]W;W)K&UL4$L! A0#% @ -C)G6;]. MAI.H @ X@4 !D ("!_KX 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ -C)G6?GOXG= ! '@H !D M ("!+\@ 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ -C)G60#(C4$#!0 )PT !D ("! M>=, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ -C)G695JB.Q^! 5!D !D ("!]-\ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ -C)G68$DJ69Q M!@ 'R< !D ("!0/ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ -C)G6;#3(0/O P :Q( !D M ("!K/P 'AL+W=O&PO=V]R M:W-H965T , "D1 M 9 " @:P# 0!X;"]W;W)K&UL M4$L! A0#% @ -C)G6;.;U7/2"0 8'0 !D ("!6P&PO=V]R:W-H965T&UL4$L! A0#% @ M-C)G6?HVO?&PO=V]R:W-H965T&UL4$L! A0#% @ -C)G69LM-FV3 P MUQ$ !D ("!KR0! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ -C)G68@Z#L=' P B0D !D M ("!DC ! 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ -C)G665C"R3] P .!4 !D ("!ECL! 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ -C)G M621F;L4R @ N@0 !D ("!#T8! 'AL+W=O&PO=V]R:W-H965TWYE>' ( #TG : " 9M5 0!X;"]?]7 0!;0V]N=&5N=%]4>7!E&UL4$L%!@ !* - $H /10 Y: 0 $! end XML 79 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 80 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 82 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 206 275 1 false 52 0 false 7 false false R1.htm 0000001 - Document - COVER Sheet http://www.auriniapharma.com/role/COVER COVER Cover 1 false false R2.htm 9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) Sheet http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) Statements 4 false false R5.htm 9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) Sheet http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) Statements 5 false false R6.htm 9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY Sheet http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY Statements 6 false false R7.htm 9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 9952157 - Disclosure - Organization and Description of Business Sheet http://www.auriniapharma.com/role/OrganizationandDescriptionofBusiness Organization and Description of Business Notes 8 false false R9.htm 9952158 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 9952159 - Disclosure - Fair Value Measurements Sheet http://www.auriniapharma.com/role/FairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 9952160 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Investments Sheet http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestments Cash, Cash Equivalents, Restricted Cash and Investments Notes 11 false false R12.htm 9952161 - Disclosure - Inventories, net Sheet http://www.auriniapharma.com/role/Inventoriesnet Inventories, net Notes 12 false false R13.htm 9952162 - Disclosure - Prepaid Expenses and Deposits Sheet http://www.auriniapharma.com/role/PrepaidExpensesandDeposits Prepaid Expenses and Deposits Notes 13 false false R14.htm 9952163 - Disclosure - Intangible Assets Sheet http://www.auriniapharma.com/role/IntangibleAssets Intangible Assets Notes 14 false false R15.htm 9952164 - Disclosure - Property and Equipment, net Sheet http://www.auriniapharma.com/role/PropertyandEquipmentnet Property and Equipment, net Notes 15 false false R16.htm 9952165 - Disclosure - Lease Obligations Sheet http://www.auriniapharma.com/role/LeaseObligations Lease Obligations Notes 16 false false R17.htm 9952166 - Disclosure - Accounts Payable and Accrued Liabilities Sheet http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities Accounts Payable and Accrued Liabilities Notes 17 false false R18.htm 9952167 - Disclosure - Deferred Compensation and Other Non-current Liabilities Sheet http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilities Deferred Compensation and Other Non-current Liabilities Notes 18 false false R19.htm 9952168 - Disclosure - License and Collaboration Agreements Sheet http://www.auriniapharma.com/role/LicenseandCollaborationAgreements License and Collaboration Agreements Notes 19 false false R20.htm 9952169 - Disclosure - Shareholder's Equity Sheet http://www.auriniapharma.com/role/ShareholdersEquity Shareholder's Equity Notes 20 false false R21.htm 9952170 - Disclosure - Net Income (Loss) per Common Share Sheet http://www.auriniapharma.com/role/NetIncomeLossperCommonShare Net Income (Loss) per Common Share Notes 21 false false R22.htm 9952171 - Disclosure - Share-based Compensation Sheet http://www.auriniapharma.com/role/SharebasedCompensation Share-based Compensation Notes 22 false false R23.htm 9952172 - Disclosure - Income Taxes Sheet http://www.auriniapharma.com/role/IncomeTaxes Income Taxes Notes 23 false false R24.htm 9952173 - Disclosure - Related Party Transactions Sheet http://www.auriniapharma.com/role/RelatedPartyTransactions Related Party Transactions Notes 24 false false R25.htm 9952174 - Disclosure - Commitments and Contingencies Sheet http://www.auriniapharma.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 25 false false R26.htm 9952175 - Disclosure - Restructuring Sheet http://www.auriniapharma.com/role/Restructuring Restructuring Notes 26 false false R27.htm 9952176 - Disclosure - Subsequent Events Sheet http://www.auriniapharma.com/role/SubsequentEvents Subsequent Events Notes 27 false false R28.htm 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies 28 false false R29.htm 9954472 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.auriniapharma.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.auriniapharma.com/role/FairValueMeasurements 29 false false R30.htm 9954473 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Investments (Tables) Sheet http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsTables Cash, Cash Equivalents, Restricted Cash and Investments (Tables) Tables http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestments 30 false false R31.htm 9954474 - Disclosure - Inventories, net (Tables) Sheet http://www.auriniapharma.com/role/InventoriesnetTables Inventories, net (Tables) Tables http://www.auriniapharma.com/role/Inventoriesnet 31 false false R32.htm 9954475 - Disclosure - Prepaid Expenses and Deposits (Tables) Sheet http://www.auriniapharma.com/role/PrepaidExpensesandDepositsTables Prepaid Expenses and Deposits (Tables) Tables http://www.auriniapharma.com/role/PrepaidExpensesandDeposits 32 false false R33.htm 9954476 - Disclosure - Intangible Assets (Tables) Sheet http://www.auriniapharma.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://www.auriniapharma.com/role/IntangibleAssets 33 false false R34.htm 9954477 - Disclosure - Property and Equipment, net (Tables) Sheet http://www.auriniapharma.com/role/PropertyandEquipmentnetTables Property and Equipment, net (Tables) Tables http://www.auriniapharma.com/role/PropertyandEquipmentnet 34 false false R35.htm 9954478 - Disclosure - Lease Obligations (Tables) Sheet http://www.auriniapharma.com/role/LeaseObligationsTables Lease Obligations (Tables) Tables http://www.auriniapharma.com/role/LeaseObligations 35 false false R36.htm 9954479 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) Sheet http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesTables Accounts Payable and Accrued Liabilities (Tables) Tables http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities 36 false false R37.htm 9954480 - Disclosure - Net Income (Loss) per Common Share (Tables) Sheet http://www.auriniapharma.com/role/NetIncomeLossperCommonShareTables Net Income (Loss) per Common Share (Tables) Tables http://www.auriniapharma.com/role/NetIncomeLossperCommonShare 37 false false R38.htm 9954481 - Disclosure - Share-based Compensation (Tables) Sheet http://www.auriniapharma.com/role/SharebasedCompensationTables Share-based Compensation (Tables) Tables http://www.auriniapharma.com/role/SharebasedCompensation 38 false false R39.htm 9954482 - Disclosure - Restructuring (Tables) Sheet http://www.auriniapharma.com/role/RestructuringTables Restructuring (Tables) Tables http://www.auriniapharma.com/role/Restructuring 39 false false R40.htm 9954483 - Disclosure - Organization and Description of Business (Details) Sheet http://www.auriniapharma.com/role/OrganizationandDescriptionofBusinessDetails Organization and Description of Business (Details) Details http://www.auriniapharma.com/role/OrganizationandDescriptionofBusiness 40 false false R41.htm 9954484 - Disclosure - Summary of Significant Accounting Policies- Narrative (Details) Sheet http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies- Narrative (Details) Details 41 false false R42.htm 9954485 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) Sheet http://www.auriniapharma.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) Details 42 false false R43.htm 9954486 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Investments - Narrative (Details) Sheet http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsNarrativeDetails Cash, Cash Equivalents, Restricted Cash and Investments - Narrative (Details) Details http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsTables 43 false false R44.htm 9954487 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Investments - Schedule of Cash, Cash Equivalents, Restricted Cash and Investments (Details) Sheet http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsScheduleofCashCashEquivalentsRestrictedCashandInvestmentsDetails Cash, Cash Equivalents, Restricted Cash and Investments - Schedule of Cash, Cash Equivalents, Restricted Cash and Investments (Details) Details 44 false false R45.htm 9954488 - Disclosure - Inventories, net (Details) Sheet http://www.auriniapharma.com/role/InventoriesnetDetails Inventories, net (Details) Details http://www.auriniapharma.com/role/InventoriesnetTables 45 false false R46.htm 9954489 - Disclosure - Prepaid Expenses and Deposits (Details) Sheet http://www.auriniapharma.com/role/PrepaidExpensesandDepositsDetails Prepaid Expenses and Deposits (Details) Details http://www.auriniapharma.com/role/PrepaidExpensesandDepositsTables 46 false false R47.htm 9954490 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) Sheet http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails Intangible Assets - Schedule of Intangible Assets (Details) Details 47 false false R48.htm 9954491 - Disclosure - Intangible Assets - Narrative (Details) Sheet http://www.auriniapharma.com/role/IntangibleAssetsNarrativeDetails Intangible Assets - Narrative (Details) Details 48 false false R49.htm 9954492 - Disclosure - Property and Equipment, net (Details) Sheet http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails Property and Equipment, net (Details) Details http://www.auriniapharma.com/role/PropertyandEquipmentnetTables 49 false false R50.htm 9954493 - Disclosure - Lease Obligations - Narrative (Details) Sheet http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails Lease Obligations - Narrative (Details) Details 50 false false R51.htm 9954494 - Disclosure - Lease Obligations - Schedule of Lease Cost (Details) Sheet http://www.auriniapharma.com/role/LeaseObligationsScheduleofLeaseCostDetails Lease Obligations - Schedule of Lease Cost (Details) Details 51 false false R52.htm 9954495 - Disclosure - Lease Obligations - Schedule of Maturities of Lease Liabilities (Details) Sheet http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails Lease Obligations - Schedule of Maturities of Lease Liabilities (Details) Details 52 false false R53.htm 9954496 - Disclosure - Accounts Payable and Accrued Liabilities - Schedule of Accrued Liabilities (Details) Sheet http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesScheduleofAccruedLiabilitiesDetails Accounts Payable and Accrued Liabilities - Schedule of Accrued Liabilities (Details) Details 53 false false R54.htm 9954497 - Disclosure - Deferred Compensation and Other Non-current Liabilities (Details) Sheet http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilitiesDetails Deferred Compensation and Other Non-current Liabilities (Details) Details http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilities 54 false false R55.htm 9954498 - Disclosure - License and Collaboration Agreements (Details) Sheet http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails License and Collaboration Agreements (Details) Details http://www.auriniapharma.com/role/LicenseandCollaborationAgreements 55 false false R56.htm 9954499 - Disclosure - Shareholder's Equity (Details) Sheet http://www.auriniapharma.com/role/ShareholdersEquityDetails Shareholder's Equity (Details) Details http://www.auriniapharma.com/role/ShareholdersEquity 56 false false R57.htm 9954500 - Disclosure - Net Income (Loss) per Common Share - Schedule of Earnings Per Share, Basic and Diluted (Details) Sheet http://www.auriniapharma.com/role/NetIncomeLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails Net Income (Loss) per Common Share - Schedule of Earnings Per Share, Basic and Diluted (Details) Details http://www.auriniapharma.com/role/NetIncomeLossperCommonShareTables 57 false false R58.htm 9954501 - Disclosure - Share-based Compensation - Narrative (Details) Sheet http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails Share-based Compensation - Narrative (Details) Details 58 false false R59.htm 9954502 - Disclosure - Share-based Compensation - Schedule of Share-based Payment Award Valuation Assumptions (Details) Sheet http://www.auriniapharma.com/role/SharebasedCompensationScheduleofSharebasedPaymentAwardValuationAssumptionsDetails Share-based Compensation - Schedule of Share-based Payment Award Valuation Assumptions (Details) Details 59 false false R60.htm 9954503 - Disclosure - Share-based Compensation - Schedule of Option Activity (Details) Sheet http://www.auriniapharma.com/role/SharebasedCompensationScheduleofOptionActivityDetails Share-based Compensation - Schedule of Option Activity (Details) Details 60 false false R61.htm 9954504 - Disclosure - Share-based Compensation - Schedule of Allocation of Share-Based Payments (Details) Sheet http://www.auriniapharma.com/role/SharebasedCompensationScheduleofAllocationofShareBasedPaymentsDetails Share-based Compensation - Schedule of Allocation of Share-Based Payments (Details) Details 61 false false R62.htm 9954505 - Disclosure - Share-based Compensation - Allocated Share-Based Compensation Expense (Details) Sheet http://www.auriniapharma.com/role/SharebasedCompensationAllocatedShareBasedCompensationExpenseDetails Share-based Compensation - Allocated Share-Based Compensation Expense (Details) Details 62 false false R63.htm 9954506 - Disclosure - Income Taxes (Details) Sheet http://www.auriniapharma.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.auriniapharma.com/role/IncomeTaxes 63 false false R64.htm 9954507 - Disclosure - Related-Party Transactions (Details) Sheet http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails Related-Party Transactions (Details) Details 64 false false R65.htm 9954508 - Disclosure - Restructuring - Narrative (Details) Sheet http://www.auriniapharma.com/role/RestructuringNarrativeDetails Restructuring - Narrative (Details) Details 65 false false R66.htm 9954509 - Disclosure - Restructuring - Schedule of Restructuring and Related Costs (Details) Sheet http://www.auriniapharma.com/role/RestructuringScheduleofRestructuringandRelatedCostsDetails Restructuring - Schedule of Restructuring and Related Costs (Details) Details 66 false false All Reports Book All Reports auph-20240930.htm auph-20240930.xsd auph-20240930_cal.xml auph-20240930_def.xml auph-20240930_lab.xml auph-20240930_pre.xml http://fasb.org/srt/2024 http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 true true JSON 84 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "auph-20240930.htm": { "nsprefix": "auph", "nsuri": "http://www.auriniapharma.com/20240930", "dts": { "inline": { "local": [ "auph-20240930.htm" ] }, "schema": { "local": [ "auph-20240930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "auph-20240930_cal.xml" ] }, "definitionLink": { "local": [ "auph-20240930_def.xml" ] }, "labelLink": { "local": [ "auph-20240930_lab.xml" ] }, "presentationLink": { "local": [ "auph-20240930_pre.xml" ] } }, "keyStandard": 250, "keyCustom": 25, "axisStandard": 23, "axisCustom": 0, "memberStandard": 35, "memberCustom": 17, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 206, "entityCount": 1, "segmentCount": 52, "elementCount": 452, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 714, "http://xbrl.sec.gov/dei/2024": 29, "http://fasb.org/srt/2024": 1 }, "report": { "R1": { "role": "http://www.auriniapharma.com/role/COVER", "longName": "0000001 - Document - COVER", "shortName": "COVER", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "longName": "9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "unique": true } }, "R3": { "role": "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "longName": "9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "unique": true } }, "R4": { "role": "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS", "longName": "9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-15", "name": "us-gaap:CostOfRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "unique": true } }, "R5": { "role": "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical", "longName": "9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-15", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "longName": "9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-53", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-53", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "unique": true } }, "R8": { "role": "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusiness", "longName": "9952157 - Disclosure - Organization and Description of Business", "shortName": "Organization and Description of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies", "longName": "9952158 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.auriniapharma.com/role/FairValueMeasurements", "longName": "9952159 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestments", "longName": "9952160 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Investments", "shortName": "Cash, Cash Equivalents, Restricted Cash and Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.auriniapharma.com/role/Inventoriesnet", "longName": "9952161 - Disclosure - Inventories, net", "shortName": "Inventories, net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.auriniapharma.com/role/PrepaidExpensesandDeposits", "longName": "9952162 - Disclosure - Prepaid Expenses and Deposits", "shortName": "Prepaid Expenses and Deposits", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "auph:PrepaidExpensesAndDepositsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "auph:PrepaidExpensesAndDepositsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.auriniapharma.com/role/IntangibleAssets", "longName": "9952163 - Disclosure - Intangible Assets", "shortName": "Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.auriniapharma.com/role/PropertyandEquipmentnet", "longName": "9952164 - Disclosure - Property and Equipment, net", "shortName": "Property and Equipment, net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.auriniapharma.com/role/LeaseObligations", "longName": "9952165 - Disclosure - Lease Obligations", "shortName": "Lease Obligations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities", "longName": "9952166 - Disclosure - Accounts Payable and Accrued Liabilities", "shortName": "Accounts Payable and Accrued Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilities", "longName": "9952167 - Disclosure - Deferred Compensation and Other Non-current Liabilities", "shortName": "Deferred Compensation and Other Non-current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.auriniapharma.com/role/LicenseandCollaborationAgreements", "longName": "9952168 - Disclosure - License and Collaboration Agreements", "shortName": "License and Collaboration Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.auriniapharma.com/role/ShareholdersEquity", "longName": "9952169 - Disclosure - Shareholder's Equity", "shortName": "Shareholder's Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.auriniapharma.com/role/NetIncomeLossperCommonShare", "longName": "9952170 - Disclosure - Net Income (Loss) per Common Share", "shortName": "Net Income (Loss) per Common Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.auriniapharma.com/role/SharebasedCompensation", "longName": "9952171 - Disclosure - Share-based Compensation", "shortName": "Share-based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.auriniapharma.com/role/IncomeTaxes", "longName": "9952172 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.auriniapharma.com/role/RelatedPartyTransactions", "longName": "9952173 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.auriniapharma.com/role/CommitmentsandContingencies", "longName": "9952174 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.auriniapharma.com/role/Restructuring", "longName": "9952175 - Disclosure - Restructuring", "shortName": "Restructuring", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.auriniapharma.com/role/SubsequentEvents", "longName": "9952176 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.auriniapharma.com/role/FairValueMeasurementsTables", "longName": "9954472 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsTables", "longName": "9954473 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Investments (Tables)", "shortName": "Cash, Cash Equivalents, Restricted Cash and Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.auriniapharma.com/role/InventoriesnetTables", "longName": "9954474 - Disclosure - Inventories, net (Tables)", "shortName": "Inventories, net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.auriniapharma.com/role/PrepaidExpensesandDepositsTables", "longName": "9954475 - Disclosure - Prepaid Expenses and Deposits (Tables)", "shortName": "Prepaid Expenses and Deposits (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.auriniapharma.com/role/IntangibleAssetsTables", "longName": "9954476 - Disclosure - Intangible Assets (Tables)", "shortName": "Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.auriniapharma.com/role/PropertyandEquipmentnetTables", "longName": "9954477 - Disclosure - Property and Equipment, net (Tables)", "shortName": "Property and Equipment, net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.auriniapharma.com/role/LeaseObligationsTables", "longName": "9954478 - Disclosure - Lease Obligations (Tables)", "shortName": "Lease Obligations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesTables", "longName": "9954479 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)", "shortName": "Accounts Payable and Accrued Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.auriniapharma.com/role/NetIncomeLossperCommonShareTables", "longName": "9954480 - Disclosure - Net Income (Loss) per Common Share (Tables)", "shortName": "Net Income (Loss) per Common Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.auriniapharma.com/role/SharebasedCompensationTables", "longName": "9954481 - Disclosure - Share-based Compensation (Tables)", "shortName": "Share-based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.auriniapharma.com/role/RestructuringTables", "longName": "9954482 - Disclosure - Restructuring (Tables)", "shortName": "Restructuring (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusinessDetails", "longName": "9954483 - Disclosure - Organization and Description of Business (Details)", "shortName": "Organization and Description of Business (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-62", "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-64", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "unique": true } }, "R41": { "role": "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "longName": "9954484 - Disclosure - Summary of Significant Accounting Policies- Narrative (Details)", "shortName": "Summary of Significant Accounting Policies- Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:ConsolidationPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:ConsolidationPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.auriniapharma.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "longName": "9954485 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)", "shortName": "Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsNarrativeDetails", "longName": "9954486 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Investments - Narrative (Details)", "shortName": "Cash, Cash Equivalents, Restricted Cash and Investments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-3", "name": "auph:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:InterestReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "unique": true } }, "R44": { "role": "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsScheduleofCashCashEquivalentsRestrictedCashandInvestmentsDetails", "longName": "9954487 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Investments - Schedule of Cash, Cash Equivalents, Restricted Cash and Investments (Details)", "shortName": "Cash, Cash Equivalents, Restricted Cash and Investments - Schedule of Cash, Cash Equivalents, Restricted Cash and Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.auriniapharma.com/role/InventoriesnetDetails", "longName": "9954488 - Disclosure - Inventories, net (Details)", "shortName": "Inventories, net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryFinishedGoods", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryFinishedGoods", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.auriniapharma.com/role/PrepaidExpensesandDepositsDetails", "longName": "9954489 - Disclosure - Prepaid Expenses and Deposits (Details)", "shortName": "Prepaid Expenses and Deposits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-3", "name": "auph:PrepaidAssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "auph:PrepaidAssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails", "longName": "9954490 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)", "shortName": "Intangible Assets - Schedule of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.auriniapharma.com/role/IntangibleAssetsNarrativeDetails", "longName": "9954491 - Disclosure - Intangible Assets - Narrative (Details)", "shortName": "Intangible Assets - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-15", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails", "longName": "9954492 - Disclosure - Property and Equipment, net (Details)", "shortName": "Property and Equipment, net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails", "longName": "9954493 - Disclosure - Lease Obligations - Narrative (Details)", "shortName": "Lease Obligations - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-15", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "unique": true } }, "R51": { "role": "http://www.auriniapharma.com/role/LeaseObligationsScheduleofLeaseCostDetails", "longName": "9954494 - Disclosure - Lease Obligations - Schedule of Lease Cost (Details)", "shortName": "Lease Obligations - Schedule of Lease Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails", "longName": "9954495 - Disclosure - Lease Obligations - Schedule of Maturities of Lease Liabilities (Details)", "shortName": "Lease Obligations - Schedule of Maturities of Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesScheduleofAccruedLiabilitiesDetails", "longName": "9954496 - Disclosure - Accounts Payable and Accrued Liabilities - Schedule of Accrued Liabilities (Details)", "shortName": "Accounts Payable and Accrued Liabilities - Schedule of Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-3", "name": "auph:CommercialRelatedAccrualsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "auph:CommercialRelatedAccrualsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilitiesDetails", "longName": "9954497 - Disclosure - Deferred Compensation and Other Non-current Liabilities (Details)", "shortName": "Deferred Compensation and Other Non-current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherLiabilitiesNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true }, "uniqueAnchor": null }, "R55": { "role": "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails", "longName": "9954498 - Disclosure - License and Collaboration Agreements (Details)", "shortName": "License and Collaboration Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-165", "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "unique": true } }, "R56": { "role": "http://www.auriniapharma.com/role/ShareholdersEquityDetails", "longName": "9954499 - Disclosure - Shareholder's Equity (Details)", "shortName": "Shareholder's Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-174", "name": "srt:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-174", "name": "srt:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.auriniapharma.com/role/NetIncomeLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails", "longName": "9954500 - Disclosure - Net Income (Loss) per Common Share - Schedule of Earnings Per Share, Basic and Diluted (Details)", "shortName": "Net Income (Loss) per Common Share - Schedule of Earnings Per Share, Basic and Diluted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-178", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "unique": true } }, "R58": { "role": "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails", "longName": "9954501 - Disclosure - Share-based Compensation - Narrative (Details)", "shortName": "Share-based Compensation - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofSharebasedPaymentAwardValuationAssumptionsDetails", "longName": "9954502 - Disclosure - Share-based Compensation - Schedule of Share-based Payment Award Valuation Assumptions (Details)", "shortName": "Share-based Compensation - Schedule of Share-based Payment Award Valuation Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofOptionActivityDetails", "longName": "9954503 - Disclosure - Share-based Compensation - Schedule of Option Activity (Details)", "shortName": "Share-based Compensation - Schedule of Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofAllocationofShareBasedPaymentsDetails", "longName": "9954504 - Disclosure - Share-based Compensation - Schedule of Allocation of Share-Based Payments (Details)", "shortName": "Share-based Compensation - Schedule of Allocation of Share-Based Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-185", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-185", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.auriniapharma.com/role/SharebasedCompensationAllocatedShareBasedCompensationExpenseDetails", "longName": "9954505 - Disclosure - Share-based Compensation - Allocated Share-Based Compensation Expense (Details)", "shortName": "Share-based Compensation - Allocated Share-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-15", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.auriniapharma.com/role/IncomeTaxesDetails", "longName": "9954506 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true }, "uniqueAnchor": null }, "R64": { "role": "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails", "longName": "9954507 - Disclosure - Related-Party Transactions (Details)", "shortName": "Related-Party Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-202", "name": "us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "unique": true } }, "R65": { "role": "http://www.auriniapharma.com/role/RestructuringNarrativeDetails", "longName": "9954508 - Disclosure - Restructuring - Narrative (Details)", "shortName": "Restructuring - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-62", "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true }, "uniqueAnchor": null }, "R66": { "role": "http://www.auriniapharma.com/role/RestructuringScheduleofRestructuringandRelatedCostsDetails", "longName": "9954509 - Disclosure - Restructuring - Schedule of Restructuring and Related Costs (Details)", "shortName": "Restructuring - Schedule of Restructuring and Related Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:RestructuringCostsAndAssetImpairmentCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-15", "name": "us-gaap:RestructuringCostsAndAssetImpairmentCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240930.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsAndOtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsAndOtherReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts and Other Receivables, Net, Current", "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock", "presentation": [ "http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Compensation and Other Non-current Liabilities", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Noncurrent [Text Block]", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as noncurrent at the end of the reporting period." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesScheduleofAccruedLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesScheduleofAccruedLiabilitiesDetails", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued liabilities", "totalLabel": "Total accounts payable and accrued liabilities", "label": "Accounts Payable and Accrued Liabilities, Current", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r52", "r53" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Payable and Accrued Liabilities", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r51", "r53", "r56", "r940" ] }, "us-gaap_AccountsPayableTradeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableTradeCurrent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesScheduleofAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesScheduleofAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables", "label": "Accounts Payable, Trade, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r16", "r51" ] }, "auph_AccountsReceivableCreditTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "AccountsReceivableCreditTerm", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receivable standard credit terms (in days)", "label": "Accounts Receivable, Credit Term", "documentation": "Accounts Receivable, Credit Term" } } }, "auth_ref": [] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net amortization of premiums and discounts on short-term investments", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r80" ] }, "auph_AccruedResearchCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "AccruedResearchCurrent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesScheduleofAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesScheduleofAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued R&D projects", "label": "Accrued Research, Current", "documentation": "Accrued Research, Current" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r30", "r161", "r620" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r18", "r19", "r69", "r168", "r616", "r645", "r646" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive (Loss) Income", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r1", "r8", "r19", "r468", "r471", "r527", "r641", "r642", "r858", "r859", "r860", "r867", "r868", "r869", "r871" ] }, "us-gaap_AdditionalCashFlowElementsSummationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalCashFlowElementsSummationsAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets", "label": "Additional Cash Flow Elements, Summations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r61" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid in capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r661", "r867", "r868", "r869", "r871", "r942", "r1000" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r40", "r41", "r392" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r424", "r433" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for doubtful accounts", "label": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r169", "r241", "r277", "r280", "r281", "r968" ] }, "auph_AmendedAndRestatedEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "AmendedAndRestatedEquityIncentivePlanMember", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amended and Restated Equity Incentive Plan", "label": "Amended and Restated Equity Incentive Plan [Member]", "documentation": "Amended and Restated Equity Incentive Plan" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r5", "r295", "r301", "r776" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.auriniapharma.com/role/NetIncomeLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r25" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.auriniapharma.com/role/NetIncomeLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r25" ] }, "us-gaap_AreaOfRealEstateProperty": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AreaOfRealEstateProperty", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Area of property (in sqft)", "label": "Area of Real Estate Property", "documentation": "Area of a real estate property." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r103", "r112", "r164", "r190", "r224", "r227", "r234", "r235", "r274", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r463", "r465", "r500", "r612", "r688", "r771", "r772", "r805", "r833", "r907", "r908", "r957" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r157", "r172", "r190", "r274", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r463", "r465", "r500", "r805", "r907", "r908", "r957" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total financial assets", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r479", "r480", "r794" ] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets:", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current assets", "label": "Assets, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedGain", "crdr": "credit", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsScheduleofCashCashEquivalentsRestrictedCashandInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Unrealized Gain", "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r884" ] }, "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsScheduleofCashCashEquivalentsRestrictedCashandInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Unrealized Loss", "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r885" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsNarrativeDetails", "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsScheduleofCashCashEquivalentsRestrictedCashandInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Fair Value", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r246", "r285", "r479", "r606", "r794", "r797", "r882", "r946", "r947", "r948" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails", "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofAllocationofShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r395", "r396", "r397", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r419", "r420", "r421", "r422", "r423" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "auph_BeinheimFranceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "BeinheimFranceMember", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Beinheim", "label": "Beinheim, France [Member]", "documentation": "Beinheim, France" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r22", "r159", "r758" ] }, "auph_CashCashEquivalentsAndRestrictedCashMember": { "xbrltype": "domainItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "CashCashEquivalentsAndRestrictedCashMember", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsScheduleofCashCashEquivalentsRestrictedCashandInvestmentsDetails", "http://www.auriniapharma.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, cash equivalents, and restricted cash", "label": "Cash, Cash Equivalents And Restricted Cash [Member]", "documentation": "Cash, Cash Equivalents And Restricted Cash Member" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 }, "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, cash equivalents, and restricted cash", "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of period", "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of period", "totalLabel": "Total cash, cash equivalents, and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r22", "r78", "r187" ] }, "auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndInvestments", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsScheduleofCashCashEquivalentsRestrictedCashandInvestmentsDetails": { "parentTag": "auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndInvestmentsAmortizedCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsNarrativeDetails", "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsScheduleofCashCashEquivalentsRestrictedCashandInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total cash, cash equivalents, restricted cash, and investments", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Investments", "documentation": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Investments" } } }, "auth_ref": [] }, "auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndInvestmentsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndInvestmentsAmortizedCost", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsScheduleofCashCashEquivalentsRestrictedCashandInvestmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsScheduleofCashCashEquivalentsRestrictedCashandInvestmentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total cash, cash equivalents, restricted cash and investments, Amortized Cost", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Investments, Amortized Cost", "documentation": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Investments, Amortized Cost" } } }, "auth_ref": [] }, "auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndInvestmentsUnrealizedGains": { "xbrltype": "monetaryItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndInvestmentsUnrealizedGains", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsScheduleofCashCashEquivalentsRestrictedCashandInvestmentsDetails": { "parentTag": "auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndInvestmentsAmortizedCost", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsScheduleofCashCashEquivalentsRestrictedCashandInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total cash, cash equivalents, restricted cash and investments, unrealized gains", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Investments, Unrealized Gains", "documentation": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Investments, Unrealized Gains" } } }, "auth_ref": [] }, "auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndInvestmentsUnrealizedLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndInvestmentsUnrealizedLosses", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsScheduleofCashCashEquivalentsRestrictedCashandInvestmentsDetails": { "parentTag": "auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndInvestmentsAmortizedCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsScheduleofCashCashEquivalentsRestrictedCashandInvestmentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Total cash, cash equivalents, restricted cash and investments, unrealized losses", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Investments, Unrealized Losses", "documentation": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Investments, Unrealized Losses" } } }, "auth_ref": [] }, "auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsScheduleofCashCashEquivalentsRestrictedCashandInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, cash equivalents, restricted cash and investments", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Short Term Investments", "documentation": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Short Term Investments" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net decrease in cash, cash equivalents, and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r78" ] }, "auph_CashFlowLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "CashFlowLesseeAbstract", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities", "label": "Cash Flow, Lessee [Abstract]", "documentation": "Cash Flow, Lessee" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.auriniapharma.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r165", "r166", "r167", "r226", "r342", "r343", "r344", "r346", "r349", "r354", "r356", "r652", "r653", "r654", "r655", "r783", "r840", "r865" ] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r462" ] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsScheduleofCashCashEquivalentsRestrictedCashandInvestmentsDetails", "http://www.auriniapharma.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r90", "r328", "r827", "r828", "r829", "r830" ] }, "auph_CommercialRelatedAccrualsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "CommercialRelatedAccrualsCurrent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesScheduleofAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesScheduleofAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial accruals", "label": "Commercial Related Accruals, Current", "documentation": "Commercial Related Accruals, Current" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 18)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r57", "r104", "r614", "r675" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.auriniapharma.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r89", "r322", "r323", "r740", "r901", "r904" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common Shares", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r823", "r824", "r825", "r827", "r828", "r829", "r830", "r867", "r868", "r871", "r942", "r999", "r1000" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in usd per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r60" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r60" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, outstanding (in shares)", "periodStartLabel": "Beginning Balance (in shares)", "periodEndLabel": "Ending Balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r9", "r60", "r676", "r694", "r1000", "r1001" ] }, "us-gaap_CommonStockValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValueOutstanding", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares - no par value, unlimited shares authorized, 143,109 and 143,833 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively", "label": "Common Stock, Value, Outstanding", "documentation": "Value of common shares held by shareholders. Excludes common shares repurchased and held as treasury shares." } } }, "auth_ref": [ "r60", "r676" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income (loss)", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r20", "r177", "r179", "r183", "r607", "r626", "r627" ] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer equipment", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerSoftwareIntangibleAssetMember", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Internal-use software implementation costs", "label": "Computer Software, Intangible Asset [Member]", "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks." } } }, "auth_ref": [ "r753", "r757", "r892", "r893", "r894", "r895", "r896", "r898", "r899", "r900" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r27", "r28", "r45", "r46", "r239", "r739" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r27", "r28", "r45", "r46", "r239", "r648", "r739" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r27", "r28", "r45", "r46", "r239", "r739", "r844" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Major Customers", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r49", "r117" ] }, "auph_ConcentrationRiskNumberOfCustomers": { "xbrltype": "integerItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "ConcentrationRiskNumberOfCustomers", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of customers", "label": "Concentration Risk, Number of Customers", "documentation": "Concentration Risk, Number of Customers" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk (as percent)", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r27", "r28", "r45", "r46", "r239" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r27", "r28", "r45", "r46", "r239", "r739" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r42", "r767" ] }, "us-gaap_ContractTerminationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractTerminationMember", "presentation": [ "http://www.auriniapharma.com/role/RestructuringScheduleofRestructuringandRelatedCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract terminations", "label": "Contract Termination [Member]", "documentation": "Termination of a contract associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [ "r777", "r778", "r779", "r780" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r358", "r359", "r378" ] }, "us-gaap_CorporateBondSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateBondSecuritiesMember", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate bonds", "label": "Corporate Bond Securities [Member]", "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)." } } }, "auth_ref": [] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r71", "r190", "r274", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r500", "r771", "r907" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Total cost of sales and operating expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r74" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]", "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r149", "r150", "r194", "r195", "r338", "r344", "r534", "r555", "r611", "r764", "r766" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r82", "r239" ] }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "crdr": "credit", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsScheduleofCashCashEquivalentsRestrictedCashandInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r247", "r285", "r289", "r290" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss", "crdr": "credit", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain on available-for-sale securities", "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r884", "r885" ] }, "us-gaap_DebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Debt Securities, Current", "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading), classified as current." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesNoncurrent", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term investments", "label": "Debt Securities, Noncurrent", "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent." } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCompensationArrangementWithIndividualCompensationExpense", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments of deferred compensation", "label": "Deferred Compensation Arrangement with Individual, Compensation Expense", "documentation": "The compensation expense recognized during the period pertaining to the deferred compensation arrangement." } } }, "auth_ref": [ "r38", "r96" ] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": [ "http://www.auriniapharma.com/role/PrepaidExpensesandDepositsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Prepaid Expenses and Deposits", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth_ref": [] }, "us-gaap_DepositsAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositsAssetsCurrent", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/PrepaidExpensesandDepositsDetails": { "parentTag": "auph_PrepaidExpensesAndDepositsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/PrepaidExpensesandDepositsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid deposits", "label": "Deposits Assets, Current", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter." } } }, "auth_ref": [ "r857" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r5", "r29" ] }, "us-gaap_DerivativeAverageRemainingMaturity1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAverageRemainingMaturity1", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, average remaining maturity (in months)", "label": "Derivative, Average Remaining Maturity", "documentation": "Average remaining period until maturity of the derivative contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r390", "r394", "r425", "r426", "r428", "r791" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r837" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r838" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "auph_DrRobertTFosterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "DrRobertTFosterMember", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dr. Robert T. Foster", "label": "Dr. Robert T. Foster [Member]", "documentation": "Dr. Robert T. Foster" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss) per share:", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "calculation": { "http://www.auriniapharma.com/role/NetIncomeLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS", "http://www.auriniapharma.com/role/NetIncomeLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in usd per share)", "totalLabel": "Net income (loss) per share, basic (in usd per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r184", "r201", "r202", "r203", "r204", "r205", "r206", "r212", "r214", "r217", "r218", "r219", "r223", "r458", "r461", "r476", "r477", "r608", "r628", "r768" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://www.auriniapharma.com/role/NetIncomeLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Numerator:", "label": "Earnings Per Share, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasicLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicLineItems", "presentation": [ "http://www.auriniapharma.com/role/NetIncomeLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r214", "r215", "r217" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "calculation": { "http://www.auriniapharma.com/role/NetIncomeLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS", "http://www.auriniapharma.com/role/NetIncomeLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in usd per share)", "totalLabel": "Net income (loss) per share, diluted (in usd per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r184", "r201", "r202", "r203", "r204", "r205", "r206", "r214", "r217", "r218", "r219", "r223", "r458", "r461", "r476", "r477", "r608", "r628", "r768" ] }, "us-gaap_EarningsPerShareDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDilutedAbstract", "presentation": [ "http://www.auriniapharma.com/role/NetIncomeLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Denominator:", "label": "Earnings Per Share, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.auriniapharma.com/role/NetIncomeLossperCommonShare" ], "lang": { "en-us": { "role": { "terseLabel": "Net Income (Loss) per Common Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r211", "r220", "r221", "r222" ] }, "auph_EdmontonAlbertaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "EdmontonAlbertaMember", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Edmonton, Alberta", "label": "Edmonton, Alberta [Member]", "documentation": "Edmonton, Alberta" } } }, "auth_ref": [] }, "auph_EmployeeBenefitObligationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "EmployeeBenefitObligationsMember", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Benefit Obligations", "label": "Employee Benefit Obligations [Member]", "documentation": "Employee Benefit Obligations" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesScheduleofAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesScheduleofAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee accruals", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r53" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized share-based compensation expense weighted average recognition period (in years)", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r427" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized share-based compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r938" ] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeSeveranceMember", "presentation": [ "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.auriniapharma.com/role/RestructuringScheduleofRestructuringandRelatedCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee severance and one time benefits", "label": "Employee Severance [Member]", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockMember", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock [Member]", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r835" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r835" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r835" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r839" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r835" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r835" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r835" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r835" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r9", "r155", "r180", "r181", "r182", "r196", "r197", "r198", "r200", "r205", "r207", "r209", "r225", "r275", "r276", "r307", "r357", "r448", "r449", "r455", "r456", "r457", "r459", "r460", "r461", "r467", "r468", "r469", "r470", "r471", "r472", "r475", "r501", "r502", "r503", "r504", "r505", "r506", "r508", "r510", "r527", "r624", "r641", "r642", "r643", "r661", "r718" ] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]", "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r43", "r44" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r339", "r381", "r382", "r383", "r384", "r385", "r386", "r478", "r480", "r481", "r482", "r483", "r489", "r490", "r492", "r542", "r543", "r544", "r781", "r782", "r787", "r788", "r789", "r794", "r797" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r485", "r487", "r488", "r489", "r492", "r493", "r494", "r495", "r496", "r605", "r794", "r798" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r339", "r381", "r386", "r480", "r490", "r542", "r787", "r788", "r789", "r794" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r339", "r381", "r386", "r480", "r481", "r490", "r543", "r781", "r782", "r787", "r788", "r789", "r794" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r339", "r381", "r382", "r383", "r384", "r385", "r386", "r480", "r481", "r482", "r483", "r490", "r544", "r781", "r782", "r787", "r788", "r789", "r794", "r797" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r339", "r381", "r382", "r383", "r384", "r385", "r386", "r478", "r480", "r481", "r482", "r483", "r489", "r490", "r492", "r542", "r543", "r544", "r781", "r782", "r787", "r788", "r789", "r794", "r797" ] }, "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Finance Lease, Interest Expense", "documentation": "Amount of interest expense on finance lease liability." } } }, "auth_ref": [ "r513", "r518", "r804" ] }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestPaymentOnLiability", "crdr": "credit", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofLeaseCostDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Operating cash flows for finance leases", "label": "Finance Lease, Interest Payment on Liability", "documentation": "Amount of interest paid on finance lease liability." } } }, "auth_ref": [ "r515", "r520" ] }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease Payments", "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiability", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails", "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease, liability", "verboseLabel": "Total", "label": "Finance Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": [ "r512", "r524" ] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease liabilities", "label": "Finance Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": [ "r512" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease liabilities", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": [ "r512" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Finance Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r524" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finance Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r524" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finance Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r524" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finance Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r524" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finance Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r524" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remainder of 2024", "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r955" ] }, "auph_FinanceLeaseLiabilityToBePaidDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "FinanceLeaseLiabilityToBePaidDueAfterYearFour", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finance Lease, Liability, to be Paid, Due after Year Four", "documentation": "Finance Lease, Liability, to be Paid, Due after Year Four" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: imputed interest", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r524" ] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.auriniapharma.com/role/LeaseObligationsScheduleofLeaseCostDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Principal portion of finance lease payments", "negatedLabel": "Financing cash flows for finance leases", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r514", "r520" ] }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance right-of-use assets, net", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": [ "r511" ] }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease, right-of-use asset, amortization", "label": "Finance Lease, Right-of-Use Asset, Amortization", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": [ "r513", "r518", "r804" ] }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails", "http://www.auriniapharma.com/role/LeaseObligationsScheduleofLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease, weighted average discount rate", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } }, "auth_ref": [ "r523", "r804" ] }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease, operating lease, weighted average remaining lease term (years)", "label": "Finance Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r522", "r804" ] }, "auph_FinanceRightOfUseAssetObtainedInExchangeForLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "FinanceRightOfUseAssetObtainedInExchangeForLeaseObligations", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance right-of-use asset obtained in exchange for lease obligations", "label": "Finance Right-of-Use Asset Obtained in Exchange for Lease Obligations", "documentation": "Finance Right-of-Use Asset Obtained in Exchange for Lease Obligations" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsScheduleofCashCashEquivalentsRestrictedCashandInvestmentsDetails", "http://www.auriniapharma.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r278", "r279", "r282", "r283", "r284", "r286", "r287", "r288", "r340", "r354", "r473", "r497", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r625", "r774", "r794", "r795", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r806", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r886", "r887", "r888", "r889", "r943", "r946", "r947", "r948", "r949", "r950" ] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r162", "r292", "r300", "r776" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r294", "r296", "r297", "r298", "r299", "r300", "r302", "r303", "r573", "r574", "r753" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Carrying Value", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r292", "r300", "r574", "r776" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r294", "r300", "r302", "r303", "r305", "r573", "r753", "r776" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r294", "r296", "r297", "r298", "r299", "r300", "r302", "r303", "r753" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired intellectual property and other intangible assets, net", "totalLabel": "Net Carrying Amount", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r573", "r898" ] }, "auph_ForeignTranslationOnFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "ForeignTranslationOnFinanceLeaseLiability", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign exchange on finance lease liability", "label": "Foreign Translation on Finance Lease Liability", "documentation": "Foreign Translation on Finance Lease Liability" } } }, "auth_ref": [] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r73", "r698" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r73" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r70", "r106", "r111", "r609", "r622", "r770", "r771", "r873", "r875", "r876", "r877", "r878" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r308", "r309", "r314", "r484", "r486", "r491", "r638", "r640", "r703", "r753", "r796", "r970" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r309", "r314", "r484", "r486", "r491", "r638", "r640", "r703", "r753", "r796", "r970" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.auriniapharma.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r191", "r438", "r440", "r441", "r442", "r443", "r444", "r445", "r450", "r452", "r453", "r454", "r657", "r793" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS", "http://www.auriniapharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Income tax expense", "terseLabel": "Income tax (benefit) expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r116", "r121", "r208", "r209", "r224", "r232", "r235", "r439", "r440", "r451", "r629", "r793" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash paid for income taxes", "label": "Income Taxes Paid, Net", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r23", "r186", "r446", "r447" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable, accrued and other liabilities", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Inventories, net", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "verboseLabel": "Net changes in operating assets and liabilities", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r845", "r864" ] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Non-current operating assets", "label": "Increase (Decrease) in Other Noncurrent Assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": [ "r864" ] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInReceivables", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accounts receivable, net", "label": "Increase (Decrease) in Receivables", "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets", "label": "Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r293", "r304", "r306", "r752", "r753" ] }, "us-gaap_IntellectualPropertyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntellectualPropertyMember", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired intellectual property and reacquired rights", "label": "Intellectual Property [Member]", "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights." } } }, "auth_ref": [ "r14", "r892", "r893", "r894", "r895", "r896", "r898", "r899", "r900" ] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest Expense, Nonoperating", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [ "r231", "r862" ] }, "us-gaap_InterestReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestReceivable", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest receivable", "label": "Interest Receivable", "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable." } } }, "auth_ref": [ "r855", "r1002" ] }, "us-gaap_InventoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoriesMember", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized under inventories", "label": "Inventories [Member]", "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale." } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.auriniapharma.com/role/Inventoriesnet" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories, net", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r291" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/InventoriesnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods inventories", "label": "Inventory, Finished Goods, Gross", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r856" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/InventoriesnetDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/InventoriesnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods, net of reserve", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r84", "r761" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.auriniapharma.com/role/InventoriesnetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.auriniapharma.com/role/InventoriesnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories, net", "totalLabel": "Total inventories, net", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r170", "r759", "r805" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/InventoriesnetDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/InventoriesnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r84", "r763" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/InventoriesnetDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/InventoriesnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work in process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r84", "r762" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r224", "r230", "r235", "r771", "r861" ] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestments" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Investments", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": [ "r108", "r123", "r242", "r243", "r498", "r499", "r966" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Lease Cost", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r954" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r86", "r525" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r517", "r526" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r517", "r526" ] }, "auph_LesseeOperatingLeaseLeaseTerminationTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "LesseeOperatingLeaseLeaseTerminationTerm", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease termination option term (in years)", "label": "Lessee, Operating Lease, Lease Termination Term", "documentation": "Lessee, Operating Lease, Lease Termination Term" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturities of Lease Liabilities", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r955" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r524" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r524" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r524" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r524" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r524" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remainder of 2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r955" ] }, "auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, After Year Four", "documentation": "Lessee, Operating Lease, Liability, to be Paid, After Year Four" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r524" ] }, "auph_LesseeOperatingLeaseNumberOfExtensionOptions": { "xbrltype": "integerItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "LesseeOperatingLeaseNumberOfExtensionOptions", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of extension options (in years)", "label": "Lessee, Operating Lease, Number of Extension Options", "documentation": "Lessee, Operating Lease, Number of Extension Options" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining lease term (in years)", "label": "Lessee, Operating Lease, Remaining Lease Term", "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r526", "r952" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease extension term (in years)", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r953" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease term (in years)", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r953" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligations" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Obligations", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r509" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r15", "r52", "r53", "r54", "r55", "r56", "r57", "r58", "r190", "r274", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r464", "r465", "r466", "r500", "r674", "r769", "r833", "r907", "r957", "r958" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES", "label": "Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and shareholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r65", "r105", "r618", "r805", "r866", "r890", "r951" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r54", "r158", "r190", "r274", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r464", "r465", "r466", "r500", "r805", "r907", "r957", "r958" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current liabilities", "label": "Liabilities, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LicenseAgreementTermsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicenseAgreementTermsMember", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License Agreement Terms", "label": "License Agreement Terms [Member]", "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others." } } }, "auth_ref": [] }, "auph_LicenseRoyaltyAndCollaborationRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "LicenseRoyaltyAndCollaborationRevenueMember", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "License, collaboration, and royalty revenue", "label": "License, Royalty and Collaboration Revenue [Member]", "documentation": "License, Royalty and Collaboration Revenue" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "auph_LongTermCorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "LongTermCorporateDebtSecuritiesMember", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsScheduleofCashCashEquivalentsRestrictedCashandInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total long-term investment corporate bond", "label": "Long-Term Corporate Debt Securities [Member]", "documentation": "Long-Term Corporate Debt Securities" } } }, "auth_ref": [] }, "auph_MajorCustomerOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "MajorCustomerOneMember", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Major Customer One", "label": "Major Customer One [Member]", "documentation": "Major Customer One" } } }, "auth_ref": [] }, "auph_MajorCustomerTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "MajorCustomerTwoMember", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Major Customer Two", "label": "Major Customer Two [Member]", "documentation": "Major Customer Two" } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": [ "r239", "r786", "r816", "r820", "r911", "r969", "r971", "r972", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998" ] }, "us-gaap_MarketableSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesLineItems", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsScheduleofCashCashEquivalentsRestrictedCashandInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities [Line Items]", "label": "Marketable Securities [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesTable", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsScheduleofCashCashEquivalentsRestrictedCashandInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities [Table]", "label": "Marketable Securities [Table]", "documentation": "Disclosure of information about investment in marketable security." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesTextBlock", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash, Cash Equivalents, Restricted Cash and Investments", "label": "Marketable Securities [Table Text Block]", "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails", "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.auriniapharma.com/role/ShareholdersEquityDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r124", "r126", "r128", "r129", "r131", "r153", "r154", "r324", "r325", "r326", "r327", "r388", "r434", "r483", "r571", "r637", "r639", "r647", "r666", "r667", "r727", "r729", "r731", "r732", "r734", "r750", "r751", "r773", "r783", "r790", "r797", "r798", "r802", "r803", "r817", "r909", "r959", "r960", "r961", "r962", "r963", "r964" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails", "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.auriniapharma.com/role/ShareholdersEquityDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r124", "r126", "r128", "r129", "r131", "r153", "r154", "r324", "r325", "r326", "r327", "r388", "r434", "r483", "r571", "r637", "r639", "r647", "r666", "r667", "r727", "r729", "r731", "r732", "r734", "r750", "r751", "r773", "r783", "r790", "r797", "r798", "r802", "r817", "r909", "r959", "r960", "r961", "r962", "r963", "r964" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]", "documentation": "Single external customer or group of external customers." } } }, "auth_ref": [ "r239", "r786", "r816", "r820", "r911", "r969", "r971", "r972", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Cash (used in) provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r185" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r185" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r78", "r79", "r80" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 }, "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 }, "http://www.auriniapharma.com/role/NetIncomeLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails": { "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.auriniapharma.com/role/NetIncomeLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r72", "r80", "r107", "r156", "r176", "r178", "r182", "r190", "r199", "r201", "r202", "r203", "r204", "r205", "r208", "r209", "r216", "r274", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r458", "r461", "r477", "r500", "r623", "r696", "r716", "r717", "r831", "r907" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r772", "r874" ] }, "us-gaap_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OfficeEquipmentMember", "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Office equipment", "label": "Office Equipment [Member]", "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Income (Loss) from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r111", "r770", "r873", "r875", "r876", "r877", "r878" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease costs", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r519", "r804" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease Payments", "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails", "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liability", "terseLabel": "Total", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r512" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r512" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r512" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofLeaseCostDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Operating cash flows for operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r516", "r520" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating right-of-use assets, net", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r511" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails", "http://www.auriniapharma.com/role/LeaseObligationsScheduleofLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, weighted average discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r523", "r804" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, weighted average remaining lease term (years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r522", "r804" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusiness" ], "lang": { "en-us": { "role": { "terseLabel": "Organization and Description of Business", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r50", "r100", "r649", "r650" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesScheduleofAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesScheduleofAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other accrued liabilities", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r53" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r171", "r805" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r163" ] }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain on available-for-sale securities, net of tax of nil", "verboseLabel": "Unrealized gain on available-for-sale securities, net", "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": [ "r3", "r8", "r101" ] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on available-for-sale securities, net of tax", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax", "documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r173", "r174", "r175" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive (loss) gain:", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities (of which $0.8 million and $0.8 million at September 30, 2024 and December 31, 2023 is due to a related party, respectively)", "verboseLabel": "Other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r53", "r805" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilitiesDetails", "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred compensation and other non-current liabilities (of which $7.0 million at September 30, 2024 and $7.6 million in December 31, 2023 is due to a related party, respectively)", "verboseLabel": "Other non-current liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r56" ] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other, net", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r80" ] }, "us-gaap_OtherOperatingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "negatedLabel": "Other expense (income), net", "label": "Other Operating Income (Expense), Net", "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations." } } }, "auth_ref": [] }, "us-gaap_OtherRestructuringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherRestructuringMember", "presentation": [ "http://www.auriniapharma.com/role/RestructuringScheduleofRestructuringandRelatedCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other costs", "label": "Other Restructuring [Member]", "documentation": "Restructuring and related activities classified as other." } } }, "auth_ref": [ "r777", "r778", "r779", "r780" ] }, "auph_OtuskaPharmaceuticalCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "OtuskaPharmaceuticalCoLtdMember", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Otuska", "label": "Otuska Pharmaceutical Co., Ltd. [Member]", "documentation": "Otuska Pharmaceutical Co., Ltd." } } }, "auth_ref": [] }, "us-gaap_PatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PatentsMember", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patents", "label": "Patents [Member]", "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." } } }, "auth_ref": [ "r99", "r892", "r893", "r894", "r895", "r896", "r898", "r899", "r900" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsForProceedsFromTenantAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromTenantAllowance", "crdr": "credit", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Proceeds from tenant improvements", "label": "Payments for (Proceeds from) Tenant Allowance", "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy." } } }, "auth_ref": [ "r21", "r75" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchase of common shares", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r77" ] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Capitalized patent costs", "label": "Payments to Acquire Intangible Assets", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r76" ] }, "us-gaap_PaymentsToAcquireLeaseReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireLeaseReceivables", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Upfront lease payment", "label": "Payments to Acquire Lease Receivables", "documentation": "The cash outflow for the purchase of receivables arising from the lease of real estate, equipment or other fixed assets for a specified time in exchange for payment, usually in the form of rent." } } }, "auth_ref": [ "r75" ] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of investments", "label": "Payments to Acquire Marketable Securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": [ "r883" ] }, "us-gaap_PaymentsToAcquireOtherProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireOtherProductiveAssets", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property and equipment", "label": "Payments to Acquire Other Productive Assets", "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other." } } }, "auth_ref": [ "r76" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937" ] }, "auph_PrepaidAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "PrepaidAssetsCurrent", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/PrepaidExpensesandDepositsDetails": { "parentTag": "auph_PrepaidExpensesAndDepositsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/PrepaidExpensesandDepositsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid assets", "label": "Prepaid Assets, Current", "documentation": "Prepaid Assets, Current" } } }, "auth_ref": [] }, "auph_PrepaidExpensesAndDepositsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "PrepaidExpensesAndDepositsCurrent", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.auriniapharma.com/role/PrepaidExpensesandDepositsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.auriniapharma.com/role/PrepaidExpensesandDepositsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and deposits", "totalLabel": "Total prepaid expenses and deposits", "label": "Prepaid Expenses and Deposits Current", "documentation": "Prepaid Expenses and Deposits Current" } } }, "auth_ref": [] }, "auph_PrepaidExpensesAndDepositsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "PrepaidExpensesAndDepositsTextBlock", "presentation": [ "http://www.auriniapharma.com/role/PrepaidExpensesandDeposits" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid Expenses and Deposits", "label": "Prepaid Expenses and Deposits [Text Block]", "documentation": "Prepaid Expenses and Deposits" } } }, "auth_ref": [] }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidInsurance", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/PrepaidExpensesandDepositsDetails": { "parentTag": "auph_PrepaidExpensesAndDepositsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/PrepaidExpensesandDepositsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid insurance", "label": "Prepaid Insurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r760", "r775", "r891" ] }, "us-gaap_ProceedsFromInterestReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromInterestReceived", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash received for interest", "label": "Proceeds from Interest Received", "documentation": "Interest received on loans and other debt instruments during the current period." } } }, "auth_ref": [ "r863" ] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from investments", "label": "Proceeds from Sale and Maturity of Marketable Securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of stock options and employee share purchase plan", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r2", "r12" ] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Product revenue, net", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r784" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS", "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r133", "r134", "r135", "r136", "r137", "r138", "r151", "r236", "r572", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r755", "r784", "r815", "r817", "r818", "r821", "r822", "r854", "r905", "r906", "r911", "r969", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS", "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r133", "r134", "r135", "r136", "r137", "r138", "r151", "r236", "r572", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r755", "r784", "r815", "r817", "r818", "r821", "r822", "r854", "r905", "r906", "r911", "r969", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r6", "r525" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnet" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment, net", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r85", "r118", "r119", "r120" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r86", "r160", "r621" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r525" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 }, "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r6", "r525", "r610", "r621", "r805" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r86", "r525" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails", "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.auriniapharma.com/role/ShareholdersEquityDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r124", "r126", "r128", "r129", "r131", "r153", "r154", "r324", "r325", "r326", "r327", "r380", "r388", "r420", "r421", "r422", "r434", "r483", "r545", "r554", "r571", "r637", "r639", "r647", "r666", "r667", "r727", "r729", "r731", "r732", "r734", "r750", "r751", "r773", "r783", "r790", "r797", "r798", "r802", "r803", "r817", "r825", "r902", "r909", "r947", "r960", "r961", "r962", "r963", "r964" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails", "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.auriniapharma.com/role/ShareholdersEquityDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r124", "r126", "r128", "r129", "r131", "r153", "r154", "r324", "r325", "r326", "r327", "r380", "r388", "r420", "r421", "r422", "r434", "r483", "r545", "r554", "r571", "r637", "r639", "r647", "r666", "r667", "r727", "r729", "r731", "r732", "r734", "r750", "r751", "r773", "r783", "r790", "r797", "r798", "r802", "r803", "r817", "r825", "r902", "r909", "r947", "r960", "r961", "r962", "r963", "r964" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Domain]", "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r240", "r387", "r531", "r532", "r613", "r619", "r669", "r670", "r671", "r672", "r673", "r693", "r695", "r726" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r192", "r193", "r531", "r532", "r533", "r534", "r613", "r619", "r669", "r670", "r671", "r672", "r673", "r693", "r695", "r726" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Axis]", "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r531", "r532", "r956" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Domain]", "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r240", "r699", "r700", "r703" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Axis]", "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r240", "r387", "r531", "r532", "r613", "r619", "r669", "r670", "r671", "r672", "r673", "r693", "r695", "r726", "r956" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r528", "r529", "r530", "r532", "r535", "r658", "r659", "r660", "r701", "r702", "r703", "r723", "r725" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]", "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r149", "r150", "r194", "r195", "r338", "r344", "r534", "r555", "r611", "r765", "r766" ] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "documentation": "Information by form of arrangement related to research and development." } } }, "auth_ref": [ "r436", "r941" ] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned", "crdr": "credit", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Upfront payments received", "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned", "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others." } } }, "auth_ref": [ "r437" ] }, "auph_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationReceived", "crdr": "credit", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Regulatory and pricing approval milestone revenue", "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Received", "documentation": "Research and Development Arrangement, Contract to Perform for Others, Compensation Received" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]", "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r436", "r941" ] }, "auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tiered royalty percentages on future sales", "label": "Research And Development Arrangement, Contract To Perform For Others, Tiered Royalty, Percent", "documentation": "Research And Development Arrangement, Contract To Perform For Others, Tiered Royalty, Percent" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others." } } }, "auth_ref": [ "r436", "r941" ] }, "auph_ResearchAndDevelopmentArrangementNewDrugApplicationEligibilityPaymentReceivableUponApproval": { "xbrltype": "monetaryItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "ResearchAndDevelopmentArrangementNewDrugApplicationEligibilityPaymentReceivableUponApproval", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Eligible to receive a payment", "label": "Research And Development Arrangement, New Drug Application, Eligibility Payment Receivable Upon Approval", "documentation": "Research And Development Arrangement, New Drug Application, Eligibility Payment Receivable Upon Approval" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r435", "r753", "r771", "r965" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_RestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash and Cash Equivalents", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r22", "r102", "r159", "r187", "r615" ] }, "auph_RestrictedStockUnitsAndPerformanceAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "RestrictedStockUnitsAndPerformanceAwardsMember", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofAllocationofShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Share sand Restricted Stock Units (RSUs)", "label": "Restricted Stock Units And Performance Awards [Member]", "documentation": "Restricted Stock Units And Performance Awards" } } }, "auth_ref": [] }, "auph_RestructuringAccrualsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "RestructuringAccrualsCurrent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesScheduleofAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesScheduleofAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring accruals", "label": "Restructuring Accruals, Current", "documentation": "Restructuring Accruals, Current" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://www.auriniapharma.com/role/Restructuring" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r310", "r311", "r313", "r316", "r321" ] }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "presentation": [ "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.auriniapharma.com/role/RestructuringNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of positions eliminated, percent", "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent", "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)." } } }, "auth_ref": [] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring charges", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r5", "r317", "r318", "r903" ] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.auriniapharma.com/role/RestructuringScheduleofRestructuringandRelatedCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Type [Axis]", "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r312", "r313", "r318", "r319" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.auriniapharma.com/role/RestructuringScheduleofRestructuringandRelatedCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r312", "r313", "r314", "r315", "r318", "r319", "r320" ] }, "us-gaap_RestructuringCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCosts", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring expenses", "label": "Restructuring Costs", "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r5" ] }, "us-gaap_RestructuringCostsAndAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostsAndAssetImpairmentCharges", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/RestructuringScheduleofRestructuringandRelatedCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring costs and asset impairment charges", "label": "Restructuring Costs and Asset Impairment Charges", "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r5" ] }, "auph_RestructuringCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "RestructuringCostsPolicyTextBlock", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Expenses", "label": "Restructuring Costs [Policy Text Block]", "documentation": "Restructuring Costs" } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanAxis", "presentation": [ "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Axis]", "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanDomain", "presentation": [ "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Domain]", "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r62", "r95", "r617", "r644", "r646", "r656", "r677", "r805" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r155", "r196", "r197", "r198", "r200", "r205", "r207", "r209", "r275", "r276", "r307", "r448", "r449", "r455", "r456", "r457", "r459", "r460", "r461", "r467", "r469", "r470", "r472", "r475", "r508", "r510", "r641", "r643", "r661", "r1000" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS", "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total revenue, net", "terseLabel": "Revenues", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r109", "r110", "r224", "r228", "r229", "r233", "r235", "r236", "r237", "r239", "r376", "r377", "r572" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Product Revenues", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r122", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r754" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreements" ], "lang": { "en-us": { "role": { "terseLabel": "License and Collaboration Agreements", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r122", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r379" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease liability arising from obtaining right-of-use assets", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability." } } }, "auth_ref": [ "r521", "r804" ] }, "auph_RockvilleMarylandMember": { "xbrltype": "domainItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "RockvilleMarylandMember", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rockville, Maryland", "label": "Rockville, Maryland [Member]", "documentation": "Rockville, Maryland" } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Benchmark", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r239", "r843" ] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": [ "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast", "label": "Forecast [Member]", "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact." } } }, "auth_ref": [ "r389", "r853", "r870" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]", "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r152", "r210", "r389", "r841", "r870" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r462" ] }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Allocation of Share-Based Payments", "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]", "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit." } } }, "auth_ref": [ "r39" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.auriniapharma.com/role/NetIncomeLossperCommonShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Earnings (Loss) Per Share, Basic and Diluted", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r872" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "presentation": [ "http://www.auriniapharma.com/role/NetIncomeLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]", "label": "Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]", "documentation": "Disclosure of information about basic earnings per share by class of stock. Includes, but is not limited to, two-class method." } } }, "auth_ref": [ "r24", "r26", "r214", "r215", "r217" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r944", "r945" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": [ "r294", "r300", "r302", "r303", "r305", "r573", "r753", "r776" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r776", "r897" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.auriniapharma.com/role/InventoriesnetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventories, Net", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r17", "r66", "r67", "r68" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6", "r525" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]", "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": [ "r47", "r48", "r699", "r700", "r703" ] }, "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]", "label": "Research and Development, Contract to Perform for Others [Table]", "documentation": "Disclosure of information about research and development arrangement accounted for as contract to perform research and development for others. Includes, but is not limited to, royalty arrangement, purchase provision, license agreement, and commitment to provide additional funding." } } }, "auth_ref": [ "r436", "r941" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.auriniapharma.com/role/RestructuringScheduleofRestructuringandRelatedCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } }, "auth_ref": [ "r312", "r313", "r314", "r315", "r318", "r319", "r320" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": [ "http://www.auriniapharma.com/role/RestructuringTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs", "label": "Restructuring and Related Costs [Table Text Block]", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": [ "r31", "r87", "r88" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationAllocatedShareBasedCompensationExpenseDetails", "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails", "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofAllocationofShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r391", "r393", "r395", "r396", "r397", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r419", "r420", "r421", "r422", "r423" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r10", "r11", "r97" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Payment Award Valuation Assumptions", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r98" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.auriniapharma.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r32", "r33", "r34", "r35", "r36", "r37", "r91", "r93", "r94", "r95", "r165", "r166", "r167", "r226", "r342", "r343", "r344", "r346", "r349", "r354", "r356", "r652", "r653", "r654", "r655", "r783", "r840", "r865" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r834" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r836" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": [ "r125", "r127", "r130", "r132", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r237", "r238", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r663", "r664", "r665", "r728", "r730", "r733", "r735", "r738", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r756", "r785", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r819", "r825", "r911", "r969", "r971", "r972", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998" ] }, "us-gaap_ServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ServiceMember", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service Revenue", "label": "Service [Member]", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service." } } }, "auth_ref": [ "r784" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofAllocationofShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r412" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofAllocationofShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average exercise price (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r412" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofAllocationofShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r410" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofAllocationofShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average grant date fair value (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r410" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofAllocationofShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding - Beginning of Period (in shares)", "periodEndLabel": "Outstanding - End of Period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r407", "r408" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofAllocationofShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, Weighted average exercise price - Beginning of Period (in usd per share)", "periodEndLabel": "Outstanding, Weighted average exercise price - End of Period (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r407", "r408" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofAllocationofShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price $", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofAllocationofShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r411" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofAllocationofShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average grant date fair value (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r411" ] }, "auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate": { "xbrltype": "percentItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofSharebasedPaymentAwardValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated forfeiture rate (as percent)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofSharebasedPaymentAwardValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate (as percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r422" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofSharebasedPaymentAwardValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend", "documentation": "Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term." } } }, "auth_ref": [ "r421" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofSharebasedPaymentAwardValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annualized volatility (as percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement." } } }, "auth_ref": [ "r420" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationAllocatedShareBasedCompensationExpenseDetails", "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails", "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofAllocationofShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r391", "r393", "r395", "r396", "r397", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r419", "r420", "r421", "r422", "r423" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofAllocationofShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares (in thousands)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of additional shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r792" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited or cancelled (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r918" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited or cancelled (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r918" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r403" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofSharebasedPaymentAwardValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair value per common share option (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r413" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r399", "r400" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares (in thousands)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Beginning balance (in usd per share)", "periodEndLabel": "Ending balance (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r399", "r400" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price $", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares purchased (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award", "documentation": "Number of shares purchased for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r939" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails", "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofAllocationofShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r395", "r396", "r397", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r419", "r420", "r421", "r422", "r423" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised (in usd per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r404" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in usd per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r403" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r390", "r398", "r417", "r418", "r419", "r420", "r423", "r429", "r430", "r431", "r432" ] }, "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Performance Shares Activity", "label": "Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]", "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares." } } }, "auth_ref": [ "r13" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofSharebasedPaymentAwardValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected life of options in years", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r419" ] }, "auph_ShortTermCorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "ShortTermCorporateDebtSecuritiesMember", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsScheduleofCashCashEquivalentsRestrictedCashandInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate bonds", "label": "Short-Term Corporate Debt Securities [Member]", "documentation": "Short-Term Corporate Debt Securities" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r81", "r188" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r9", "r60", "r63", "r64", "r155", "r180", "r181", "r182", "r196", "r197", "r198", "r200", "r205", "r207", "r209", "r225", "r275", "r276", "r307", "r357", "r448", "r449", "r455", "r456", "r457", "r459", "r460", "r461", "r467", "r468", "r469", "r470", "r471", "r472", "r475", "r501", "r502", "r503", "r504", "r505", "r506", "r508", "r510", "r527", "r624", "r641", "r642", "r643", "r661", "r718" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r125", "r127", "r130", "r132", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r237", "r238", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r663", "r664", "r665", "r728", "r730", "r733", "r735", "r738", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r756", "r785", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r819", "r825", "r911", "r969", "r971", "r972", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r196", "r197", "r198", "r225", "r510", "r572", "r651", "r662", "r668", "r669", "r670", "r671", "r672", "r673", "r676", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r689", "r690", "r691", "r692", "r693", "r695", "r697", "r698", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r718", "r826" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [ "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Axis]", "label": "Scenario [Axis]", "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r152", "r210", "r389", "r841", "r842", "r870" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r196", "r197", "r198", "r225", "r240", "r510", "r572", "r651", "r662", "r668", "r669", "r670", "r671", "r672", "r673", "r676", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r689", "r690", "r691", "r692", "r693", "r695", "r697", "r698", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r718", "r826" ] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares in conjunction with ESPP program (in shares)", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r9", "r59", "r60", "r95" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.auriniapharma.com/role/SharebasedCompensationScheduleofOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued on exercise of stock options and vesting of performance awards and restricted stock units (in shares)", "negatedLabel": "Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r9", "r59", "r60", "r95", "r404" ] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares in conjunction with ESPP program", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r9", "r59", "r60", "r95" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued on exercise of stock options and vesting of performance awards and restricted stock units", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r9", "r60", "r63", "r64", "r95" ] }, "auph_StockOptionsRSUsPerformanceAwardsAndESPPMember": { "xbrltype": "domainItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "StockOptionsRSUsPerformanceAwardsAndESPPMember", "presentation": [ "http://www.auriniapharma.com/role/NetIncomeLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options, RSUs, performance awards and ESPP", "label": "Stock options, RSUs, performance awards and ESPP [Member]", "documentation": "Stock options, RSUs, performance awards and ESPP" } } }, "auth_ref": [] }, "srt_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.auriniapharma.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, authorized amount", "label": "Share Repurchase Program, Authorized, Amount", "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [ "r910" ] }, "auph_StockRepurchaseProgramPercentage": { "xbrltype": "pureItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "StockRepurchaseProgramPercentage", "presentation": [ "http://www.auriniapharma.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, percentage", "label": "Stock Repurchase Program, Percentage", "documentation": "Stock Repurchase Program, Percentage" } } }, "auth_ref": [] }, "us-gaap_StockRepurchaseProgramPeriodInForce1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchaseProgramPeriodInForce1", "presentation": [ "http://www.auriniapharma.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, period", "label": "Share Repurchase Program, Period in Force", "documentation": "Period share may be purchased under authorized share repurchase plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Shares repurchased and cancelled, inclusive of transaction costs (in shares)", "label": "Stock Repurchased and Retired During Period, Shares", "documentation": "Number of shares that have been repurchased and retired during the period." } } }, "auth_ref": [ "r9", "r59", "r60", "r95" ] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Shares repurchased and cancelled, inclusive of transaction costs", "label": "Stock Repurchased and Retired During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)." } } }, "auth_ref": [ "r9", "r59", "r60", "r95" ] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://www.auriniapharma.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchased during period, (in shares)", "label": "Stock Repurchased During Period, Shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r9", "r59", "r60", "r95", "r655", "r718", "r736" ] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.auriniapharma.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchased during period, value", "label": "Stock Repurchased During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r9", "r59", "r60", "r95", "r661", "r718", "r736", "r832" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "Total shareholders' equity", "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r60", "r63", "r64", "r83", "r678", "r694", "r719", "r720", "r805", "r833", "r866", "r890", "r951", "r1000" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "SHAREHOLDER\u2019S EQUITY", "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.auriniapharma.com/role/ShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholder's Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r92", "r189", "r341", "r343", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r355", "r357", "r474", "r721", "r724", "r737" ] }, "us-gaap_StockholdersEquityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityPolicyTextBlock", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Common Shares", "label": "Stockholders' Equity, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income." } } }, "auth_ref": [ "r7", "r722" ] }, "auph_StrategicRestructuringPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "StrategicRestructuringPlanMember", "presentation": [ "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Strategic Restructuring Plan", "label": "Strategic Restructuring Plan [Member]", "documentation": "Strategic Restructuring Plan" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r507", "r537" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r507", "r537" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r507", "r537" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.auriniapharma.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r536", "r538" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.auriniapharma.com/role/LeaseObligationsScheduleofLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental cash flow information", "verboseLabel": "Supplemental disclosure of noncash transactions", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesScheduleofAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesScheduleofAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes payable", "label": "Taxes Payable, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r52", "r53" ] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable, net", "label": "Accounts Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r113", "r114", "r115", "r879", "r880", "r881" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsScheduleofCashCashEquivalentsRestrictedCashandInvestmentsDetails", "http://www.auriniapharma.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r340", "r354", "r473", "r497", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r625", "r794", "r795", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r806", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r886", "r887", "r888", "r889", "r943", "r946", "r947", "r948", "r949", "r950" ] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.auriniapharma.com/role/RestructuringScheduleofRestructuringandRelatedCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Restructuring [Domain]", "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r312", "r313", "r318", "r319" ] }, "us-gaap_USTreasuryBillSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasuryBillSecuritiesMember", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsScheduleofCashCashEquivalentsRestrictedCashandInvestmentsDetails", "http://www.auriniapharma.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury bills", "label": "US Treasury Bill Securities [Member]", "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government." } } }, "auth_ref": [ "r967" ] }, "us-gaap_USTreasuryBondSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasuryBondSecuritiesMember", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandInvestmentsScheduleofCashCashEquivalentsRestrictedCashandInvestmentsDetails", "http://www.auriniapharma.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury bonds", "label": "US Treasury Bond Securities [Member]", "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities greater than ten and as long as thirty years, are interest bearing, and are backed by the full faith and credit of the United States government." } } }, "auth_ref": [ "r967" ] }, "auph_VispSwitzerlandMember": { "xbrltype": "domainItemType", "nsuri": "http://www.auriniapharma.com/20240930", "localname": "VispSwitzerlandMember", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Monoplant", "label": "Visp, Switzerland [Member]", "documentation": "Visp, Switzerland" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "presentation": [ "http://www.auriniapharma.com/role/NetIncomeLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options, RSUs, performance awards and ESPP (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r872" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.auriniapharma.com/role/NetIncomeLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails": { "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS", "http://www.auriniapharma.com/role/NetIncomeLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "verboseLabel": "Weighted average common shares outstanding diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r213", "r219" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average common shares outstanding:", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.auriniapharma.com/role/NetIncomeLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails": { "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS", "http://www.auriniapharma.com/role/NetIncomeLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic (in shares)", "terseLabel": "Weighted average common shares outstanding basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r212", "r219" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "44", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-44" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483043/710-10-30-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/942-320/tableOfContent" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "b", "Publisher": "SEC" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column C", "Footnote": "5", "Publisher": "SEC" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column C", "Footnote": "4", "Publisher": "SEC" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column C", "Footnote": "2", "Publisher": "SEC" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column F", "Footnote": "7", "Publisher": "SEC" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column A", "Publisher": "SEC" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column B", "Publisher": "SEC" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column C", "Publisher": "SEC" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column D", "Publisher": "SEC" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column E", "Publisher": "SEC" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column F", "Publisher": "SEC" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column A", "Footnote": "4", "Publisher": "SEC" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "m", "Subparagraph": "(1)(iii)", "Publisher": "SEC" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "m", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "L", "Publisher": "SEC" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "M", "Paragraph": "Question 2", "Publisher": "SEC" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/420/tableOfContent" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/985-20/tableOfContent" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r754": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r755": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r756": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r757": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r840": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r841": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r842": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "11", "Subsection": "03", "Publisher": "SEC" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-16" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/940-320/tableOfContent" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" } } } ZIP 85 0001600620-24-000108-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001600620-24-000108-xbrl.zip M4$L#!!0 ( #8R9UG2Q@9'VQD! ," $ 1 875P:"TR,#(T,#DS,"YH M=&WLO6MWXDBR+OQ]_PJ]S#Z[J]8"2C=NKF[.HFP\S1Z7[3'VGCWOEUF)E!A- M"8G6Q67ZUY^(E(3!@$%&H)2J*>;[G.;[\H M=?D7B3J&:UK.XV^_](;G@\$O_[?['[_^?[7:_WZ[NY(N7".<4B>0SCU* FI* M/ZU@(@43*OW#]7Y83T2ZM4DP=KUIK1;==N[.YI[U. DD55;UY++D6^]L/"** MTE";-5E6FC5=USNU44MIUQK:J$4TO:$KIEY]/&LV6^V&HIJU)FVU:[HBDUK' M:)BUMCZ61WJ#M#55KIIGLJH0TE(;)J%M?30B(\T8*T1OF$:C-=8,E;UW$L"< M8=Z.?V8]_U:9!,'L[,N7GS]_UI]'GEUWO<3T+,!M'47G"WQ;6,3QD6HD !S@[!LU MN5W3E.6)FR\S7WY?\TOTY>*5OJNK2NNM58JN6$S&KST2,EO<,";^B%T?6O3.L++E2__^_UJ:$SHE-1>$^L9EN/']O7';Y-+3?IJ M+9(UA2]61@+KOWDAWEI\5:[):DU1DX>LC6MU.?'K$?&C>9S9!#BW0IW:P[#2 M_75"B=G]=4H#(N']-?I':#W]5CEWG0"XN'8_G\%M1O37;Y6 /@=?&,Z^=/_C M/_[CU\ *;-I%$-<2F/[Z)?KPUR_1HT>N.>_^:EI/DA_,;?I;Q;3\F4WF9X[K M4!B ]7R&%U(O^M4R3>JP7^'[:Q EGF5$[W\.[NCXMXI1 \PY9(I/HM99#X2- MB0+GTB:/%2E:I=\JL*QG8^N9FK4QL7'FEOE;95Q3&Y4N^^#7+RMO2/'"1,!= M6KY![']2XEW")_[B#GSW^A\\?!VI2NCI 6^5>7WO^0\]+R55>H[Y@4HA%42F?!);0I/F=1,\C*& M3J6KJ"!(M!_0W(1M2?^8R388 28\^S /#\6\6WIC,;V8%] M-O%P_"L@KC_[)D"_E)?$[?3?TV%],V)^%CA6P@?L@LZE?23Z?4N*''NU& M?T5?_OIE];OD;WS&VO-"&,/KA\62\>QA>)'V68"D(0YB\4S@2R=2:! MZ[WSM6OWXX<7U'&GEK/IL?LNS/R)=K MCT/DG,5?IGO@'^/UIX%N/L,O4CT)F) Z:*']RYVACM@\QM=7[?.*F,796Y#% MD\\I$R+)7T )^'ML44]B'$FY=!Y6 9(N,DB&:FP"(T M%P^*OWG/S#3>9K9"LT-FIO,U,ZT6:[C#9]8X]LQBWHHD7/2G"2][GMF6807? M*0I9R;2FD7!!9 L\.;]'&Y88*';\;_/E;WK/%BC-3?=$3_[U MR\87+M9F,:[+(.N+G/\;?8K M_%H]MDZO'MN"')O)H>U/#BT[^Q+CPS90SFZ4Y,=/9@; M=P5_.CZ]<^?$!NWMF.>N;9.1Z['PX!U]HDY(2ZE8E*,[7B4D53Y*1SFZ)UE" M4N6DD([N&I>05#GIJJ/[^@51!$=WN0LB98_N^1:$+[AS.1/+>1C G/">_A\A M[KJYTYGKP)_^JH$-GT]=9QBXQH]C1[V:&46]%.[\RI1KWC--"Q4&L6^)90Z< MNZVX[*;&G0?%DT[CP A5N?.;>%6 /!"+VUU2 MGK4E#X3C=G>5&]7* Y6XVX+E25D=)^U +;K3FY,#EMGZ%]X!SM\!RXH66M&= MX5,[8)DM?-$]WU,)?BT[SU#C;ANT ((_R_4ONF>>M^#/DA9%=\)/*OBS7'@> MMB*/-+6BNYRGB[SEL^VI%=W;S"?REA.Q"N^FYAYYRXEP1?=O3QQYRX=*>M$] MWQ,Z8)F=)2NZTYN3 Y;9^A?> <[? =*_JBIIAK:.B;_?FX:5DN?Y% M]\SS]E*RI$71/?:3>BE9+CP/IVZ/-+6B>[XG37W(X:1SH^@>5.+A\.\!CJBVI+0/6@=N'=$[Z@=>: 38U.+QW/6# MGF/"9]1[>E5@KC^=V>Z-X-8FSE(=H6'@P9(_6L;:15F] M?1B.?/I'B.SZ!#^PF\+JO%]=Z(\YC M/$O\\[OE6--PFL63%RIJ:%"' $Y>WI)\7]#[%#^FV^^/5W>"+QC,G\"N22O2JO%A<-G%D8^.P*)2NQ>6DYQ#$L M;'"*P028ZYI :H6<% M%BU,N;P6=P')8BGKLL" N^!?L51T66# 7:#MHZQ\F[LX4E'5\71*/;SBEL#Z M%X;\W$6QBJJ&BTG^4L?03JE^BTE^?B-F95WQ4H>D3J=N'X;W'B5^Z,V_6;9= M0+.+WTA4H?1NX7%0ZFC8Z11PX7' ;SBL]$M?ZA!4+BJYF)$0?F-0157)A<1! MI]01L5Q4,=BDD?LA0ZI#- M1\DWS;!&;Z?4L9N/DF^:)2#X#>(4PG,H'R#X#2U]'!J4.JQ3[GS3#&&@R*4. MZY0[X313'/ ;UBF$DBX-#OB-,95^Z4L=5RIGSFFF]"]U0*N<2:>9TK_4D;1R M9IUF2G]^ V>E7?)2AZ9*GG>:*1#X#4D52O<6'PBECHN5//,T2R H_ ;&RK_V MI0Y&E3SW-%,@\!N-*JI:+B@02AT;*WGV::9 X#=(5OZU+W6 ZKCYIYG2@=] M$?<)J)G2H=31H^-FH&9*AP\=O'D''=Y?J#FSIB"*4NI R[&)ED]M844M7E D MQ\P]+BC&;RCE38H-)ZX7W%-ONLCJN*"CH'AGMA25WQ &9P3@@EWXC3/DO@?+ M!7U*X?X?.2K/!:'XC17P$Z?A@E#\!A/>U$]7KO-8"ON WR "7^O/!;/P&VG@ MW?_)*>RY.X*9&DK"$2^0U.#9:[<">F4]47/@ !H?K9%- M>[Y/ __;/&J%;!/?7Q7YM[ 0X!,6)FBB\>R'IU]^N)+:-C6"$(Q7SX6E".;% MH07/'G9Z6H ;,0L#Z@W=/35G84AB\ZSW\VGA,I2F^L\.](%D%"9TH)G MI[E8$BI3LG#K(B<(O[5A>-[?+GRGZN?6E4RW_9>B! M,@\]"A=>6L_X6X'4 +<.-=\TR)0/N'6D4]$@,4^+IP<:W+K,'!,@2PYH<.RD ?N<:/YXL\(Z_$V\.!#*/NMYR3=8R6V_N M'&/^UCM3 <.=Q\O?>FUL%?4;)B!.R]WG_7N MFU.8ANOT;+@Y($==;;6FR)F)'NZ5P'*192'_UY*3)XZ1.LY"N[3=J M.1-J32\]XACTR)1AQN5^E'D5=#B,,H5T@H]-F2,91LU">L G7.PL[:(F=QYM M$A*^HS[%\C4]8%PL3^.RN'#/@_5]9(0XAYEXQ CNW5OJC5UO>NEZ-\&$>O[& MW7;+@#?0WJ-'V=V8_KMKGV4O8)R[(:RH-P-)-+\F4[J$B9L@]'^0VPGQIL2@ M88"0.7>O@F/K+WE__25G&!UIM"RSM]]X[7(?H9?CG=\NQIN'TR&&B#-T- M[@(7 GCO QYY+A;PN(OA".!EX?UU:JJ^M_?WB)ZM1>+6F-#*)([2.'H5_ASI5:VIG3W6Z M?.EA1.8NA'S*\"@7%. NEGK*."$7%. VJ-B#)YB6#3KMB;Y4R^D_&W9H4O/2 M[]\-'_Q8R>.6 M:N\G\4PL =H?WMZ6U /F-@3X82B?DT7>YC9@]V$HGU, H@(CVR^\FI[7 LUC)@3:L4YAA%F[MH")_+SP6K]^@_SW#[HIS!CC:WP0[N*993D*+#;9"">XKEI)0ZW 87N*=83D&! M#K=!@;TH]E?J4(_80+">.;4<"ZP,@M&!4FNR#K.H[E>G;Q1M(9&$'J6\W@.)(@RF:CWM"VK@S[14U0T MRXNSN(VE[$VIQ5$PZDTMAVFBDM**VQC*WK1B1_16KBX\J;Y8SV<>]=W0,Z@? M_3FAQ&2#-ZVG[J_P@U'0DE6%D);:, EMZZ,1&6G&6"%ZPS0:K;%FJ/]"X_3E M'C^8VT!)P'1M0JW'27"FJ_568Q9\_6F9P>1,D>7_4V&7=G_U9\3I_CKROL # MHM^CYZP]#<=<(V"Q.6>8L$D]>$) 1C9-+ABY'HR]9KBV368^/4M^^6I:_LPF M0!+ M%)C)B^-)U6%27]8_[[3K'7GS5W)=89]_8<_SDB_C-=-F087= Q/!E?FMHE5> MS34>/5PIF6Z(:_$78).O,V*: - S65+@&M/>J8TX2WLSY_13%OP'$::>.:*BOAXN![<]R^DX7WOOC]]874_]_SWWO7?^U+YS??OP^&P\'-=8Y34/>:PC]ZP]\'UW^] MO[FN2A?G$FA8O9/CH.6]!OVO-/_;.ILE%FARQ *7-W??I5]!+CNNPP7=!6Y]GTOUX=(W% MZ4DU!BBZNAPINS0J0ZVW]=:;&F-OY:/7.ZBR=BN?;9HFT27J[%EZI1UL.EY? M W>V/V#^ 0_&A_OOADJTMJD9Y.\A&%/4L\'5G;E>4)%8SF@ ELYS<#:VGJE9 M SMOP4-JI?M??^FT].;7K6P4F'DLX'XW-U+ MMP]WPX?>];UT?R.!=KL'%28IFG1S)RF-3^9GZ>92NO^]+RTIOH72ZYW?X]=* M1]-75H@S.V0_273I>A(8_](?"6BDR*"6V'FB=XCG6W9[/[+25[%GPBHD6-3 U*"S(')H-+DJH?V_MW1?E8?<+/'-W=J(A:@6HIK9 M,AB:M# TLEU6CXGM+X2U'@MKO6CS$M:6R!N'1"5 QG*;12GP6D+N'F:W9OPD<- M#+DI-:VIJTJ)O0=N"*[N-[.TA+VCCRQ/SPGP/'1"W&:EV\,@ID6DU3I?OC1P MC'KAZ/VI_TR,0,(I2NY8>IFT1'QI.*,&AHE-R7(D*_"E\PFSY#YS/ZUL8=S8 M N-"&%KZ[C!JAH_*UM**YE\Y+<3:>QD2<8?':FJ%@*Y6BQBH+> M_-PU5YT:&)EQ1LU'XLT\]\F(KGIQ:%J@Q(A#3/*VT-G#:%L-=[^+>A$IMM(O M4P+M# $R GUB:RN!5>/B#I3T;Q#;OFFQO7H0=6SGQ%JF!;O4>R2.]2?[^W,* MLS>#%2P8_M/"OF>:'O7]^)\K>)Z2 +E=Z?Y%T<$C5W1-:4@U25':4N^).B'E M1Y\>=57.X=<;[][]N6#N3J6;]))]O0;I14[\%L80-]XM"!, _@99PZJ[H*S! M![P(&D5>B+O78WGO4&Y=>)?]_UNS2.C%[U' /VM<2?JP>;!(RUE$'01\F*8-%@ MM=2&_/D \85)]/;MQ'5>>?N*7NFV=+VFZNW6>Z+))W&1]]LT?7'^_NLO;55I M??6E@-ITAI..XR-5\ 2Q"!PPB41@E6'%3%HB;_!]<8U_AS[PW/S8$4U]X^0& MCHG<3J717#(FU/@AP4!_2#\GE)F]&-+S7KSZ3\IG:0*N/<:\3(G8-GR)T6$? M_OTCM#SX,'"E$8TO@&<.:60R*QH:R%%,%"0M/O>ELI_4?S8F6*A7ZAD!?HTQ M4C?, .\GET*-^$HXN=@H-QG@V"#)'X@ M=63))'._+OW77Y2F_'7]9UJM?1YZ'KPFBL+#N]$,"_V%_&A4NO^D_FO1L?+" M&)$9[3CL!ZOGE&_-$M+;5O[:S7U9W'*+!V0;X)BI%03 8R#\CP;2Z( &1, +^6GJ\/&,6>GZ(CX8O[D*X4I<;<:0QM",C95B[ MESXA35M?54VMQQ<$$\N'$9,9!AR/+4JB\2XD!%B+]:S8?VF]<+EB:;!@_Z9@ M?\'^O+ _)Z%<82'NG7CIQ+@MK;A"W\*4@/>X26*#WAE M"BLPKZ(A 0\#[8MK]B@]>N[/8))\70>[@K*1F71L.6PKDCEW:)6J,,DMXV-? M*U^3RW9>L'U\R85H3,07;QEK11VR%O9 K$-#Z$ MIAX^_]#H7H9TU;]NBM>F..B2DN;Y7E82:7>]R1#*7M;P \L/(6Z&D9T8B9J% ML1C]&9N!I9$]:?4U6YMOH0\/\OV=&:9*>[\44R'MBL 7_3 U%P,-3Q9/C,,'.(8%K'15<&\ M+KP8B]N86'E?PA0,RWP5/'W9A_E$/F\,,8BXV%'C8OZ$VG8").D3P(/%IZ+L MV+>C/]NCR?^D/C]!31'K/21A?(CXV%?NJS*+L6^6^+G1H;!PHR-GI %7/@XQNPL),? MX-X3II"R<"P>.:Q+/7;)M?O$#A9&R]B,#A=6UU7*XM3CI1=5C9)"QXHP%;VS M\@IG:@6DC&&!F>W_5AE<7V[87F9#9KU<6/,]_^9EVJLPA 6JF6Y0BQ\(>A]L M+'B6O EGGG7M:K2ZE359B>!9S+6[MH*+2_QOA'N?)"RE*H0$81ZV_2K^FFT MT*\@N\_V/"%0E#"]IM=;2CN3B+C2K*N=;.+T>J/>;#>.%!(_9>[>/L<0H[$! M&\:9YV7E7IWEN!31?BBHFFXB0N'CQYCS!I/9Q/1Z[]<>:='+^BB+"10= US8CX=O5@Q*J#B(,K(9KXIOD M#^FOMCL"%_\[.)8TD*ZNSG<'/0])RQ8UW;*HZ?:J[M[,C>([9Q[6=K6>Z%HE MOI=1L-?++[>0D>_:8;!^RZ[B?6F+"+86100GW@MK/M+:R*/D1XV, 2!GQ/Y) MYCXNP$DK#>:1[]U[N!M<#WK2[>^]N^^]\_[#_>"\=S64!M?G=59D;OCP;3BX M&/3N!KD6R-MO-O>];U=]K#-Q?G-]W[^^WS[B8CHDK7H[I3^R_7.MK6?BCK25 MNM9H9=L;U-B:IDFF("Y'-R[!>&:D3V^:<-K,;6%^#VA MS(D8F)SVC6O.$5A)8')-/+3._K)'&5T9B-*[NY<&]5^_D -.P)^.?N-Q)JNY MR=9]R]7<2-E\QI*.O)>#Z][U^:!W!6HO)V-26P(:S3"EA M@"(5[80O+CRMR2TT2K=04"GDB+D;QGE+Y#WW3'0/#^*7B_B<%UN-'!S"7XC1E$++_Y M&[&Q38XTG%"*PB!<"(-XYYSAIZB3'M)"#S\N=5SH.2SJ-+.C>!?4B*LW*^Q3 M;5D\Y2'3MQX1%FJP-&JP*=2@4(,(A,Y6-;AD#X/.NYG1Z#4^$UJ8$.C1";;/ M>BJP0H'92U%;X6+/H="C_U3HT5^YF,I4X E\+O3H5\SSI.)1 (^@3$X5>FX. MW%+H"21U;.+.*$6>RJ+)2J%GL>IY%'HJY2*()N*,Y7*P@+9J 1VL90P(!RL# M)H^2>/=PL-@IEXEKPRO\N%"IU/\CM(+Y&R9..?0KKE'QQ3G.HB3ZM7P$*8%^ M%5(W'>FWD5RHWX\$A,9QU&]QA6(#XPK%'GYQ@R(X_+(8;8U"[R7C\ MOX#3* M8W$V2F%Q-DIE<8J(SBO:ZL*D%":EVM[3I#PG_D2ZM-V??LE,R';!MZ9P F6Q MPMJET)OM\A@RI2.(,&1*9L@ ;1L%-&1$[E_&3*XI6-L[@#$%KK3%HME\/"84 MQV/**1L0$DUQ&)%+VBAR_]^^.7:I.R-@<92P06>V43L:6A3H= M49"NU"(6"PK01V)'5BQE[;XXH+00L1DSL1"QO%)'5Q,1VQ,RMHPR%@F,,5CI MDAB!ZPGQ6D(&%N*56^HT1!)#J:4KT/?!66I&.21VU(0T/DVYU+(2H[4//FL1 M%YN[0AB7D-TUD:3 *W7:(DFAU,(8Z'M!QX0E@SW,7 >DKV.YWI(0YH#N0N!F MS-)"X/)*G8;"4R:"$+A9"URD[W>X!ZS>,05C=RD)C -Z"T&;,2L+0"TA[VJB 9!@\W\I3;G2'<+2DD!XJ>5C=*2N]F8A^B\!&=DT^7QI MS>-AZ&J]U8"ASER?'3 ^\ZC-3KA]_6F9P219F*4;(P*>R2^WD)'OVF&P_99M M].W^.O*^O![ZTD]\A&7^5MFOS7)\T\1[0>8CK8T\2G[4R!C>>D;LGV3N(Y27 M!C>UG-JKQ7@]CUVCS17*:]G^*@X[2M5GI\S5KUNZD"]/),52:Y4-\YX2[Q$6 MDO4?5T%P]W@^M!3[K]O0=T/>\_W _. M>U=#(/1Y7>I=7TC#AV_#P<6@=S?H#]>7@)_9,/J=WUQ?]*^'_0L)?AO>7 TN M>O?PQ[?>%>"W+PU_[_?OJ#+:S @ MF\Q\>I;\\M6T_)E-YF>6PY[+;OH:\U8L>%% O3YSB!./OGZ1774YDE^QJ1>_ M.?ZZ#E]]6?^\)=>;;6WC5W)=2?FYUM93W;%M4(I:USM-_@:E-=Y>J6Q#& N[ M*8_3:BLEH6+N.Z;A&+$O5TNPJ/JWJ&3X45=B0T?CI878@?H1,7X\>B[X,K5X MO(9!*;A1[SIFG\/ALA+:3OR=4]V!BJWWQ]J#V5JS0&+EW*1DXH<^_+2# M2XV6,?L?CVC9[%*>AYX'+"P1WZ=+-F@:U+R:L88T*5'#%;M+72LX Z#0:%O5@ +#HZ>?6#4 ! F-:PIL?W?*OB7 M0Z84KZP]$C([0\SA?_T7P-TMH(9?]!QS]8.E*RM2M.L*_O%S<.:$TYKILD 5 MO@Z ",M%&231A1[7L#Z.UJHJNOKKE]49+,(E>;#=?_U%:K[59CC6GS89R,;,$"V /#B>L%-?#K MII+E/ $]5P.461N':KHUW"A12JTK+^@H>,F9CTWVM.R$/0D5I=J4U_FI0$KP M#9XZAA+\"/ ]NM;(!+X:)F,!?!7]4'60$80^CGO8,PR81^"#+VA0T.8CFU8E MAP9'BS&]Q5'[FIBE5@@)1<#<8FFH=PO"^-">'8;ICLZJWM2+K!WZCZX2AH;E2ZJEZ5VQWA/9P8&0-P&9S ]4#7OU]-? 3#Z^AJ(J'$'-@H+?\T M01NTJZT-YE:!M('P%HJG#0X!+>85=ZJM#2ZN\!&."X!;C\Z(94KT>89]O*+J M*B9E.9COBQQ]!-/J:!J A+/)64R3?DP2,*\N8H*\TZ9J5[J*5FTKA8X@"0^A M.#KA.##N5+H=\'.;PC,X,2*B([/&:5).BFYH'=T[8-3H,2*\CY%T;#L#UI9< M9'4@7(3BJ(/LD*N )5.5\0QBF?P$?B7_O1L0.PO)GY$YM5<6*)?,=?R]A4/X M2JUT=5VNZHWUL&N!=$):D!3 ?R@NX(^__7 (X#4 O*I7VQN,( Y!5_IT]FO7 MJ9W(O]CC_JVTS#W9/<7(/DX,\\IU'K/)>OL(09\39[T!9QN;1/38>J9F[4_J MN1NDLXZJGQTQ+X$Y4C"+@VOPGCCG;1F\:R#%3 7Y8$]4!"/?%8QT3F&TBI7W+$ TO[68_80NZ5-_L/& 6FVWUSFK0&I!&/K%4PM9 M8KA3Z6I5K7'P"1?A"Z0^X0)4PW9A%E#>MJD1A,269LLZPV7N GQ/G$<+2V5% MWH+(<,Y5@UQ:<"^]LIZH.5B0)C;24O-?0ZYT]6I#+O3>E7 MBJ=#LD4QGINO M=EK"QS@U(J*JGE1B"U)SQ[70/UQ-? 0C[11J BES18E/[_ 5-^,'/^*PM-RE M5KJ=9DD2'(2C42PED16&M4I7D?%PERBM*IB4Q!W$ 0ZYWUO;9"NQ+\:H?/BRPY42IX6J'1K'0;>J>J-==S6@JD^PJ2 UY:KLZH3F?QN/I$^>YIN;J% M7-VNRLWU&KH<_;X&IPO]PU)]\,=PW(9+HA;HWQEN*^)87@A-0^&QT?PX$]6 MW/$V(E#/,7L1>:Y>J/.^TVJ--BCQ9K75$B?V!:9/:W,>#],=-$RKVN&%'OD* M4NVM2G*%R 4=4P\3ISSZ1)V0BBWNW/JIP,7XF']8P>0\]&%.U$N8:_X^UFJR M?"A-+G0)2+'573QM<0PLLZRHMK)>W+K0.][OZ68>/Z*&UY\I[1,T0]ZG&MB2 MZR%],*]BT[<9-;#- MNCU_Z:CZTKI=V,ZG/A9YL)W/3YK.?*A=W 2UH%<[JC@X*4"<6S[SH2!N,1 W-YS<*K1W M5P#M\)+/G(U^^ @FUXD3F0]EKC:KE:N(@BL"Q3EF,J^C> VH6->_;-M _$K^ MU9+.G/@%N^M:#T28\;"NLO ML@M;33 YZNLXVB.[\)C9D&\.N85#7N_DNQBRY>23^?@1+.J39SZ^7T;B'J9< M;>OB*(. <*[9C^^'<(=!N*.4LE,0YW'G:*^3$S^PH)L^I]SC3,E;;1EXJZE4 MM6)7=4V%CP+XB04%^BEW-],"'?N>M^2J(F>51\_1ON:!?F1.A5G#N_A/)4IY/&R/C ._Y$^+!0VO26TQY2[TA7O>F 3JXOMS$G*XS#%SC MQRWQ;KQA@*&E_R%V2%\>N:-YL;Q@8_UMR;%MD/I)!]FH=!UW@]'\.AXW(Y[T MA.^HPB1L"V08-1-BD#"8N![0TJQN)TMT;>JB&(NYLHGY-V'@!Z!G 9%I3:?F M&^3(9G #WP^IF79<[.R+!B;=)M_E-1G0Q$@YBYVU&C*913OUZJ8=UP&D[T1+ MW-;6JT>L+W$,:HLM0Q3W?WESF@/ZJ\%H$8O.N[[. D],5KX?3AV,-E15N5EM M;BA'4J!X@XA'%R]VD"&,E0C&7#\=E2QA,&C N-;2J)9=8L M1S+(S J(+5*4/_GP6=CTO,GJ M5 !:$]9' U"CTFUM2"4].8 ^D"6_))Q-.K8,2[2 Y$ 6W]& P)O,/O$<6 ]_ MB4P7$972&D#-2K>CM:J=SGJ@=G_V$K9TD>5S]J!J :ATM:JIZVV93@ZJ#U+R MA 7X)ZYM4L__1:)_A%8PS]-Z/JS%&W_B/,.(#'-48U+U&:'2\E<;#>IV59;7 M^:M $9B"-#/\&*@_>NSF<-1W /4M,%4:Z^B;*<]DP_9QO&F>FA-XR\ M/=,_(UJ\[K.'BU+8_J.'=A7.?H%XD5^G3.3O.>;!T@S&5XJ.Q)DC*B?'\>/* ME$-[&I=7IISRS$0V,D7)K!\R%WS-;*@O 3;G2W+,EI)XI\1[M!SVZM8J-QD4 MB. =#Q_LB6>X]6@9;R-&99;2A&(S4W<*HYECOIWC!F@N>=CG5+)@K(\>2YGP M LD=2\&$^A2!9%+'9T?V';:L+!@[9O5\+/3X,466Y=S75]/PEI8H'H:N1D<9 M9Z[/]D_/V/ERZXE^_6F9P20!]M*-,<'EEUO(" 81!MMO.>'ZO[G:RJNDQ*6? M.%ID%4M6%4)::L,DM*V/1F2D&6.%Z W3:+3&FJ'^2P%G([YIXKUDC3_2VLBC MY$>-C&&"9\3^2>8^(G49EH#)5^O^>LFBA>G^.O*^=#>-=C/(%?6T*-]F6;5T MW"!XN!M<#WK2[>^]N^^]\_[#_>"\=S64!M?G=:EW?2$-'[X-!Q>#WMUR,_#7 ML^-E-N/?PQO(=_OO>O[X?2S:5T<]N_Z]T/X (V MP?.;[[=W_=_AML'_]''>-]_[TJ>KF^'P,\_S93SRR7) S+@A/,/TJQ)]-BB( MYQGU(O]- EE#TLV"">D7Z<&4 LS&)C.?GB6_?#4M?V:3^9GEL#&QF[[&$(]% M#O++:Q\7WQ=]';-2IU-O-S3DIMC#CE\<,UH=YOAE_7.]69=U?>-7U%K\#4KIM/D;%)2<(*8*/1K*_:$7O:\R37FY=U MUB[;X-5$TH&KB,#]Q*-4FL)U$U^B8&*9>T2G2KD2U_!)VH400-O_$.CR@9J/ MBK&TBY #OI;B1?M6#>!\T?'PUCXA]X-KA*_$!M:]_S2A ?Z75#N4A_=;N/UK M5_"_9 *%N:"PX):EJI1.(G\*'1*:>+I\-?WIU!40\IC['7VB3DB/EHLD[B_+ M_3G*K71U 35N6&[S#M6MYYJA$4A>Q'I5R:&99V\?G%S+G:!*O>/)Y9[EX7D0 MK;?W+&-Y?NFY4RSTA$_\AQ5,SD,?ID>]_K-AA[@L/=^G\'^3G>A(N8VI5KJ- M1K4ABP.F'YY7,\I.X))7#\\O:.?/JUJEJ^,!VH,K M^$;KMV+JMDS^_Z)6N MTL">I86N^BZ852BW8RLW1JQ]3I4=>/#<.;&#>>)LBXIX1U;ABI*_5&ABU9BJVEP7"@52X:*H M!H\Z3\T?W5B[5:NVM*R.V0F$<24_=YQS.@7"L/%5L]K<<$I!R,^/C.X,Y.>. M$S>G0#F=F(:<%1YQ<3N>?:*-@^6M-KNJ9;6^<&I9<>3$%S,Z]F5')?H\ MPSV.XY7/1R =;L:Q;D^MK_5*MUF5M76WJG@&;,',5*YA>_R@P6&P;2!L6\WU$N," M.GE#Y^B>_6'(:5:ZJEIM=LK@L@O8FVJZW&^@$6GJ##E7W] MQF9G$>SK(;7AP\>J]$@=BM7\,#>0F%/+L?S 8\7V1#.KW*SNOT9$Z3EF;X4D M_2CHD9J]VY4N]K=HMHJLED0""X]J:8Y>))P:1B M#W%-KW:*;:X+)/,H%W>8ZUE#&?N(ZP#E)M]9T%R9\ 4/D=]1GQ+/F##3W03' MSW9G6%];1,MSS-Z+2 )L??%"D/?RM%KI:E59+[31+F))/"JGG2EW6<*8)6U4 MFW)6R74"2UR)Q%-"26<'&9NM0A]D%##F423NS&[+$L<-T.R=JJZ(>/M'B;<# M?@(O-(+0.TGR6M$=\).8ZB\$P$YAC;^)G3U,EW:EB_LOA4[I$]#E4>[MML / MD'N=8L@]KDSN@L?';X()]1)36_ID.88[I9]S/_K.-1L?P^[V8?SPVVM^9N19 MG.<9,.K$_O0U#=+J)4VN=/5JHR6J5 I ']L>/PV@E4I7K39U$37G#U1'L-/? MB:EUV."I\0W944(*?F3 ;J;+IRS-\_1(U2K=9F==O'WF RA<6>)A#BL*AWJUU5VX4.>0BXCL$T'O=,A3Y?9T:,-938%\ H&O*.$_H^(/*72;:H O?53;]Q# MCRL#O^#Y\@, H$?](-DE$)L$N:B<'09^0J5DH\]U%ML[J1D?-ZZKJGR(RA'! M)"Z =Q0S^WC P_.I57U#^R,!O((![QA&]O%PIZ.-W6ROY^H(W!4,=R=(K\D2 M> TF\)J'I-Z($/K;Z?%:4Y,/G%B,?.$] !SQ,'CG-"652/I.P_!QZ!);4)_ MK[AHR*Q_>ULNM.6?%G-%#F9QSS^GS)/AB9,45JD2%/ 1(V,"R,52!,71 RIV M+5-;9:C,([B'!^XY9>H03XRD5;H-I2IOZ(95!#7 E5]6W&,&X'X=E'OT$6(J MI_*S@-WC?<]OU*%C:U,Y@89>Z>J-0OM (NK'8]1OY^['W@AM5+IJY^ #P@(E M/,JQ=X(DI66"9WZKG8;8VQ#X/?7>QMY2KE7I=M8!RA-(N+*0R[!SD?4NQ1'3 M!'-_ET@G88_R M<_QFVI:=XT^Y>W08[W?8?H^^H<,>]YG00I\*?7H<7_4@EFJR,MR:J/HGM*G0 MIMQHTWTWX0YC?85MFRD;*I9SKTVYB@@4<,\L:K4!R)EY=$(=WWI:)#4^$LLY M.]H.VA[W+V%) \"8;CBRZ2J8WOMH,;1B#HTK=C\P &A:3_GP_(/C41C+G]1D M/"Z!$B)/Q+()4*,&JJ.&-;\EGQJA9P46]5GC':P%CCOK\,_[_<'!]>7&ZO/G MR_+G19'UDE%=NMX0QC1<#.F>/._L(=5\47#J(3'UO :M'1)LRVO0^@$>35YC M;E2ZCF5O\'O>\4&L+1EOB]ZPIZ];N04O"ZP *OP5K/3,?X?1V1^PH6_& )U; MU\-Q](+ LT9A@'?=N[?$@TLV&<]X>K?8S:M$4T4>]W5W9*_D@/16I=LZN.^Y M !N/8I4[K+4K76U#/$)(U8\,].-GR^2 =-S*.KQR0EE[VQ[SU>(J+L(H7$=- M-^O6%0F104;5&_&U%#&U NT(';H#G&[RO.BO4S1_6U-=B5I*NRO4BD^GJX7V M;5,!):=LYG*R^*&;OL5D\5.F4&7)[-$!>FU#((O[XNV"UX0Z/4[<(TL&4S&] MJMD4S9 $@PMERF$&59:\'I!?J)WCJYULM$Z3@;X, MYUT%UPFM2ZYC.9I!=6'884#/'A*AMAPQY%$+9 M;^&^.7M>Y%-NSFB,SDURJ5U\=S0=&OC?JBT2)V>_5UL(3N; OWV#ISL'>[B" MI81RY&+:QW>9M_-16RZ^TRP86>A&+J9]4B_\#9Y6#O;#\V*I'+*5]()G*V56 M$T@,K=!#$]&MPZRP?[ _J%DC,"KR2+&&VA1D.,M9\B4W#/R .&PZ(H%)W%\D M;A0)3"6KFY#2CXQ$6-JCIXE [$7R\#J^,I&=N8) M+ST2G=J&KJA"='YD:&+Q7&$[ZX,N^Y=K9/FDJR%R=O M6"[N.#E/ S^FS1I#I^9E;)&I-ZK-8IOXF[E+-,G,74^]S\3/#-VMS(Q\@3!. MY6>^ &M'XE,N1>*: #=OXO-]9GYFZ.YD9N@?%6%'-_2_L'JR28 MH^6P'<'6*O8,"H3TC@U'-D0GW<7'-,[%Z-"^6P\@P$8"6-+81]Z8JGY/*4&"JZ6F\UX"DSU[>0R<\\:I/ >J)??UIF,$ED MV-*-$6>>R2^WD!$ !:3/UEM.R"-O11\J-&QC#!,V+_)',?IW??>>?_A M?G#>NQI*@^OSNM2[OI"&#]^&@XM![V[0'VZ%9_Z388@YO[F^Z%\/^Q<2_#:\ MN1I<].[AC^$]_/.]?WT_E&XNI2',M/_[S=5%_V[XB]3_^\/@_I^\3^R3Y8#$ M=T-XA.E_EK@?;NB0T+1 %7U.-52FQ%\D%\OE@2';9.;3L^27KXD!8#GLS>RF MKS%[Q>(.>?65B<+>%WW]PL9U.6+E.$X8OSG^N@Y??5G_7)/K2EO?^!5\D_)S M36^FNF/;H-IU34WW)#$F7L:DJ'59X0U0BEQ7M39O@U+J367S5\FC#@W['R6A MJ7/0MD,D'D_C)>^4[TF=?\SIB]Q7D<8G[E_1'8QE@O&BD$38C,7?T: Z);#?C?(#&-[8BGW74K#"*>AC?%)MGZL MI1C[;:7$-/ODTQ6K=1J5FQ8K_,X5OJ!CR[ $L^^M[-T@YG.FB":N#1+?_X5] MTO\CM(+YRE*6Z_S YB7Y1FSB&%0B@?3?H4/739XW M=S;G -]L&+C&CX.W%SMRE)W1:1>ZV55:X'!:*^XPX',G6U(7DMM__@5E^$U] M.G9P.^/S6%-%.BHUCV.+JZHJ-ZJ-AN!RP>6"RW/@\L[1N1P/"BIJ56T5.@U. M\+C@<8XFGJKEEBKOV7)K$[>O,[16Z;8;&90F%[S$%:0$+^W%2VM)Y2EX*:7F MU"O=3D.M:GK)F&VOL0A._'B):!^?'1 M=8CKXV6OB.,Q*!ZT/<3#@-'R(O1@+6YA6&Y\+H9]>1,1LQ]3V=PD(?"$K,KW M 1B!H7?JE_X&D)>/$)KW2.A)[&D4@'M'4LM<%G M5]>#[*D+R@H0'=^Z:ZN*^E7PN""/(,]1-?RN\BJ9"-Y.I:MJO%B(.]RT8YZ5 M%E?E=U6Y\L4V']EECEMM1*(3Z=,9=7R"G"9*T)Y O8E2@((\@CPIXPMK_M^J M]=$S_QWZ 2N@<>^^G :X)98Y<,ZC(P!,Z#&9=[XD\N[H'Z'E6P$=4N_),FAD MMMQ1PWUTV%.8!9,R'*'*,KB054T5)7&+@D8A+ 1Y!'EX\"2YD^4*7[+\(VP? M/C@>A6'\"?[)([$_>@@'C!)O,#;72U5OKNX\";7RB30@#KLF3I6>2@S#0>!(& M&6V-1,"1-[@@[&\+:^4&9[7.>G' 7)$$%)2L]Y>Z^+C! 1&[$>01Y!'D$>01 MY.'9_%-W]-@! R"R][#L5>HH,NMC6-4:ZP>[!7:*CYU=KL-AV&EPAIUR;4%L M+HZ^5%/KC5JB.6PW?/#"6NJ.5CX9%M92Y6;4MT>1U\^5%.A08UK@Y!2).B[P M>1(P*0\NIYY_01E^DTVV@]L//KBLRJVHL%:SVE0*W6):<+G@SZ,8T%KUO ,*:ZERI]+5-K333'U(M[2\]*$9J;1< MI!U2GBZ=SE3D2K>CM:J=SB$EM5)1JF@\]M'9K&",E]EI,'[3#;$#YEM5^,2[^'Q7OI/:L^_: M(6/KK%VV027QU]4E;:_";,E8QLM.O4G'<_,_333_$\W_BK+$HOF?:/['1VLZ MT?Q/-/_C:_U$\[]]F_]IXI3",=.0M+76!L=+0U+4* U):Q8Z#8F?Q-6#X.QX[+XCJH)]?]K5ME;H M313!BX(7CY\ZL+:E>;S4@09KQZ"N*\C4O;@$3PB>.")/I&HL<1A/-$%3R6H5 M9B^X0G %SU;;/K7^#^.%5J6K==2JVA%F6]F.4XJ&<$4ZR[PENKGC*'P6#>%4 MI8WM/M;;18I26@7#T"85\CX 9=803E6PETQ5WA"B$_#B$U[I[/:U7@0YKM\#NZ$N<:9 M,/\(.TUO]@X#^K'^89+H'R;B.((\@CR"/((\A[B7.RH7GKYED*I7NAN*' JP M\0DV(0NX)D^6WDD.LJ#!D2SX"/LCV"/,=OWW9:=]W!B "-$(\@CR"/((\@CR M\)UVN&\-ZX/Z/:G8=D:KZGJK% >%!(#>\A&. J 6/P JUY;#SA(\;Y0>S*]7 M6+0XFRJ4?O!F8OI:-?7C5?%1VU$5GZ:\WK6@0&?>,D=63H&KG%F'.QGVWJ+P M62Q0067*!OV^2Z $(!&"1 B2K8+DZ(7,-!D$B=RI MMI3U$Q1"C @Q(L0(IV(D5/>5,R[5D N(#%,MXFCAHU1:(2 M,?"$-G'F6$C+<0-X'_'@8T>R8*R/'K&E&?$"K+$53*A/$=DF=:*CW0Y;>^Q3 M(8TMASB&!9?[ 7S CM?4MZY)/ RU4U<;,/B9Z[/S,V<>M4E@/=&O/RTSF"2< MMG1C# GYY18R@D&$P?9;3KC^;Z[VZ_922S]QM,C(EJPJA+34ADEH6Q^-R$@S MQ@K1&Z;1:(TU0_T7)NO%-TT6K0YGY)'61AXE/VID#!,\(_9/,O<1T4OK,+6< M9$"Z6F_ANK]>LNUX7J/@E'B/\$#&A.JFAB G;_W1TK%URL/=X'K0DVY_[]U] M[YWW'^X'Y[VKH32X/J]+O>L+:?CP;3BX&/3N!OUA?BR[/?PQO(=_OO>O[X?2S:4TA)GV?[^YNNC?#7^1^G]_&-S_D_>) M?;(3'7'MD&UZYJ:[DEB3+R,25'KLL(;H!2YKFIMW@:EU)O* MYJ^21[VC=?'1.WV)^\7]I;C_T-RRHTRD0V?[&@BK>>)?>Y[&^^YSJ)_]/'76#203KE>IN@@G=E:BA;2IUYBT4,Z MY0**)M)OG6"YH$9L]BCY-Y+^Z.=3=G1BRO)\BJ9'YU/:VGK%B +M,Z<%3DZ' M(H\+?.[D2^K6:F5)UDR52W+TOFL:Z\NIRG)55=9K4@HN%UPNN/SH7+Y/XXS# MN!SK!ZARM=46/"YX7/!X'CG=J?J3[3QVT<(Z;AFT#1:\Q!6D!"_MQ4MK-5:/ M=SZBC>>;U*JFKOHA7+T!V,NM0=&D0Y!'D.4$3C\HX'E;?+R4MM!>J6K575U/1HD2IT7"%CO M=>9VHNI=?5=U3'-I5YM*IURHROO^(_7BO!XUZY]^A$\'EIQ5,I/[P]E::>>ZC1Z9B"X?;+9S^ M=&:[10B2E,P(&6\4;,51*E%.C94J<1^#'= $@%_01Y!'L[W8]+(7A#VW98L6I6?>$^F M-B)1N=_IC#H^P247>RTB.B7((\C#G29:]P=655'/_'?H!ZPZ^;W[4M+GEECF MP#F/ZO@PH<=DWOF2R+NC?X26;P5T2+TGRZ"1#KNCAOOHL*>\*^+8P%Q"M=IL MK&=X"3CR"4;)AK&MR,[\GSK>OA.'I!X%FCD/6)N7=O MP8IQ@DTVA[9Y.TJ@C4^T"6' -7DR]$YRD 4Z3[(@H^V1"#?R!B^$_6UA,\+@ MK-99[YV5*Y" @GA01Y!'EXMOX:ZMOF'Q@ D;V' M[2M21Y(;E:Y>U=2#4UT$=#B$S@['X3#D-/E"3KFV(':VQ3AA.[ ]'/#]6E5Q MQV&9-,50UVKK'J\I1J,5-<50Y/5S8P4J5Y@*-3G%GXX(>>[DROZU2---OJ!\ MOD&3[F+RPRN1-MI1+XQFM:D4NN.-8&Z^8"Z8>R=SKU7TSIRY.\#<2J?::@G6 M%JPM6/MTU?K5M:/!AW2^:,J5KM;.X$RF8"%.P"18:"<+::E./A^D)YM*I=O1 M6M5.YY"Z**7FL8_.9@7CM%2,=FPSM*FB^FI797F]#DJ)S- L6#P.)R>#2(;; M ;>QO][UKK;MR3>R^PT&+_IAB.;KHHO\2+QHHWO.G0OY-"^ZQOO[QRT%\-A MW_8HL"]%07T>VMV+^SFY?P?_%6G+\1H^D;[#91-?ZCLF-==W'K4]L)]>SKUM MLG,N&O:7"3LG_$%6K#<%QMKGN%Q*Q5J0V2_.E/XZ\KYT9P2(:#GL=R,Z7OIA M5\8PPFEHDX":;#E8LCO[;27CG7WR"?-8/DN#?;.A/\2"7="Q95@?EK/NW2!F M*B:38_?Y%_9)Y$2OK$RY2BWMS"*ZH$:LRA6FRM4\SQ!\Y"2BQH[83Y9)1$T- MDXC4JMI<+U5:H"A0*M3DE(MZ1,AS)U:R:VAY4W&Y4N<+;>%IPM.%MP]ND2(!J-TR5 -%D3@:9R>%L8 MP6&<8$UPV&X.:YZ.PUJ@19LZ&,CK.1""QP2/%8G'4K'8T4^P--N5KBZ#@:JM M)\@* [6L)U4WKWG<8MEBK1BP5":-.V!C S8?H2:Y46MLUGKYB?H!3 V_A-L" MSS(":L;7(:B/EU[QP:I+;8D^[W, 9EL7MBU]SE/*C@X+7*DM3FI*"8B]&V*; M=,_[\,5J(V<"KY:,YZ^JBK[N5PE\\8FO=/Y#JE,^1T6: NY%55'6!9GHV\8= MQD2-3$$>09Z35"+:Q_L\JES&HR]55B:'"P.@7(E&7#3=%C7!3N'NI6JZW=(J M757AI4N) !(O3EUF3;=;.@ ,S&T!L:) [/1^779@:T0EFM9MB-0;1P)G?#H/ M@CR"/((\I_/MTC3E;C4KW8[01Y!'D$>OLF3*@&QN=9">4L"XD&]E-M*I=O MXXD9=)82 .(*0.M.PE$ I/(#H')M.J1OQ+U/.?QCU]"-%F>M*VH M=F^G76TTUX\S";$AQ(80&URL22JQL>8_9BXV\%":W*FVE/7:-D)H"*$AA 87 M:Y(J:*"K638M;^.Y*?V0@D2".05S"N9,F'.MB\?1:A6W6\"Y2J.J"^X5W"NX M-PM[_.A=.MIX"*"C5-NM=9X5]GBJ380O+-\)_C6MI^ZO[$FS>MYA)\F4R ME[5^A,>#)7OB&1XSL8RW2<#J8=U/J$0,/$=-G#F6.W;< -Y'//C8D2P8ZZ-' M;&E&O !+9@43ZE/$KTF=Z "VPU886SM*8\LACF'!Y7X '[!#,/6M:Q(/0U?K MK08,?N;Z[)3+F4=M$EA/].M/RPPF"3\MW1@37GZYA8Q@$&&P_983KO^;JZVO MKL;R3QPMLJLEJPHA+;5A$MK61R,RTHRQ0O2&:31:8\U0_Z4"-\9^XC;I7686D[MU;J_7K+M>%ZCX)1XC_! QFKJIJZ; MIQ>^+1W;C3[<#:X'/>GV]][=]]YY_^%^<-Z[&DJ#Z_.ZU+N^D(8/WX:#BT'O M;M ?\L"SVV;#,'-^"_,Q\0J3M\G,IV?)+U]- MRY_99'YF.6P*[*:O,4)BCD6XO9*N['W1US$2.YUZNZ$A&./]VOC%,4[KL"1? MUC]OMNNRW-SXE5Q74GZNM1NI[M@V*$6K-]NMC ;5T-3,!M79_%7RJ#U;Q>_9 MDW?C99V"MN[=T7H^3=_>+):Q?#W7558.=7>R0D8]ZF/)].H9)5I,[3V07+:0 MV:MVN)^P4'E%22P';%(WA&>8_EKXX?U2J2P(^!0Z)#0ML,X_IP%"*1*BSHD_ MD<:V^].7QIX[E=P9]0AKZ8*N[Q,[W7*TO*@BWI_1X1@F-M0&-^C8?DK&8LF- MTB<\+;./\$B5<7IPEBEW#+5_H&_3%,L3L-NQ?WY8UFRGTM6KFKI>KJ- @3I^ MTKZ+S(2;25$.)BQ,%GM'+ET6>S'T\U(A)2EP)8\"]0W+IE@JAQUOQ4_Q=P/- MO!"#T5AI1]AXI[/QM!;G&+J@,\"-QC#9$ M7RLT]K>%&][!6:VS80OK!,'/[2&,98V&&_0 T:D53J,6QK!+"C6Y@JN MK 74FX*AA,V-F6TEJ@X>+RMOAQKL&89'626=)1K>C"\2HO4<\S:FYN"%8*DE MCU;I=JJMABH:Q/ $KZ,XP+G@2\?FLFUMO0?&R?'UH7P;=B!X0QL,B3[C[U2X M-WFY-XPRWUZ7=T[-5XU*5U6KS4:ASUT*1Z> CDY& &Z6L_)X09V%2]>#/U$] M&!/B/%)T":*$72K9%(@MV1896;85S(5/<'*?@(2SR5E,HGL/!F-'UIIS&9'H M"BETE1!H$[>U*MV6LAY>$$8^=Z(Z$R,_+6!2RNXVUGW0M$,VO811GQX:K#SO M^[M!? 3SYPCF^Y9]8T:,:]?!#<9H [D?N5:;&*:#UKHPU0563QSD>0.DJ42^ M)F.=;G W.^7*<^!>Y&,0/[+(_5<)#+Y/@RB.GUCF(IGA>,D,NL9'GON6;!@C MWLCQJ$&M)SQ<)M"MT&J<;^F,VV=.X'JBE1\WSMLZ5RT1:1/CX#9YIPSE MZD0 K^#B?P6H*<4_VXSOM ^Q(CB,V^TC_7-%Q*U'9\0RD[WWR&MST367C-## MSEBQ.R?L=8[L]9AJ[PV8-#"E4Y;7=8:PV#^:R#X024TPVJOM=LE";PVU:'OD MUZY32^3UZT"EN(\KU'+,7D>[JA5Z; MV*Q3Z7:T=2^U0-$68;H7,+/UO0!.9\\KK.5UM;W!\BA!YBOOVN1F8;BOIK4> M<_.\Z#;9,6SXO0/S"X+M2G+5%.Q)NN% A+#GN9/:QRGE@GRIC236C[2JMLK@!>3?J>1C\\&)RXD=BR5TT%"M:JN50?+.D=M@ M?+#2L5'!#'[*BAU>_IJ#D7VH77_D(L:#C[RK=DCDCP;W; M,_X(+8]^)]X/ROI6#*D1>N\3X0T0X4VL%WF(ERIBB\6P$$X!*#Q%W^I45:5D M&;W[2.S\,@' NH.AFROJ7]3+RM4534AR"109$A:J_TX"9*OYS3@35FM%LEO7 MUX_1%\@E%2'. FY,'1_<<0M(M;W> C(?@&5ZL%^K;]0G_*::/=OPZ5=+)9C?,%FAQ@*=.S]X63 MRLM1FIF'NU3!G"6A42#T[-TB^B/82,>W_U^S'&UO/ MU*S]23UW$]LI:%NW547]*NQ]@>6NQ_B "F M\5Y#3.++$@3]YZ7HO!+H9GS/R# /7^)$ZT(_E"-I5G8>Z MZ@)+)]W?3XFEMP/7[>V!Z^+OY?.?RNM9H/]GQ)9FV%H85V=H^JE[)G2$1HJJ-=#JSW3FED?TM+0SSF4W>US+^(QA0ITW^19K= M1"3KQ[0T4[.BPCHJ;"915U"H===TX*;0SP+5&84'!E^VHY4VJ M3?%!4=N #Q7S5D :'ZU## MZ@'ZP:<[C@ZV'>K!M'PPM>)818#MZN(#+7 R^Y8ZY^L'3E M+4S$-==+<1EVB(O;CQM,WY& ]L=C:@2IE6:#G8=H:8<<>4Z%A0)X304%]2D3 M+CA'=3.N[I/!YA]'U7T*ZKSMJ<:JTH@^6HZ#[AR>"6(@$;LZ1PL#ZF\;R =Q M>&J&Q7H [6I[ \,6*$8HMITX= 0;.QS!T^*\7>EV]*K2*EFY:DYTT/:LPKUU M$,4V" =IGS>,T.,F^W*W\/]YM 3:O2'.OQK6>!)/':R 557T=?%4(#5Q:8J\V 4G3=D;Q."ZBQ&7 M6NLKK$.NO+XA5" 7@)](7)%Y\E!#GF>>/&WRX<%,R?(.&QL.110Z;!BEM!>N M=S73Z-B$/-;FACNE4D">LS]">G!^;X$U^J8I\B(]3M*(&U!UCZ"Z!:1=T]2; MX#IV?:KJ!QVDXB?KO[#AIR0_6:O&KUO8Y#Z46, M0W%W_ZEC2:;UE%>9"N 1P[(MDIQZ3I$0*@6N%$PHLAE83WAP GYCT5:"EXR( MS_;$K.M&M='(ZF 4)U$JKA%_Q\]9(*X3 M28^N\=;R,-:R+]89IE7I-I0RY%IQ$" J#5*/+_W? ]5VI=O>4)#[8Y0].$$8 M8+-\NG>3A)*T9T'3>_,'&(IQ1E"T7J^3@@XY3E=\]R^3I>%%-)4KVUDO1;9S MACCCU TMHW3)R'TME70I6?IT([/TZ9Q9G%E;7UA3W,2P@!_)<*?$>[0<]M[6 M*GL9%+->C@<;]L0SUAK*>!M(*K.E)E0BAN%.8308XY <-X#W8>5!&![F9#YZ M6&B6> 'NMP03ZF_=0HD+3\'E?@ ?L J5]57;:VF)XF'H<:++S/4MA,&91VV" M#G&F-3RRRUD!(,(@^VWG'#]WUSMQBM+=.DGCA9YQ))5A9"6 MVC );>NC$1EIQE@A>L,T&JVQ9JC_PLJ!\4V3Q8[JC#S2VLBCY$>-C&&"9\3^ M2>8^(G49EH#)5^N^;L^^O(^]+=2M/EF]0W<+_I,>]^V DMNY8. MJ]1[N!M<#WK2[>^]N^^]\_[#_>"\=S64!M?G=:EW?2$-'[X-!Q>#WMV@/]RZ M5!S,AD'R^N:^/Y3N;Z3SF^N+_O6P?X&_#6^N!A>]>_CCF7IIGRFH2RD9Z0JK\,I/,A8SYE:5>@W MWB-QK#_9)OGY0D##'Z#(;\$UQ@,9^.?-^#*1V,.%P+ZP?,-V_="C]_"*;S:K M#)\H;R6R+2PGI&8OB#_# 5!0]#,$@!?27&B>Z/,:FJ]G:KO.CC@MKP0+#%S M0#UKEJ0/? M]>([_LL.[LLX)_>'#>-;1@Q:K45.VR\Q7$NO?H1]8XWE.>J<7 M>I9C$>EV0L!8,VC(;!I?&CA&7?J4?.MZ+$'B/#(&/DL6V '2.+3M>6((L$0) MRYVM/$:*K0>P! U6D!*6R*0VJ' /#0IL*TIF6(,R<*49=6=@F\&7^-5/*YA( M) Q<:SH-'2J9EH\U;_SHBPE, S;*0VD*379FQQ,':[#L*7_)D -;RZIP,C5 MY6'C4%D34QC(UQ7%M(L1VKOT&NP;A4=/8W:^M2Y@\/H"YNRW] M:TX.-X.,].G)14$P'T@/]6%=NG1=,^(H+WR4>B98%A:X"!&# M?+J\Z'V6R RKDB(>T(*,8#!GR<'XK !LE0 E#O(A,4,[P#:F%HJ@&!>L#:UD MA[/0!\+/)AZLHR]]NKK^S%Z<""*&*[1(0R.0#)@(0TH4!7P,8DJ,(&GH@M@I,A#0#.;@"L2K0[:T@[UV$HLOS2:U'2*57@!#W\NDIP60[0< M-N1^B)W! 1(/#EOM_@/0Y[\)@*2*[_M);1O_Q4OA"ASSWX#;3'=:E>Y"W[=( M51K"+/ZDG@WOK$K7K@>V8E7Z!@CU0K\J#0P:?7-E46,2@*D?4"L2H \_/ )8 MD3[AG"@CD3V/T!&OR3WU@%* &NI_WF[]-&2S)"%ENP4;&'>-2NL ]L.I*!WAK>5[%1/XUR&ND@-1*@)]@[07)5B#]!.EB M3>.SO:S0] J^EP&(TA80/*/.,@_]XD?& IH*+W01ZOH =?WHN3^#",>XT&AR MK2(:I!. 7I7ENG0_ 46Z2J>?%B@-^ CU,(IZZ:?K_0 -9=!(4B2ZZ##!H.4B M,P-DB&%[P#92UL)$Z*FP7EC< \KQ:) .0_$@70M5%L;"0JK XR#+KB_2? M:8*US=5@;>/--3IGXWG9F6Z^S!F\5V5]SLB.Z8;3R&8X6%!U_1B"!(Q@)ZX9 M0V D%98D!6LSUOKJOQA!+R92(G3F*$;P'O088$ )+Y@>^B!OA""Y%<7WR_X, M -+VW827F59'*\.:,>$#EIX/'E+$VF#_@9(:@V9"P8S<495FH)_P#_2>GF%M M*-B>D6FY;))O\L*8G1 @3>%](Q=6]%OO\E+Z]*UFH(G)BH$3)O\O@:"N%]GE MO=N[P14XE=*MY]K6.'Y9;8 &.EY[98%/;GZN2Z!OAG061 IG#TLK,F+0>F:< M"B)M GIH1$&UF&[4"$%B)KD/^E@"Q_[1QM4!L8"! 7:-]&G8N_@,U S-^:I MI!)\$W_!D(C+ZD=0],F8!FCDNC;,9F39%OX5.\'N#R "C"C./(B*M/HX%G"4 M 6 _ (%LA:-WX1=@:=G!9"X]N3:86Q0NJ$9>A4D"M.IFE#D:*[;;A-CC6,0T M"@CH6,R"WDB:TJ@I2EOJ M/5$P%JI2WYS"6]$2Z]D H "^G%K9;T,)L!-.^P0].YY1D IV$(]TLMY#3\^ F0 F/Y#LY"Y#"I&;TZ6=042:-P@;^?#IR0?8\W/[^ M:IF_O K3I0KVMBJ[J953+%M]7Q!X"*"R -- O)[!_#H0@K<@D0UPS#>$=IL; M0KM-CD.[PW Z11\=9.+25*67N4K)9*7W17?9Y#3-*V221&,L;#,63@VO;X8N-I#2;WJ!LGFADFK>? M7^HG6=.E 2T5VF*J=L,0\+&6$]GP3)2#G+^$FR1%KOT],N?0W +-I\A(W;LH MI(I/'-;^MX"*;A M)=K1L4<+CR2/C&Z1\9D!^2U6M!\>A7:DB1.>1KFI>"M8 M.W$Q=P>I@UZW$7K,OURZ-KK49':10S%2B,(.Z3PFEH>P6G#9)KHNL!%IXWW. MO&+(&(5I8I)'Z3B:'!GF+.8#PXG*=6$7RV1AP$@/V2;0KE49A9B; Z1TW&!U MB:(GF(N=1PQ._!%:7M3/;'4NZ=)/8&IN:,-CT)4GC 7@GG^#4\%6;L$#2U3> MC[8+\_PEHM6+IG%'V=X"/#UAI+\M-CWFE'A83)GB3J2QO,P*6V8M(E<4AV'D M<&KBIQC99HLR>Q7M! M",""+1R1Y,6X%1A- 1U&\,]<%A4=A^#^T[@X]&MO^[7.3:4Y5S:OM^K+]@8U MW=Y@N11!/$4 /TSJ)$(L="((K7K44?C[Y\1%O>/^Q-T&/QR!J+$(;MF\1'RC MO2W&?=5XH_B"VN0G0FG91_B\$D>+[[JRIFS\GQ[^MGHQ>&6V'>FJ9-LXED+1 M5@AX!8Z?[(>\J%&Z"/?%+/R""W9;Q"8L-+/:P3B;W9L/ MG$O7W)Y+QW-:G/RNM+AM3DJ;I:!L=V'4C2Z,]@&D(>N='5E)D=!@9H2)._$L MWC:QC F&.U9U.-N-M>UD*Q<8',;CK$C(7T#A1>8#6CU@N5''F#.][5&\GEF1 M'@MC.>[B@DBPQ:;SBYTGA3-W39[YL3*>4H+64+)[\TC 4D?5"T:2'P=1P';$ M#.>%-;)EA9;69<6FB*0Q6! T0/.2A9*C1;"M*-")_C,\T5V2OF2Q+(O)14.) MQXL7@06QO-X83\/AT;B)E<2$=1SZ6;5"<$H(D4:O?LG4I08D5%: ME[XG0XO+W+&^[=%+ 3=TZF]Y,>@S#R32^@)Z;-:7\<>+<44D9Q-/:&[YS'MP M5@ %H(!A!O8"*QMHM$S%Q=+B8*58HZ^8M7O!)P[@OD P,@B3E?@4K<[G*IB= MF]3;JCH[)'Z'1=EWAG.TC;)0YT<6I@RY[ A[%<\WOU\1Q?[2]);#(DE4CQF' MZ--$O!)[I<$$MWF64G!,EO$Y.I;#5HTQ'\ @4'(S5D%_TW9_OH)\*M?GCK)] M#BR3>A[GGOT#!-TY$ A8RMOF##5E7MV>E."^93F<@12O0P'1_ _0:+A-NMBX M7DFHQ/#>-/+#,44&/&VP7X)YLJMHQ>X06?K*Q 1+:Q0&KA?M-?IT:M7&F'@Y MP:V:>,5,4%%&$#W7#5$:UY@J3M(.HS2]12PE!I3/;!SZ1PA2WEYZ%WW%,_%; MP')(*!/Q7?)VG]A+I@EP\)^8,CF)TW^2MTGN*&"JC>55NO8K-_7E/8FAYAJ@ MQ_S(6HISB^>+@F[Q0^L2ER!)>2#K#JCB/=$HW,/2UI@?'QNF[D_F*I])>>8: MW6ZD-;,!8CL']'W\+<#\Q*8OM*JZ\@QE?TV@I0:0[+"LYCG,9-H'56>Q$)D9D M/#M<=X]=Y/N@CG"._DM*%'OX(M@2]3-@<_ED+;\4G8$9F;-O7J'V,PNF+0S; M^=MW$L;&\V6EL_(P3GD@A=I?(=N"LDM49\#8@AE&*6(;H1W'MQ$+3&B$ :SN MG_%YA)?0)LNHE:84S(8(3LL!J"W@W?)N\/Y80G3\"@LF9#!;?!L35Z4IF2, M0?+^&WV/*(\=DYJL.!W<6H\WOV(M0*V]D(1 4;3_6=Z.%4''FS6HC60+H7U'\NRA6V>#G]-&5HB#'6Z!O M.\2_);9>07[*L![5F'/6 ::8J!M#S#)1>MW#^&+5Y!;#5I$,4-#"B"3,)U*32I%NMB, MFY^%I6O!W%YFZN#PC?$;BLU2S21M4N#<<)C N61JJZA+G@KWLG)ZR[$DY^7N-J@3*X>QCD>P > M=EZ3:IX@?+@+V6?WF#ZI5CK%[;+O%O M>NB->+\(6A=49-$'^>4D@MON\"BN:(THOBPNM^'2W_._]R9M?5!\J=/NEOR] M-^Z7>F+3HKJ]]J [J=NB]'9/06K?1>G#K:\J'I/2VS(E9<\Q#[6;67*:Y^MQ MVXY&K)*U 4MFF]]Z^;NN9!MUO4N!5X&WN7=EVA]>*)$?W%!NP1"FMA$@:#"GO.K?*OJ&S/@Y>M&32M_#R MIRZ@PS-I'2 ;BW!_ ']Q)M!LNZE8LTP;%QN;!J'!BY5G#I:5BSPC>FTFW,R= MF-11BD<;TEX;L&+0.P!V#$ 'MDKN-@YRX>0VR9WVXOGAG-(6XEB\9:ROBK_#QU#RLLL;$>]GG M"O$N;>8^&;XEHTB83A*)4%@<6Y0)TVU9+EFP35Z,+,/ML2=U1H7:@3@R"AMD ML"0&J-B/SQB&R&0VG&CZ(T.5@FB2I?'/QF[=$/M,B!>(@O-4> '=U7%Q.M4C M8"2)GXS(=\L"$5UPF\TRD:8$H$A$R0*/RGC"SX!,+W_)83T'[FN$81^RU M"_KII!O8E%KICC8_!Z]T1#S.[PT']JR(M\R$ND)[WI()AI*OH<<=_L2NA4N MH9ON&Q4O 6Y9TTOBHE;1,^9ESB@JG;2-%-U'TMDWHF@%NTK!:\"JPER.62H[ M28B'PL08.^"I-+Q#3Q+4G[+PA8E<2TIDFO'&5'0+G)^-BMF3QS7G3$*FR.1G M]I(R@);&BF02I?E,,(\G(RZ. ]N'$-;1J9 M'8L]&?$:)?0L0!5HR:(/M$0T2B]/OURB!>8Y8)\ESF-Y8B!(>M@'8E2Z!8#, M?5K36]J%>E12E0E,&'5L4-2Q2PXH+)BY&V9/@V^B*.>,IU3&KXWSQM)' X:, M_2S0UC7(O,PE!!<*"?B@Q9!)V=0UDW+AGEH@FV+Z^\2,07EHH_R MXQ\\_YT73<-9Y.394'9LQLS^R:S[?S/?*V#IHZ3A2'G)7-LI&!>T M+H.V=AC8IB/L+!XJUQH'FQ#]BF2+Z,7<@'=#7XH6Z1\IR H(^04H(%BSZD;] M1MIOM.5[VK.6WO1E$\G3,F3F.<1.'[^]U;Y[2SC%47?<.O7R2B;GIT&GW6O? M0FH-EOKQDM!LQ>GRY-?A BQ=0RJK]4 )D>T\S?2&1-U>*Y]#;_&N(V0X@[BF MAH' QZF;USV_&QL#6.A8LDB^R+;"@6B_BS4IGA^L>\6P;" H7$56KB:?E[\\ M^2C?J$XST3*>>$\Q;*?C,-[![)GQ?BL\Q[MPZ4+9R68JT]%Z2^$S!/V*^"$* M%;'35U\>@U]:Z5&#_!GDS7#UZ[<_ MX:81GYYIP:*B9MS!*YA@WLM?>R"3/1 MJ?9%/*$A!])>O?_VY8MHJU9T(*2O)>O+G@?(X[@L-P\YD6.^7JK#Y?BZ9-TD MW=.PB1V0L>9HF',;U!PK[\IC0B\S>$W?:AM:I;-ZX;89LT/J$Q,C2+9#M@&K[0=Y^6FOYI-Z?72V;A5M#\ATR7;6174 MQV!3S=]HT$B1E-F@]EZ4;%]6(&77),O(9=NFE#\02Q DS0981X'8WTI,-4XY MG*&A[A^DE'/Z=UO[+57*3GHJORT(/),ZMXHI"&LMB,4@@]7&$KNDD(@7CZ#V M:\5E3#$O ')(. BW $34P2,1W-<[=1.^[W\"!P) O;.#I1?0N 4XD\]31\3& M@LL*W[AG=!XQ>&>;%$I,F"DJ!I ,4-=& J7E*T9B)%,O ?CA0$V M\A4[+]RB;$NT1B:QGQ,VPAOB8B.ZR!=B)&F4H)G85A1+6Z1*D;9TX\^0/P0- MC"@$F)AOR!6Y$'$F/V[@NEFM^V2:X1>U/N)84JW79!^(*1/(^R:\O M#=M*@IRI=FUR'6(B0%9A9(224KVB_NN&CSI1D!3N<:FTWK<7(ZV,AH30CP0K M)J07?CG=P*M8IB40I2?$4CS4J;!0Z:!&6'OV">G='13Y!3Q-M6_U/=Z6G(R& M[2:7K<>?OA\=NO'.%YURE' M>XILWG83!-3CMS^T3UZ;[K_O3*AK'G8'^F[\Q'9%J%:-^IU?7FL?%S09*RZ4 M2^[3WN6:8)(FBIJ '*$F1/J&2EW*#7(#E(U73Q>(YT' MR: $4;L=?P:S94B0> 7-DHY8F&B&**DL$XRONN=/' M15C.;R/?@7PRC>UKSBN!?VG,%[C+,G$T47J7&&M)JE6< BB#77.;Q>VK<"($ M:($XS.E^8?S ]B%?UCXI## Q22*I-I>?))1(4Z2SN8DM$C^ )5T[33)Z\T[2 MKSHK2?;$@" \[SBTR8M]DU)?V=[@,((H[OZU7EV[ITP?UK=W?Z_-XQCY/\OI M'Q] =_L?5-U2!%.@;!1TPAT5=,+%MVGT.NWWQ#TFE):8"FC[RW53/0]'-&S3U%>_P(+3YX]Z:+J<4&7,I8V'*3",*I,,!?@[F MP ?OT=87P=JV]GZ#6SH..=\#'[K'E#A@NE-D=2"$Q;?!A$@:X 6,_2%PN##A26 ]= M%2?H31%@)(-M=QEAH&+!9ZU0=XTLN ,/S#2R.RVVQ.1Q3%M9:V/!0QSX-=O- M?2UR"[X7%ACKL*]HL12)RZ25SKT73:PL-?$)9#)/&Z;6-\70X.F3!J*2+6U8 MWGZ"\ 7=1/L,CKGA7,IQ$W(I&R1B4MB- ]JH?_\]H&J&S8)NZF,IRRJ9:I9J M>B5CNX#X'C+.?PMWL""J2/AJ$_Z1>K,1R.#ZZ[V99&;D3F]8"$W^DTU\X?4] MWG0A^"(;T8<7'+^Y!BZ=3RCZ#0?V:5WM7ONC M2 %BH03-OR5!M7U>*=\5;Y4<,_0=A91G1\H>(.4?!=J7&/V=),XF7@T>;8Q5 M,N_%3:MEQ]1-?3-!@D4.^SR+[=A'0J-'UTI%P84M:GUVO\J)2#15[#MNH,#: MG=0\;+;9WN3BF-1\W@R%9MG%0CTQ0@6UO=K;UI0]^(2]^7_MH$A1;41;E_ZD/1J-ZM87I-,>3 9J4P^V\:18F"'MI#\#LWO%-@4Q7("L+LIX"V?X@^^Z%AE.& M*^?;>)DF8ZDV7O5BUSE%G7;]84T+?[T/RNS:>.G^9^+YC:A4!AW5X@ZBXAJL MK#2]K;7-*TMO*=LOXV2XB+>%J/'M!@N85W!DK."U($(9:MW2;; ,J#M:O1A< M,5O_RSI#*[7%]-9\?&NM]E:F8':D9WHQ]'(%L\3^"U(PLC6R;K2XM[SP7KPJ M+I3MQ1ZK,?8T&+6Z?;V@5O8B7L0.=V120LH1R(#LJQ125-, 5)'DU9)DKQ*2 M+"A;3U%CE_OPN_H;18Z*'!4Y;B''_AG(45?DJ,A1D>,^Y#@XE\+:4PIK3)*J MH?0E^W7OZU*D8QW5AI%M<&9X_M*C"JVIYUK!R1R+>CGP%4J!AK/*X1DTE_Y5 M:"Y;Z.D4FHO"W[WP=W0P_N;Q='#W,.SD6X,J'%4X>A2.CL_ 8X>*QRK\/1'^ M3BKDL2/%8_']>K4%BA\%$H7$V^Q%86/.DH%JSP]T3X6TUR MP6X6/.DJ%GRP.=!@]_YWGXKN5MK4=ASEW3\A)9\A+V%R'7D)RO-41_P]5R!_ MTKM[Z$Z&K?Y(N:84$E>,Q&<(L4Y4B%7A[ZGP]_ 0:TDF/%!,^#;C XE!<'"Z MCS+M]Z+E,X2B)]<1BE:NJ3KB[^&AZ)*R: 2RJ*NW!IW\4&.%Q J)CT'BR1E" MM!,5HE7X>RK\/5>(=C)13%C55S2KOJ+>=A8VJLFU3ZPZ +/K&='70[0S[ $I M6%Z$S1&IM\=^38&NK2"O2M!!5XFWL7@??O-'UE^[B7$37\5;-=KFUBB5K4OHM2LUT. MUR[CR>*]+I\LKD:[E$.+:YD@H4:[' @R-=I%C791HUW4:)?:S2BI]>*:M#(U MVD6-=JD3Q);*0442M4$;11*")*HIIMU#>1K53'E2T<L$T'X?@B7/)O,G=0Z_7&HWSO6 4(ET# M(E531+R5&W6W-,E52'0-2'2N^L!NMV;DJ&J2V+>SY2VE+XUU M\R@D2B%1-?53>[!EK(28M'J=OD*DJT2D:L*3V[G1EM:I"HFN 8FJ">;MP8T& M->-&M^1'5#,%SD9/9X@$=JN+!"K+O99(=*[861<;>>IZ:]P9*DRZ2DPZ0UBC MJ\(:UXU$W7.%-;J3NK&C6_(DJC[S9R.H,X1W].K".\IRKR42G2N\HW>!*W<& MK8E>%]-=85*UF'2&L(:NPAI7CD3G"FOHO;JQ(Y7PV82$SWKKWJKW>$VS]*^Q MFU\5[/Y:%>TJVKUYVCV;IV0$HG?0:0TGG8:3K_*PJ'[)S;U+@??<[:@%M_L4+8"; MFYO:4W?UK*#]5Q2$]FQU?@FBDPMPSK2WW@*^O/I;H(F>IYKM!J$/VW## /YN M.I'%J)?9GBW/M'!NA)KA,^T998FE10'P8>W/R,,[ !8_6*@MX0$6M+7'R+== MV]#@%2!10MA:"&N:@2#B3P>:-X-%/,-UN2 X'UFA;K$I\'QFPDM"F\%RGCS@ MYR[>22M+_=-GCH'?3^ZF.TQD_S,0 "'_E,667F##=Z8K+31^X,)M-_10F@8V M2!J#)"TNC?X&STQ# ^!J:3/?6\#B;=^Z7QI^N*(MXO-P-L]\L]\S6\//A9D# M2._3=(P@@)7!FU]L>*TKCD?7;%B<$2!<(]RUEA-LM]>JML MOBPNB0[,+0(21V-8JP$G:CPQ^,0"X([?1$4'58S(<.#[H5PG0%<@5XS:>@;" M+[ %S5@N?>\GH9ZSTOXS0\,Y\V>\KC:]@]N>87?/[)$OZZM]\(:MN1H$" M.C5?6Y&_@!?/$YUI'.MRF[X\.=&7)WM(5D:CJ,A.<$)XE'=PW'#8W,X9N:W MD/R^A8 4AF]I_V$LEF^T+Y[G_RV@F^ -"1.2+X$G?O<\:T7&X^A-@#=^L$-S MWL[V8&P"7_X$#,=GEAUJH(4#R3F.]V(@N;T8 6"^B4HOD (A^2$4901IS@,* M-2S=]4(@>,<&2J&+D0M2D3B91?0NV+#K+8 L\*)@,? 3?)U8,/YJ ML9#Y"V+$Q/_PE5*FX%I2BX6](AAQOP$<-7%_-P3JMP$:^-D&(LQ79,AX I] MR&K]EG;BL4/TQM=V"'LW]U@>;YB*?VKOT]K#UT1SX+?@47Y,4.9"PY-HS2W) MQD"I\?T5LAAC ?9I*"0@5R=25/($_#?07G$4^X44B-629?67-=1"3HNLWG:Y M.I%!-K&:OMX>X102TDO@GM?T:6#\R?"1OV:[Y I3N9,\8DS!,(["S8_D>GY? M"(\G:_!)_8FK1;%E=_2N88ST@66P<7\Z-:8]<]8U^@/+'(QF/5/_OSY(-?'0 MW)<[6(*,O)_"8?VX-V:PP=>&\V*L E3FTP0.U+T&]W60<< \_.?4__M#T6HW MLXOS=TPGF/;;G/WG_]RN=*RK'"FZ_.B^ \W[T;5^)V:,VB?2=;CZ%NN)$""I:EWS5#-#QNTQ):.Q5OJ2/,#4O[R^'#]P82FXQH M.7^-QX/_I8XO.3R\ -B3_2%U)UQ+'6KL@QPF>-2E<7SM_# ^#>#KX,)QUZ5V MT[_<;G3RJ&[9#5IR 6I,(!1 C4%M9X.UOF:I\]-/Z^A!M !$)G$&NJ#W CK; MX>A3!;K$#NIGPW:0SWSP_&^PG831("=*_E4$P![-@V[GZSLJ1X4^@+>L>T.TE[D-)C@Z8E"#04\"*,;D?Q Z-+DA&JCMQMIM M*?F5R*KD J$T&!=W#1DF%R_/1P67[KH-+).M^S'3[XHO=V?#-6B]EK4H+/] MX^<=)G?(;)$:SC"*I:DF!:D:,U<.8:YEFM7CPH/%H+KUU@M"-0=L?\C]D3A> M_H&.E]K";M_91N=WP>P$[&_DRMI_A)'"30["]\+Q;&F84:-12LU%1];%;JMS MIRB=9U+6\1ET#7F_G>JW="E35*^H7E']A?3\_>-S M)77[B=+M56G-I>\Z]X#VBSB6*IA2=PM=EJK0H'9T#CS,:9+CG?W.W<-@,FDR MXU1=PFJ)O[N:%I:W^_/(V[U[:+3,5ZA[]:A;TGCM;^F>J!!;(?9)=8K2"90I MO.W=/0P[^;& MX>SM]#$L))1A+?0D_]XHAWO:-E[CN!IOP]Z5JNCY[.C&T3> M:N)$#;&[J^_J2'W"\&!_U%SV)@C.\>NI-AJ]=5'@2%WU5K8KNZ<%81BM*V>WF@SL!0F M-<"G>;,D45)'.1W-'Q0I7 DI;%"&*NE@_PTU MW^^@^&9:V9?4E"9<4QKU\YWN%;W<6*2,C"_'&744,BABNE1C*2H;KZ%F@B.%J MB&&'IG183' [#?04#=2Q=*E)D:R3AZ].Z*5I<+O.MH M<:)80[V(1+&&I@>TAR,5T"[AB)$KD&L= -E7FQURAN=34.H!*"POPM'AI69@ MJJ4U=6GGG87=K)&H[Y@I)EYW:>)U3TV\+H<6US(;5TV\OOJ)U_6&W=I0:P6\ MGJ;),1UOJ#Q3E*JLO-J-L8/5.U MH+FJ%C07<32H\<9GTR0FES>B1_K=0Z_7&HSRN:6JQ?05X%BO<_JV*Z,>"$B% M/@I]*C9VMG3,5,AU!M7W\]M?,QA5[095R'5JY'IU.>SB["N/13AP+X<_ MN<0YA3J71IU*9=_)E,J)D'='6\)J0*H:D%H[LNKN< 2<0Z4<=X!AZWIK-,B7 MM2B'P!4@64\_O;-RC-&\_&PAA3\*?X[R5HZW- !3R'4%R+5+ IY*L1SWN-0; M=^H2HKL%=Z6:F'DVNMHQW?DLFF4?:*PS:$TZO9I8;PK)JM4,-I3L5ZI9#NX> M"IKT*/Q1^'.<9KFES8M"KBM KET2\&2:Y4A(/;TA/LO+9X V^R[5>%:-4&P, M6ZR#63"^>^@-.JU^MRK3^_+E-@HMCU4%2TKK@TR)R=W#J*J46H5S=<2YDOD0 M52+=AGR(2>>X? B%;C5&MPHD;VW:&TZZ0BR/JXKCU6C60U,;U)0?G%=I>YHR M_H2;)>QN;W *I3I/H/K=@]XY.KN^"27J"N_VPKN227F'Z,R37I'ZHE!.H=S9 M/?:3ZBK7%$)>#4+ND+W[>_GS^(:1QT[]F9_R/]=_\!D'7J[E]&VVVJD2--?# MRD[I'ZAJ:-IDR'T$PZI=]TDWBO1WCT2;C.X>CF_(I4A;D?8U MDW:I(-/9:5L./,L3]Y&5N8JL%5E?,UG7D*I+Z^<3H9]/JFK"'K.F_SW-GQ#V=IN@$ MFC?3OK%E2%.5^%GU.C1:J<]=&7+BDK@FQB[!-=/T(X:NCI"A#T3SX49 )SRD MF>]E$N^T%R/0_G+X4+[!NGOMH_CHU_B;,58.)58..IV[ATX[KU9J $@'%X#; M*[6J?A6KZN*J\C7/P\0SQP;?> I!KI'N(,:OX9\*+*7CH59]2]_1K[N&: M\]5%\9J!J*)D5- 3FCT:;D5^[![XZWT ;]6">"4MS64A/AD:/[-(T-)>YK8Y MUPR? 5693H0'#A1EP,872\_%L#P\A__PV9RY 3R%-WH+IKUR8 N_X,<1$0!0 MQ"QI"D\0PO\X?<+3WI+Y!NXB.!+G>L?BW/#TY]?'\\LKI4?@W.CTBQ[L6'3# MD>YMY/OP.WXYC3^6!^+.]4(2-' LH0?+=YR,> GG1B@6"D>7A@(N1%MZ@1T2 M:R7?/+PJ@'L<^P=L,_.M%X"D-F4 !]",?)9\#&]*?W#* )9XG^F!*K$B ()@ M]34C'DMG>B 3IT9@!Q*2"V.%+X>E@FJ%\ ?N_CU#*0'@$.;; *59?%/XX2<, M7Q8>;7I)( <3I$7N!\[I\;/-G M'2F&\'9D#NVU> @@,U*2[48&GVA[3>K5?Z[M3NK+OU9Y:;3 MT5D-VARV^3__,V,&Y)6-=27P&0[.\U?O[, $8H+S^0ZW_^IXYH^$EP^Y (&C M8-9C*'[#ES'@^TL\ 5"N[Q[DRR2GSILD:P>Q^92*45%\M6 M^ET]:2H%$F+Y MSSA&T +V"!8A"">0+ZYE^)S_(L=:L'#N6;"XIQ5)0VUF^T%X;X,TX'_S(L&G MB4?A*TE&69I@OXX'O)"+.B EX) H,3DO)F.'%I#EY'"$=DB,-2!B)GR@YP-X MTJ&W@VA9^IX5F2B_/!0,("31G**/@H%KNP8]%/D!P\]/HP" $0393RV,'PB( M6'#PP\75RC4@$-87 =(+GA'?Q]W#@D@^ C-_TCQ8@:_-0+_P?, [!$=$;*@$ M[Q9GUM?;HP&;&M<"Y=(*D'AX)J=XCM( M/K_]\>6___?3QV_:JVD MZ,6@ZOH +WB6KQJ)#72T)X;;!M&!^;E<=S(<$"#$.,CAXF)ZMC'U?#36&&X1 MN0;7ZH0VFM8MHN42%F7.87%(]2:PD5:**9"J"0S0>T'%@O M@Y?@ B5SA+W=\[V] -_$:=4HIX#5VH!%9H"?>K:!+XO1IHB-:+6D( '7VM5I M(77#YS2C-E"M1LTZCW;)03 #[ 2?(3X@CH!U9'LD*F*[0+-G&IDJ8#^P>PM. M#"\7B20\-Y?A48,<:6M'N/H>$6-M@U;NHY8/=B+S04?%-\[@4C!'"\+SK"!# M)B@QJO3Y"2A]$%_\!WXPXZJ&(\65>1+Y(7&%-W[ O)R(@5=ZN@+FF@ MM,!2B^!U@;).@89$\Z&H!BS?,98!>RW_\D96_H-DP4700V^$U234)=0/UH(: M=&K\Y_Z*;!40^L!%@UP\?\OF=LV[/R!SN(;C[F-1 MJTDI>[*6QE<'.ZF):%()R8#N%EH6?C5>-.E\K;QCX<%% W7/.BG&INJFL=8V MM:1XXX=KW[F"EE@_ \3\7>+E)Q9^GGT5QD#)I)%!%SL4M$8=/:?GRN.Z!-U5 M7&5SS@RT6R3X4X]?KBW!G[PETPD(ODL$WS^ZAN,<1'<+ S?^Z?D_M,0CJ"9N M7%RXXHE\=+_P\SB.V' 4<+\U*'[5TWT+RXL,C&&X^BK?_>@MSKZ-9AB-;"VK@:7SR_UPR-V!8FOV.43)T MD,^'ZH[SR?O=<;Z0X *;ESAWCPSSM3YN#["V0VQ.D[L3B8=\?S$2%!9>E\HL M>\=FS/=YNZD@E= KO@] _8Q9[H]!P,)@6ZE&-Y]QMB&QFN"^K;+ES070LCAU M39X"BT]A1ZK:9L+BF[)="YCDZ^XXKM\Y)$=7I<.I=#B5#G>=*5TJ'>Y"Z7"7 MGU1VHGEF#8RI2+EKD-JATOI46M^%/&%I0X/KP*+NHJR%JW?N'D:M4:_1:08J MBZ^.S/(&Z/NT'>$JH6\P:8>M\20?&JXAC=U"*$ZJ$-:ZST1E[9TYBB2]5L?1 MEW[WT&]U"X:?-4A^JC2]YDB&:K$7QS2U>OVJPALJ+V]_ 1 WB%"I>)>2 .(H M/LJ3*$T^?22?\22?UMH@YJ_R[IK'_(]&W $BKMX_>F1K0W/P+CR+:ID+W[D% M!H$:.*5R\YHC4W>D/ARJH Z!4?5:XVY>0VV0B%79>DUD'RI;[T(.SPK9Q^CN M8=+JCYL^=FY#^EXV76\]Z^J4G?B.2_H;=NO;1WA4+N,O-3O"<)]L.*#=*6EZ M0=*?7N>DOV1SVF,V\GU\HE_20@YKB$+VF_W,K'5H;N@FI^^=V\?!6P#TM5:J MM-2K(TY%^]S#J M-CK/].1D? L)Y(^F&&Z*@Z0CC,ZO2 MF+,[:'7U1F<=JI3S>JJ+AR-S5>HBYM2"OMC+H_?^^J+"KBOCE ?T;NH-[AYZ MK9%JH'TC=14?Q5S-^RC 6;RS\(4FRB^6#LVKY^D -+53%5R4H!G+- M#*24KGLX!ZE(T^UWR*L]&!ZCZBJ25B1]S21]'HH^P-?:[V(7I$>='I^M7X M%1??C%3MS>V4N=1R4:KVYB*=H.L9C5&E-ZKT1I7>-!F.JO1&E=[4KN=S/>VR MX_N?=/N=\WIK^SHU*>R/3MT!N@XA1D5KUTYKY4+X1Q!;58Y-:K&K3_+DI\I? M%.4UB?+.17C%Y2_]_MW#8)!/YJR;$%,E**H$Y>S$UCVS2CG86(*BRD#JB4\E MU:;#$:HJM0D;OW9:H]XQ>I/"KBOC5H>$)D<8FNP5#&A1I1BJ%..JZ4P_LU8P MWI2LKLHAZHE.)96"P_&I*J5@0AC6RS>#5^40M4.N<^%6L;M@T+E[Z(UKPHE. MEQ&1C41>55I@2=?;-67_G7Q^4-6B?X ]GB:M<;^L0Z!6F;J*P&Z;P$JI0X=3 M6$7*T #CNOW6>)BW;#=J0XK<%+G59NOGH;8#7$:#'KJ,)J.R&1/U21PO-1Q& M'$I?;X\P\9L&[L SKWT&/ I FN1[_S4[+$/LM),\8DQA7U&X^9%<(MR%QFET MNVMC]E)_SOV$0SVQ^ZG/C!_WQ@P6^]IP7HQ5@$!/I^;;[OT:#->WOWEH3CPQ M9E_:6433G(\(S!.L](K_CS;)UMQ&QAF+"%_MU#IYVO M>=4 G ZN!I=>;HG#JIYJ5)? M1"["%\=PPT?7>O]G9"\Q]K!M+M>@8"[7H& NUY=THD/\9AJME)^(E3ZU:K90 ML/"]YV#1=IHA43)09ADH:QA. H;#!V(%K_>>6=64(KG!N#WNERWQ.GGIU[C= MZ]>N<@\7-:JB'JU>UN)YJZJ:5:^R8X#5#4'BJ')"R>- )+'- +G\72?(F!"2 MK5;ND-^8$;"YYUB8*.%[SY0J49]BI+J[UTX]J*"VSK4*FM'U=S2+V*B*'A0L M&F)HMJ7WKZ%EY][HTK2JC+J3^ZD+,VI+[E4D6^SPIE=,[MU-Y%Y#DCM!]48= M=8W/LYEMLL2J5L49)Q2N@^.H+4]0^MW#L-=MLO14B?FUE O#JC&U5XRI5Y-Y M7T?>_B'RX9 C?Z]6,C>9KUH%4]\QW:UB%0IGXK2Z@WQ@KT$\7R5>UY+G[YC) M4S$B#S8AC<(9-P5%+PUB_DKAKR/S M'^QHTE$>4T?%F-I,A;_TL(^*GC^HKV"SF>9Y Q#CNX=!2Q_F>I-RMS33]I(%0>]2YT(_-UA M^!<@@W2FZ482*4L=HPZ65O<*:AY4NY7:\=@J"]4NAG!8,MJ:=/,=WH:6-6.? ;4 M7.X3I74'^9JM43]?;#;JYXO-Z'GM\Q0.BL ?["PQ*ZK[XF\N^-[V^N(+E7Y] MGS,-8U:&N]+F1D!5J;S6"P"J.001+X'(ZWW+O\Y:W$9O?&V'\#ESCSU_!>1X MMAV'M;3?#7\%/,FJY;:V;N)=Y.,)P0;,.=:C=%IT=O(LJ8"&MXWV-$,<))8= MVV&@_='^U@8,70!6@PWJ:![/4;1=K0 T])2AA5Y(=VH;Q4+PYRS,QSTRY<:= MG$GL,^/S["LSG/=!"(:Q%!3["85.0N(#$ J=UJ @ TH+_HRPB''&6(CK%YN% M,S-96T/\Y\!![#'^VU'H[@QKLQ:*^RF_0O[[#=S+;!8PP M7UN1_P*B)V!NLL?AW4/ GIFKK9CAYY@3V9JT"5?SEG0TY2R-:S@NW"(N:,O_S[+U\]6=ZS&<_>$_OGN8V<_L'L&?@SZ\VO8L@#YVKR!2Q$8I2%T2D:I8,R[V M\^PM/(J@*%PVKBY9\X0WX%A;+"$0(0NC(ERK&'EPY;8+B"]V=4'D'W>V(G]; M>PP0QAO;)X09.6LL0*;2F.1(L"? &JK8 8/N]J[FA@E_O<1O%)/H6I3Y!F"^=%V(3H MJ &8N:+/!M1T27E)X^-F>J4G(\D2Z/_)&"" M^?@,OSZQ=P(\7U%'!JV=HD "X<"PC#$.5,1!0=^DOP(](HEZG)YF(-1=TOQE M.S&DK=1QM+0GYCWYQG*.K@L@V"?)JJ0R0P"I)UZ6M ;?6]B "9L /3IP;*%1 MRTWM8PM^-D,/.Q0 @NO;K4%/VC<T-SV+MC?F@B5&!6-W3V+/1 MUMNAS@Y/JLY8J=SKE,D;:0\&$)%;$3P8RRQ^MZ MH88VNT\FF)=^Y=^" @Y83UZVE>P_(*DZ#M]SD*5X$&T1F'C/!NP?G=D2\H%0 MQN0_I#XGH2G8/")UB-J/N78?Z7W?_O$?QF+YYI%N17(370@M/!GZ,C ;?AY% M"Z!';N!\Q5R"P_6I[.6;YQUO83H'F.^F4 M3(_>T9UQOX]VBYM&GK$SX7[KU$L"IXIO]A V^9;Q5;9$%-1UDSUN]2;TN*48 M5%%DJE>?/H4EE???/==;8E"Y>=+A,8RU;Y.1@M/#,=SK416'N,0*['/E#NLY X' M=P^3(D=M9H,@A,&*GJ-.BL<+^G& ?HEGPXF8-+N!YNU%M%AW?4S![G8I&/5? M$1PUBG2>4?AS:9/%![J8WNF5\F;P[Q;Y-(PP045<;6G_1@;F_6T@/\R[,1FB MG[F;'\+P5PEC=,N@/HB,V"O/EMBKC < M,0\]:21@$Y<5'K21WG'NO'&3]@+?(+<9H]YF;7LC_RP21_L\=W:^NSM0%+-; MT0+7M7;P)^GM/D3='A_!D?,L:00L:5# QAOZQ2>:YF^ M,_YSUH.:5'I0&)CMC*OMFUYFB5M.:M@!\VW2V1*!7#^I#\<8L'2(Z>[XR,5+ M-O?O''PVV;E >5!0+'9+/.R 200[#+HC%HMSBGKG.C>;G,I!&,^@..VY?12? M>\^_5K3]'K;YKW9J1(FSVF.!H!+W]F> M;1I2AIHOS+;A1\6M=S+WIF1V?B) MFY3T$$K-#)-+EZQ*R",IF'<<+3583@3WA3Q2PUS36 98"H88"(HIQ6 DK%K: M!Y_>$\Y!)T]YRZ6+%G1-_I[_BH!:D1JU%SNP(UVG#@;+L'=:@V78N:#!TCR"JYEB/LPECQRA[PT[(W3 ;LF1.D V ME5C@5FUOC$O;6VDX8LY*[*'^CB&A7*+^L),?KM($Q/V>R9GG4T]\)AP]W&WP M(OC'O<$92"K/.&'9W,:7F3 \;HH1MSY?I %[S0/1&K5&JK5QY'/[K81M2M!_IS-%*E\'$TE#;+JC&5;JYB+-=1R2;CY M7+_NS@J<8;>#-N!DW0)6IWO:&O5BDW^[P5]!!O:PVZ4,[+R/[Z^G;GVVE:'% M22/G/J /:9?86JY*U2W/CH-??;%[3]ZUQ5]U&.?2$94'E7"N6SZ^:IC3\=[( M;F^3-S+/FK)]*6K7M>!;M%PZTG5L&L%BV:['*<1V*EL")%ENS;)5KE. ME.NDJ:Z3NO+!8D/O$\:4?^%5$2 MD((WKKWCBJ!<:E3PI5G+$<=]@%%RN43^4E._$WOENCQ1Q4!XBPK5TK!%ZQ\J MO@]RA?^\N)L76)3M,#KO]NX=Q:S+(6\I- M;-#>9*(XMEEKG8FB@G[SW1VC$:NE"FRQU^J/\_FUU]!%OI[2-(D)GDJ:'M$= MNLZ,HZ(.\;5D'.>5IC*K7;"-SV[)0)6 MQ1:TK5:F9AWDQG6@^QEDXO[X/L$J\'SGODL9D?([$C1]'O%ON+_YTL]?H8)1 M+#,RF2A8NN-X&!7!B A@-RD=H0_OYUA^(C6CT<_?C#-'ID(6M2F?A@;<3[&U MN.T+JJFY 2S*U:-FHR4EG?CXX= M18:M?D%,I7D3_Y3W27F?3C9);Y.B?7:*Q:'!W5ZK,\R3[&7(Y@IURCUJ)M+] M+GR;9B',?&\A5 9JF)'3)Y0W2WFSJM 2I'&_#[\YHJ-FBNGHZ!QHC0N"S U2 M$Y1#K@YJ0ITI]G1JPOE)M@RX%JXV-!S2^[F&0YM[IV_NDCZZ6"'O&O(,!"!,49 =7+A[A4=VO_*UN1E1%P9$]-U\7\^IXATAO_PS 6->4 MM!FCZN?9!QOMI?^EKAHES:H!CCC4)_E$B08Y0DIA3TTC*7LW2[HUTK]=ZM]J M<>[@ GE"']X]Z./\D.@K(O,J*/VZC(QBL(-:,SB9:JR7@U4A-[MJJMXJT]]% M[!.\Z?L+:32MUR>VH3"[4GE5!8:/ <-;W7X^$G![ M"'X+-CG(J^')NGQLH^I]DYRNFJIWR2O4-[^_>*6)>"+$5+Y,LT%47)],/870 M58NI Q&[UR'I5)#.=GMX?2/6U$A94[663CAUL#09=Z]!/BDSJGDH74H^'83: M.DFH2;Y!P.UA]HW83V-E/]590GWPHM*1NUY/"*AK"-TI ZI!&%U&0!V$V7V4 M3WK!<)/;0^Q;L*"^SYG/*--7V5'GINETN5^6D+][O[(OAFT!(3_BV1Q,S0/0 M0+JM04$_M@:1LS*D&H;36X64Q.WC$)OW&>RH&K(;:J[QW<,&++SR82E4'>TT MS3+***3'98]=)1?8U_XJ3?:CNX=)OS4<7H/===)<*D4#=:&!?2VVTK2 305; M/;VC2*%>9MS%Y"-BVFO-7BRCD-I,\:ZU)VY'=IV:<*F^B8<(P3]<2TQT9-;[ MGR:C5IX2*WJ &O6MOR\RY3 _ M[+2^'IR2Y458ZRUWK2IE*@-0O3G5J>5?:4;4O8:N095C4;T+ZA0?47RD.CZR M0=4IS4GTNX=A:W(5.:*7920;NC!ENRZM]V4J[HR4]);A ,AW#<+G\ 3MCMXU MC)$^L PV[D^GQK1GSKI&?V"9@]&L9^K_-P*=]?)#[7/DP)LP==IR6Z4:(#V: MI,P'7XP5@OO1M> 7/V+6;TD'H'=Q9_)\$Z1^CQ,;G NS'D/Q&WYGK372^8$B MT? >N?IKO=<>X.G(#6MBQYKA6IK8L_9;P03:]?9?Y9M,?3/GS(H<]GF6A^V& MWE+]?7M+<6"7[[1T9E9$.!J#?ID"O2% G^DX=7,]I89Z&^1'W=HW#=O]?J^. MBSJJIU0]LV@J:AVU9X>C9C4RBGO/:;+MW*U"XATS!2"Z!(A>!A WX\EZZRU M\IJVX7#Y 8K]1?U:JK'3+3=VHM2D!"6_8J]7QO5HN/-MY/OL +]8.MZ* ML2H4B]N-1U?HG94'(D@NY3LYE.JPEU*_U1TW.L%)I58T1WB<#I7'H"3JK?[X M: &BAP#B4I'#'<&H\:74>O"G";)QPJ MQ.%!!_L_]PIJ;6^CWO5B4N%S.&=^44A+&1$73O' @\E'7P^EKR[2UW#4Z)0Q M94 T3T94C,;ZW<.@U9WD[6!E/)P4(V2ZR=?_,!;+-^^TI>_]BYE'35Z]!17L MM $<<2A?6< ,WYP?2E,]L,A;O5ZCVQ@K\Z$YHJ%*W.VC/!@4])A79L-)T>"C M:WH+IH7&3Q8GQRF+X;(6PW<\#&&+'TI/ ZQQZW0:W?)*F0G-D05;<3>/GL.[ MA^'P:!^14O[+#B,,0C\R<>:N^W3B]+6K49].J_IGCB27TY$G'!K&SF2^F'W1J7TK]C,P9[L;2W MWF+)W(#7I:-6R_-@8+/W8K?[5]:OMW' ,=@N1\A.)[ MU]KB',7PW^? M,X*;X:XTGYG()"S-([BY*;BER^*]F?:7P]6U06$R0>I<$MR,F>8P04Z=>DSD MLR(U@(TCS[W4\OI5+J]'R\MS]&1Y!+^XDIAS>EE.W*+5R^):<4U4V+;@>((E M@]<],V?5UO#@IH:#G:=0\&C C^?:$I# L\"T\V$_/F"+9KNF$^&96I)*S R5 M^+[A/C'>:OH%9R5,5YH)G-ZP79)G@ ?L)S,C_"RL?&;#Q4#LXG<,\FEC7%]7 MUU[@84PA>+;QXBA#(@< 1L,SK:#UPJ)[@9D^(QYY+[_1,?H8F[@FP M(]XQ7S![1GBTM<\N7<+<'+RB0 MHOT"*=JOL13]#?#:#;@WZ"VV(P&%D?.(QR>?<0ZQLQE-H?"C71? 0J]/OQAZ MXVL[A,^9>PC-SV$0_3 TB0DY_7.["S&XL<8A+ 5$ >I5DO-:#@+9<] MY,$9]$"$<23R2%3A[%O "3DWOLX"(G*\)5W'I\RXCM7^-W\7<#YXK:/]]L>7 M__[?3Q^_:3;GU^)%WT&"V< 500Q+KN'Z\CR.QC#G(KLY?4 M*EO:DD]>B+DF/OGH C8[P#>7GD_2 [ZZT+J=^_^.=[5B!LA(%X5>L>1NET>! MIJ#.8T"2+0?V+/J *&.@/H \!$UL.?/AM9II!',YY**T1MD=#K8K;3(#"8R@ M=PG2/2;*CB3=[]X7YJ-LAW,E32](&Q'O#=]EUGZ&?4H)'(!AWVEO2F>5FB"@ M-E):C$=Y&D(:092-X5<-D&0@IPH(?15+*PVCX;XP\ME3!$J+YZ\('J#9FA2P M7J*J":0I-2QXA($P=I$UI(T:H9$&6L 6]OT,E,M@C@J9[UF12:@7,QN@><%H MD*T!.(/P?NE$ >C9@0TJ7S W*%@.\MLP;5"@!-HO/-=;@B;.3TR<%G >FQB- M[ZT,APPGA"T^#Q2PT#8>)0 /6$C^-(?IT_SXZ4-5Q_F=EOF55KF"BV;:M $A M'1\9AIOS!X90*[V7T5GWL@]JIC>*U:P%&UWR]VFO++9DY X@YYU@!:? N"V/LP^N 7JM8!AF.)VV??11RP>X%3^[K[1%V MAUMZ@8WWO";: %Q,FL+]-:MS"5]A)WG$F :>$X6;'\DUIKJ0Z.GVUP"4^G/N M)VVUGMC]U&?&CWL: OC:<%Z,58!NR[3J"7KG&@S7M[]9+N]2?O6:>G[0","E M @^->6):M6ZGI<+D$=XSH@+2\]S(CK/.AU_P,0]%$H(J4U MH FY"G=I0'^TO[4U"\G(#SA!Q)H/'!RA2UIH.-Z+B/K<6[#N,*5]"-'#18Z' MKB_' .P#98B.$7U50>0(U;TDS">[U/&MWI/W/]%'B0E%08!#/ZSOQL^RX,2F MR'N ,^%T+URQ]IY<(&H+/9I99N7S-4L+],\(T)SY#61$'X1]@6H(=^^X< \J MK>$\$(;K1G_TFADGH54./>!LJD>// 9TR;V7KQHY/#30A7>>8^48U!BV\RG0 M53BC MGP7R/<*9S9 _!&=VQ+LJ6CG.,>^U\Z7?Q3BSEWO_4*_4GF&!28W# KTVQ^+\ MGR5[K(>>^0-M/3!&W_\9@=* L9=MG>M'@[QS?#3(!PJ^S4'=XV_^6Z#Q=^<= M\54X&C>8,K2H>IHRH&M_8%,?1/1*ZPZD["K*R-N8/',VCRFJW[91I/OSX-_< ML!*%WB"?$_JDEQ&HK308V/>>?&-!<+=N:;406UL.=FF%&(A ^Q1A'4A;1H@PD*FSF>TO MT'%GAQ3>G8'\1/U9J(;B1J!*P*P7C,+['G'>+69KXSW_:9+3)Y+DWAJN8=FX M&F8"HG.OIW3@(GP,'-B'&06+)644^&#]L5GL Q>@I-* T9M@(_;#H0C,P&-) M*QQ $/'-@CY*.B='&;>YGK$?B[%4.!J-ISUGW*9\C2-TJN:'/<>^1L!%1#H[ M""**GUB:%X5!"'_!C0N$)5_,2MLNJ4;#0EE5M!G;LSZZH *:+$MO@"OF:ROR M7SS?"IB;;&*,6M0]:8?K(DDF:N )9\YCTS)'E2V3UI,L$M2/WC"W/*[2MD2> M# (UT8ME\I- .HPKV$',@!?&"CU8]F+ID-9,K!Q$R]-<\Y8,3$W#_P'V-NQ[ MZ=O/1HB:N\N>O-#F&2%B/P7?-C2,)M" 6U?XQC!I!YZ/DV(X3R+G+F7V8."( M/_PU<6++!9#1U46N1Q&E810G O/(84\4(P)UR>[F M0>?3U '- &A+XBM.%H97B'<2X=%.9P:EY?!MIB!B\U0BI,.W7)I\X\19L#N; MX M$1,E;=*:IE9#')W4XCO'2,/]G5^>AX6V);MFPO)5"#J'^_ 26232SD7]S M[I?CWQM"2QO8B?6.2MDX._DFWIA3(\8=8![M_F8S$;8J-+N_!6OJ!'*^EZ(;R3"\T*$]O&>HTMV/YAB6V8X@"''@#^$/;G M#538=LUSF3[! )!M#)Y]9L7!+\@3\]PY8/RV/B>"R!1HSRVK2K[KT8 M^(#T8=D8XK4H'N A A :;KC>:R+)=T%PABV9Q-OP"=L 5N'8 M7D1CYEY'^ MGD%M>&(:UZXEKTA95XG^FO@99=XR2D:Q(A&0;A4O-EXE,0+ :&0D4]I@_CZA MD_C,""(P5P)DH*"R@ %AX2NB@.M8L83FR6KX652OV&S&S'#-*@0NSU_C+86* M\/7;'_#GDBYQSL_;-"T8B MC@M&(B)L7%P2VF@B#I[P!46TH<-QT133@B\:0E\RHW2V^:XVD2 MAXT8;,3@O?Z@#?NKVXR[;GO8G:A%-7A1^O97'=OU8,=0N\.>GYRTM=KE\IB* M"]^_4XCM=QY9>X_V_C[.OXLNF=MRF6F()VX3EZ#$%9W\)U0U&G7PNX[\NIJH M[#$*M86&+P EI9-:1FCL,R'U:-ZZ;SUWS4>)[CE&=5?5^Q8XW X@>PKO*L<[ MA5X;T.L"G1(O& 7=(,*EW?SZ" 5HGZYT>SQ_/*:JE35R91?H3UVG= 1.B#F_ M)#FN9%[!3L_5^R_?3F/"E#F$NG6P6I2\UK--> AG%U)L.*&K_5D@R+]_:J7/7).AT&L 'X6[4$B4WT M>ZU^/Y\KGK/V%3THL70YL71*J33D QWS-39**-T8$2JAM"/7_2Q":73W,.BV MNOU\!O'9A9*P0M=:$G3[E!%U9N.Y0N-[O8VJ6MJU+^VVW"G%"L>[) /H&,_F M.;(%U//G?_ZV7/_%ZL _1<+CO4QXW)CFV.+^1C5:J4K+9T/R_PZ?G#RT1WYF MGRA']?.,Y_U_3HZ,,BQ+:V-8!M7OM3H#-755X?;N^\('I-.IQU]@:-=BTIU*XIZ\QY8\Z)VUVA%HSS7IK;F'57 M1_7]?5S5$Q?Z<-Q1]JYZOD;V;J;"<5B3#%ZR_DW9OV?0X4;C R2=J"/, MB;M'"S%L<W^<4*RZIFI>-. M/5@I9@*VAH.\WT6QTEM&\FI8Z?@0KT^UK'10-U:JS.."Z)9,E-\2Y1*WG-A^ MWD:WXODCYCLW7VP=%@';1-*EI17VV^P/0%XU.@96"I$NE#UX Q1QR;A9910Q MJBQRIK"R%EAYP6A;94@YYFRZ4S#02[%I11#-B=%51A&3RJ)T)\=*E6JMEG85 M2U.6=E'E>MQ+Z/C$T2URJQ-@%PFP,[E\C=^9S:%:&ST5\NEJ MV+1.6-+H_%F%IK7F:Z.*^5H/,;:7'TIQJ=KEFZYGVVJ''!_:VV)=[FE1BB[L M:T8E F4/D[..ZM2Q5DS5X*D+R[J8!21\B46LJM]\&ZAB=+E0_LY1V]NRM[HS MBV-MKZK!4Q=F40.[;0O;&!QMN55\;HIJ:R#*%-5>RGC>0JK#YIO/BE;9YCF9Q9,SLSD(?;T]PC%IIXASNS/^D-2?\S@[8VD\L?NISXP? M]\8,%OO:<%Z,58!@3T^RL]W[-1BN;W_S?/A=8RN;,J#R>VHFL&7S,:Y\+"W3 M3)S]:L>)YSC;E>;Z130;EGZ]YW.B<6XE&9PE>$ ]="6E>!\7N2F 9;L)ZW(TEX,'%B)+,2> 5FY(;6;-QPG'F>Y MA/MI,O@^0V@WGV^)";6#/2;47N+ -PRM'1PVM/:='9B.%T0^^SQ[FSKNK\AM MF/46AQ9+US.SOA@KFOR=&Y$YZHQS(S+AMQJ/MOV6PO/TQ@\9:"MV6K#_!O*+ MOP7:(QRR)09 ?V5!2+/KW_\9V>$*QP$#!F"3AR_ $+17R CP;[_(T=9(RX;E M+4/Q AI!_LR'WZZ-?<4CF'L.L!V:5_M?DL4I?9E,^ M L[A(X;#$RH?HW#N^7 DB>XS3*AG/%1<<$P^6SQ \/,INFZZ<$CT M"?B%X(Y0MRTQ-?T)UAW2&/FU6;L%709>?7D,X#3Q'?#)$+ ?CY(_AW"%.[!# MP2_P>2/4%L8*V+X6L#!T^'Q;TPCF]'2&V;>U1R?PUHYY"SX4HE#V_O>+I>.M M&--X_X0O8CJZ0$S\ G5+B#$SA53XHCQ6E<:BWJFQ: _QM\?08L$"P.H?/DMYA;,0<-[ X49TE764C! MTX*<- ;>'B#$VXP](:*5V2-69HS?!FAX$9&2 FA:8 M8,S@QI9 "$F[]&0 Z#86_PROSE5?\73D[I M#[XPG\5K17F%A"3H##>V]V&>[N3HC:_M$!#%W$/=YA+G,P=THU Q5O=(2OH, MM#JD..*W/YEOVLC?D?_@ 3'#G MT(G8*" .RWF$!/F"(4?9@/B 6P&9_L#!Y M=C?;\_@+IJ#/N/A*"U0)>[%@E@T(ZJSP52BJ/;K+$IH>H1%'L5\]X#)2.>!; M@/\32IJ^33C.-2%A0P*;18F#C-9GN"?^&DDNJ _D:$[#0;2(_YPSDT(*=$*Z M\+U4>M(V\U*82&VMF6@AV0L-?4,H_.H8YH_[;R8H9GAF'!GPE.G00:83'T&X M(U^A1V:&[6O/AA/%B"!A+)@ ![P! %^("YD9S99B]"9XR6EL'U1WR7L^*?E+L#T8A,"/3,.3 QT*W,[/?@ M[8@J67P%3BBVB5O'Z[,H!,M9JD>$^M MNT);BJ.5H)65S1S8T[-A.^2S@9^? /E]EUCUE+GF'.E0FWJN)103Q&$DD9_\ M?!!UX6CP]CT\*3?ME!PVP"G)G0Q%KH=>0UP//EN ZH(4!=!;()-&1 /*6V,")15^&T0#.AO=2 MI*14(GPSCG3 8Y@R4%9!3JWS^U)>.."NS (M2AA\>0T;&8S0-OX'^"K7S!/V M^1V90=XIU]5S[K],Q#8QWA_B*J5379/R4M-DBSY**JK S2K(A47;P$ MZ,= EKGA''5@M!Z\/D?@QBZ.84<(V*4@%$'>,9R[^\ >4% MK._5:]LEN-%#;\3K!:]%YK(6GZ+O\M[3:=7T#K7 M;'HA76J5!/%(9@*Z6%,:_$%H4U''O(8VL"B9CL8CP^4RT0[V4WX E0"U)Y;2 MG-9Z8?Q/?/9?09&(/9BH8DN="O3JT35TD#Q14XW+(-A?%:F>NM?,!E)=SP.K M%:WV@5;SW?-NBEZ*3_FOQ\GXW:I-'67\UV)7W,F4PZ87O%8OR_LGY0]XOA_@ M>#^*T]W(%@9W#_UV)Y]MT2 A7D6Y;I-$]2W0VPD$C3$A]=/1_"\S><]ZA6!S[>]\!OQ,IX+Z)0 ME,XP8S9E""@[XZQV1MSRUHB6\VIUG@_QH6[4=K#_;:_=Z X73="TE'EQ4="D M1>^A)W^<]^0W2.K6IS5RD^GY]CK85](FJ78$W4?W[:1?!R-Z<_ND="..HPLK MTJ!.%U8\PL:?[7"UH9A"'UQ!,84H,H@6L%YX29 JC.#M'S1#0"$N4-N[-B)? M_K"U#X^J>% 5#[6H>)A<6PY_3)^:),U*S;-+E9WLG8!9\^/Y%'=#2YKZ *?U M(GBI%>2Z'58+HEL'OM21XFK"M:8'?SFU2[UQTRQ2DT"U>^T=,P5KZ?*BQ],, MLKB!]/M*9A_WMT]Z/=:^2)W])Q$.+#4+=J3C$/MN:S#(MW5MD,?@M!4 9^WU M? B5--AK6&[S#64-6_P/_9.Z'U+L(1=,X%+U"PK5(K?#"/A"ISV\HB;QIYM. M?>V!E'_PA@PJ<>>4FD+WM)I"UA/Y#]\+@B)U8'SWT-/SO2H;1/3UB1[<*GZ? M+GP6'.-NWRGR)NAI'^>;7]X>\M](IIK$B,,DV^UFJ6T>2'*8:,,8ST=J[OB. M6CYQ\N5=:],!H/B\"B17CY)-\Y*K]'"2&IB*5XX^-10<$K,.E1V]+LJ.;J,K MEBO"_Q/81(USR8K<>&P+ZFLF]F5VG*-&"M^NEEFUK#G2C$JJ'H)'UWK_]U>G48#2X0L8:2JYC\;&L(.M1S"C?Y&.2F71G8W]]QUL=786*Z''B%XZOF M-,#(X(-]H@"' 1A33\Z>S7P!2_.2P0!6=K;*$N?'>%&0&4@4_"TWV*APB)$< M3Y3,JSAF'$0ARTSA@1@+B,CPAXL#*H G;J]>Z VOM7H!#EB<;Z6U"Z5 HRH9 M5"5##9+H525##0[AAI+I525#G2H94A./5"U#L>TEE250_!S4HUJJGJ%>/L7N M>' BKR(?7__1!3,K(COB,RB(_O>YX0H_PR=/(,>!WL;1W<.H->ZHT2"JT$$5 M.IP_#)IE'-5Y(??G&X>T7^B-[QXF;?T:/)2J#$*50=2)66Q2,(:74C"RV>.E M]8O)W4._-6QVQ93*)+HT56P5H<,+B=#CVQCU.WJK#AM MMNOEI"4_WT.E9;^+::]]/=^H4!5LU XKFR6LLHAYD+#2T>B[BKPT9=J5*]A0 MQMVURJOXB \669@:WQJ.\@:>JM2H'6(V2V2EJC@.DE?]NX=Q>Z*,*Q5$+0JB M-K%PH[,M:_Y60JVCAH9:^P/@1ZW>J-%]9"K'TIJ&8V\@Z'KUH=43-;$_;6BU M/[Q[&+4GU]!X\@Q=]?'?>.RV&QD<2BG50VRAK[='F*"\] (;[WGM,P=N?F9) M7O)?LSJ+8&N=Y!%C"APL"C<_DDNZNU#F>7>TIL*D_IS[C%6 0$_GD-ON_1H,U[>_N55^7#^0/AZ)Y)TQR.U-^>JC>I>\$%.X MYR48:F]^3"PQ9/[17'9*:/B?%CBHLMPKG/&)5B[%UVT:+; MBR_VJ "(%W\$>]=G-*48HS]H#\>UJWOHMH?=B5I4@Q>E;W_5#O_%GKGUMU6$ M\IWXVN^N MI$ E5ZYUZ'9O!UX]A44*BRK&HG.'+"[A5OG* F;XYIS,"8L],\=;HCE7=7J8 MJCVYY=J3O&-TO#V"(IP)S"KV) @_1U&$ _OD%_1L;)[K4I62U81%7CLYEY_9 MFR?G237D7#*:.<&\GTE!-%-17$,H3@G0?5+VBDANTEDGN0!V '\[#^T-L*M_ M:W14SITBNWJQ_&LGNPH$W61'%_,3$1L.,6@-1_D\PKH)NG//&+@$PGQC#OSX MU-*>F,M\PR'3V; 6MFL'H4]A?96L?CK3<:)?A 1U:E+2S9=%-]CC>S#,UU(II+HT4E7!)7?,MSX14O7O'O1>JZ\WNI>3PNA:LLD= M_G!89C#$^&JCZ^!44X-:2H4=I5B'8^P(,+; O:FPYM)84P6? M.U7X>8!="57EC,+8ROE<11'6/,9.[A[&DZI"J,I_O(?_>$=92-7.XUW/G&Q. M7X/CRE6"IBY1$3?-BAHO6K\"G5?1JA8B.5QLFOD8U4H,Q4Y&4HR4:Z M=P_=;FO<&5?DR5.TW"A:5BK!252"BY"R?O>@ZZUALQM!*C;21#:B5(*3J 05 MN7%+\I'>W4.OUQKTCW;S7IB6#Q[N>^Y&)YL0ICL A'D,<"#>QH87V.*(:2]& MH/VE#&IELVL&ZYCU?K%TO!5CWYC_;(OYL#G\BMLI\2G"W[W0<-8[FWSRPO]E M\%'9_H.&$8MV3/LAYC!!3,RC&+3S%B^'"<#>P6T#M"*W3,,1:CL$%T,/'A2] M" W:4CQ7^&5NFW/-#N@94]P\9>F^)A[@H69H+Z*UU+TD[JVX*F.Y]+V? ML+F0.2NM7 >:DQT(;R[[P?/%3WA?-W,R@+CF:ROR5\SPD[/ 6>CMWCI!:7A3 ML#:K>&LOJ'W)KJB5$;X&UV-W]*YAC/2!9;!Q?SHUICUSUC7Z \L 6H8PZ74T7]T 6O9=^/G.SLP'2^(_((>0<,AIW" ,1Q_*'[# MEZUU#CK_SB4?OT?]Y+7>:P^PK0[?E0;;2B4OK#<1RQY8$0ILZ&-%6Z]=N].X M+1*;S1C.EF9::/S4?& (P0G;'EDV?,Z'QV>^MZ!OO#5T D+%I) ,Y9&.4%12JZO M.:-S@CUF)D(Y_)6Y;&:'1=)V=/?0:>=#8)J4LWB2Y=96V=* F^OMO)D;+^TH M6@(L7G+J=%9M[9QG-ZP,0!,\N[S^?L39C:I:VZB#:^N>XO!Z18=7<$RI%J"2E^9DXG';U4RP,PSX_[\BWPXLFU8=X#?@B?3;X9^NA\_. A9J4^"- M='G*(8*<,DSAU!S^+5@C5S)!L=-FD0/(DWY# U? 8&O0>G"#JC4Z3-7ZRBV!+X8?KKZ#ZA]PW RV:5ZC;E[S&G5K MK'F)36JT2RV]S>UZV 95B_9:-[0HEL.?W523-;TK>4::'(%]>S:9?._\-GP3 M[@RU[VWM YA.\! H1GCWKQ[85VVZ15P H@?@!+9%BI81VY1+ G)@([W.B3=X M+I,:$AI9\"S[R##N_$#>(%?U,O>H>R7\_#OUI1GCVKLZV?T@;YYM M9(HO=C@'UH%S&;2E%S(X*\/1F+ <8P;D3>$HZ BYTNFS!; U0!/^@O1W\;(1 M,[[$D@WA5(B[HLQ+O0YY%\>1)_@Z;)7>YIEFY/L,04"VN7R?6"K#).8@ TW< M%O+0=3BN@67*PA?&7 TY,'!L0#".F8F>*VZ$CP&XA)Z,=XMCQIX^F3/%)>=1 MI*WM=L*D&'I)T:IW.MME*[6Q_LTVIK8#YCD+WA(T"V6KCK(U'\H[7.Z77MPG MSS4WKZ^'/;2W*&X 9/$T%_R>>R__[23?2'ML$JQ9%_[\S-XQ,WUDA41_P)'M MT&5+'%F_^B,KN;CM1S; (\OG;I[PR+9:N?N(A;T*\6"'2[>4^QBM%VUSQXW21=F M@#03@D7X$-(,7]H"EEALQH%;I7[;WT._O90R.SY,F84S6]@A[T+NPC$+L6P" M-6[59\<%^NRXQOIL:I]$)IF='J;2CANCTG[/L+U52^@^-EJ\'OV_A7&*()K^ M"^@.?S,=PUYP2#GL"11$T!]-QA"N@3;UO0A>KAE/H* %(=B7FLV5.!<# @Y@ M1N1S1\,Z/E;D*S%7,/+[!9HY;@%*,O20E MT!OW'PC!C_$#G!H:-RDV4<_&:[];V["M9(;8-'1#/X2^0B^S%V$SYZ@$MOGTMH608R AR@# M$2*-S5-A9\54]@_>*,99M80'+K54\1#'6.8O;&'914OX Z@&WM_B^T%]PIYA MT,)8>!$^:T6,WY=^D(=_!3\ -D-;FF5NP3W15?@MML#C-7%G(H(#V8SX%#T2 MORS6.#F?R&T*66-B_6980BA63/Y*8$K)BE#A<5C,"_>#;8GXZTW.XAEOGL53 M0F< MIIQ.&J.Q#6P=QIX BU#W M@561LAIPSBN\UJ@,P5XY%V3NG&(CE/0S]QQDQ!@[86WM$6%N&\+=2EY:T_-! M2Q(J9W(N4JF:V3[HP'_"^D.N#Z+4M")<;NQ5G3/#,E$:4)RF*,,G;ZZ[8DQE MEC*&^M:Q>!OHA')ZZ'V?9U\$)P[>.S:)-9G> W^::??.O1Y3T+B#254YD_VO MV:8PSI-_$ZAE M#Q]S%DM%P)$K%C:2CHP" /YZ2X9=]]*W)=:0A3]86;L(4T%8[#$3CTM=#[40 MH"=X#,,4(B;Z"N.6OZ O[[AH>]&67C"KL( 'CT& 0L_ HK;/N[\ M+3"-)Q;DL]^ 8%\\WPJ8FR"9?O?@VD[>UU5U6D2IA>=<&NF5H%=0-RW0!Y=ID97KU1>S0I MOE1RAM[5%/ M-.[?/0Q;G8*!% TJ2[RZ'N$78ZMOI7\YY7L]/0^]A7:B5;")';U,3LDFL**H MU>TTFDTTM)WIQ9@!#]&9B$CG4J.NNJ=:%2Q@1Q^20_P1*2H?WCT,KD(54 )_ M3_!2&>HE!?PM-F10?5TNT-?EE-K1"">MC :-YISU[P>Q;ZGZ]LC1<;7J -KZ M)J/JG<.B_-^B:<#^C( WE.Y1T'4KB#O=%SGO--D2QK?TT'A_'%SR3">#*XG]5-O?<-^TO[+F[L!!AXSA5._^^WX"A9 +K"RG/(M>QW> M0@+C3!A]\FVJ&Z*\)QZ8#YAK>WXJC7.1I)/ZGB-*S)^P'0<5-9D4PL;D-!'5 MG]I>R,RY"U![PM(@"X#JK^=,->$\,$!?Q/TW,MYS+2S.[G "+Y/B8807DE:T MK.*2/L0_GX5VID$"+P9C>80762PJPVY'AMVDB@R[;J=WRA2[(@+OQ)*U0:EW ME(BNIQ/K_^/_&>O=T9M P^2Y* AD-NFC:SBKP";V^B'FH&\]U[+CC-.O5/M. MMWR.LT#JR1XW)H1O9IAQX@+E-*5 8Z1 XT5I 6-FP.,GX$DER01S+W(LWA+* MH*Q\>.I?P/?H.CRJ:04G$T'-+ M>Y6_\1?9UT:\L/N^X(7O?_("BM2;^P5O3M\&[TU:+:1J5? ^L?G F#&0##X8 M(W*W)APL'L!T)"G8R_=190DX(Z8M\KR BFUF(GR+907X9DR1>-K2IE%(:\2*%TQ.Y*6@K?2]F/TI=#;\CDC]Q)(F7B>> M4%O\4[Z6)[[D8UEYQ.#>I>_]B_=L(S\S_4 I3WSG2P=XS!O-(S2PL18)L"C9 MY!M"BQ]LE2JIEY%_O/.W/[[\]_]^^OCM#2W:@!M,>VG(?'T#TP7N*5T@F^AF MDAL@3C2%9X%#R$Q3>!"5#*I<[0X0\'_I3I*,+>(FL&$ZV<[D3?;-!M7_4',3 MTPCFHO%=+AU0"XQG*OG"W<;J]U_Z'?D=OB%X-:_)HNS7%\9+KW@6+-WPXOD_ M '@7[G\U_[@K^(EU#2/ X7>@S]F5TVOG2$4L)G" @L;4B>.;0RP-0(: ZLW M%]4A3_SQDA(M?42M+ - )&3X1EX@8\;W@7'D>&":1HZ!4LX).8QY![!7[!\? MOOZB64!.<"H^>X+UNZ*\2'8TC$+;$95 B,#X,1.6ACX7+<3:M: E\K,I,1I? MA'4\6$OD^9(GX*\ $)!ZU'V,3;$)6HNJX5SF\(1CK+$1KY)T197!M#'-L+#U MI8N50!(Y.:)Q2A2+39&#RS!_&_]!_$QP"*P^CM_)RVK6>CB-.BTX5R+#T0#_ M^D86_>"V8 <&@>?QCZ\ZW/;M\1W@162M..YSIANOD,K^@D@@N)2O!\',%!F!"$O" -E2YL!=I'1_(:SLDZ)] IO93@D8WC5$L%.UBQQ5O,Y#*(?AO8%6-;",%E$WK4 M,:V]EMH MM5O8)([?T]8^ E%@;C"P'CS.E1?!7]'9@&^_EN"C.M71#EK[M620M=?SB53_F>& M+9P*[@:FGWL)>EO<@GUS3UKN)1(Q\A= #02R6/\=F_X%C!D%EQS[!]#'^J^1 M*QY)-!U LP (!OD-0!DN!J1W\)6+=H.[$42J&QGUXMES +-_N-X+U\XCE__= MMX,?@'^9RN-4U:+D15P/! P#+(T"+M%$C9_0\UO('T@QXIP&1?G,-Y"K(S&: M\AT&441&XMP!J0"=N@E21LW5AXJ,/)\E!0,EKY M#[[F(@5; QDF=?;QR7"!-Q)'%:X8&Y8C>B@!3Y6'R&\-WB3:Q,FH9C#Z:'(OF1.I^E6AQ*76RITTL!UA'YA\""O\_F=$+J.8 M62>VH"RS7F?.J=)3DFG4&V5%54N\)$F*[JQJ)!147KI!"FRL?Q)EF?!I:;1N M?#+94P(S*5N>/$_8E[C\N;T,$H,UB*@EJ ]?%;6GLNC4WUP%3,HR[;U4QH3U9F)A0(/WL:YCQ"6*"4P30*P* M $: H8K>5=QLR_;CDFMD.ZEV6FV**U N^],\[>9.=4TPPK7C#8C26W$U%QVO8XO=RS?/ M%7NA9A'QAXR8E/!$\(81W,S'3HW[L7%0:I[(/ =UC,%]3E*"305ZN!0AGK[" M&[4/_#DIH.!QWM1!]'3H/LKSQF8(6SHJD.D/*K1LOH;?^Z/]K9UV4.!J8^\# M-2'@_A:OH#B2;J8W[? '@&(.ZCNISD8$",)_;FO_L#G&[ \[KJ,)]Q6R2F : M)M:I8QD]D,/_W]ZW-K=M9 O^%52N,R-O030!\&G/SI8BVXDR?EW+J=GYM 4" M31$Q"#!X2.;]]7O.Z6Z@00(4*5$D(.)6W4DBDD#W>;^/1P@.Y4,WJ9H+/P[U M>[^7$V'!P5P/2X0!GRLL8CZND \4MP*8PU,[VG_RLU/<;3VH1=WS:,9GH*51 M(T@><"8^&B+C7L}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end XML 86 auph-20240930_htm.xml IDEA: XBRL DOCUMENT 0001600620 2024-01-01 2024-09-30 0001600620 2024-11-06 0001600620 2024-09-30 0001600620 2023-12-31 0001600620 us-gaap:RelatedPartyMember 2024-09-30 0001600620 us-gaap:RelatedPartyMember 2023-12-31 0001600620 us-gaap:ProductMember 2024-07-01 2024-09-30 0001600620 us-gaap:ProductMember 2023-07-01 2023-09-30 0001600620 us-gaap:ProductMember 2024-01-01 2024-09-30 0001600620 us-gaap:ProductMember 2023-01-01 2023-09-30 0001600620 auph:LicenseRoyaltyAndCollaborationRevenueMember 2024-07-01 2024-09-30 0001600620 auph:LicenseRoyaltyAndCollaborationRevenueMember 2023-07-01 2023-09-30 0001600620 auph:LicenseRoyaltyAndCollaborationRevenueMember 2024-01-01 2024-09-30 0001600620 auph:LicenseRoyaltyAndCollaborationRevenueMember 2023-01-01 2023-09-30 0001600620 2024-07-01 2024-09-30 0001600620 2023-07-01 2023-09-30 0001600620 2023-01-01 2023-09-30 0001600620 us-gaap:CommonStockMember 2024-06-30 0001600620 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001600620 us-gaap:RetainedEarningsMember 2024-06-30 0001600620 2024-06-30 0001600620 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001600620 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001600620 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001600620 us-gaap:CommonStockMember 2024-09-30 0001600620 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001600620 us-gaap:RetainedEarningsMember 2024-09-30 0001600620 us-gaap:CommonStockMember 2023-06-30 0001600620 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001600620 us-gaap:RetainedEarningsMember 2023-06-30 0001600620 2023-06-30 0001600620 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001600620 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001600620 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001600620 us-gaap:CommonStockMember 2023-09-30 0001600620 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001600620 us-gaap:RetainedEarningsMember 2023-09-30 0001600620 2023-09-30 0001600620 us-gaap:CommonStockMember 2023-12-31 0001600620 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001600620 us-gaap:RetainedEarningsMember 2023-12-31 0001600620 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001600620 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-30 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-09-30 0001600620 us-gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0001600620 us-gaap:CommonStockMember 2022-12-31 0001600620 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001600620 us-gaap:RetainedEarningsMember 2022-12-31 0001600620 2022-12-31 0001600620 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001600620 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-09-30 0001600620 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001600620 2024-01-01 2024-03-31 0001600620 us-gaap:EmployeeSeveranceMember auph:StrategicRestructuringPlanMember us-gaap:SubsequentEventMember 2024-11-07 2024-11-07 0001600620 srt:MinimumMember srt:ScenarioForecastMember us-gaap:EmployeeSeveranceMember auph:StrategicRestructuringPlanMember 2024-10-01 2024-12-31 0001600620 srt:MaximumMember srt:ScenarioForecastMember us-gaap:EmployeeSeveranceMember auph:StrategicRestructuringPlanMember 2024-10-01 2024-12-31 0001600620 auph:MajorCustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001600620 auph:MajorCustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001600620 auph:MajorCustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001600620 auph:MajorCustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001600620 srt:MinimumMember 2024-01-01 2024-09-30 0001600620 srt:MaximumMember 2024-01-01 2024-09-30 0001600620 us-gaap:FairValueInputsLevel1Member auph:CashCashEquivalentsAndRestrictedCashMember 2024-09-30 0001600620 us-gaap:FairValueInputsLevel2Member auph:CashCashEquivalentsAndRestrictedCashMember 2024-09-30 0001600620 us-gaap:FairValueInputsLevel3Member auph:CashCashEquivalentsAndRestrictedCashMember 2024-09-30 0001600620 auph:CashCashEquivalentsAndRestrictedCashMember 2024-09-30 0001600620 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateBondSecuritiesMember 2024-09-30 0001600620 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateBondSecuritiesMember 2024-09-30 0001600620 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateBondSecuritiesMember 2024-09-30 0001600620 us-gaap:CorporateBondSecuritiesMember 2024-09-30 0001600620 us-gaap:FairValueInputsLevel1Member us-gaap:CommercialPaperMember 2024-09-30 0001600620 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2024-09-30 0001600620 us-gaap:FairValueInputsLevel3Member us-gaap:CommercialPaperMember 2024-09-30 0001600620 us-gaap:CommercialPaperMember 2024-09-30 0001600620 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryBillSecuritiesMember 2024-09-30 0001600620 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBillSecuritiesMember 2024-09-30 0001600620 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryBillSecuritiesMember 2024-09-30 0001600620 us-gaap:USTreasuryBillSecuritiesMember 2024-09-30 0001600620 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryBondSecuritiesMember 2024-09-30 0001600620 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBondSecuritiesMember 2024-09-30 0001600620 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryBondSecuritiesMember 2024-09-30 0001600620 us-gaap:USTreasuryBondSecuritiesMember 2024-09-30 0001600620 us-gaap:FairValueInputsLevel1Member 2024-09-30 0001600620 us-gaap:FairValueInputsLevel2Member 2024-09-30 0001600620 us-gaap:FairValueInputsLevel3Member 2024-09-30 0001600620 us-gaap:FairValueInputsLevel1Member auph:CashCashEquivalentsAndRestrictedCashMember 2023-12-31 0001600620 us-gaap:FairValueInputsLevel2Member auph:CashCashEquivalentsAndRestrictedCashMember 2023-12-31 0001600620 us-gaap:FairValueInputsLevel3Member auph:CashCashEquivalentsAndRestrictedCashMember 2023-12-31 0001600620 auph:CashCashEquivalentsAndRestrictedCashMember 2023-12-31 0001600620 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateBondSecuritiesMember 2023-12-31 0001600620 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateBondSecuritiesMember 2023-12-31 0001600620 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateBondSecuritiesMember 2023-12-31 0001600620 us-gaap:CorporateBondSecuritiesMember 2023-12-31 0001600620 us-gaap:FairValueInputsLevel1Member us-gaap:CommercialPaperMember 2023-12-31 0001600620 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2023-12-31 0001600620 us-gaap:FairValueInputsLevel3Member us-gaap:CommercialPaperMember 2023-12-31 0001600620 us-gaap:CommercialPaperMember 2023-12-31 0001600620 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryBillSecuritiesMember 2023-12-31 0001600620 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBillSecuritiesMember 2023-12-31 0001600620 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryBillSecuritiesMember 2023-12-31 0001600620 us-gaap:USTreasuryBillSecuritiesMember 2023-12-31 0001600620 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryBondSecuritiesMember 2023-12-31 0001600620 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBondSecuritiesMember 2023-12-31 0001600620 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryBondSecuritiesMember 2023-12-31 0001600620 us-gaap:USTreasuryBondSecuritiesMember 2023-12-31 0001600620 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001600620 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001600620 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001600620 us-gaap:FairValueInputsLevel2Member 2023-01-01 2023-12-31 0001600620 us-gaap:FairValueInputsLevel2Member 2024-01-01 2024-09-30 0001600620 auph:CashCashEquivalentsAndRestrictedCashMember 2024-01-01 2024-09-30 0001600620 auph:ShortTermCorporateDebtSecuritiesMember 2024-09-30 0001600620 auph:ShortTermCorporateDebtSecuritiesMember 2024-01-01 2024-09-30 0001600620 us-gaap:CommercialPaperMember 2024-01-01 2024-09-30 0001600620 us-gaap:USTreasuryBillSecuritiesMember 2024-01-01 2024-09-30 0001600620 us-gaap:USTreasuryBondSecuritiesMember 2024-01-01 2024-09-30 0001600620 auph:LongTermCorporateDebtSecuritiesMember 2024-09-30 0001600620 auph:LongTermCorporateDebtSecuritiesMember 2024-01-01 2024-09-30 0001600620 auph:CashCashEquivalentsAndRestrictedCashMember 2023-01-01 2023-12-31 0001600620 auph:ShortTermCorporateDebtSecuritiesMember 2023-12-31 0001600620 auph:ShortTermCorporateDebtSecuritiesMember 2023-01-01 2023-12-31 0001600620 us-gaap:CommercialPaperMember 2023-01-01 2023-12-31 0001600620 us-gaap:USTreasuryBillSecuritiesMember 2023-01-01 2023-12-31 0001600620 us-gaap:USTreasuryBondSecuritiesMember 2023-01-01 2023-12-31 0001600620 2023-01-01 2023-12-31 0001600620 auph:LongTermCorporateDebtSecuritiesMember 2023-12-31 0001600620 auph:LongTermCorporateDebtSecuritiesMember 2023-01-01 2023-12-31 0001600620 us-gaap:PatentsMember 2024-09-30 0001600620 us-gaap:IntellectualPropertyMember 2024-09-30 0001600620 us-gaap:ComputerSoftwareIntangibleAssetMember 2024-09-30 0001600620 us-gaap:PatentsMember 2023-12-31 0001600620 us-gaap:IntellectualPropertyMember 2023-12-31 0001600620 us-gaap:ComputerSoftwareIntangibleAssetMember 2023-12-31 0001600620 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001600620 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001600620 us-gaap:OfficeEquipmentMember 2024-09-30 0001600620 us-gaap:OfficeEquipmentMember 2023-12-31 0001600620 us-gaap:FurnitureAndFixturesMember 2024-09-30 0001600620 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001600620 us-gaap:ComputerEquipmentMember 2024-09-30 0001600620 us-gaap:ComputerEquipmentMember 2023-12-31 0001600620 auph:RockvilleMarylandMember 2020-03-31 0001600620 auph:RockvilleMarylandMember 2024-09-30 0001600620 auph:RockvilleMarylandMember 2023-12-31 0001600620 auph:RockvilleMarylandMember 2023-01-01 2023-12-31 0001600620 auph:RockvilleMarylandMember 2020-03-12 0001600620 auph:EdmontonAlbertaMember 2022-10-31 0001600620 auph:VispSwitzerlandMember 2023-07-31 0001600620 auph:VispSwitzerlandMember 2024-09-30 0001600620 auph:VispSwitzerlandMember 2023-12-31 0001600620 auph:VispSwitzerlandMember 2024-07-01 2024-09-30 0001600620 auph:VispSwitzerlandMember 2024-01-01 2024-09-30 0001600620 auph:BeinheimFranceMember 2020-03-01 2020-03-31 0001600620 auph:BeinheimFranceMember 2023-07-31 0001600620 auph:BeinheimFranceMember 2024-09-30 0001600620 auph:OtuskaPharmaceuticalCoLtdMember us-gaap:LicenseAgreementTermsMember 2020-01-01 2020-12-31 0001600620 auph:OtuskaPharmaceuticalCoLtdMember srt:MinimumMember us-gaap:LicenseAgreementTermsMember 2020-12-31 0001600620 auph:OtuskaPharmaceuticalCoLtdMember srt:MaximumMember us-gaap:LicenseAgreementTermsMember 2020-12-31 0001600620 auph:OtuskaPharmaceuticalCoLtdMember us-gaap:LicenseAgreementTermsMember 2024-09-24 2024-09-24 0001600620 auph:OtuskaPharmaceuticalCoLtdMember us-gaap:LicenseAgreementTermsMember 2024-07-01 2024-09-30 0001600620 auph:OtuskaPharmaceuticalCoLtdMember us-gaap:ServiceMember us-gaap:LicenseAgreementTermsMember 2024-07-01 2024-09-30 0001600620 auph:OtuskaPharmaceuticalCoLtdMember us-gaap:ServiceMember us-gaap:LicenseAgreementTermsMember 2024-01-01 2024-09-30 0001600620 auph:OtuskaPharmaceuticalCoLtdMember us-gaap:ServiceMember us-gaap:LicenseAgreementTermsMember 2023-07-01 2023-09-30 0001600620 auph:OtuskaPharmaceuticalCoLtdMember us-gaap:ServiceMember us-gaap:LicenseAgreementTermsMember 2023-01-01 2023-09-30 0001600620 2024-02-15 0001600620 2024-02-29 2024-02-29 0001600620 srt:MinimumMember 2024-02-29 2024-02-29 0001600620 srt:MaximumMember 2024-02-29 2024-02-29 0001600620 auph:StockOptionsRSUsPerformanceAwardsAndESPPMember 2024-07-01 2024-09-30 0001600620 auph:StockOptionsRSUsPerformanceAwardsAndESPPMember 2023-07-01 2023-09-30 0001600620 auph:StockOptionsRSUsPerformanceAwardsAndESPPMember 2024-01-01 2024-09-30 0001600620 auph:StockOptionsRSUsPerformanceAwardsAndESPPMember 2023-01-01 2023-09-30 0001600620 auph:AmendedAndRestatedEquityIncentivePlanMember 2021-06-01 2021-06-30 0001600620 us-gaap:EmployeeStockMember 2021-06-30 0001600620 us-gaap:EmployeeStockMember 2024-01-01 2024-09-30 0001600620 auph:RestrictedStockUnitsAndPerformanceAwardsMember 2023-12-31 0001600620 auph:RestrictedStockUnitsAndPerformanceAwardsMember 2024-01-01 2024-09-30 0001600620 auph:RestrictedStockUnitsAndPerformanceAwardsMember 2024-09-30 0001600620 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001600620 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001600620 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001600620 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001600620 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-01 2024-09-30 0001600620 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0001600620 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-09-30 0001600620 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0001600620 us-gaap:InventoriesMember 2024-07-01 2024-09-30 0001600620 us-gaap:InventoriesMember 2023-07-01 2023-09-30 0001600620 us-gaap:InventoriesMember 2024-01-01 2024-09-30 0001600620 us-gaap:InventoriesMember 2023-01-01 2023-09-30 0001600620 auph:EmployeeBenefitObligationsMember auph:DrRobertTFosterMember 2024-09-30 0001600620 auph:EmployeeBenefitObligationsMember auph:DrRobertTFosterMember 2023-12-31 0001600620 auph:DrRobertTFosterMember 2024-01-01 2024-09-30 0001600620 auph:DrRobertTFosterMember 2023-01-01 2023-12-31 0001600620 us-gaap:EmployeeSeveranceMember 2024-01-01 2024-09-30 0001600620 us-gaap:ContractTerminationMember 2024-01-01 2024-09-30 0001600620 us-gaap:OtherRestructuringMember 2024-01-01 2024-09-30 shares iso4217:USD iso4217:USD shares pure auph:segment utr:sqft auph:extension_option false 2024 Q3 0001600620 --12-31 10-Q true 2024-09-30 false 001-36421 Aurinia Pharmaceuticals Inc. Z4 #140, 14315 - 118 Avenue Edmonton AB T5L 4S6 98-1231763 (250) 744-2487 Yes Yes Large Accelerated Filer false false false 143179269 Common shares, no par value AUPH NASDAQ 37142000 48875000 311605000 301614000 36483000 24089000 38714000 39705000 13815000 9486000 2700000 1031000 440459000 424800000 0 201000 868000 1517000 2887000 3354000 4509000 4977000 96459000 108715000 4179000 4498000 549361000 548062000 56770000 54389000 4304000 4813000 800000 800000 1590000 2388000 14927000 14609000 1018000 989000 78609000 77188000 65955000 75479000 5951000 6530000 7000000.0 7600000 10844000 10911000 161359000 170108000 0 0 143109000 143109000 143833000 143833000 1206613000 1200218000 119773000 120788000 -385000 -730000 -937999000 -942322000 388002000 377954000 549361000 548062000 55503000 40781000 158604000 116218000 12268000 13734000 16662000 14200000 67771000 54515000 175266000 130418000 6035000 6769000 22696000 8753000 42367000 47759000 134996000 144964000 3047000 13605000 12678000 39413000 0 0 7755000 0 -4574000 -2645000 -159000 695000 56023000 70778000 178284000 192435000 11748000 -16263000 -3018000 -62017000 1208000 1400000 3689000 1465000 4267000 4514000 12982000 12429000 14807000 -13149000 6275000 -51053000 457000 298000 1952000 92000 14350000 -13447000 4323000 -51145000 0 0 0 0 474000 73000 345000 114000 14824000 -13374000 4668000 -51031000 0.10 -0.09 0.03 -0.36 0.10 -0.09 0.03 -0.36 143051000 142847000 143353000 143085000 145651000 142847000 145010000 143085000 142984000 1205554000 112270000 -859000 -952349000 364616000 125000 1059000 -824000 235000 8327000 8327000 474000 474000 14350000 14350000 143109000 1206613000 119773000 -385000 -937999000 388002000 143369000 1196480000 98832000 -1020000 -902000000 392292000 236000 2080000 -929000 1151000 11808000 11808000 73000 73000 -13447000 -13447000 143605000 1198560000 109711000 -947000 -915447000 391877000 143833000 1200218000 120788000 -730000 -942322000 377954000 2548000 23966000 -23320000 646000 3424000 18619000 18619000 152000 1048000 -345000 703000 22650000 22650000 345000 345000 4323000 4323000 143109000 1206613000 119773000 -385000 -937999000 388002000 142268000 1185309000 85489000 -1061000 -864302000 405435000 1127000 11141000 -8117000 3024000 210000 2110000 -1204000 906000 33543000 33543000 114000 114000 -51145000 -51145000 143605000 1198560000 109711000 -947000 -915447000 391877000 4323000 -51145000 14583000 6698000 9752000 8836000 22650000 33543000 718000 1335000 -220000 1659000 12394000 24463000 -991000 8984000 6001000 2889000 12000 16000 934000 11812000 -550000 -499000 14274000 -47773000 461140000 379213000 461448000 391287000 44000 11864000 0 419000 225000 240000 39000 -449000 18435000 0 8959000 3482000 1348000 3929000 -26046000 447000 -11733000 -47775000 48875000 94172000 37142000 46397000 2803000 3559000 1459000 339000 36630000 45557000 512000 840000 37142000 46397000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Organization and Description of Business</span><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurinia Pharmaceuticals Inc. (Aurinia or the Company) is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (voclosporin), the first U.S. Food and Drug Administration (FDA) approved oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. Aurinia contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for development and commercialization of LUPKYNIS in the European Union (EU), Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine (collectively, the Otsuka Territories).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 15, 2024, the Company announced the conclusion of its previously announced strategic review process and actions designed to enhance shareholder value. Aurinia executed a corporate restructuring in the first quarter that reduced employee headcount by approximately 25% and discontinued its AUR300 research and development program. For further discussion, refer to Note 19, Restructuring.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 7, 2024, Aurinia announced it was implementing a strategic restructuring to sharpen the Company's focus on continued LUPKYNIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> growth and the rapid development of AUR200. This restructuring will result in a workforce reduction of approximately 45% and Aurinia anticipates a one-time restructuring charge in the fourth quarter of 2024 of approximately $15 to $19 million and will focus the Company’s LUPKYNIS commercial strategy on the highest growth drivers.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also developing its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). On September 5, 2024, the Company announced the first participant has been dosed in a Phase 1 single ascending dose (SAD) study of AUR200. The SAD study will assess the safety, tolerability, pharmacokinetics, and changes in biomarkers for AUR200 in healthy volunteers, with data expected in the first half of 2025.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurinia's head office and registered office is located at #140, 14315-118 Avenue, Edmonton, Alberta, Canada T5L 4S6. Aurinia also has a United States commercial office located at 77 Upper Rock Circle Suite 700, Rockville, Maryland, 20850.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurinia is incorporated pursuant to the Business Corporations Act (Alberta). The Company’s common shares are traded on the Nasdaq Global Market (Nasdaq) under the symbol AUPH.</span></div> 0.25 0.45 15000000 19000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Summary of Significant Accounting Policies </span><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of September 30, 2024 was derived from audited annual consolidated financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. The results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the full year or any other future periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation and operate in one segment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements are presented in U.S. dollars, which is the Company's and all of its foreign subsidiaries' functional currency. Therefore, there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statements of operations. All monetary assets and liabilities denominated in a foreign currency are remeasured into U.S. dollars at the exchange rate on the balance sheet date. Non-monetary assets and liabilities (along with their related expenses) are translated at the rate of exchange in effect on the date the assets were acquired. Monetary income and expense items are translated at the average foreign currency rate. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the consolidated statements of operations and recorded in other expense (income), net.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's significant accounting policies have not changed from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, other than as stated below.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenues</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor, and semi-finished product directly to our ex-U.S. partner Otsuka. These customers subsequently distribute the Company's products. Revenues from product sales are recognized when the customer obtains control of the Company's product, which occurs upon delivery to the customer. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for discounts and allowances: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are recorded at the net sales price, which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a liability (if the amount is payable to a party other than the customer). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgment is required in estimating variable consideration. In making these estimates, the Company considers historical data, including patient mix and inventory sold to customers that has not yet been dispensed to patients. The Company uses a data aggregator and historical claims to estimate variable consideration for inventory sold to its specialty pharmacies that has not yet been dispensed. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment. As of September 30, 2024, the Company did not have any material adjustments to variable consideration estimates based on actual results. These specific adjustments are detailed further in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Customers:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company currently has two main specialty pharmacies for U.S. commercial sales of LUPKYNIS and a collaboration partnership with Otsuka for sales of semi-finished product and royalty, collaboration, and manufacturing services revenue in the Otsuka Territories. Revenues from our two main customers represented approximately 49% and 38% of revenues for the nine months ended September 30, 2024. Revenues from our two main customers represented approximately 50% and 39% of revenues for the nine months ended September 30, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.526%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late March 2022, the Company provided a nominal additional discount to both of its two main U.S. specialty pharmacies, applicable for the 2022 calendar year, in connection with holding additional amounts of LUPKYNIS on hand for risk mitigation and supply chain concerns. In December 2022, the Company extended the nominal discount to the end of 2024. Such discounts, or any future discounts, may result in reduced sales to these customers in subsequent periods and substantial fluctuations in revenues from period to period. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances. Global economic conditions and customer specific factors may require the Company to periodically reevaluate the collectability of its receivables and based on this evaluation the Company could potentially incur credit losses. The Company has had no historical write-offs related to customers or receivables.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable, net:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accounts receivable are stated at their net realizable value. The Company's accounts receivable primarily represent amounts due to the Company from product sales and from its Otsuka collaboration agreement (Note 12). As </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of September 30, 2024, and December 31, 2023, accounts receivable, net are $36.5 million and $24.1 million, respectively. The Company's standard credit terms range from 30 to 45 days. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised good to the customer and receipt of payment will be one year or less. The Company estimates the allowances using the current expected credit loss, or CECL, model. Under the CECL model, the allowances reflect the net amount expected to be collected from the accounts receivable. Aurinia evaluates the collectability of these cash flows based on the asset’s amortized cost, the risk of loss even when that risk is remote, losses over an asset’s contractual life, and other relevant information available to the Company. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. Given the nature of the Company's accounts receivable, it determined that an allowance for current expected credit losses was nil as of September 30, 2024, and December 31, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Compensation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date using the graded accelerated vesting method for all share-based payments related to stock options, performance awards (PAs), restricted stock units (RSUs) and purchases under the Company's 2021 Employee Share Purchase Plan (ESPP). The estimated fair value of performance-based awards is measured on the grant date and is recognized when it is determined that it is probable that the performance condition will be achieved. The Company has elected a policy for all share-based awards to estimate forfeitures based on historical forfeiture experience at the time of grant and revise in subsequent periods if actual forfeitures differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring Expenses: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring expenses consist primarily of employee severance, contract termination costs and other costs. Liabilities for costs associated with a restructuring activity are recognized when the liability is incurred and are measured at fair value. According to ASC 420, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exit or Disposal Cost Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, one-time employee severance and termination benefits are expensed at the date the entity notifies the employee of the plan, unless the employee must provide future service, in which case the benefits are expensed in the period when the service ends. One-time termination benefits include severance, continuation of health insurance coverage for certain employees, and other benefits such as outplacement support services for a specified period of time.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Shares: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s shares have no par value or stated value and therefore, upon issuance or repurchase of shares, all amounts related to the shares are recorded under common shares on the balance sheet. The value of common shares includes cash amounts paid or received for the shares and the fair value of equity awards and warrants. Amounts for common shares are offset by share issue costs or transactions costs associated with repurchases or equity offerings.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued final guidance in ASU No. 2023-09, Income Taxes (ASC 740): Improvements to Income Tax Disclosures requiring entities to provide additional information in the rate reconciliation and disclosures about income taxes paid. For public business entities, the guidance is effective for annual periods beginning after December 15, 2024. The Company is not early adopting, and therefore, this ASU is not adopted in the current period. The Company is currently assessing the potential impact this ASU may have on the consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures which requires public entities to disclose significant segment expenses regularly provided to the chief operating decision-maker. Public entities with a single reporting segment have to provide all disclosures required by ASC 280, including the significant segment expense disclosures. For public business entities, the guidance is effective for annual periods beginning after December 15, 2023. This ASU does not have a material impact on the consolidated financial statements.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of September 30, 2024 was derived from audited annual consolidated financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. The results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the full year or any other future periods.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation and operate in one segment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements are presented in U.S. dollars, which is the Company's and all of its foreign subsidiaries' functional currency. Therefore, there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statements of operations. All monetary assets and liabilities denominated in a foreign currency are remeasured into U.S. dollars at the exchange rate on the balance sheet date. Non-monetary assets and liabilities (along with their related expenses) are translated at the rate of exchange in effect on the date the assets were acquired. Monetary income and expense items are translated at the average foreign currency rate. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the consolidated statements of operations and recorded in other expense (income), net.</span></div> 1 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenues</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor, and semi-finished product directly to our ex-U.S. partner Otsuka. These customers subsequently distribute the Company's products. Revenues from product sales are recognized when the customer obtains control of the Company's product, which occurs upon delivery to the customer. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for discounts and allowances: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are recorded at the net sales price, which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a liability (if the amount is payable to a party other than the customer). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgment is required in estimating variable consideration. In making these estimates, the Company considers historical data, including patient mix and inventory sold to customers that has not yet been dispensed to patients. The Company uses a data aggregator and historical claims to estimate variable consideration for inventory sold to its specialty pharmacies that has not yet been dispensed. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment. As of September 30, 2024, the Company did not have any material adjustments to variable consideration estimates based on actual results. These specific adjustments are detailed further in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Customers:</span> The Company currently has two main specialty pharmacies for U.S. commercial sales of LUPKYNIS and a collaboration partnership with Otsuka for sales of semi-finished product and royalty, collaboration, and manufacturing services revenue in the Otsuka Territories. 2 0.49 0.38 0.50 0.39 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable, net:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accounts receivable are stated at their net realizable value. The Company's accounts receivable primarily represent amounts due to the Company from product sales and from its Otsuka collaboration agreement (Note 12). As </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of September 30, 2024, and December 31, 2023, accounts receivable, net are $36.5 million and $24.1 million, respectively. The Company's standard credit terms range from 30 to 45 days. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised good to the customer and receipt of payment will be one year or less. The Company estimates the allowances using the current expected credit loss, or CECL, model. Under the CECL model, the allowances reflect the net amount expected to be collected from the accounts receivable. Aurinia evaluates the collectability of these cash flows based on the asset’s amortized cost, the risk of loss even when that risk is remote, losses over an asset’s contractual life, and other relevant information available to the Company. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. Given the nature of the Company's accounts receivable, it determined that an allowance for current expected credit losses was nil as of September 30, 2024, and December 31, 2023.</span></div> 36500000 24100000 P30D P45D 0 0 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Compensation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date using the graded accelerated vesting method for all share-based payments related to stock options, performance awards (PAs), restricted stock units (RSUs) and purchases under the Company's 2021 Employee Share Purchase Plan (ESPP). The estimated fair value of performance-based awards is measured on the grant date and is recognized when it is determined that it is probable that the performance condition will be achieved. The Company has elected a policy for all share-based awards to estimate forfeitures based on historical forfeiture experience at the time of grant and revise in subsequent periods if actual forfeitures differ from those estimates.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring Expenses: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring expenses consist primarily of employee severance, contract termination costs and other costs. Liabilities for costs associated with a restructuring activity are recognized when the liability is incurred and are measured at fair value. According to ASC 420, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exit or Disposal Cost Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, one-time employee severance and termination benefits are expensed at the date the entity notifies the employee of the plan, unless the employee must provide future service, in which case the benefits are expensed in the period when the service ends. One-time termination benefits include severance, continuation of health insurance coverage for certain employees, and other benefits such as outplacement support services for a specified period of time.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Shares: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s shares have no par value or stated value and therefore, upon issuance or repurchase of shares, all amounts related to the shares are recorded under common shares on the balance sheet. The value of common shares includes cash amounts paid or received for the shares and the fair value of equity awards and warrants. Amounts for common shares are offset by share issue costs or transactions costs associated with repurchases or equity offerings.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued final guidance in ASU No. 2023-09, Income Taxes (ASC 740): Improvements to Income Tax Disclosures requiring entities to provide additional information in the rate reconciliation and disclosures about income taxes paid. For public business entities, the guidance is effective for annual periods beginning after December 15, 2024. The Company is not early adopting, and therefore, this ASU is not adopted in the current period. The Company is currently assessing the potential impact this ASU may have on the consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures which requires public entities to disclose significant segment expenses regularly provided to the chief operating decision-maker. Public entities with a single reporting segment have to provide all disclosures required by ASC 280, including the significant segment expense disclosures. For public business entities, the guidance is effective for annual periods beginning after December 15, 2023. This ASU does not have a material impact on the consolidated financial statements.</span></div> Fair Value Measurements<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist primarily of cash, cash equivalents, restricted cash, investments, accounts receivable, accounts payable, and accrued liabilities. The carrying value of accounts receivable, accounts payable, and accrued liabilities approximate their fair value because of their short-term nature. Estimated fair value of available-for-sale debt securities are generally based on prices obtained from commercial pricing services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market participants would price assets and liabilities). As a basis for considering such </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1 - Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2 - Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3 - Unobservable inputs that reflect the reporting entity’s own assumptions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the financial assets (cash, cash equivalents, restricted cash, and investments) measured at fair value on a recurring basis:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37,142</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37,142</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">601</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">601</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,028</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,028</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bills</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">196,471</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">196,471</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112,505</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112,505</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37,142</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">311,605</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">348,747</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bills</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,806 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,806 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,924 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,924 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,875 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,815 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,690 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Level 1 instruments include cash, cash equivalents, and restricted cash that are valued using quoted market prices. Aurinia estimates the fair values of investments in corporate debt securities, government and government related securities and certificates of deposits by taking into consideration valuations obtained from third-party pricing services. The fair value of the Company's investments classified within Level 2 is based upon observable inputs that may include benchmark yield curves, reported trades, issuer spreads, benchmark securities and reference data including market research publications. At September 30, 2024 and December 31, 2023, the weighted average remaining contractual maturities of Aurinia's Level 2 investments were approximately 7 months for both periods. The Company's policy is for these investments to have an overall rating of A-1, or higher, by Standard &amp; Poor's, or an equivalent rating by Moody’s or Fitch.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No credit loss allowance was recorded as of September 30, 2024 and December 31, 2023, as the Company does not believe the unrealized loss is a result of a credit loss due to the nature of the investments. Aurinia also considered the current and expected future economic and market conditions and determined that the estimate of credit losses was not significantly impacted.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents, Restricted Cash, and Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the carrying amount and related unrealized gains (losses) by type of investment.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the financial assets (cash, cash equivalents, restricted cash, and investments) measured at fair value on a recurring basis:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37,142</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37,142</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">601</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">601</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,028</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,028</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bills</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">196,471</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">196,471</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112,505</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112,505</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37,142</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">311,605</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">348,747</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bills</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,806 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,806 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,924 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,924 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,875 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,815 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,690 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 37142000 0 0 37142000 0 601000 0 601000 0 2028000 0 2028000 0 196471000 0 196471000 0 112505000 0 112505000 37142000 311605000 0 348747000 48875000 0 0 48875000 0 33781000 0 33781000 0 39304000 0 39304000 0 122806000 0 122806000 0 105924000 0 105924000 48875000 301815000 0 350690000 P7M P7M Cash, Cash Equivalents, Restricted Cash, and Investments<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, and December 31, 2023, the Company had $348.7 million and $350.7 million, respectively of cash, cash equivalents, restricted cash, and investments summarized below. As of September 30, 2024, and December 31, 2023, $311.6 million and $301.8 million were available-for-sale debt securities which are carried at fair market value.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.660%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37,142</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37,142</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">599</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">601</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,028</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,028</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">196,311</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">160</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">196,471</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112,246</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">259</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112,505</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash, and short-term investments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">348,326</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">421</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">348,747</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term investment corporate bond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash, and investments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">348,326</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">421</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">348,747</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,875 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,875 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,580 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,305 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,757 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,806 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,903 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,924 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash, and short-term investments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,416 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,489 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term investment corporate bond</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash, and investments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,616 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,690 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, and December 31, 2023, accrued interest receivable from investments was $0.5 million and $0.7 million, respectively. During the three and nine months ended September 30, 2024, the Company had $0.5 million and $0.3 million of unrealized gains on available-for-sale securities, net of tax, respectively, which are included as a component of comprehensive income (loss) on the consolidated statements of operations. During the three and nine months ended September 30, 2023, the Company had $0.1 million and $0.1 million of unrealized gains on available-for-sale securities, net of tax, respectively, which are included as a component of comprehensive income (loss) on the consolidated statements of operations. Currently, the Company does not intend to sell investments that are in an unrealized loss position, and it is unlikely the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. The Company has determined that the gross unrealized gains on investments at September 30, 2024, were temporary in nature. Realized gains or losses were immaterial during the three and nine months ended September 30, 2024, and 2023.</span></div>The Company's short-term investments as of September 30, 2024 mature at various dates through August 2025. 348700000 350700000 311600000 301800000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.660%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37,142</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37,142</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">599</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">601</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,028</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,028</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">196,311</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">160</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">196,471</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112,246</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">259</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112,505</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash, and short-term investments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">348,326</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">421</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">348,747</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term investment corporate bond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash, and investments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">348,326</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">421</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">348,747</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,875 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,875 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,580 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,305 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,757 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,806 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,903 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,924 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash, and short-term investments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,416 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,489 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term investment corporate bond</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash, and investments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,616 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,690 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 37142000 0 0 37142000 599000 2000 0 601000 2028000 0 0 2028000 196311000 160000 0 196471000 112246000 259000 0 112505000 348326000 421000 0 348747000 0 0 0 0 348326000 421000 0 348747000 48875000 0 0 48875000 33576000 4000 0 33580000 39305000 0 1000 39304000 122757000 49000 0 122806000 105903000 21000 0 105924000 350416000 74000 1000 350489000 200000 1000 0 201000 350616000 75000 1000 350690000 500000 700000 500000 300000 100000 100000 Inventories, net<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued under a standard costing methodology on a first-in, first-out basis and are stated at the lower of cost or net realizable value. The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. Capitalized costs of inventories for LUPKYNIS (voclosporin) mainly include third party manufacturing costs, transportation, storage, insurance, and allocated internal labor. Due to the nature of the Company's supply chain process, inventory that is owned by the Company, is physically stored at third-party warehouses, logistics providers, and contract manufacturers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses recoverability of inventory each reporting period to determine if any write-down to net realizable value is necessary. As of September 30, 2024, and December 31, 2023, Aurinia recorded reserves of finished goods inventories of nil and $0.8 million, respectively, which were primarily related to potential inventory obsolescence. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory, net are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,702</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34,990</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,376 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods, net of reserve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,714</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,705 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 800000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory, net are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,702</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34,990</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,376 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods, net of reserve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,714</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,705 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1702000 1746000 34990000 37376000 2022000 583000 38714000 39705000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Prepaid Expenses and Deposits</span><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses are as follows:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,730</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,892 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,189</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,896</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and deposits</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,815</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,486 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses are as follows:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,730</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,892 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,189</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,896</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and deposits</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,815</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,486 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 7730000 6892000 4189000 1345000 1896000 1249000 13815000 9486000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Intangible Assets</span><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of intangible assets, net of accumulated amortization. </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,073</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,354)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">719</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and reacquired rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,126</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11,336)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,790</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,873</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,873)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,072</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15,563)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,509</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,847 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,297)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and reacquired rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,737)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,873 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,835)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,846 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,869)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,977 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for the three months ended September 30, 2024, and 2023, was approximately $0.2 million and $0.5 million, respectively. Amortization for the nine months ended September 30, 2024, and 2023, was approximately $0.7 million and $1.4 million, respectively.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of intangible assets, net of accumulated amortization. </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,073</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,354)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">719</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and reacquired rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,126</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11,336)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,790</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,873</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,873)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,072</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15,563)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,509</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,847 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,297)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and reacquired rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,737)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,873 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,835)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,846 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,869)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,977 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2073000 1354000 719000 15126000 11336000 3790000 2873000 2873000 0 20072000 15563000 4509000 1847000 1297000 550000 15126000 10737000 4389000 2873000 2835000 38000 19846000 14869000 4977000 200000 500000 700000 1400000 Property and Equipment, net<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net are as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,243</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,243 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">631</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,155</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">235</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,264</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,264</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,377)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,910)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,887</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,354 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net are as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,243</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,243 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">631</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,155</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">235</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,264</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,264</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,377)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,910)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,887</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,354 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3243000 3243000 631000 631000 1155000 1155000 235000 235000 5264000 5264000 2377000 1910000 2887000 3354000 Lease Obligations<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has the following lease obligations:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rockville, Maryland</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During March 2020, the Company entered into a lease for its U.S. commercial office in Rockville, Maryland for a total of 30,531 square feet of office space. The lease has a remaining term of approximately seven years and has an option to extend for two five-year periods after the initial term of 11 years has elapsed and has an option to terminate after seven years. As of September 30, 2024, the Company had a right-of-use (ROU) asset of $4.1 million and lease liability of $6.8 million included in the condensed consolidated balance sheets. As of December 31, 2023, the Company had a right-of-use asset of $4.5 million and lease liability of $7.4 million included in the condensed consolidated balance sheets. The Company recorded leasehold improvement incentives in the amount of $2.3 million as additions to the lease liability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When measuring the lease liability, the Company discounted lease payments using its incremental borrowing rate at the lease commencement date on March 12, 2020. The incremental borrowing rate applied to the lease liability was 5.2% based on the financial position of the Company, geographical region and term of lease.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Edmonton, Alberta</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During October 2022, the Company entered into a long term lease in Edmonton for a total of 4,375 square feet of office space. The lease is a six year lease and has an option to renew after five years at prevailing market rates. The lease commenced on November 1, 2022 and the Company recorded the lease as an operating lease. The lease is not material to the Company's financial position.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all leases, the Company incurs variable lease costs. These costs include operation and maintenance costs included in SG&amp;A and are expensed as incurred. The variable lease costs are not material to the Company's financial position.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating lease costs for all leases for the three and nine months ended September 30, 2024, and September 30, 2023, were $0.2 million and $0.6 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Monoplant</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At lease inception, the Company recorded an ROU asset of approximately $117.6 million and a corresponding lease liability of $94.1 million, which is the present value of the minimum lease payments beginning July 2023 and expiring in 2030. The incremental borrowing rate applied to value the lease liability at inception is 6.19%, which was based on the financial position of the Company, geographical region and term of lease. As the monoplant finance lease is denominated in Swiss francs, the company incurs unrealized and realized foreign exchange gains and losses each reporting period related to the valuation of the lease liability and timing of lease payments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, the ROU asset, net and corresponding lease liability balance were $95.6 million and $80.7 million, respectively. As of December 31, 2023, the ROU asset, net and corresponding lease liability balance were $108.7 million and $90.1 million, respectively. For the three and nine months ended September 30, 2024, ROU amortization was $4.4 million and $13.1 million, respectively. For the three and nine months ended September 30, 2024, interest expense was $1.2 million and $3.7 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Beinheim</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into an equipment and facility finance lease for a backup manufacturing encapsulation site in Beinheim, France that commenced operations during June 2024 with a lease term of seven years. The incremental borrowing rate applied to value the lease liability at inception is 6.19%, which was based on the financial position of the Company, geographical region and term of lease.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, the ROU asset, net and corresponding lease liability balance were $0.8 million and $0.1 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the weighted-average remaining lease terms and discount rates as of September 30, 2024:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.27%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.19%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows for finance leases</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,959)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,482)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for finance leases</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,354)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(718)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(831)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(805)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of noncash transactions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance right-of-use asset obtained in exchange for lease obligations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">96,459</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,069 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liability arising from obtaining right-of-use assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">80,882</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities of lease liabilities as of September 30, 2024 are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Lease Payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Lease Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,295</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">283</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,203</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,141</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,204</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,169</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,204</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,198</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,205</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,227</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,554</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,302</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">94,665</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,320</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13,783)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,351)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">80,882</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,969</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 30531 P7Y 2 P5Y P11Y P7Y 4100000 6800000 4500000 7400000 -2300000 0.052 4375 P6Y P5Y 200000 200000 600000 600000 117600000 94100000 0.0619 95600000 80700000 108700000 90100000 4400000 13100000 1200000 3700000 P7Y 0.0619 800000 100000 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the weighted-average remaining lease terms and discount rates as of September 30, 2024:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.27%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.19%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows for finance leases</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,959)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,482)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for finance leases</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,354)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(718)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(831)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(805)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of noncash transactions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance right-of-use asset obtained in exchange for lease obligations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">96,459</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,069 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liability arising from obtaining right-of-use assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">80,882</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P6Y10M24D 0.0527 P5Y6M 0.0619 8959000 3482000 3354000 718000 831000 805000 96459000 113069000 80882000 85521000 <div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities of lease liabilities as of September 30, 2024 are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Lease Payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Lease Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,295</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">283</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,203</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,141</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,204</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,169</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,204</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,198</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,205</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,227</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,554</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,302</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">94,665</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,320</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13,783)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,351)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">80,882</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,969</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4295000 283000 17203000 1141000 17204000 1169000 17204000 1198000 17205000 1227000 21554000 3302000 94665000 8320000 13783000 1351000 80882000 6969000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Accounts Payable and Accrued Liabilities</span><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial accruals</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,523</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee accruals</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,180</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,486 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade payables</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,878</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,672</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,190 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued R&amp;D projects</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,331</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,007</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring accruals</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">179</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,770</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,389 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial accruals</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,523</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee accruals</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,180</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,486 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade payables</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,878</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,672</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,190 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued R&amp;D projects</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,331</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,007</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring accruals</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">179</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,770</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,389 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 25523000 16216000 14180000 22486000 8878000 4327000 4672000 5190000 2331000 5503000 1007000 667000 179000 0 56770000 54389000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Deferred Compensation and Other Non-current Liabilities</span><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded other non-current liabilities of $10.8 million and $10.9 million as of September 30, 2024, and December 31, 2023, respectively. The balance for both periods primarily included deferred compensation arrangements whereby certain former executive officers as of March 8, 2012 were provided with future potential employee benefit obligations for remaining with the Company for a certain period of time. These obligations were also contingent on the occurrence of uncertain future events. One of the former officers, Dr. Robert T. Foster, is considered a related party following his appointment to the Board of Directors (the Board) on September 21, 2023. For further discussion, refer to Note 17, Related Party Transactions.</span></div> 10800000 10900000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">License and Collaboration Agreements</span><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otsuka Contract</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 17, 2020, the Company entered into a collaboration and license agreement with Otsuka for the development and commercialization of oral LUPKYNIS in the Otsuka Territories. For full description of the agreements the Company has entered into with Otsuka, please refer to the Annual Report on Form 10-K for the year ended December 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the agreement, the Company received an upfront cash payment of $50.0 million in 2020 for the license agreement and has received $50.0 million in regulatory and pricing approval related milestones. The Company provides semi-finished product of LUPKYNIS to Otsuka on a cost-plus basis, sharing capacity of the monoplant and receives tiered royalties ranging from 10 to 20 percent (dependent on territory and achievement of sale thresholds) on net product sales by Otsuka, along with </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional milestone payments based on the attainment of certain annual sales. In addition, certain collaboration services are to be provided to Otsuka on agreed upon rates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 24, 2024, the Company announced that the Japanese Ministry of Health, Labour, and Welfare has approved LUPKYNIS, a second-generation calcineurin inhibitor, in combination with mycophenolate mofetil (MMF) to treat LN. As part of the December 2020 agreement with Otsuka, the Company is eligible to receive a payment of $10.0 million U.S. dollars upon approval in Japan along with low double-digit royalties on net sales once launched. As a result, the $10.0 million milestone was recognized as collaboration revenue in the quarter.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, the Company recognized $12.3 million and $16.7 million, respectively of license, collaboration, and royalty revenue from services provided under the Otsuka agreement. For the three and nine months ended September 30, 2023, the Company recognized $12.7 million and $13.2 million, respectively.</span></div> 50000000 50000000 0.10 0.20 10000000 10000000 12300000 16700000 12700000 13200000 Shareholder's Equity<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 15, 2024, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurinia announced that the Board had approved a share repurchase program of up to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$150 million common shares of the Company, affirming its confidence in the Company's growth prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 29, 2024, Canadian securities regulators granted exemptive relief for the Company’s share repurchase program, authorizing the Company to purchase up to 15 percent of its issued and outstanding shares in any 12-month period for up to 36 months, including under the current program. This program may be implemented through open market or privately negotiated purchases, including under a plan intended to comply with the affirmative defense under Rule 10b5-1, Rule 10b-18 or an automatic securities purchase plan, an accelerated share repurchase program, or other mechanisms. The timing and amount of repurchase transactions will be determined by management based on its evaluation of market conditions, share price, legal requirements, including applicable blackout period restrictions, and other factors. The purchase price of any Common Shares will be determined in accordance with applicable U.S. securities laws.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of September 30, 2024, the Company had repurchased approximately 3.4 million of Aurinia's common shares for $18.6 million (including transaction costs, which consist of commissions and excise tax). The cost of repurchased shares are reported as a reduction in common shares and under Alberta law, the shares were cancelled and not reissued.</span></div> 150000000 0.15 P12M P36M 3400000 18600000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Net Income (Loss) per Common Share</span><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding. For the periods in a loss position, diluted net loss per share is the same as basic net loss per share. The treasury stock method is used to determine the dilutive effect of the Company's stock options, RSUs, performance awards and ESPP. The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.683%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> September 30,</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) used for the calculation of basic and diluted EPS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,350</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,447)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,323</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,145)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">143,051</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,847 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">143,353</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,085 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive shares:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options, RSUs, performance awards and ESPP</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,657</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average diluted common shares outstanding, diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">145,651</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,847 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">145,010</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,085 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share, basic</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.03</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share, diluted</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.03</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.36)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not include certain shares issuable under share-based compensation plans because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.</span></div> The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:<div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.683%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> September 30,</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) used for the calculation of basic and diluted EPS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,350</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,447)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,323</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,145)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">143,051</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,847 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">143,353</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,085 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive shares:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options, RSUs, performance awards and ESPP</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,657</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average diluted common shares outstanding, diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">145,651</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,847 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">145,010</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,085 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share, basic</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.03</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share, diluted</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.03</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.36)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 14350000 -13447000 4323000 -51145000 143051000 142847000 143353000 143085000 2600000 0 1657000 0 145651000 142847000 145010000 143085000 0.10 -0.09 0.03 -0.36 0.10 -0.09 0.03 -0.36 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Share-based Compensation</span><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Amended and Restated Equity Incentive Plan (the Plan), which was adopted and approved by the Company's shareholders in June 2021, allows for an issuance of up to an aggregate of 23.8 million shares (inclusive of then outstanding awards) and provides for grants of stock options, performance awards (PAs), and restricted stock units (RSUs) that may be settled in cash and common shares. Also in June 2021, the Company's shareholders adopted and approved the Company's Employee Stock Purchase Plan (2021 ESPP), which allows for the issuance of up to 2.5 million shares. The 2021 ESPP is intended to qualify as an “employee stock purchase plan” under Section 423 of the Internal Revenue Code but also permits the Company to include the employees, including non-United States employees, in offerings not intended to qualify under Section 423. The purpose of the 2021 ESPP is to provide eligible employees with opportunities to purchase the Company’s common shares at a discounted price. As of September 30, 2024, 0.9 million shares have been purchased under the ESPP.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to stock options, PAs and RSUs granted under the Plan, the Company has granted certain stock options and RSUs as inducements material to new employees entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The inducements were granted outside of the Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan requires the exercise price of each option not to be less than the closing market price of the Company’s common shares on the business day immediately prior to the date of grant. The Board approves the vesting criteria and periods at its discretion. The options issued under the Plan are accounted for as equity-settled share-based payments. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used the Black-Scholes option pricing model to estimate the fair value of the options granted. The assumptions used for the annual volatility and expected life of the options are reviewed and updated annually. The Company considers historical volatility of its common shares in estimating its future stock price volatility. The risk-free interest rate for the expected life of the options was based on the yield available on government benchmark bonds with an approximate equivalent </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">remaining term at the time of the grant. The expected life is based upon the contractual term, taking into account expected employee exercise and expected post-vesting employment termination behavior. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted average assumptions were used to estimate the fair value of the options granted during the nine months ended September 30, 2024, and September 30, 2023:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annualized volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.08</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of options in years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated forfeiture rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per common share option</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.82</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the option award activity for the nine months ended September 30, 2024:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of shares (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price $</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,556</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.63</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">325</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.89</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or cancelled</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,006)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.81</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - September 30, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,750</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.09</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units and Performance Awards</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has granted RSUs and PAs under the Plan, as well as inducements for certain new hires as discussed above. The RSUs and PAs are fair valued based on the previous business days' market price of common shares on the date of the grant.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the RSU and PA activity for the nine months ended September 30, 2024:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of shares (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average fair value price $</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance, December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,807</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.29</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,663</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.89</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,422)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,673)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.99</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance - September 30, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,375</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.96</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation expense for the three and nine months ended September 30, 2024, and September 30, 2023, as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.683%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/> September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">306</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,975 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,773)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,679 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,812</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,427</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,969 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized under inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">209</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">996</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">895 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,327</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,808 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,650</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,543 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September 30, 2024, there was $25.7 million of unrecognized share-based compensation expense related to unvested awards granted which is expected to be recognized over a weighted-average period of approximately 1.3 years.</span></div> 23800000 2500000 900000 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted average assumptions were used to estimate the fair value of the options granted during the nine months ended September 30, 2024, and September 30, 2023:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annualized volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.08</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of options in years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated forfeiture rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per common share option</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.82</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0.77 0.71 0.0408 0.0392 P5Y P5Y 0.130 0.127 0.000 0.000 3.82 5.94 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the option award activity for the nine months ended September 30, 2024:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of shares (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price $</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,556</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.63</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">325</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.89</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or cancelled</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,006)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.81</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - September 30, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,750</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.09</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 11556000 10.63 325000 5.89 125000 5.18 2006000 12.81 9750000 10.09 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the RSU and PA activity for the nine months ended September 30, 2024:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of shares (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average fair value price $</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance, December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,807</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.29</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,663</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.89</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,422)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,673)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.99</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance - September 30, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,375</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.96</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 7807000 9.29 4663000 6.89 2422000 9.50 1673000 8.99 8375000 7.96 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation expense for the three and nine months ended September 30, 2024, and September 30, 2023, as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.683%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/> September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">306</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,975 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,773)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,679 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,812</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,427</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,969 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized under inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">209</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">996</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">895 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,327</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,808 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,650</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,543 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 306000 1975000 -1773000 5679000 7812000 9560000 23427000 26969000 209000 273000 996000 895000 8327000 11808000 22650000 33543000 25700000 P1Y3M18D <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Income Taxes</span><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates for the three and nine months ended September 30, 2024, and September 30, 2023, differed from the Canadian statutory rate applied to income or losses before income taxes primarily as a result of the mix of income, losses and valuation allowances. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized an income tax expense of approximately $0.5 million and $2.0 million for the three and nine months ended September 30, 2024, respectively. The Company recognized an income tax expense of approximately $0.3 million and $0.1 million for the three and nine months ended September 30, 2023, respectively. The income tax expense recognized for these periods is a result of income in certain jurisdictions. This tax expense is not offset by a tax benefit as the Company has losses which are fully offset by a valuation allowance in its significant jurisdictions.</span></div> 500000 2000000.0 300000 100000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Related Party Transactions</span><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 21, 2023, the Company appointed Dr. Robert T. Foster to the Board. Dr. Foster is considered a related party since he is one of the former executive officers of the Company who, as of March 8, 2012 was provided with future potential employee benefit obligations for remaining with the Company for a certain period of time. These obligations are contingent on the occurrence of uncertain future events. Dr. Foster was not a related party of the Company between his resignation from the Company in 2014, and his appointment to the Board on September 21, 2023. As of September 30, 2024, the Company had $0.8 million and $7.0 million of current and non-current liabilities related to Dr. Foster, respectively. As of December 31, 2023, the Company had $0.8 million and $7.6 million of current and non-current liabilities related to Dr. Foster, respectively. As of September 30, 2024, and December 31, 2023, the Company made payments of $0.4 million and $0.1 million, respectively for each period as a related party for the deferred compensation.</span></div> 800000 7000000.0 800000 7600000 400000 100000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Commitments and Contingencies</span><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may, from time to time, be subject to claims and legal proceedings brought against it in the normal course of business. Such matters are subject to many uncertainties. Management believes the ultimate resolution of such contingencies will not have a material adverse effect on the consolidated financial position of the Company. Other than as described under Part II, Item I, the Company's material commitments and contingencies have not changed in any material manner from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Funding Commitments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into agreements with contract research organizations, contract manufacturing organizations and other third parties for services to be provided to the Company. Generally, these agreements provide for termination upon notice, with specified amounts due upon termination based on the timing of termination and the terms of the agreement. The actual amounts and timing of payments under these agreements are uncertain and contingent upon the initiation and completion of services to be provided to the Company.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Restructuring</span><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 15, 2024, the Company announced the conclusion of its strategic review process and actions designed to enhance shareholder value. Aurinia executed a corporate restructuring in the first quarter that reduced employee headcount by approximately 25%. The Company discontinued its AUR300 research and development program. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, the restructuring expenses are included within operating expenses on the condensed consolidated statements of operations and comprehensive income (loss). For the three and nine months ended September 30, 2024, restructuring expenses were nil and $7.8 million, respectively. Restructuring expenses consisted of the following:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.426%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.790%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="display:none"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee severance and one time benefits</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,075</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract terminations</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other costs</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">575</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,755</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0.25 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, the restructuring expenses are included within operating expenses on the condensed consolidated statements of operations and comprehensive income (loss). For the three and nine months ended September 30, 2024, restructuring expenses were nil and $7.8 million, respectively. Restructuring expenses consisted of the following:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.426%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.790%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="display:none"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee severance and one time benefits</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,075</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract terminations</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other costs</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">575</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,755</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 7800000 6075000 1105000 575000 7755000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Subsequent Events</span><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective November 7, 2024, Aurinia appointed Craig Johnson to the Board. Mr. Johnson has more than 30 years of experience serving in senior financial management roles and governing companies in the biotechnology industry.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company also announced that</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Dr. Robert T. Foster has retired from the Board effective November 5, 2024.</span></div>

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